"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2011/156883 A1,128-718-657-837-353,2011-12-22,2011,CA 2010000911 W,2010-06-14,CA 2010000911 W,2010-06-14,LIQUID FILTRATION SYSTEM,"The liquid filtration system comprises a housing, a waste liquid inlet in the housing, a filtered liquid outlet in the housing and a filter carried by the housing and interposed between the waste liquid inlet and the filtered liquid outlet in such a way that liquid flowing in the housing between the waste liquid inlet and the filtered liquid outlet will pass through the filter for the filter to retain viscous and macroparticulate matter. The liquid filtration system also comprises an agitator mounted to the housing and capable of agitating the filter for dislodging viscous and macroparticulate matter that clogs pores of the filter.",CONDINA VALENTINO;;FILTERCO ENTPR INC;;GOLDFARB ROBERT,CONDINA VALENTINO;;GOLDFARB ROBERT,,https://lens.org/128-718-657-837-353,Patent Application,yes,3,0,1,1,0,B01D29/86;;B01D29/27;;B01D29/72,B01D35/16;;B01D29/64;;B01D35/30;;E03C1/12,,0,0,,,,PENDING
2,US,A,US 4760440 A,166-107-530-938-312,1988-07-26,1988,US 54721783 A,1983-10-31,US 54721783 A,1983-10-31,Package for solid state image sensors,"A package for solid state image sensor devices, such as CCD image sensors, includes a base plate on which a plurality of the image sensor devices are mounted in end-to-end abutting relation with the detector arrays of the image sensors being over an opening in the base plate, and a cover mounted on the base plate and extending over the image sensor devices to enclose the image sensor devices between the cover and the base plate. The base plate and cover are of polycrystalline silicon so as to have a coefficient of thermal expansion which matches that of the image sensor devices.",GEN ELECTRIC,BIGLER ROBERT R;;GOLDFARB SAMUEL,RCA CORPORATION A DE CORP (1983-10-21);;GENERAL ELECTRIC COMPANY A CORP. OF NEW YORK (1987-12-11),https://lens.org/166-107-530-938-312,Granted Patent,yes,4,83,1,1,0,H01L23/06;;H01L23/06;;H01L2224/48091;;H01L2224/48091;;H01L2224/73265;;H01L2224/73265;;H01L2924/01079;;H01L2924/01079;;H01L2924/12032;;H01L2924/12032;;H01L2924/15151;;H01L2924/15151,H01L23/06,H1K KRL           RL,0,0,,,,EXPIRED
3,US,A,US 5664020 A,096-538-273-359-738,1997-09-02,1997,US 41441895 A,1995-03-31,US 41441895 A;;US 18180894 A,1994-01-18,Compact full-range loudspeaker system,"A compact full-range loudspeaker system includes an elongated enclosure having two open ends joined by a hollow interior, which enclosure may be of fixed dimension or telescoping, and has a full-range speaker mounted at each end of the cylindrical enclosure. The enclosure length is set in a range governed by the small speaker size to maximize the system response, particularly in the lower frequency range, and a dampening material is provided to construct the enclosure to minimize the structural acoustic response of the enclosure when being driven. A pair of miniature sound boards may be flat, polymer surfaces mounted to a base and positioned at each end of the cylindrical enclosure at an angle facing each speaker for reflecting sound waves emanating from the speaker in accordance with the positioning of the cylindrical enclosure to create an effective sound stage and control directionality.",BSG LAB,GOLDFARB BARRY S;;CLARK ROBERT L,BSG LABORATORIES (1995-03-31),https://lens.org/096-538-273-359-738,Granted Patent,yes,13,65,11,11,0,H04R1/02;;H04R5/02;;H04R5/02;;H04R1/02,H04R1/02;;H04R1/40;;H04R5/02;;H04R1/26,381/89;;381/88;;381/159;;181/196;;181/199,0,0,,,,EXPIRED
4,US,A1,US 2019/0358197 A1,060-258-137-068-79X,2019-11-28,2019,US 201916435756 A,2019-06-10,US 201916435756 A;;US 201815899160 A;;US 201762460941 P,2017-02-20,METHOD AND COMPOSITIONS FOR TREATING DYSTROPHIES AND MYOTONIA,Methods and compositions for treating myotonia and dystrophies.,NEXIEN BIOPHARMA INC,KLUMPERS LINDA;;SCHOSER BENEDIKT;;GOLDFARB ROBERT;;FRIEDLAND JEFFREY,NEXIEN BIOPHARMA INC (2019-06-10),https://lens.org/060-258-137-068-79X,Patent Application,yes,0,0,2,2,0,A61K31/05;;A61K31/353;;A61P21/00;;A61K9/006;;A61K31/05;;A61K9/006;;A61P21/00;;A61K47/44;;A61K31/352,A61K31/353;;A61K9/00;;A61K31/05;;A61K47/44;;A61P21/00,,0,0,,,,ACTIVE
5,US,B2,US 10702495 B2,156-137-456-451-403,2020-07-07,2020,US 201916435756 A,2019-06-10,US 201916435756 A;;US 201815899160 A;;US 201762460941 P,2017-02-20,Method and compositions for treating dystrophies and myotonia,Methods and compositions for treating myotonia and dystrophies.,NEXIEN BIOPHARMA INC,KLUMPERS LINDA;;SCHOSER BENEDIKT;;GOLDFARB ROBERT;;FRIEDLAND JEFFREY,NEXIEN BIOPHARMA INC (2019-06-10),https://lens.org/156-137-456-451-403,Granted Patent,yes,37,1,2,2,0,A61K31/05;;A61K31/353;;A61P21/00;;A61K9/006;;A61K31/05;;A61K9/006;;A61P21/00;;A61K47/44;;A61K31/352,A61K31/352;;A61K9/00;;A61K31/05;;A61K31/353;;A61K47/44;;A61P21/00,,38,32,158-168-729-109-481;;011-406-485-399-629;;006-501-516-517-558;;018-162-810-526-166;;032-173-551-371-649;;062-526-020-252-690;;028-327-181-928-853;;074-627-531-278-567;;038-209-998-980-344;;080-691-910-337-655;;055-759-757-605-386;;076-473-289-796-668;;016-715-142-905-391;;017-309-443-643-359;;011-735-494-422-277;;126-667-602-162-256;;035-576-816-933-842;;011-667-939-341-25X;;032-069-379-239-696;;094-953-948-419-926;;017-306-905-683-424;;014-755-155-592-578;;084-084-453-581-273;;005-984-250-179-290;;003-100-988-534-747;;064-438-798-298-107;;077-329-782-413-00X;;010-206-971-149-059;;033-354-968-818-337;;057-071-766-878-842;;062-814-134-806-475;;003-958-604-262-488,10.1007/s00415-018-9159-2;;30552503;;10.1007/s00415-019-09593-6;;31655890;;10.1016/j.nmd.2005.03.004;;16106528;;pmc3079847;;10.1038/npp.2011.6;;21307846;;pmc4707667;;24854329;;10.1111/epi.12631;;10.1002/cpt1976193300;;770048;;10.1038/sj.npp.1300340;;14583744;;28538134;;10.1056/nejmoa1611618;;pmc3136655;;10.1002/mus.22090;;21607985;;pmc3881009;;21724467;;10.1016/j.molmed.2011.05.004;;8119941;;10.1016/s0021-9258(17)37556-7;;10.1300/j175v03n04_02;;26708108;;pmc4908634;;10.1038/npp.2015.367;;10.1002/mus.24725;;pmc4979973;;26044513;;pmc4398332;;10.1016/j.euroneuro.2014.11.014;;25534187;;19896326;;10.1016/j.jpainsymman.2009.06.008;;4609777;;10.1016/0014-2999(74)90129-0;;10.1016/s0091-3057(00)00201-x;;10837858;;15079005;;10.1212/01.wnl.0000118206.49652.a3;;20439846;;pmc2871004;;10.1212/wnl.0b013e3181dc1a3a;;10.1192/bjp.bp.110.077503;;20884951;;16306858;;10.1097/01.ftd.0000177223.19294.5c;;10.1097/01.jcp.0000125688.05091.8f;;15118485;;21629954;;10.1039/c1mb05043e;;10.1191/1352458504ms1082oa;;15327042;;10.1007/bf00432554;;6285406;;22290374;;10.1177/026988119300700112;;pmc5425583;;10.3389/fphar.2017.00259;;28553229;;pmc3836266;;21289620;;10.1038/clpt.2010.318;;10.1300/j175v03n04_01;;10.1016/j.nmd.2010.07.104;;10.1038/ejhg.2011.23;;21364698;;pmc3137497,"Montagnese et al. Journal of Neurology, 2019, vol. 266, pp. 530-532 (Year: 2019).;;Montagnese et al. Journal of Neurology, 2020, vol. 267, pp. 415-421 (Year: 2020).;;Berard et al., “A Motor Function Measure Scale for Neuromuscular Diseases. Construction and Validation Study,” Neuromuscular Disorders 15 (2005) pp. 463-470.;;Bergamaschi et al., “Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients,” Neuropsychoparhamcology (2011) 36: 1219-1226.;;Cilio et al., “Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders,” Epilepsia (2014) 55(6): 791-802.;;Dalton et al., “Influence on cannabidiol on delta-9-tetrahydrocannabinol effects,” Clinical Pharmacology and Therapeutics, 19(3): 300-309.;;De Souza Crippa et al., “Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow,” Neuropsychoparhamcology (2004) 29: 417-426.;;Devinsky et al., “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome,” The New England Journal of Medicine (2017) 376 (21): 2011-2020.;;Foff et al., “Therapeutic Development in Myotonic Dystrophy Type I,” Muscle Nerve, 2011 44(2) 160-169.;;Fusar-Poli et al., “Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing,” Arch Gen Psychiatry (2009), 66(1): 95-105.;;Gomes-Pereira et al., “Myotonic dystrophy mouse models: towards rational therapy development,” Trends in Molecular Medicine (2011):1-12.;;Gronemeier et al., “Nonsense and Missense Mutations in the Muscular Chloride Channel Gene Clc-1 of Mytonic Mice,” The Journal of Biological Chemistry (1994), 269(8): 5963-5967.;;Guy et al., “A Phase I, Double Blind, Three-Way Crossover Study to Assess the Pharmacokinetic Profile of Cannabis Based Medicine Extract (CBME) Administered Sublingually in Variant Cannabinoid Ratios in Normal Healthy Male Volunteers (GWPK0215),” Cannabis: From Pariah to Prescription (ed: Ethan Russo) The Haworth Integrative Healing Press (2003), pp. 121-152.;;Haney et al., “Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis,” Neuropsychopharmacology (2016), 41: 1974-1982.;;Heatwole et al., “The Myotonic Dystrophy Health Index: Correlations with Clinical Tests and Patient Function,” Muscle Nerve, (2016) 53(2) 183-190.;;Hindocha et al., “Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users,” European Neuropsychopharamcology (2015), 25:325-334.;;Jahromi, “Advances in Myotonic Dystrophy Type 1 Drug Discovery Through Design of Novel Ligands and Mechanism Establishment,” University of Illinois at Urbana-Champaign, 2013.;;Johnson et al., “Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain,” Journal of Pain and Symptom Management (2010), 39(2): 167-179.;;Karniol, et al., “Cannabidiol Interferes with the Effects of delta-9-tetrahydrocannabinol in Man,” European Journal of Pharmacology (1974) 28: 172-177.;;Leweke et al., “Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man,” Pharmacol Biochem Behav (1999), 66(1): 175-181.;;Logigian et al., “Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1,” Neurology (2004), 62(7) 1-25.;;Logigian et al., “Mexiletine is an Effective Antimyotonia Treatment in Myotonic Dystrophy Type 1,” Neurology, (2010) 74(18), pp. 1441-1448.;;Morgan et al., “Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study,” The British Journal of Psychiatry (2010), 197: 285-290.;;Nadulski et al., “Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of delta-9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract,” Ther Drug Monit (2005), 27(6): 799-810.;;Nicholson et al., “Effect of delta-9-Tetrahydrocannabinol and Cannabidiol on Noctournal Sleep and Early-Morning Behavior in Young Adults,” J Clin Psychopharmacol (2004), 24: 305-313.;;Sativex Oromucosal Spray [summary of product characteristics]. Cambridge, UK: GW Pharma, Ltd.: 2015.;;Sativex® Oromucosal Spray [package insert]. Reading, UK: Bayer, plc; 2017.;;Sativex® Oromucosal Spray [prescribing information]. Reading, UK: Bayer, plc.: 2017.;;Staunton et al., “Identification of secondary effects of hyperexcitability by proteomic profiling of myotonic mouse muscle,” Mol. BioSyst. (2011), 7: 2480-2489.;;Wade et al., “Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerois? A double-blind, randomized, placebo-controlled study on 160 patients,” Mult Schler (2004) 10: 434-441.;;Zuardi et al., “Action of Cannabidiol on the Anxiety and Other Effects Produced by delta-9-THC in Normal Subjects,” Psychopharmacology (1982) 76: 245-250.;;Zuardi et al., “Effects of ipsapirone and cannabidiol on human experimental anxiety,” Journal of Psychopharmacology (1993), 7(1):82-88.;;Zuardi et al., “Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life,” Frontiers in Pharmacology (2017), 8(259): 1-9.;;Karschner et al. (2011), “Subjective and Physiological Effects after Controlled Sativex and Oral THC Administration,” Clin Pharmcol Ther. 89(3): 1-15.;;Karschner et al. (2011), “Plasma Cannabinoid Pharmacokinetics Following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration,” Clinical Chemistry 57(1): 66-75.;;Guy et al. (2003), “A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBME per Oral in Healthy Male and Female Volunteers (GWPK0112),” Cannabis: From Pariah to Prescription (ed: Ethan Russo) The Haworth Integrative Healing Press (2003), pp. 79-118.;;Suominen et al., “P2.32: The frequency of myotonic dystrophy type 2 (DM2) and type 1 (DM1) mutations in the population,” Abstracts / Neuromuscular Disorders (2010), 20(9-10): 628.;;Suominen et al., “Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland,” European Journal of Human Genetics (2011) 19: 776-782.",ACTIVE
6,CN,A,CN 1282242 A,140-052-375-229-583,2001-01-31,2001,CN 98812269 A,1998-12-15,US 6980497 P,1997-12-16,Multicatalytic protease inhibitors for use as anti-tumor agents,,CEPHALON INC,SIMAN ROBERT;;JANI JITECH P;;GOLDFARB RONALD H,,https://lens.org/140-052-375-229-583,Patent Application,no,0,1,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,C07D311/70;;A61K31/16;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,,0,0,,,,DISCONTINUED
7,US,A,US 3025139 A,047-511-266-863-832,1962-03-13,1962,US 65517357 A,1957-04-26,US 65517357 A,1957-04-26,Process for making boron trichloride,,STAUFFER CHEMICAL CO,DAVIS ROBERT G;;HERMAN GOLDFARB;;HEISS JOHN F,,https://lens.org/047-511-266-863-832,Granted Patent,no,7,5,1,1,0,C01B35/06;;C01B35/06,C01B35/06,,0,0,,,,EXPIRED
8,ES,T3,ES 2529180 T3,103-080-030-844-165,2015-02-17,2015,ES 03754689 T,2003-09-19,US 41218002 P;;US 41218102 P;;US 0329292 W,2002-09-20,Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona,"Una forma farmacéutica que tiene un primer y un segundo fármaco activo, comprendiendo dicha forma farmacéutica: (A) un comprimido de liberación osmótica que comprende: (i) un núcleo que comprende: (a) 50-98 % en peso del núcleo de clorhidrato de metformina; (b) 0,1-40 % en peso del núcleo de un agente aglutinante; (c) 0-20 % en peso del núcleo de un potenciador de la absorción; y (d) 0-5 % en peso del núcleo de un lubricante; ii) opcionalmente un primer revestimiento de precintado que rodea al núcleo; y (iii) una membrana semipermeable que comprende: a. 50-99 % en peso de la membrana semipermeable de un polímero; b. 0-40 % en peso de la membrana semipermeable de un potenciador del flujo y c. 0-99 % en peso de la membrana semipermeable de un plastificante, teniendo dicha membrana al menos un paso en su interior para la liberación del clorhidrato de metformina; (B) opcionalmente, un revestimiento de precinto secundario aplicado al comprimido de liberación controlada; y (C) un revestimiento que contiene clorhidrato de pioglitazona de liberación inmediata donde el revestimiento que contiene clorhidrato de pioglitazona de liberación inmediata comprende: (i) 0,1-20 % en función del peso total del comprimido de clorhidrato de pioglitazona; (ii) 0,1-30 % en función del peso total del comprimido de un aglutinante; (iii) 0-25 % en función del peso total del comprimido de un formador de poros; y (iv) 0-20 % en función del peso total del comprimido de un tensioactivo; y donde el revestimiento que contiene clorhidrato de pioglitazona de liberación inmediata se aplica sobre la membrana semipermeable (iii) o el segundo revestimiento de precinto (B) revestido sobre la membrana semipermeable (iii), usando una mezcla de disolventes que comprende agua y un disolvente orgánico y donde la forma farmacéutica proporciona un Tmáx de 8-12 horas para el clorhidrato de metformina y una Tmáx de 1-4 horas para el clorhidrato de pioglitazona.",ANDRX LABS LLC,LODIN UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT,,https://lens.org/103-080-030-844-165,Granted Patent,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
9,ES,T3,ES 2541124 T3,131-252-430-218-757,2015-07-16,2015,ES 04710656 T,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,Nueva formulación farmacéutica que contiene una biguanida y un derivado de tiazolidinodiona,"Una forma de dosificación farmacéutica que tiene un primer y un segundo fármaco activo, comprendiendo dicha forma de dosificación: (a) un núcleo de liberación controlada que comprende hidrocloruro de metformina como fármaco antihiperglucémico y al menos un excipiente farmacéuticamente aceptable; y (b) un componente que contiene pioglitazona de liberación inmediata que se aplica en forma de una capa al núcleo, en donde no menos de 90% de la pioglitazona se libera de la forma de dosificación en el plazo de 30 minutos cuando se somete a ensayo de acuerdo con la United States Pharmacopeia (USP) 26, con el Aparato 1 a 100 rpm, 37°C y 900 ml de tampón de KCl-HCl 0,3 M, pH 2,0, en donde el núcleo comprende **Tabla** en donde los compuestos relacionados con pioglitazona o impurezas totales en la forma de dosificación final no son más de 0,6% según se determina mediante cromatografía líquida de alto rendimiento; en donde cada compuesto relacionado con pioglitazona individual o impureza en la forma de dosificación final no es más de 0,25%, en donde los compuestos relacionadas con pioglitazona y las impurezas son (i) (+/-)-5-[p-[2-(5-etil-2-piridil)etoxi]bencil]-5-hidroxi-2,4-tiazolidinodiona; (ii) (Z)-5-[p-[2-(5-etil-2-piridil)etoxi]benciliden]-2,4-tiazolidinodiona; (iii) (+/-)-5-[p-[2-(5-etil-2-piridil)etoxi]bencil]-3-[2-(5-etil-2-piridil)etil]-2,4-tiazolidinodiona; (iv) (+/-)-etil-2-carbamoiltio-3-[4-[2-(5-etil-2-piridil)etoxi]fenil]propionato de metilo; (v) 3-p-[2-(5-etil-2-piridil)etoxi]fenil-propionato de etilo.",ANDRX LABS LLC,LODIN UNCHALEE;;GOLDFARB ROBERT;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/131-252-430-218-757,Granted Patent,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
10,AU,A1,AU 2003/272504 A1,016-268-994-164-579,2004-04-08,2004,AU 2003/272504 A,2003-09-19,US 41218002 P;;US 41218102 P;;US 0329292 W,2002-09-20,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/016-268-994-164-579,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
11,AU,B2,AU 2004/283059 B2,032-720-615-422-16X,2011-02-10,2011,AU 2004/283059 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,,WATSON PHARMACEUTICALS INC,CARDINAL JOHN;;NANGIA AVINASH;;KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I,,https://lens.org/032-720-615-422-16X,Granted Patent,no,2,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
12,NZ,A,NZ 545653 A,015-053-808-135-80X,2009-12-24,2009,NZ 54565304 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,"Disclosed is a pharmaceutical dosage form having a first and second active drug, said dosage form comprising: a) a controlled release core comprising at least one pharmaceutically acceptable excipient and only one active drug that consists of metformin hydrochloride; and b) an immediate release thiazolidinedione derivative containing component, wherein not less than 85 wt% of the thiazolidinedione is released from the dosage form within 45 minutes when tested according to the United States Pharmacopoeia (USP) 26, with Apparatus 1 at 100 rpm, 37 degrees Celsius and 900 ml of 0.3 M KCl-HCl Buffer, pH 2.0, wherein the thiazolidinedione derivative can be either pioglitazone or a pharmaceutically acceptable salt thereof and after storage at 40 degrees Celsius and 75% relative humidity for three months, the total thiazolidinedione related compounds or impurities in the dosage form is not more than 0.6 wt% as determined by high performance liquid chromatography and each individual thiazolidinedione related compound or impurity in the final dosage form is not more than 0.25 wt%, and wherein the thiazolidinedione related compounds and impurities are as described in the specification.",ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/015-053-808-135-80X,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/22;;A61K9/24;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;C07C279/26,,0,0,,,,DISCONTINUED
13,AU,A1,AU 2004/283059 A1,003-568-766-730-05X,2005-05-06,2005,AU 2004/283059 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,,ANDRX LABS LLC,CARDINAL JOHN;;NANGIA AVINASH;;KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I,,https://lens.org/003-568-766-730-05X,Patent Application,no,0,1,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
14,WO,A3,WO 2004/026241 A3,017-419-204-557-24X,2004-06-10,2004,US 0329292 W,2003-09-19,US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND THIAZOLIDINDIONE DERIVATIVES,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/017-419-204-557-24X,Search Report,yes,2,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,PENDING
15,EP,B1,EP 1663170 B1,191-635-417-476-545,2015-06-24,2015,EP 04710656 A,2004-02-12,US 2004/0004112 W;;US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,LODIN UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/191-635-417-476-545,Granted Patent,yes,7,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
16,WO,A2,WO 2000/070519 A2,034-575-574-508-550,2000-11-23,2000,US 0013120 W,2000-05-12,US 13459399 P;;US 46454399 A;;US 46453799 A,1999-05-17,NETWORK ACCESSIBLE QUOTATION AND SHIPPING SYSTEM,"A transportation logistics system (250) provides to vendors or shoppers, at the time of purchase, a total global delivered cost quote for shipping a product between locations. The system is accessible over packet switched networks (205), such as the Internet, or over a circuit switched network, such as traditional telephone networks, and includes a web server (260) and a proprietary database (280). A total delivered cost calculator engine (265) retrieves the necessary information from the database, given the requestor input, and performs the necessary calculations. The total delivered cost quote, which includes any applicable inland origin freight, inland destination freight, air freight, ocean freight, insurance, duties, taxes, custom clearance fee, import fee, or service fees is presented to the requestor with both ocean freight and air freight options. The transportation logistic system (250) can coordinate the shipment of the selected product to the delivery destination, and enables the payment of all quoted fees, if the requestor accepts the quote.",FROM2 COM INC;;FALIC LEON S;;GOLDFARB GARY M;;REDLHAMMER ROBERT E,FALIC LEON S;;GOLDFARB GARY M;;REDLHAMMER ROBERT E,,https://lens.org/034-575-574-508-550,Patent Application,yes,0,55,3,3,0,G06Q10/08,G06Q10/00,,0,0,,,,PENDING
17,KR,A,KR 20050053677 A,117-215-127-755-680,2005-06-08,2005,KR 20057004787 A,2005-03-19,US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND THIAZOLIDINDIONE DERIVATIVES,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,NANGIA AVINASH;;KOSITPRAPA UNCHALEE;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/117-215-127-755-680,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
18,JP,A,JP 2014196314 A,162-170-863-108-372,2014-10-16,2014,JP 2014115628 A,2014-06-04,US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING BIGUANIDE AND THIAZOLIDINEDIONE DERIVATIVE,"PROBLEM TO BE SOLVED: To provide a pharmaceutical dosage form that enables controlled or sustained release in combination with an antidiabetic and a thiazolidinedione derivative.SOLUTION: A pharmaceutical dosage form comprises a core made by surrounding an antidiabetic such as HCL methoxylsine with a semipermeable membrane for controlled release, with the core seal-coated with an immediate release coating agent, immediately dispersed or dissolved in water and comprising HCL metformin (thiazolidinedione derivative).",ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/162-170-863-108-372,Patent Application,no,12,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K31/155;;A61K9/00;;A61K9/20;;A61K9/22;;A61K9/28;;A61K9/36;;A61K31/425;;A61K31/426;;A61K31/4439;;A61K45/06;;A61K47/38;;A61P3/10,,0,0,,,,INACTIVE
19,CA,A1,CA 2537665 A1,179-117-585-450-403,2005-05-06,2005,CA 2537665 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,CARDINAL JOHN;;GOLDFARB ROBERT I;;NANGIA AVINASH;;KOSITPRAPA UNCHALEE,,https://lens.org/179-117-585-450-403,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
20,EP,B1,EP 1539144 B1,073-417-178-455-013,2014-12-24,2014,EP 03754689 A,2003-09-19,US 0329292 W;;US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,LODIN UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/073-417-178-455-013,Granted Patent,yes,5,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
21,AU,A1,AU 2011/202162 A1,146-316-773-518-123,2011-06-02,2011,AU 2011/202162 A,2011-05-10,AU 2004/283059 A;;AU 2011/202162 A;;US 66480303 A;;US 2004/0004112 W,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,,WATSON PHARMACEUTICALS INC,NANGIA AVINASH;;KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN,,https://lens.org/146-316-773-518-123,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
22,US,A1,US 2008/0003377 A1,153-052-832-049-054,2008-01-03,2008,US 82036007 A,2007-06-19,US 82036007 A;;US 81813706 P,2006-06-30,Transparent vacuum system,"A vacuum chamber has a housing within which a vacuum is sustained. Various processes may be performed and electronic circuits and elements may be supported in the vacuum chamber. The housing has walls with an interior surface that comprise crosslinked polystyrene. The vacuum chamber may have interior walls that have been machined, polished etched, chemically treated, thermally treated, electromagnetic energy treated. Circuitry, electrodes and electromagnetic processes can be performed within the vacuum chamber.",NEVADA SYSTEM OF HIGHER ED ON,SCHILL ROBERT A;;GOLDFARB STANLEY R;;KANT RICHARD A,BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA LAS VEGAS UNIVERSITY OF NEVADA LAS VEGAS THE (2007-06-01),https://lens.org/153-052-832-049-054,Patent Application,yes,20,2,1,1,0,C23C14/00;;H01J37/32431;;H01J37/32467;;C23C14/00;;H01J37/32467;;H01J37/32431,C23C14/30,427/585;;118/50.1,0,0,,,,DISCONTINUED
23,US,B2,US 8309125 B2,195-647-493-645-578,2012-11-13,2012,US 83594510 A,2010-07-14,US 83594510 A;;US 66480303 A;;US 41218002 P;;US 41218102 P,2002-09-20,Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I;;WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,ALLERGAN FINANCE LLC (2016-06-09);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/195-647-493-645-578,Granted Patent,yes,103,1,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/4439;;A61K45/06;;A61P3/04;;A61P3/10,424/465;;424/468;;424/484;;427/2.14;;514/342,61,23,187-309-160-388-508;;034-102-381-651-860;;065-340-901-539-257;;020-742-925-110-307;;146-280-751-006-918;;068-685-102-740-969;;025-555-060-539-005;;098-109-024-331-424;;123-194-397-211-55X;;010-645-872-815-401;;048-414-726-490-726;;028-568-339-494-491;;101-299-722-404-666;;031-848-215-173-885;;022-984-079-837-252;;007-767-940-873-695;;088-427-503-188-873;;012-807-787-109-539;;088-770-254-336-633;;043-841-620-298-378;;161-432-240-418-535;;059-173-900-927-503;;035-912-150-623-230,6832864;;3710634;;pmc1874707;;6847752;;10.1016/s0149-2918(00)83039-8;;11192132;;10.1056/nejm199803263381303;;9516221;;0010755495;;10755495;;10.1001/jama.283.13.1695;;10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.0.co;2-a;;9400915;;12877648;;10.1517/14656566.4.8.1417;;10.1111/j.1742-1241.2004.00318.x;;15529521;;10.1016/s0149-2918(96)80017-8;;8829014;;9209206;;10.1016/s0002-9343(96)00353-1;;7601013;;10.2165/00003495-199549050-00007;;10.1177/0145721706294260;;17102154;;10.1111/j.1572-0241.2001.03809.x;;11374713;;10.1056/nejm199602293340906;;8569826;;7623903;;10.1056/nejm199508313330903;;10.2337/diabetes.37.8.1020;;10.2337/diab.37.8.1020;;3292322;;10.2337/diabetes.45.8.1044;;10.2337/diab.45.8.1044;;8690150;;6819094;;10.1248/cpb.30.3601;;10.2337/diacare.15.8.1075;;1505314;;2036936;;10.1016/s0168-8227(05)80027-0;;10.1021/jm00049a017;;7966158;;10.2337/diabetes.43.10.1203;;7926289;;10.2337/diab.43.10.1203,"Hotta, Yutaka, Diabetes Update, No. 10, pp. 68-77, 1994, and English translation.;;ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117.;;Abdallah et al, Preparation and evaluation of Metformin Hydrochloride Controlled-Release Tablets, STP Pharma 4(1) pp. 15-20, 1988.;;Karttunen, P. et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""The pharmacokinetics of metformin a comparison of the properties of a rapid release and a sustained-release preparation"" vol. 21, No. 1-1983. pp. 31-36.;;Pentikainen, P.J., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products"", vol. 24, No. 4-1986, pp. 213-220.;;Finnish Monograph of the Diformin(R), Retard tablet, with English translation. O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update ""The status of metformin in Canada"" vol. 128, Jan. 1, 1983, pp. 24-26.;;Belcher, et al., Experiment and Clinical Endrocrinology & Diabetes, ""Safety and tolerability of pioglitazone"" Suppl. 2 (2000) pp. 267-273.;;Einhorn, et al., Clinical Therapeutics ""Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study"", vol. 22, No. 12, 2000 pp. 1395-1413.;;National Institute for Clinical Excellence Technology Appraisal Guidance-No. 21, ""Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus"" Mar. 2001. pp. 1-13.;;The Pharmaceutical Journal, vol. 265, No. 7122, p. 710 Nov. 11, 2000 Clinical (abstract only).;;ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117, Jun. 1999.;;Clinician Reviews, ""Insulin-Sensitizing Diabetes Agent"" Sep. 1999.;;Product Labeling for Glucophage(R) XR (Jul. 2002).;;ACTOS(R) product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175.;;An opposition filed in Costa Rica against a related application, 2008.;;A translation of the opposition filed in Costa Rica against a related application, 2008.;;A response to the opposition filed in Costa Rica against a related application, 2008.;;A translation of the response to the opposition filed in Costa Rica against a related application, 2008.;;An opposition filed in Chile against a related application, 2008.;;A translation of the opposition filed in Chile against a related application, 2007.;;A response to the opposition filed in Chile against a related application, 2008.;;A translation of the response to the opposition filed in Chile against a related application, 2008.;;An English translation of an opposition filed in Columbia against a related application, 2008.;;A response to the opposition filed in Columbia against a related application (in Spanish), 2009.;;An English translation of a response to the opposition filed in Columbia against a related application, 2009.;;A search report from the Georgian Patent Office (and English translation) for a related application, 2008.;;An Office Action from the Ukrainian Patent Office (and English translation) for a related application, 2009.;;Inzucchi, S. et al., Efficacy of Metabolic Effects of Metformin and Troglitazone in type II diabetes mellitus; N. Engl. J Med. Mar. 26, 1998; 338(13): 867-72.;;Fonseca, V., et al., Effect of Metformin and Rosiglitazone combination therapy in patients with type II diabetes mellitus; Apr. 5, 2000; 283(13): 1695-702.;;Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.;;Dailey, GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review (Abstract Only).;;Bailey, CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment for Insulin Resistance in Type 2 Diabetes, Int J Clin Pract Sep. 2004 58(9): 867-76.;;Campbell RK et al., Metformin: A New Oral Biguanide, Clin Ther May-Jun. 1996; 18(3): 360-71.;;Davidson, MB, et al., An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus, Am J Med. Jan. 1997; 102(1):99-110.;;Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs May 1995; 49(5):721-49.;;Zimmer, B., Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.;;Koski, R.R., Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec. 2006).;;Jagoe, D., International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Jagoe, D., International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Joynes. R.M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Nickitas-Etienne, A. International Preliminary Report on Patentability, PCT/US2004/004112, Feb. 28, 2007, the International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.;;Woodward, M., International Search Report and Written Opinion of the International Searching Authority, PCT/US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).;;Rote Liste, No. 11081 the Medicament Mediabet of MEDICE, Chem.-Pharm. Fabrik Putter GmbH & Co. KG, Kuhloweg 37-39 Iserlohn/Germany, Editio Cantor Verlag fu Medizin and Naturwissenschaften GmbH, 1993.;;Saini, ""Management guidelines for use of oral hypoglycemic agents (OHA) in complex clinical situation and important drug interactions with OHA's"", Int'l Journal of Diabetes in Developing Countries, 11:23-24 (1991).;;Bailey et al., ""Metformin"", The New England Journal of Medicine, 334 (9): 574-579 (1996).;;Stumvoll et al., ""Metabolic Effects of Metformin in Non-Insulin Dependent Diabetes Mellitus"", The New England Journal of Medicine, 333 (9): 550-554 (1995).;;Reaven et al., ""Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 hours in Patients, with NIDDM"", Diabetes, 37:1020-1024 (1988).;;Boden et al.,""Evidence for a Circadian Rhythm of Insulin Sensitivity in Patients with NIDDM Caused by Cyclic Changes in Hepatic Glucose Production"", Diabetes, 45: 1044-1050 (1996).;;Sohda et al., ""Studies on Antidiabetic Agents III. 5-Arylthiazolidine-2,4-diones as Potent Aldose Reductase Inhibitors"", Chem Pharm. Bull. vol. 30, No. 10, pp. 3601-3616 (1982).;;Hoffman et al., ""New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers"", 15 (8) Diabetes Care, pp. 1075-1078 (Aug. 1992).;;Kuzuya et al., A pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus, 11 Diabetes Research And Clinical Practice, pp. 147-154 (1991).;;Gimenez Miralles, J., Supplementary European Search Report issued in EP 04 71 0656, Munich, European Patent Office, 80298 Munich, Germany, Dec. 13, 2011. This European application is related to the present application.;;Cantello et al., ""[[w-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents"", 37 (23) J. Med. Chem., pp. 3977-3985 (1994).;;Oakes et al., ""A New Antidiabetic Agent, BRL49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat"", 43 (10) Diabetes, pp. 1203-1210 (Oct. 1994).;;Drug Facts and Comparisons, pp. 635-642 (1999) published by Facts and Comparisons, St. Louis Missouri.;;Physicians' Desk Reference, Glucophage, 53rd Ed., pp. 833-837 (1999).;;Physicians' Desk Reference, Glucophage, 50rd Ed., pp. 752-757 (1996).;;Chiao, ""Sustained release drug delivery systems, Remington: The Science and Practice of Pharmacy"", pp. 1660-1669 (1995).;;Kong, Notice of Paragraph IV Certification Letter for Actoplus MET(R) XR, dated Nov. 21, 2011.;;Hotta, N, Diabetes Update, No. 10, Kashikojima Seminar, pp. 68-77 (1994) (and English translation), Japanese document and English translation considered and attached with Notice of Allowance.",EXPIRED
24,KR,A,KR 20100137023 A,197-428-226-940-17X,2010-12-29,2010,KR 20107027556 A,2003-09-19,US 41218002 P;;US 41218102 P,2002-09-20,PHARMACEUTICAL TABLET,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/197-428-226-940-17X,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/22;;A61K9/00;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/55;;A61K45/06,,0,0,,,,DISCONTINUED
25,US,A1,US 2004/0106660 A1,093-755-694-419-024,2004-06-03,2004,US 66480303 A,2003-09-19,US 66480303 A;;US 41218002 P;;US 41218102 P,2002-09-20,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,"
   A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. 
",KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I.;;CARDINAL JOHN;;NANGIA AVINASH,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ANDRX LABS LLC (2003-12-24);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/093-755-694-419-024,Patent Application,yes,66,20,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,514/369;;514/635;;424/468,0,0,,,,EXPIRED
26,CN,A,CN 101675929 A,113-237-329-563-881,2010-03-24,2010,CN 200910181176 A,2004-02-12,US 66480303 A,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,UNCHALEE KOSITPRAPA;;AVINASH NANGIA;;JOHN CARDINAL;;GOLDFARB ROBERT I,,https://lens.org/113-237-329-563-881,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K31/4439;;A61K9/00;;A61K9/22;;A61K9/28;;A61K9/30;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/44;;A61K45/06;;A61P3/10,,0,0,,,,DISCONTINUED
27,EP,A2,EP 1539144 A2,114-947-065-299-310,2005-06-15,2005,EP 03754689 A,2003-09-19,US 0329292 W;;US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,LODIN UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/114-947-065-299-310,Patent Application,yes,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/22;;A61K9/24;;A61K9/28;;A61K9/00;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
28,EP,A1,EP 1663170 A1,001-714-220-815-633,2006-06-07,2006,EP 04710656 A,2004-02-12,US 2004/0004112 W;;US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,LODIN UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/001-714-220-815-633,Patent Application,yes,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
29,CN,A,CN 1681496 A,123-759-033-124-098,2005-10-12,2005,CN 03822362 A,2003-09-19,US 41218002 P;;US 41218102 P,2002-09-20,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,,ANDRX LABS LLC,GOLDFARB ROBERT I;;AVINASH NANGIA;;JOHN CARDINAL;;UNCHALEE KOSITPRAPA,WATSON PHARMACEUTICALS (2008-08-29),https://lens.org/123-759-033-124-098,Patent Application,no,0,11,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
30,EP,A1,EP 2604266 A1,009-754-744-448-851,2013-06-19,2013,EP 13001210 A,2003-09-19,US 41218002 P;;US 41218102 P;;EP 03754689 A,2002-09-20,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,"A method of preparing a pharmaceutical dosage form having a first and second active drug, comprising 
(a) forming a controlled release core comprising metformin or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient; 
(b) coating a coating solution on said controlled release core to form an immediate release coating, said coating solution comprising: 
(i) pioglitazone or a pharmaceutically acceptable salt thereof; 
(ii) water; 
(iii) an organic solvent; 
(iv) a binder; 
(v) optionally a surfactant; 
(vi) optionally a pore forming agent; 
 
wherein the ratio of water to organic solvent is 50:50 to 2:98, and the ratio of binder to pioglitazone or the salt thereof is 1:9 to 1:11; 
wherein said dosage form releases not less than 75% of the pioglitazone or the salt thereof from the dosage form within 0.5 hour when tested in a United States Pharmacopeia (USP) Type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C.",ANDRX LABS LLC,LODIN UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/009-754-744-448-851,Patent Application,yes,39,1,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K31/425;;A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/426;;A61K31/55;;A61K45/06,,2,0,,,"""Encyclopedia of Polymer Science and Technology"", vol. 10, 1969, JOHN WILEY & SONS;;""Remington's Pharmaceutical Sciences"", 1995",DISCONTINUED
31,KR,A,KR 20110126761 A,021-021-898-127-352,2011-11-23,2011,KR 20117025667 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/021-021-898-127-352,Patent Application,no,0,1,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/22;;A61K9/00;;A61K9/20;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
32,HK,A1,HK 1078783 A1,042-223-182-596-177,2006-03-24,2006,HK 05110822 A,2005-11-28,US 0329292 W;;US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND THIAZOLIDINDIONE DERIVATIVES,,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/042-223-182-596-177,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K/;;A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P/,,0,0,,,,DISCONTINUED
33,KR,A,KR 20120034211 A,112-554-018-289-03X,2012-04-10,2012,KR 20127002220 A,2003-09-19,US 41218002 P;;US 41218102 P,2002-09-20,PHARMACEUTICAL TABLET,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/112-554-018-289-03X,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/22;;A61K9/00;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/55;;A61K45/06,,0,0,,,,DISCONTINUED
34,US,B2,US 7785627 B2,143-669-332-916-50X,2010-08-31,2010,US 66480303 A,2003-09-19,US 66480303 A;;US 41218002 P;;US 41218102 P,2002-09-20,Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ANDRX LABS LLC (2003-12-24);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/143-669-332-916-50X,Granted Patent,yes,100,8,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/14;;A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,424/484;;424/468;;514/369;;514/365,55,14,187-309-160-388-508;;034-102-381-651-860;;065-340-901-539-257;;020-742-925-110-307;;146-280-751-006-918;;068-685-102-740-969;;025-555-060-539-005;;098-109-024-331-424;;123-194-397-211-55X;;010-645-872-815-401;;048-414-726-490-726;;028-568-339-494-491;;101-299-722-404-666;;031-848-215-173-885,6832864;;3710634;;pmc1874707;;6847752;;10.1016/s0149-2918(00)83039-8;;11192132;;10.1056/nejm199803263381303;;9516221;;0010755495;;10755495;;10.1001/jama.283.13.1695;;10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.0.co;2-a;;9400915;;12877648;;10.1517/14656566.4.8.1417;;10.1111/j.1742-1241.2004.00318.x;;15529521;;10.1016/s0149-2918(96)80017-8;;8829014;;9209206;;10.1016/s0002-9343(96)00353-1;;7601013;;10.2165/00003495-199549050-00007;;10.1177/0145721706294260;;17102154;;10.1111/j.1572-0241.2001.03809.x;;11374713,"Abdalla et al, Preparation and evaluation of Metaformin Hydrochloride Controlled-Release Tablets, STP Pharma 4(1) pp. 15-20, 1988.;;P. Karttunen et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""The pharmacokinetics of metformin: a comparison of the properties of a rapid release and a sustained-release preparation"" vol. 21, No. 1-1983. pp. 31-36.;;P.J. Pentikainen, International Journal of Clinical Pharmacology, Therapy and Toxicology, ""Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products"", vol. 24, No. 4-1986, pp. 213-220.;;Finnish Monograph of the Diformin®, Retard tablet, with English translation.;;O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update ""The status of metformin in Canada"" vol. 128, Jan. 1, 1983, pp. 24-26.;;G. Belcher and D.R. Matthews Experiment and Clinical Endrocrinology & Diabetes, ""Safety and tolerability of pioglitazone"" Suppl. 2 (2000) pp. 267-273.;;Daniel Einhorn, MD et al., Clinical Therapeutics ""Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study"", vol. 22, No. 12, 2000 pp. 1395-1413.;;National Institute for Clinical Excellence Technology Appraisal Guidance-No. 21, ""Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus"" Mar. 2001. pp. 1-13.;;The Pharmaceutical Journal, vol. 265, No. 7122, p. 710 Nov. 11, 2000 Clinical (abstract only).;;Product Labeling for Glucophage® XR (Jul. 2002).;;ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117.;;Website www.findarticles.com, Clinician Reviews, ""Insulin-Sensitizing Diabetes Agent"" Sep. 1999.;;ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175.;;An opposition filed in Costa Rica against a foreign equivalent of the present application.;;A translation of the opposition filed in Costa Rica against a foreign equivalent of the present application.;;A response to the opposition filed in Costa Rica against a foreign equivalent of the present application.;;A translation of the response to the opposition filed in Costa Rica against a foreign equivalent of the present application.;;An opposition filed in Chile against a foreign equivalent of the present application.;;A translation of the opposition filed in Chile against a foreign equivalent of the present application.;;A response to the opposition filed in Chile against a foreign equivalent of the present application.;;A translation of the response to the opposition filed in Chile against a foreign equivalent of the present application.;;An English translation of an opposition filed in Columbia against a related foreign application.;;A response to the opposition filed in Columbia against a related foreign application (in Spanish).;;An English translation of a response to the opposition filed in Columbia against a related foreign application.;;A search report from the Georgian Patent Office (and English translation).;;An Office Action from the Ukrainian Patent Office (and English translation).;;Efficacy of Metabolic Effects of Metformin and Troglitazone in type II diabetes mellitus; Inzucchi Se et al. N. Engl. J Med. Mar. 26, 1998; 338(13): 867-72.;;Effect of Metformin and Rosiglitazone combination therapy in patients with type II diabetes mellitus, Fonseca V, et al.; Apr. 5, 2000; 283(13): 1695-702.;;Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. 1997 Nov; 14 (11): 919-28.;;Dailey GE., Glyburide/Metformin Tablets: A New Therapeutic Option for The Management Of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review (Abstract Only), Abstract only considered.;;Bailey CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment For Insulin Resistance In Type 2 Diabetes, Int J Clin Pract (2004) Sep. 58(9): 867-76.;;Campbell, RK et al., Metformin: A New Oral Biguanide, Clin Ther (1996) May-Jun; 18(3): 360-71.;;Davidson, MB, et al., An Overview of Metformin in The Treatment of Type 2 Diabetes Mellitus, Am J Med. (1997) Jan; 102(1):99-110.;;Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs (1995) May; 49(5):721-49.;;Zimmer Barbara, Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.;;Koski, Renee Rae, Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec. 2006).;;Jagoe, Donna, International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Jagoe, Donna, International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Joynes, Robert M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Nickitas-Etienne, Athina, International Preliminary Report on Patentability, PCT/US2004/004112, Feb. 28, 2007, the International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.;;Woodward, Michael, International Search Report and Written Opinion of the International Searching Authority, PCT/US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).;;An opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;A translation of the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;A response to the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;A translation of the response to the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;An opposition filed in Chile against a foreign equivalent of the present application, 2007.;;A translation of the opposition filed in Chile against a foreign equivalent of the present application, 2007.;;A response to the opposition filed in Chile against a foreign equivalent of the present application, 2008.;;A translation of the response to the opposition filed in Chile against a foreign equivalent of the present application, 2008.;;Product Labeling for Glucophage® XR (Jul. 2002).;;ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117, Jun. 1999.;;Website www.findarticles.com, Clinician Reviews, ""Insulin-Sensitizing Diabetes Agent"" Sep. 1999.;;ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175.;;Rote Liste No. 11081 the Medicament Mediabet of MEDICE, Chem.-Pharm. Fabrik Pütter GmbH & Co. KG, Kuhloweg 37-39 Iserlohn/Germany, Editio Cantor Verlag fü Medizin and Naturwissenschaften GmbH, 1993.",ACTIVE
35,WO,A2,WO 2004/026241 A2,157-295-652-061-541,2004-04-01,2004,US 0329292 W,2003-09-19,US 41218002 P;;US 41218102 P,2002-09-20,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/157-295-652-061-541,Patent Application,yes,0,24,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,PENDING
36,US,A1,US 2010/0316708 A1,054-332-321-203-133,2010-12-16,2010,US 83594510 A,2010-07-14,US 83594510 A;;US 66480303 A;;US 41218002 P;;US 41218102 P,2002-09-20,Novel Pharmaceutical Formulation Containing A Biguanide and a Thiazolidinedione Derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,ALLERGAN FINANCE LLC (2016-06-09);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/054-332-321-203-133,Patent Application,yes,26,1,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/4439;;A61K45/06;;A61P3/04;;A61P3/10,424/465;;514/342;;424/468;;427/2.14,1,0,,,"Hotta, Yutaka, Diabetes Update, No. 10, pages 68-77, 1994, and English translation.",EXPIRED
37,WO,A3,WO 2000/070519 A3,067-578-234-364-213,2001-04-19,2001,US 0013120 W,2000-05-12,US 13459399 P;;US 46454399 A;;US 46453799 A,1999-05-17,NETWORK ACCESSIBLE QUOTATION AND SHIPPING SYSTEM,"A transportation logistics system (250) provides to vendors or shoppers, at the time of purchase, a total global delivered cost quote for shipping a product between locations. The system is accessible over packet switched networks (205), such as the Internet, or over a circuit switched network, such as traditional telephone networks, and includes a web server (260) and a proprietary database (280). A total delivered cost calculator engine (265) retrieves the necessary information from the database, given the requestor input, and performs the necessary calculations. The total delivered cost quote, which includes any applicable inland origin freight, inland destination freight, air freight, ocean freight, insurance, duties, taxes, custom clearance fee, import fee, or service fees is presented to the requestor with both ocean freight and air freight options. The transportation logistic system (250) can coordinate the shipment of the selected product to the delivery destination, and enables the payment of all quoted fees, if the requestor accepts the quote.",FROM2 COM INC;;FALIC LEON S;;GOLDFARB GARY M;;REDLHAMMER ROBERT E,FALIC LEON S;;GOLDFARB GARY M;;REDLHAMMER ROBERT E,,https://lens.org/067-578-234-364-213,Search Report,yes,3,0,3,3,0,G06Q10/08,G06Q10/00,,0,0,,,,PENDING
38,KR,A,KR 20060076299 A,101-980-986-849-64X,2006-07-04,2006,KR 20067005202 A,2006-03-15,US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/101-980-986-849-64X,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/22;;A61K9/00;;A61K9/20;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
39,WO,A1,WO 2005/039540 A1,111-875-154-919-025,2005-05-06,2005,US 2004/0004112 W,2004-02-12,US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/111-875-154-919-025,Patent Application,yes,2,1,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,1,0,,,See also references of EP 1663170A4,PENDING
40,NZ,A,NZ 580804 A,122-355-326-902-44X,2011-02-25,2011,NZ 58080404 A,2004-02-12,US 66480303 A,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,"Disclosed is a pharmaceutical dosage form comprising: (A) a controlled release osmotic tablet core comprising metformin hydrochloride that exhibits the following dissolution profile when tested in a USP Type 2 apparatus at 75 rpms in 900 ml of simulated intestinal with a pH of7.5 and at 37 degrees C: 0-25 wt% of the metformin hydrochloride is released after 2 hours; 10-45 wt% of the metformin hydrochloride is released after 4 hours; 30-90 wt% of the metformin hydrochloride is released after 8 hours; not less than 50 wt% of the metformin hydrochloride is released after 12 hours; not less than 60 wt% of the metformin hydrochloride is released after 16 hours; and not less than 70 wt% of the metformin hydrochloride is released after 20 hours; and (B) an immediate release pioglitazone hydrochloride layer surrounding the osmotic tablet that releases not less than 90 wt% of the pioglitazone hydrochloride from the dosage form within 30 minutes when tested according to the United States Pharmacopeia (USP) 26, with Apparatus 1 at 100 rpm, 37degrees C and 900 ml of 0.3 M KCI-HCl Buffer, pH 2.0 and the dosage form contains not more than 0.25 wt% of the following compounds: (i) (+/-)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-5-hydroxy-2,4-thiazolidinedione; (ii)(z)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzylidene]-2,4-thiazolidinedione; (iii)(+/-)-5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-3-[2-(5-ethyl-2-pyridyl)ethyl]-2,4-thiazolidinedione; (iv)(+/-)-ethyl-2-carbamoyltio-3-[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl-]propionate; and (v) ethyl-3-p-[2-(5-ethyl-2-pyridyI)ethoxy]phenyI-propionate. (62) Divided Out of 545653",ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/122-355-326-902-44X,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,C07C279/26;;A61K9/00;;A61K9/16;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
41,CA,C,CA 2537665 C,143-128-410-676-985,2012-08-14,2012,CA 2537665 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/143-128-410-676-985,Granted Patent,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
42,JP,A,JP 2011148819 A,094-475-596-137-410,2011-08-04,2011,JP 2011062093 A,2011-03-22,US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING BIGUANIDE AND THIAZOLIDINEDIONE DERIVATIVE,"<P>PROBLEM TO BE SOLVED: To provide a controlled release or sustained release formulation for an antidiabetic compound. <P>SOLUTION: A pharmaceutical dosage formulation contains the following (A) and (B); wherein, (A) is a controlled release osmotic tablet core comprising metformin hydrochloride that exhibits a dissolution profile when tested in a USP Type 2 apparatus at 75 rpms in 900 ml of simulated intestinal with a pH of 7.5 and at 37°C: 0-25 wt.% of the metformin hydrochloride is released after 2 hours; 10-45 wt.% of the metformin hydrochloride is released after 4 hours; 30-90 wt.% of the metformin hydrochloride is released after 8 hours; not less than 50 wt.% of the metformin hydrochloride is released after 12 hours; not less than 60 wt.% of the metformin hydrochloride is released after 16 hours; and not less than 70 wt.% of the metformin hydrochloride is released after 20 hours; and (B) an immediate release pioglitazone hydrochloride layer surrounding the osmotic tablet core. <P>COPYRIGHT: (C)2011,JPO&INPIT",ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/094-475-596-137-410,Patent Application,no,2,1,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K31/155;;A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/425;;A61K31/426;;A61K31/4439;;A61K45/06,,0,0,,,,INACTIVE
43,KR,A,KR 20130039344 A,031-587-681-730-738,2013-04-19,2013,KR 20137005362 A,2003-09-19,US 41218002 P;;US 41218102 P;;US 0329292 W,2002-09-20,PHARMACEUTICAL TABLET,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/031-587-681-730-738,Patent Application,no,0,2,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/55;;A61K45/06,,0,0,,,,EXPIRED
44,AU,A8,AU 2003/272504 A8,117-388-162-766-663,2004-04-08,2004,AU 2003/272504 A,2003-09-19,US 41218002 P;;US 41218102 P;;US 0329292 W,2002-09-20,Multistage formulation containing a biguanide and thiazolidindione derivatives,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;NANGIA AVINASH;;CARDINAL JOHN,,https://lens.org/117-388-162-766-663,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
45,AU,A,AU 2000/048459 A,130-992-658-130-88X,2000-12-05,2000,AU 2000/048459 A,2000-05-12,US 13459399 P;;US 46454399 A;;US 46453799 A;;US 0013120 W,1999-05-17,Network accessible quotation and shipping system,,FROM2 COM INC,FALIC LEON S;;GOLDFARB GARY M;;REDLHAMMER ROBERT E,,https://lens.org/130-992-658-130-88X,Patent Application,no,0,1,3,3,0,G06Q10/08,G06Q10/00,,0,0,,,,DISCONTINUED
46,EP,A4,EP 1539144 A4,137-150-529-652-482,2010-06-09,2010,EP 03754689 A,2003-09-19,US 0329292 W;;US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,LODIN UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/137-150-529-652-482,Search Report,no,3,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
47,AU,B2,AU 2011/202162 B2,180-665-203-170-127,2013-11-21,2013,AU 2011/202162 A,2011-05-10,AU 2004/283059 A;;AU 2011/202162 A;;US 66480303 A;;US 2004/0004112 W,2003-09-19,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,Abstract A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a 5 thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC,NANGIA AVINASH;;KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN,,https://lens.org/180-665-203-170-127,Granted Patent,no,7,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
48,BR,A,BR PI0414471 A,024-837-578-132-364,2006-11-14,2006,BR PI0414471 A,2004-02-12,US 66480303 A;;US 2004/0004112 W,2003-09-19,nova formulação farmacêutica contendo biguanida e um derivado de tiazolidinadiona,"""NOVA FORMULAçãO FARMACêUTICA CONTENDO BIGUANIDA E UM DERIVADO DE TIAZOLIDINADIONA"". Uma forma de dosagem farmacêutica compreendendo um componente de liberação controlada compreendendo uma droga antihiperglicêmica em combinação com um segundo componente compreendendo um derivado de tiazolidinadiona é aqui divulgada e descrita.",ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/024-837-578-132-364,Patent Application,no,0,0,29,65,0,A61K9/209;;A61K9/209;;A61K9/0004;;A61K9/0004;;A61K9/20;;A61K9/28;;A61K9/282;;A61K9/282;;A61K31/155;;A61K31/155;;A61K31/425;;A61K31/425;;A61K31/426;;A61K31/426;;A61K45/06;;A61K45/06;;A61P3/04;;A61P3/10;;A61P43/00,A61K9/00;;A61K9/22;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
49,EP,A4,EP 1663170 A4,144-811-897-501-951,2012-01-25,2012,EP 04710656 A,2004-02-12,US 2004/0004112 W;;US 66480303 A,2003-09-19,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,,ANDRX LABS LLC,LODIN UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN;;NANGIA AVINASH,,https://lens.org/144-811-897-501-951,Search Report,no,5,0,29,65,0,A61K9/0004;;A61K9/209;;A61K9/282;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/04;;A61P43/00;;A61P3/10;;A61K9/28;;A61K9/20;;A61K9/209;;A61K31/425;;A61K9/282;;A61K31/155;;A61K31/426;;A61K45/06;;A61K9/0004,A61K9/28;;A61K9/00;;A61K9/16;;A61K9/20;;A61K9/22;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,1,0,,,See also references of WO 2005039540A1,EXPIRED
50,HK,A1,HK 1136780 A1,025-102-017-902-452,2010-07-09,2010,HK 10104549 A,2010-05-11,US 41218002 P;;US 41218102 P,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND THIAZOLIDINDIONE DERIVATIVES,,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/025-102-017-902-452,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K/;;A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,DISCONTINUED
51,CA,C,CA 2499597 C,124-171-122-262-993,2012-01-17,2012,CA 2499597 A,2003-09-19,US 41218002 P;;US 41218102 P;;US 0329292 W,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND THIAZOLIDINDIONE DERIVATIVES,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;NANGIA AVINASH;;CARDINAL JOHN;;GOLDFARB ROBERT I,,https://lens.org/124-171-122-262-993,Granted Patent,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K31/425;;A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/426;;A61K31/55;;A61K45/06,,0,0,,,,EXPIRED
52,CA,A1,CA 2499597 A1,153-433-043-725-960,2004-04-01,2004,CA 2499597 A,2003-09-19,US 41218002 P;;US 41218102 P;;US 0329292 W,2002-09-20,MULTISTAGE FORMULATION CONTAINING A BIGUANIDE AND THIAZOLIDINDIONE DERIVATIVES,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,GOLDFARB ROBERT I;;NANGIA AVINASH;;CARDINAL JOHN;;KOSITPRAPA UNCHALEE,,https://lens.org/153-433-043-725-960,Patent Application,no,0,0,24,65,0,A61K9/0004;;A61K9/209;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/06;;A61P43/00;;A61K9/20;;A61K31/425;;A61K31/55,A61K9/00;;A61K9/22;;A61K9/24;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,,0,0,,,,EXPIRED
53,US,B2,US 7959946 B2,053-279-588-820-345,2011-06-14,2011,US 77754204 A,2004-02-12,US 77754204 A;;US 66480303 A;;US 41218002 P;;US 41218102 P,2002-09-20,Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ANDRX LABS LLC (2004-02-10);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/053-279-588-820-345,Granted Patent,yes,98,7,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K9/24;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,424/473;;424/484;;514/369;;514/635;;514/866,52,20,031-848-215-173-885;;025-555-060-539-005;;098-109-024-331-424;;123-194-397-211-55X;;010-645-872-815-401;;048-414-726-490-726;;028-568-339-494-491;;101-299-722-404-666;;031-848-215-173-885;;025-555-060-539-005;;123-194-397-211-55X;;010-645-872-815-401;;048-414-726-490-726;;028-568-339-494-491;;146-280-751-006-918;;068-685-102-740-969;;187-309-160-388-508;;034-102-381-651-860;;065-340-901-539-257;;020-742-925-110-307,10.1111/j.1572-0241.2001.03809.x;;11374713;;10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.0.co;2-a;;9400915;;12877648;;10.1517/14656566.4.8.1417;;10.1111/j.1742-1241.2004.00318.x;;15529521;;10.1016/s0149-2918(96)80017-8;;8829014;;9209206;;10.1016/s0002-9343(96)00353-1;;7601013;;10.2165/00003495-199549050-00007;;10.1177/0145721706294260;;17102154;;10.1111/j.1572-0241.2001.03809.x;;11374713;;10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.0.co;2-a;;9400915;;10.1111/j.1742-1241.2004.00318.x;;15529521;;10.1016/s0149-2918(96)80017-8;;8829014;;9209206;;10.1016/s0002-9343(96)00353-1;;7601013;;10.2165/00003495-199549050-00007;;10.1056/nejm199803263381303;;9516221;;0010755495;;10755495;;10.1001/jama.283.13.1695;;6832864;;3710634;;pmc1874707;;6847752;;10.1016/s0149-2918(00)83039-8;;11192132,"Http://www.answers.com/topic/biguanide-1 (2007).;;Http://www.medicinenet.com, (2007). for thiazolidinedione.;;Menon et al., The American Journal of Gastroenterology, vol. 96, No. 5, pp. 1631-1634 (2001).;;An opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;A translation of the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;A response to the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;A translation of the response to the opposition filed in Costa Rica against a foreign equivalent of the present application, 2008.;;An opposition filed in Chile against a foreign equivalent of the present application, 2008.;;A translation of the opposition filed in Chile against a foreign equivalent of the present application, 2008.;;A response to the opposition filed in Chile against a foreign equivalent of the present application, 2008.;;A translation of the response to the opposition filed in Chile against a foreign equivalent of the present application, 2008.;;Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.;;Dailey GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review. (Abstract Only) .;;Bailey CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment for Insulin Resistance in Type 2 Diabetes, Int J Clin Pract (Sep. 2004) 58(9): 867-76.;;Campbell, RK et al., Metformin: A New Oral Biguanide, Clin Ther (May-Jun. 1996); 18(3): 360-71.;;Davidson, MB, et al., An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus, Am J Med. (Jan. 1997); 102(1):99-110.;;Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs (May 1995); 49(5):721-49.;;Zimmer Barbara, Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.;;Koski, Renee Rae, Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec. 2006).;;Jagoe, Donna, International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Jagoe, Donna, International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Joynes, Robert M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Nickitas-Etienne, Athina, International Preliminary Report on Patentability, PCT/US2004/004112, Feb. 28, 2007, The International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.;;Woodward, Michael, International Search Report and Written Opinion of the International Searching Authority, PCT/US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).;;Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.;;Dailey GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review. (Abstract Only).;;Bailey CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment for Insulin Resistance in Type 2 Diabetes, Int J Clin Pract (Sep. 2004) 58(9): 867-76.;;Campbell, RK et al., Metformin: A New Oral Biguanide, Clin Ther (1996) May-Jun.; 18(3): 360-71.;;Davidson, MB, et al., An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus, Am J Med. (Jan. 1997); 102(1):99-110.;;Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs (May 1995); 49(5):721-49.;;An English translation of an opposition filed in Columbia against a related foreign application, 2008.;;A response to the opposition filed in Columbia against a related foreign application (in Spanish), 2009.;;An English translation of a response to the opposition filed in Columbia against a related foreign application, 2008.;;A search report from the Georgian Patent Office (and English translation), 2006.;;An Office Action from the Ukrainian Patent Office (and English translation), 2006.;;Efficacy of Metabolic Effects of Metformin and Troglitazone in type II diabetes mellitus; Inzucchi SE et al. N. Engl. J Med. Mar. 26, 1998; 338(13): 867-72.;;Effect of Metformin and Rosiglitazone combination therapy in patients with type II diabetes mellitus, Fonseca V, et al.; Apr. 5, 2000; 283(13): 1695-702.;;P. Karttunen et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""The pharmacokinetics of metformin: a comparison of the properties of a rapid release and a sustained-release preparation"" vol. 21, No. 1-1983, pp. 31-36.;;P.J. Pentikainen, International Journal of Clinical Pharmacology, Therapy and Toxicology, ""Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products"", vol. 24, No. 4-1986, pp. 213-220.;;Finnish Monograph of the Diformin®, Retard tablet, with English translation, 2004.;;O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update ""The status of metformin in Canada"" vol. 128, Jan. 1, 1983, pp. 24-26.;;G. Belcher and D.R. Matthews, Experiment and Clinical Endrocrinology & Diabetes, ""Safety and tolerability of pioglitazone"" Suppl. 2 (2000) pp. 267-273.;;Daniel Einhorn, MD et al., Clinical Therapeutics ""Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study"", vol. 22, No. 12, 2000 pp. 1395-1413.;;National Institute for Clinical Excellence Technology Appraisal Guidance-No. 21, ""Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus"" Mar. 2001. pp. 1-13.;;The Pharmaceutical Journal, vol. 265, No. 7122, p. 710 Nov. 11, 2000 Clinical (abstract only).;;Product Labeling for Glucophage® XR (Jul. 2002).;;ADA Professional Section Member Supplement 0474 and 0503-506 (Poster) p. A110; A117, 2001.;;Website www.findarticles.com, Clinician Reviews, ""Insulin-Sensitizing Diabetes Agent"" Sep. 1999.;;ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175, 2001.;;Rote Liste No. 11081 the Medicament MEDIABET of Medice; GLUCOBAY of Bayer; and GLUCOTARD of Boehringer Mannheim, Chem.-Pharm. Fabrik Pütter GmbH & Co. KG, Kuhloweg 37-39 Iserlohn/Germany, Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993.;;Abdallah et al., ""Preparation and Evaluation of Metformin Hydrochloride Controlled-Release Tablets"" STP Pharma 4(1) pp. 15-20, 1988.",ACTIVE
54,TW,A,TW 200529831 A,120-974-520-053-218,2005-09-16,2005,TW 94104015 A,2005-02-05,US 77754204 A,2004-02-12,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,,https://lens.org/120-974-520-053-218,Patent of Addition,no,0,0,3,65,0,,,,0,0,,,,INACTIVE
55,US,B2,US 7104743 B2,096-496-221-170-084,2006-09-12,2006,US 87278804 A,2004-06-22,US 87278804 A;;US 48023203 P,2003-06-23,Vacuum receiver with positive dump valve control,"A vacuum receiver for a pneumatic conveyor for conveying, e.g., plastic pellets, having a receiving vessel with a material inlet, a material outlet and a conveying gas outlet. A first valve member is provided for opening and closing the conveying gas outlet, and a second valve member is provided for opening and closing the material outlet. Both valve members are connected to a common valve shaft and actuated by a single actuator mounted on a vessel lid. The vacuum receiver of the invention has the advantage of affording positive control and sealing of the material discharge valve while at the same time being economical to manufacture and easily cleaned.",UNIVERSAL DYNAMICS INC,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;PAQUETTE LEONARD;;GOLDFARB WILLIAM,UNIVERSAL DYNAMICS INC (2004-10-03),https://lens.org/096-496-221-170-084,Granted Patent,yes,9,10,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G65/00;;B65G53/24;;B65G53/60,414/288;;406/171;;222/504;;141/302,0,0,,,,INACTIVE
56,US,B2,US 8668931 B2,157-349-115-989-919,2014-03-11,2014,US 201313889441 A,2013-05-08,US 201313889441 A;;US 201113151653 A;;US 77754204 A;;US 66480303 A;;US 41218102 P;;US 41218002 P,2002-09-20,Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC;;ACTAVIS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/157-349-115-989-919,Granted Patent,yes,105,1,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K9/00;;A61K9/24;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,424/473;;424/484;;514/369;;514/635;;514/866,61,24,031-848-215-173-885;;022-984-079-837-252;;007-767-940-873-695;;088-427-503-188-873;;012-807-787-109-539;;088-770-254-336-633;;065-340-901-539-257;;101-299-722-404-666;;031-848-215-173-885;;146-280-751-006-918;;068-685-102-740-969;;025-555-060-539-005;;098-109-024-331-424;;123-194-397-211-55X;;010-645-872-815-401;;048-414-726-490-726;;028-568-339-494-491;;187-309-160-388-508;;034-102-381-651-860;;020-742-925-110-307;;043-841-620-298-378;;161-432-240-418-535;;059-173-900-927-503;;035-912-150-623-230,10.1111/j.1572-0241.2001.03809.x;;11374713;;10.1056/nejm199602293340906;;8569826;;7623903;;10.1056/nejm199508313330903;;10.2337/diabetes.37.8.1020;;10.2337/diab.37.8.1020;;3292322;;10.2337/diabetes.45.8.1044;;10.2337/diab.45.8.1044;;8690150;;6819094;;10.1248/cpb.30.3601;;pmc1874707;;6847752;;10.1177/0145721706294260;;17102154;;10.1111/j.1572-0241.2001.03809.x;;11374713;;10.1056/nejm199803263381303;;9516221;;0010755495;;10755495;;10.1001/jama.283.13.1695;;10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.0.co;2-a;;9400915;;12877648;;10.1517/14656566.4.8.1417;;10.1111/j.1742-1241.2004.00318.x;;15529521;;10.1016/s0149-2918(96)80017-8;;8829014;;9209206;;10.1016/s0002-9343(96)00353-1;;7601013;;10.2165/00003495-199549050-00007;;6832864;;3710634;;10.1016/s0149-2918(00)83039-8;;11192132;;10.2337/diacare.15.8.1075;;1505314;;2036936;;10.1016/s0168-8227(05)80027-0;;10.1021/jm00049a017;;7966158;;10.2337/diabetes.43.10.1203;;7926289;;10.2337/diab.43.10.1203,"Menon et al., The American Journal of Gastroenterology, vol. 96, No. 5, pp. 1631-1634 (2001).;;Physicians' Desk Reference, Glucophage, 50th Ed., pp. 752-757 (1996).;;Chiao, ""Sustained release drug delivery systems, Remington: The Science and Practice of Pharmacy"" , pp. 1660-1669 (1995).;;Kong, Notice of Paragraph IV Certification Letter for ACTOPLUS MET (R) XR, dated Nov. 21, 2011.;;Hotta, N, Diabetes Update, No. 10, Kashikojima Seminar, pp. 68-77 (1994) (and English translation).;;Saini, ""Management guidelines for use of oral hypoglycemic agents (OHA) in complex clinical situational and important drug interactions with OHA's"", Int'l Journal of Diabetes in Developing Countries, 11:23-24 (1991).;;Bailey et al., ""Metformin"", The New England Journal of Medicine, 334 (9): 574-579 (1996).;;Stumvoll et al., ""Metabolic Effects of Metformin in Non-Insulin Dependent Diabetes Mellitus"", The New England Journal of Medicine, 333 (9): 550-554 (1995).;;Reaven et al., ""Measurment of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 hours in Patients, with NIDDM"", Diabetes, 37:1020-1024 (1988).;;Boden et al., Evidence for a Circadian Rhythm of Insulin Sensitivity in Patients with NIDDM Caused by Cyclic Changes in Hepatic Glucose Production, Diabetes, 45: 1044-1050 (1996).;;Sohda et al., ""Studies on Antidiabetic Agents III. 5-Arylthiazolidine-2,4-diones as Potent Aldose Reductase Inhibitors"", Chem Pharm. Bull. vol. 30, No. 10, pp. 3601-3616 (1982).;;O.J. Lucis, MD, PH.D., MSC, Canada Medical Association J. Pharmacologic Update ""The status of metformin in Canada"" vol. 128, Jan. 1, 1983, pp. 24-26.;;Zimmer, B., Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.;;Koski, R. R., Practical Review of Oral Antihyperglycermic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec.2006).;;Jagoe, D., International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Jagoe, D., International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Joynes. R.M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Nickitas-Etienne, A. International Preliminary Report on Patentability, PCT/US20004/004112, Feb. 28, 2007, the International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.;;Woodward, M., International Search Report and Written Opinion of the International Searching Authority, PCT/ US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P. O. Box 1450 Alexandria Virginia 22313-1450.;;Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).;;Rote Liste, No. 11081 the Medicament of MEDICE, Chem.-Pharm. Fabrik Putter GmbH & Co. KG, Kuhloweg 37-39 Iserlohn/Germany, Editio Cantor Verlag fu Medzin and Naturwissenschaften GmbH, 1993.;;D'Aleman, D.R., An English translation of a response to the opposition filed in Columbia against a related application (Mar. 3, 2009).;;A search report from the Georgian Patent Office (and English translation) for a related application (Nov. 21, 2008).;;An Office Action from the Ukrainian Patent Office (and English translation) for a related application (Apr. 10, 2009).;;Inzucchi, S. et al., Efficacy of Metformin and Troglitazone in type II diabetes mellitus; N. Engl. J Med. Mar. 26, 1998; 338(13): 867-72.;;Fonseca, V., et al., Effect of Merformin and Rosigilazone combination therapy in patients with type II diabetes mellitus; Apr. 5, 2000; 283(13): 1695-702.;;Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.;;Dailey, GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review (Abstact Only).;;Bailey, CJ, et al. Avandament: Combined Metformin-Rosiglitazone Treatment for Insulin Resistance In Type 2 Diabetes, Int J Clin Pract Sep. 2004 58(9): 867-76.;;Campbell, RK et al., Metformin: A New Oral Biguanide, Clin Ther May-Jun. 1996; 18(3): 360-71.;;Davidson, MB, et al., An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus, Am J Med. Jan. 1997; 102(1):99-110.;;Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs May 1995; 49(5):721-49.;;Actos(R) product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175.;;Mejia, A.C., An opposition filed in Costa Rica against a related application (Feb. 20, 2008).;;Mejia, A.G., A translation of the opposition filed in Costa Rica against a related application (Feb. 20, 2008).;;Valenzuela V.V., A response to the opposition filed in Costa Rica against a related application (Apr. 24, 2009).;;Valenzuela V.V., A translation of the response to the opposition filed in Costa Rica against a related application (Apr. 24, 2009).;;Nunez Tapia, J.I., An opposition filed in Chile against a related application (Nov. 22, 2007).;;Nunez Tapia, J.I., A translation of the opposition filed in Chile against a related application (Nov. 22, 2007).;;Villa Riva, A.; ""Supplementary European Search Report"" in EP 06 73 8170, dated Jun. 22, 2012, European Patent Office, Munich, Germany. This application is related to the present application.;;Rivas Sureda, G., A response to the opposition filed in Chile against a related application (Jan. 30, 2008).;;Rivas Sureda, G., A translation of the response to the opposition filed in Chile against a related application (Jan. 30, 2008).;;Villamizar, J.L.R., An English translation of an opposition filed in Columbia against a related application (Aug. 28, 2008).;;D'Aleman, D.R., A response to the opposition filed in Columbia against a related application (in Spanish) (Mar. 3, 2009).;;Abdalla et al, Preparation and evaluation of Metformin Hydrochloride Controllled-Release Tablets, STP Pharma 4(1) pp. 15-20, 1988.;;Karttunen, P. et al., International Journal of Clinical Pharmacology, Therapy and Toxicology. ""The pharmacokinetics of metformin a comparison of the properties of a rapid release and a sustained-release preparation"" vol. 21, No. 1-1983. pp. 31-36.;;Pentikainen, P.J., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""Bioavailibility of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products"", vol. 24, No. 4, 1986, pp. 213-220.;;Finnish Monograph of the Diformin(R), Retard tablet, with English translation. cited by other. O.J. Lucis, MD, PH.D., MSC, Canada Medical Association J. Pharmacologic Update ""The status of metformin in Canada"" vol. 128, Jan. 1, 1983, pp. 24-26.;;Belcher, et al., Experiment and Clinical Endrocrinology & Diabetes, ""Saftey and tolerability of pioglitazone"" Suppl. 2 (2000) pp. 267-273.;;Einhorn, et al., Clinical Therapeutics ""Piogliazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study"", vol. 22 No. 12, 2000 pp. 1395-1413.;;National Institute for Clinical Excellence Technology Appraisal Guidance-No. 21, ""Guidence on the Use of Pioglitazone for Type 2 Diabetes Mellitus"" Mar. 2001. pp. 1-13.;;The Pharmaceutical Journal, vol. 265, No. 7122, p. 710 Nov. 11, 2000 Clinical (abstract only).;;Clinician Reviews, Insulin-Sensitizing Diabetes Agent Sep. 1999.;;Product Labeling for Glucophage(R) XR (Jul. 2002).;;Hoffman et al., ""New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers"", 15 (8) Diabetes Care, pp. 1075-1078 (Aug. 1992).;;Kuzuya et al., A pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus, 11 Diabetes Research and Clinical Practice, pp. 147-154 (1991).;;Gimenez Miralle, J., Supplementary European Search Report issued in EP 04 71 0656, Munich, European Patent Office, 80298 Munich, Germany, Dec. 13, 2011. This European application is related to the present application.;;Cantello et al., ""[[w-(Heterocyclylamino)alkox] benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents"", 37 (23) J. Med. Chem., pp. 3977-3985 (1994).;;Oakes et al., ""A New Antidiabetic Agent, BRL49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat"", 43 (10) Diabetes, pp. 1203-1210 (Oct. 1994).;;Drug Facts and Comparisions, pp. 635-642 (1999) published by Facts and Comparisons, St Louis Missouri.;;Physicians' Desk Reference, Glucophage, 53rd Ed., pp. 833-837 (1999).",EXPIRED
57,US,A1,US 2015/0072001 A1,102-987-050-988-245,2015-03-12,2015,US 201414203268 A,2014-03-10,US 201414203268 A;;US 201313889441 A;;US 201113151653 A;;US 77754204 A;;US 66480303 A;;US 41218102 P;;US 41218002 P,2002-09-20,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,,https://lens.org/102-987-050-988-245,Patent Application,yes,5,0,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K9/00;;A61K9/24;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/4439;;A61K45/06,424/465;;514/342,0,0,,,,DISCONTINUED
58,US,A1,US 2011/0262538 A1,144-331-625-668-085,2011-10-27,2011,US 201113151653 A,2011-06-02,US 201113151653 A;;US 77754204 A;;US 66480303 A;;US 41218102 P;;US 41218002 P,2002-09-20,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/144-331-625-668-085,Patent Application,yes,0,0,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K31/4439;;A61K9/00;;A61K9/20;;A61K9/22;;A61K9/24;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61P3/10,424/465;;514/342,0,0,,,,EXPIRED
59,US,A1,US 2005/0019108 A1,036-422-433-720-211,2005-01-27,2005,US 87278804 A,2004-06-22,US 87278804 A;;US 48023203 P,2003-06-23,Vacuum receiver with positive dump valve control,"A vacuum receiver for a pneumatic conveyor for conveying, e.g., plastic pellets, having a receiving vessel with a material inlet, a material outlet and a conveying gas outlet. A first valve member is provided for opening and closing the conveying gas outlet, and a second valve member is provided for opening and closing the material outlet. Both valve members are connected to a common valve shaft and actuated by a single actuator mounted on a vessel lid. The vacuum receiver of the invention has the advantage of affording positive control and sealing of the material discharge valve while at the same time being economical to manufacture and easily cleaned.",UNIVERSAL DYNAMICS INC,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;PAQUETTE LEONARD;;GOLDFARB WILLIAM,UNIVERSAL DYNAMICS INC (2004-10-03),https://lens.org/036-422-433-720-211,Patent Application,yes,7,14,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G53/24;;B65G53/60,406/171,0,0,,,,INACTIVE
60,US,A1,US 2004/0161462 A1,008-668-321-937-971,2004-08-19,2004,US 77754204 A,2004-02-12,US 77754204 A;;US 66480303 A;;US 41218002 P;;US 41218102 P,2002-09-20,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,"
   A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. 
",KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I.;;CARDINAL JOHN R.;;NANGIA AVINASH,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ANDRX LABS LLC (2004-02-10);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/008-668-321-937-971,Patent Application,yes,62,17,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K9/00;;A61K9/20;;A61K9/22;;A61K9/24;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,424/471;;514/369,0,0,,,,EXPIRED
61,MY,A,MY 146095 A,114-059-040-556-485,2012-06-29,2012,MY PI20050482 A,2005-02-08,US 77754204 A,2004-02-12,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE.,A PHARMACEUTICAL DOSAGE FORM COMPRISING A CONTROLLED RELEASE COMPONENT COMPRISING AN ANTIHYPERGLYCEMIC DRUG IN COMBINATION WITH A SECOND COMPONENT COMPRISING A THIAZOLIDINEDIONE DERIVATIVE IS HEREIN DISCLOSED AND DESCRIBED.,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,,https://lens.org/114-059-040-556-485,Granted Patent,no,0,0,3,65,0,,A61K9/28,,0,0,,,,ACTIVE
62,TW,B,TW I361070 B,022-785-008-714-835,2012-04-01,2012,TW 94104015 A,2005-02-05,US 77754204 A,2004-02-12,Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,,ANDRX LABS LLC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,,https://lens.org/022-785-008-714-835,Granted Patent,no,0,0,3,65,0,,,,0,0,,,,INACTIVE
63,US,A1,US 2012/0201883 A1,190-647-997-959-325,2012-08-09,2012,US 96380310 A,2010-12-09,US 96380310 A;;US 56934305 A;;US 2005/0018633 W;;US 59826708 A;;US 2005/0018638 W;;US 59830605 A;;US 2005/0018639 W;;US 57313404 P;;US 57304204 P,2004-05-21,ANTIVIRAL COMPOSITONS,"A composition which includes a carboxamide, preferably ribavirin, for treating viral diseases in humans. A preferred embodiment of the subject invention comprises a very high dose (>600 mg) of ribavirin, and more preferably between about 800-1200 mg of ribavirin or more per dosage form.",HAHN ELLIOT;;GOLDFARB ROBERT I;;SOLOMON LAWRENCE;;KAPLAN ALLAN S;;ACCU BREAK TECHNOLOGIES INC,HAHN ELLIOT;;GOLDFARB ROBERT I;;SOLOMON LAWRENCE;;KAPLAN ALLAN S,,https://lens.org/190-647-997-959-325,Patent Application,yes,3,0,1,97,0,A61K9/209;;A61P31/12;;A61K9/209,A61K9/20;;A61J1/03;;A61K9/00;;A61K31/7056;;A61K38/21;;A61P31/12;;C07H19/056,424/465;;424/400;;424/85.4;;514/43;;536/28.7;;206/570,2,1,001-516-175-552-397,10.1016/s0169-409x(01)00097-7;;11325474,"Ribavirin, Wikipedia (2012) [retrieved on 2012-09-07], retrieved from the internet;;Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews (2001), Vol. 48, pp. 3-26.",DISCONTINUED
64,US,B2,US 8470368 B2,094-725-726-729-721,2013-06-25,2013,US 201113151653 A,2011-06-02,US 201113151653 A;;US 77754204 A;;US 66480303 A;;US 41218102 P;;US 41218002 P,2002-09-20,Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH;;WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/094-725-726-729-721,Granted Patent,yes,99,2,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K9/24;;A61K9/00;;A61K9/14;;A61K9/20;;A61K9/22;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06,424/473;;424/484;;514/369;;514/635;;514/866,61,23,187-309-160-388-508;;034-102-381-651-860;;065-340-901-539-257;;020-742-925-110-307;;146-280-751-006-918;;068-685-102-740-969;;025-555-060-539-005;;098-109-024-331-424;;123-194-397-211-55X;;010-645-872-815-401;;048-414-726-490-726;;028-568-339-494-491;;101-299-722-404-666;;031-848-215-173-885;;022-984-079-837-252;;007-767-940-873-695;;088-427-503-188-873;;012-807-787-109-539;;088-770-254-336-633;;043-841-620-298-378;;161-432-240-418-535;;059-173-900-927-503;;035-912-150-623-230,6832864;;3710634;;pmc1874707;;6847752;;10.1016/s0149-2918(00)83039-8;;11192132;;10.1056/nejm199803263381303;;9516221;;0010755495;;10755495;;10.1001/jama.283.13.1695;;10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.0.co;2-a;;9400915;;12877648;;10.1517/14656566.4.8.1417;;10.1111/j.1742-1241.2004.00318.x;;15529521;;10.1016/s0149-2918(96)80017-8;;8829014;;9209206;;10.1016/s0002-9343(96)00353-1;;7601013;;10.2165/00003495-199549050-00007;;10.1177/0145721706294260;;17102154;;10.1111/j.1572-0241.2001.03809.x;;11374713;;10.1056/nejm199602293340906;;8569826;;7623903;;10.1056/nejm199508313330903;;10.2337/diabetes.37.8.1020;;10.2337/diab.37.8.1020;;3292322;;10.2337/diabetes.45.8.1044;;10.2337/diab.45.8.1044;;8690150;;6819094;;10.1248/cpb.30.3601;;10.2337/diacare.15.8.1075;;1505314;;2036936;;10.1016/s0168-8227(05)80027-0;;10.1021/jm00049a017;;7966158;;10.2337/diabetes.43.10.1203;;7926289;;10.2337/diab.43.10.1203,"Abdalla et al, Preparation and evaluation of Metformin Hydrochloride Controlled-Release Tablets, STP Pharma 4(1) pp. 15-20, 1988.;;Karttunen, P. et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""The pharmacokinetics of metformin a comparison of the properties of a rapid release and a sustained-release preparation"" vol. 21, No. 1-1983. pp. 31-36.;;Pentikainen, P.J., International Journal of Clinical Pharmacology, Therapy and Toxicology, ""Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products"", vol. 24, No. 4-1986, pp. 213-220.;;Finnish Monograph of the Diformin(R), Retard tablet, with English translation. O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update ""The status of metformin in Canada"" vol. 128, Jan. 1, 1983, pp. 24-26.;;Belcher, et al., Experiment and Clinical Endrocrinology & Diabetes, ""Safety and tolerability of pioglitazone"" Suppl. 2 (2000) pp. 267-273.;;Einhorn, et al., Clinical Therapeutics ""Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study"", vol. 22, No. 12, 2000 pp. 1395-1413.;;National Institute for Clinical Excellence Technology Appraisal Guidance-No. 21, ""Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus"" Mar. 2001. pp. 1-13.;;The Pharmaceutical Journal, vol. 265, No. 7122, p. 710 Nov. 11, 2000 Clinical (abstract only).;;Clinician Reviews, ""Insulin-Sensitizing Diabetes Agent"" Sep. 1999.;;Product Labeling for Glucophage(R) XR (Jul. 2002).;;Inzucchi, S. et al., Efficacy of Metabolic Effects of Metformin and Troglitazone in type II diabetes mellitus; N. Engl. J Med. Mar. 26, 1998; 338(13): 867-72.;;Fonseca, V., et al., Effect of Metformin and Rosiglitazone combination therapy in patients with type II diabetes mellitus; Apr. 5, 2000; 283(13): 1695-702.;;Egger M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. Nov. 1997; 14 (11): 919-28.;;Dailey, GE., Glyburide/Metformin Tablets: A New Therapeutic Option for the Management of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review (Abstract Only).;;Bailey, CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment for Insulin Resistance in Type 2 Diabetes, Int J Clin Pract Sep. 2004 58(9): 867-76.;;Campbell RK et al., Metformin: A New Oral Biguanide, Clin Ther May-Jun. 1996; 18(3): 360-71.;;Davidson, MB, et al., An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus, Am J Med. Jan. 1997; 102(1):99-110.;;Dunn, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs May 1995; 49(5):721-49.;;Zimmer, B., Supplementary European Search Report, EP 03 75 4689, May 6, 2010, European Patent Office 80298 Munich, Germany.;;Koski, R.R., Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus, The Diabetes Educator 32 (6) 869-876 (Nov./Dec. 2006).;;Jagoe, D., International Search Report, PCT/US03/29292, Apr. 26, 2004, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Jagoe, D., International Preliminary Examination Report, PCT/US03/29292, Jan. 4, 2005, IPEA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Joynes. R.M., International Search Report, PCT/US04/04112, Aug. 12, 2004, ISA/US, Commissioner for Patents, P. O. Box 1450, Alexandria Virginia 22313-1450.;;Nickitas-Etienne, A. International Preliminary Report on Patentability, PCT/US2004/004112, Feb. 28, 2007, the International Bureau of WIPO, 34, chemin des Colombettes, 1211 Geneva 20, Switzerland.;;Woodward, M., International Search Report and Written Opinion of the International Searching Authority, PCT/US06/09082, Jul. 20, 2006, ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria Virginia 22313-1450.;;Menon, K.V, et al., Severe Cholestatic Hepatitis from Troglitazone in a Patient with Nonalcoholic Steatohepatitis and Diabetes Mellitus, The American J. of Gastroenterology, 96 (5) 1631-34 (2001).;;Rote Liste, No. 11081 the Medicament Mediabet of MEDICE, Chem.-Pharm. Fabrik Putter GmbH & Co. KG, Kuhloweg 37-39 Iserlohn/Germany, Editio Cantor Verlag fu Medizin and Naturwissenschaften GmbH, 1993.;;Saini, ""Management guidelines for use of oral hypoglycemic agents (OHA) in complex clinical situation and important drug interactions with OHA's"", Int'l Journal of Diabetes in Developing Countries, 11:23-24 (1991).;;Bailey et al., ""Metformin"", The New England Journal of Medicine, 334 (9): 574-579 (1996).;;Stumvoll et al., ""Metabolic Effects of Metformin in Non-Insulin Dependent Diabetes Mellitus"", The New England Journal of Medicine, 333 (9): 550-554 (1995).;;Reaven et al., ""Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 hours in Patients, with NIDDM"", Diabetes, 37:1020-1024 (1988).;;Boden et al.,""Evidence for a Circadian Rhythm of Insulin Sensitivity in Patients with NIDDM Caused by Cyclic Changes in Hepatic Glucose Production"", Diabetes, 45: 1044-1050 (1996).;;Sohda et al., ""Studies on Antidiabetic Agents III. 5-Arylthiazolidine-2,4-diones as Potent Aldose Reductase Inhibitors"", Chem Pharm. Bull. vol. 30, No. 10, pp. 3601-3616 (1982).;;Hoffman et al., ""New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers"", 15 (8) Diabetes Care, pp. 1075-1078 (Aug. 1992).;;Kuzuya et al., A pilot Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in Patients with Non-Insulin Dependent Diabetes Mellitus, 11 Diabetes Research and Clinical Practice, pp. 147-154 (1991).;;Gimenez Miralles, J. , Supplementary European Search Report issued in EP 04 71 0656, Munich, European Patent Office, 80298 Munich, Germany, Dec. 13, 2011. This European application is related to the present application.;;Cantello et al., ""[[w-(Heterocyclylamino)alkoxy]benzy1]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents"", 37 (23) J. Med. Chem., pp. 3977-3985 (1994).;;Oakes et al., ""A New Antidiabetic Agent, BRL49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat"", 43 (10) Diabetes, pp. 1203-1210 (Oct. 1994).;;Drug Facts and Comparisons, pp. 635-642 (1999) published by Facts and Comparisons, St. Louis Missouri.;;Physicians' Desk Reference, GLUCOPHAGE, 53rd Ed., pp. 833-837 (1999).;;Physicians' Desk Reference, GLUCOPHAGE, 50rd Ed., pp. 752-757 (1996).;;Chiao, ""Sustained release drug delivery systems, Remington: The Science and Practice of Pharmacy"", pp. 1660-1669 (1995).;;Kong, Notice of Paragraph IV Certification Letter for ACTOPLUS MET(R) XR, dated Nov. 21, 2011.;;Hotta, N, Diabetes Update, No. 10, Kashikojima Seminar, pp. 68-77 (1994) (and English translation).;;Villa Riva, A.; ""Supplementary European Search Report"" in EP 06 73 8170, dated Jun. 22, 2012, European Patent Office, Munich, Germany.;;Hotta, N., Diabetes Update, No. 10, Kashikojima Seminar, pp. 68-77 (1994) (and English translation).;;ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117 (1999).;;Actos(R) product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175 (2001).;;Mejia, A.G., An opposition filed in Costa Rica against a related application (Feb. 20, 2008).;;Mejia, A.G., A translation of the opposition filed in Costa Rica against a related application (Feb. 20, 2008).;;Valenzuela V.V., A response to the opposition filed in Costa Rica against a related application (Apr. 24, 2009).;;Valenzuela V.V., A translation of the response to the opposition filed in Costa Rica against a related application (Apr. 24, 2009).;;Nunez Tapia, J.I., An opposition filed in Chile against a related application (Nov. 22, 2007).;;Nunez Tapia, J.I., A translation of the opposition filed in Chile against a related application (Nov. 22, 2007).;;Rivas Sureda, G., A response to the opposition filed in Chile against a related application (Jan. 30, 2008).;;Rivas Sureda, G., A translation of the response to the opposition filed in Chile against a related application (Jan. 30, 2008).;;Villamizar, J.L.R., An English translation of an opposition filed in Columbia against a related application (Aug. 28, 2008).;;D'Aleman, D.R., A response to the opposition filed in Columbia against a related application (in Spanish) (Mar. 3, 2009).;;D'Aleman, D.R., An English translation of a response to the opposition filed in Columbia against a related application (Mar. 3, 2009).;;A search report from the Georgian Patent Office (and English translation) for a related application (Nov. 21, 2008).;;An Office Action from the Ukrainian Patent Office (and English translation) for a related application (Apr. 10, 2009).",EXPIRED
65,US,A1,US 2013/0266647 A1,119-585-587-606-126,2013-10-10,2013,US 201313889441 A,2013-05-08,US 201313889441 A;;US 201113151653 A;;US 77754204 A;;US 66480303 A;;US 41218102 P;;US 41218002 P,2002-09-20,NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE,A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.,WATSON PHARMACEUTICALS INC,KOSITPRAPA UNCHALEE;;GOLDFARB ROBERT I;;CARDINAL JOHN R;;NANGIA AVINASH,ALLERGAN FINANCE LLC (2016-06-09);;ACTAVIS HOLDCO US INC (2016-07-19),https://lens.org/119-585-587-606-126,Patent Application,yes,0,0,7,65,0,A61K9/0004;;A61K9/282;;A61K9/2866;;A61K31/155;;A61K31/425;;A61K31/426;;A61K45/06;;A61K9/209;;A61K31/4439;;A61P3/10;;A61K31/155;;A61K31/426;;A61K9/282;;A61K9/0004;;A61K9/2866;;A61K31/425;;A61K45/06;;A61K9/209;;A61K9/0002;;A61K31/4439;;A61K9/2009;;A61K9/2013;;A61K9/2027;;A61K9/2031;;A61K9/2054,A61K9/20;;A61K9/00;;A61K9/22;;A61K9/24;;A61K9/26;;A61K9/28;;A61K31/155;;A61K31/425;;A61K31/426;;A61K31/4439;;A61K45/06,424/465,0,0,,,,EXPIRED
66,AU,A,AU 1999/019154 A,043-434-484-444-562,1999-07-05,1999,AU 1999/019154 A,1998-12-15,US 6980497 P;;US 9826607 W,1997-12-16,Multicatalytic protease inhibitors for use as anti-tumor agents,,CEPHALON INC;;UNIV PITTSBURGH,SIMAN ROBERT;;JANI JITESH P;;GOLDFARB RONALD H;;DOU QING PING,,https://lens.org/043-434-484-444-562,Patent Application,no,0,0,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,C07D311/70;;A61K31/16;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,,0,0,,,,EXPIRED
67,US,B2,US 10779752 B2,065-731-955-016-492,2020-09-22,2020,US 202016808452 A,2020-03-04,US 202016808452 A;;US 201715417655 A;;US 201414221714 A;;US 64815806 A;;US 11611805 A;;US 3754805 A;;US 94427004 A;;US 91257804 A;;US 82991704 A,2004-04-21,Guidewires for performing image guided procedures,Guidewires and methods useable in conjunction with image guidance systems to facilitate performance of diagnostic or therapeutic tasks at locations within the bodies of human or animal subjects.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K,,https://lens.org/065-731-955-016-492,Granted Patent,yes,1232,3,6,298,0,A61B5/062;;A61B5/062;;A61B5/055;;A61B5/06;;A61B5/06;;A61B5/6851;;A61B5/6851;;A61B6/032;;A61B17/24;;A61B17/24;;A61B17/320725;;A61B17/320725;;A61B17/320758;;A61B17/320758;;A61B17/320783;;A61B17/320783;;A61B17/3478;;A61B17/3478;;A61B34/20;;A61B34/20;;A61B90/16;;A61B90/16;;A61B90/361;;A61B90/361;;A61B90/39;;A61B90/39;;A61B2017/22042;;A61B2017/22042;;A61B2017/22061;;A61B2017/22061;;A61B2034/2048;;A61B2034/2048;;A61B2034/2051;;A61B2034/2051;;A61B2090/363;;A61B2090/363;;A61B2090/365;;A61B2090/365;;A61B2090/3958;;A61B2090/3958;;A61B2090/3983;;A61B2090/3983;;A61M25/09;;A61M25/09041;;A61M25/09041;;A61M29/02;;A61M2025/0166;;A61M2025/0166;;A61M2025/09083;;A61M2025/09175;;A61M2025/09175;;A61M2029/025,A61B5/06;;A61B5/00;;A61B5/055;;A61B6/03;;A61B17/22;;A61B17/24;;A61B17/3207;;A61B17/34;;A61B34/20;;A61B90/00;;A61B90/16;;A61M25/01;;A61M25/09;;A61M29/02,,352,72,025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;043-068-503-393-610;;066-559-118-020-405;;062-351-127-043-686;;004-569-239-507-13X;;015-741-985-781-596;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;130-657-825-626-105;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;118-873-204-442-663;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640;;075-344-428-432-470;;035-586-137-258-637;;089-247-655-233-31X;;068-237-019-427-50X;;061-764-129-861-905;;024-069-245-302-733;;082-361-279-623-107;;137-659-727-058-857;;012-462-482-441-732,4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;19623527;;10.1177/014556130908800708;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1177/000348940501400308;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;10947988;;10.1126/science.289.5482.1197;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783;;8374351;;10.1007/978-3-642-84913-8_3;;10.1055/s-2007-997515;;9487485;;10416252;;10.1002/ccd.1810150211;;3052851;;10190702;;10.1016/s0165-5876(98)00119-0;;10.1001/archopht.116.5.688;;9596514;;10.1017/s0022215100141052;;9764294;;11209511;;10.1177/014556130108000103;;8001106;;10.1002/ccd.1810330117,"Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni—Ti Alloy Guidewire (2001).;;Aust, R., et al. ‘The Functional Size of the Human Maxillary Ostium in Vivo’ Acta. Otolaryn. (9178) vol. 78 pp. 432-435.;;Baim, D.S., MD ‘Grossman's Cardiac Catheterization, Angiography, and Intervention’ (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. ‘Be Wary of Neurocranial Restructuring (NCR)’ Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html.;;Bartal, N. ‘An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia’ J. Laryngol. Otol (1988) vol. 102 pp. 146-147.;;Becker, A.E. ‘Restenosis After Angioplasty’ The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter-Balloon Catheter—Thomas Fogarty. Www.inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al.; Adult Chronic Rhinosinusitis: Defintions, Diagnosis, Epidemiology, and Pathophysilogy Arch Otolarygol Head and Neck Surg. vol. 129 (Sep. 2003) pp. A1-S32.;;Bent et al. ‘The Frontal Cell as a Cause of Frontal Sinus Obstruction’ American Journal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191.;;Binner et al. ‘Fibre-Optic Transillunination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease’ Clinical Otolaryngology. vol. 3 (1978) pp. 1-11.;;Brown, C.L. et al., ‘Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation’ Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al. ‘Endoscopic Lothrop Procedure: the University of Miami Experience’ American Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339.;;Casserly, I.P. et al., Chapter 7. ‘Guides and Wires in Percutaneous Coronary Intervention’ Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. ‘Nasal Systemic Drug Delivery’ Drugs and Pharmaceutical Sciences, vol. 39, pp. 60-63.;;Cohen et al. ‘Endoscopic Sinus Surgery: Where we are and where we're going’ Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38.;;Colla, A. et al., ‘Trihaloacetylated Enol Ethers—General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine’ Synthesis, (Jun. 1991) pp. 483-486.;;Costa, M.N. et al. ‘Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil’ Clinics (2007) vol. 62, Issue1, pp. 41-46.;;Cussler, E.L. ‘Diffusion: Mass transfer in Fluid Systems’ Cambridge University Press (1996).;;Davis, G.E. et al. ‘A Complication from Neurocranial Restructuring’ Arch Otolaryngol Head Neck Surg. vol. 129 (Apr. 2003) pp. 472-474.;;Deutschmann, R. et al. ‘A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication’ Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al. ‘Handbook of Biodegradable Polymers’ Harwood Academic Publishers (1997).;;Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints.htm.;;Draf, W. ‘Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept’ Op Tech Otolarymol Head Neck Surg. vol. 2 (1991) pp. 234-240.;;Edmond, C. et al. ‘ENT Surgical Stimulator’ Nov. 1989.;;ENT Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. ‘Needles for Puncture and Drainage of the Maxillary Sinus’ Meditsinskaya Tekhnika, No. 5 (1974) pp. 54-55.;;Feldman, R.L. et al., ‘New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. ‘A Multipurpose Laryngeal Injector Device’ Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M., M.D., et al. ‘Frontal Sinus Surgery: Endoscopic Technique’ Operative Techniques in Otolarynology—Head and Neck Surgery. vol. 12, No. 2 (Jun. 2001) pp. 60-65.;;Friedman, et al. ‘Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination’ Laryngoscope. vol. 110 (Apr. 2000) pp. 683-684.;;Friedman, et al ‘Middle Turbinate Medialization and Preservation in Endoscopic Surgery’ Otolaryngology—Head and Neck Surgery. (2000) vol. 123, No. 1, part 1, pp. 76-80.;;Fung, M.K.T. ‘Template for Frontal Osteoplastic Flap’ Laryngoscope. vol. 96 (1986) pp. 578-579.;;Gatot, A. et al. ‘Early treatment of Orbital Floor Fractures with Catheter Balloon in Children’ Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al. ‘β-Ethoxyvinyl Polyfluroroalkyl Ketones—Versatile Synthones in Fluoroorganic Chemistry’ Journal of Fluorine Chemistry. vol. 69 (1994) pp. 195-198. Elesvier Science S.A.;;Good, R.H. ‘An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage’ Laryngoscope. vol. 18 (1908) pp. 266-274.;;Gopferich ‘Polymer Degradation and Erosion: Mechanisms and Application’ Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11.;;Gorlov, D.V. et al ‘Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Teriary Amines’ Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottmann, et al. ‘Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses’ CIRSE (Sep. 25, 2004) pp. 1-27.;;Gottmann, et al. ‘Balloon Dilatation of Recurrent Ostial Occlusion of the Frontal Sinus’ CIRSE Abstract (Mar. 2001) B-04353.;;Gottman, et al., Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus OASIS—Online Abstract Submission and Invitation System, 1996-2006, Coe Truman Technologies, Inc.;;Gottmann, et al. ‘Successful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation’ CIRSE. (Oct. 5, 2002).;;Gottmann, D. ‘Treatment of Stenoses of Upper Air Routes by Balloon Dilation’ Proceeding of the 83rd Annual Convention of Association of West German ENT Physicians (1999).;;Gupta, D. et al., ‘Dacrystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus’ Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi_m0BUM/is_7_88/ai_n32428620/.;;Hashim, et al. ‘Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery’ Scandinavian Journal of Plastic and reconstruction Sergery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al, ‘Electrophilic Substiutions of Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides Chemistry Letters’ (1976) pp. 499-502. Chemical Society of Japan.;;Hopf, J.U.G. et al. ‘Minature Endoscopes in Otorhinolaryngologic Applications’ Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al. A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al. ‘Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation’ American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9.;;Hosemann, M.E. et al. ‘Experimentelle Untersuchungen sur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss und medikamentose Effekte im standardisierten Wundmodell.’ HNO 39 (1991) pp. 48-54, ‘Experimental investigations on wound healing of the paranasal sinuses. II. Spontaneous wound closure and pharmacological effects in a standardized animal model.’ HNO 39 (1991) pp. 48-54.;;Hosemann, W.G. et al. ‘Minimally Invasive Endonasal Sinus Surgery’ Thieme, Stuttgart, New York (2000).;;Hosemann, M.E. et al. ‘Normal Wound Healing of the Paranasal Sinuses—Clinical and Experimental Investigations’ Eur Arch Otorhinolarygol. vol. 248, (1991) pp. 390-394.;;Hosemann, W. et al. ‘Behandlung nach Nasennebenhohleneingriffen, part 2: Theapeutische Maßnahem’ HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. ‘Transillumination Durning Osteoplastic Frontal Sinusotomy’ The Laryngoscope. vol. 91 (Sep. 1981) pp. 1560.;;Ijaduola, T.G.A. ‘Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery’ Ther Journal of Laryngology and Otology, (1989) vol. 103. pp. 375-378.;;Ingals, E.F. ‘New Operation and Instruments for Draining the Frontal Sinus’ Ann. Otol. Rhinol. Laryngol. vol. 14 (1905) pp. 644-649.;;Iro, H. et al., ‘A New Device for Frontal Sinus Endoscopy: First Clinical Report’ Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. ‘100 Years of Frontal Sinus Surgery’ Laryngoscope. vol. 107 (1997) pp. 1-36.;;K-Splint Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html.;;Kaiser, H. et al ‘Cortizontherapie, Corticoide in Klinik und Praxis’ Thieme, Stuggart (1992) pp. 390-401.;;Kennedy, D.W., M.D. et al. ‘Diseases of the Sinuses: Diagnosis and Management’ (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al. ‘Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description’ Pharmaceutical Chemistry Journal. vol. 35, No. 11 ( Nov. 2001) pp. 627-629.;;Kingdom, T.T. et al. ‘Image-Guided Surgery of the Sinuses: Current Technology and Applications’ Otolaryngol. Clin. North Am. vol. 37, No. 2 (Apr. 2004) pp. 381-400.;;Klossek, J.M. et al. ‘Local Safety of Intranasal Trimcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis’ Rhinology. vol. 39, No. 1 (2001) pp. 17-22.;;Kozlov et al. ‘Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters’ Rhinology (1996) vol. 34, pp. 123-124.;;Kuhn, et al. ‘The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation’ Operative Techniques in Otolaryngology—Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231.;;Laliberte, F. et al. ‘Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids’ Allergy. vol. 55, No. 8 (2000) pp. 718-722.;;Lang, E.V., et al., ‘Access Systems for Puncture at an Acute Angle’ J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. ‘Postoperative Care and Avoiding Frontal Recess Stenosis’ Internatinal Advanced Sinus Symposium (1993) Jul. 21-24.;;Large, G.C. ‘Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis’ Canad. M.A.J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. ‘Maximal Medical Therapy for Chronic Rhinosinusitis’ Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310.;;Maran, A.G.D. et al. ‘The Use of the Foley Balloon Catheter in the Tripod Fracture’ J. Laryngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902.;;May, M. et al. ‘Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach’ Op Tech Otolaryngo Head Neck Surgery. 6 (1995) pp. 184-192.;;Medtronic, xomed.com—MicroFrance Catalog Browser. Www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al., ‘Coronary Angioplasty through 4 French Diagnostic Catheters’ Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al ‘Synthesis of Trifluromethylnaphthalenes’ Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd.;;Metson, R., et al., ‘Endoscopic Treatment of Sphenoid Sinusitis’ Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. ‘Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study’ Laryngoscope. vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18.;;Miller, et al. ‘Management of Fractures of the Supraorbital Rim’ Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512.;;Min, Y-G et al. ‘Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer’ Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842.;;Mols, B. ‘Movable Tool Tip for Keyhole Surgery’ Delft Outlook, vol. 3 (2005) pp. 13-17.;;Mooney, M.R., et al., ‘Monorail™ Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System’ Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al. ‘Additional-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins’ J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523-3528. American Chemical Society.;;Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html.;;Park, K. et al. ‘Biodegradable Hydrogels for Durg Delivery’ (1993) Technomic Publishing Inc. Lancaster.;;Piccirillo, J.F. et al. ‘Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)’ Copyright 1996 Washington University, St. Louis, MO.;;Piers, et al. ‘A Flexible Distal Tip with Two Degrees of Freedon for Enhanced Dexterity in Endoscopic Robot Surgery’ Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L et al. ‘Balloon Technique for Treatment of Frontal Sinus Fractures’ The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al., ‘Diagnostic Nasal Endoscopy’ plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458.;;Prince, et al. ‘Analysis of the Intranasal Distribution of Ointment’ J Otolaryngol. vol. 26 (1997) pp. 357-360.;;Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Maxillary Sinusitis’ J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Purulent Maxillary Sinusitis’ Texas State Journal of Medicine (May 1952) pp. 281-288.;;St. Croix et al. ‘Genes Expressed in Human Tumor Endothelium’ Science, vol. 289 (May 15, 2000) pp. 1197-1202.;;Sama, A., et al., ‘Current Opinions on the Surgical Management of Frontal Sinus Disease’ ENT News. Www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63.;;Sanborn, T.A. et al., ‘Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance’ Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon Washington 98070 USA.;;Saxon, R.R. et al., ‘Technical Aspects of Accessing the Portal Vein During the TIPS Procedure’ J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. ‘Rhinology and Sinus Disease: A Problem-Oriented Approach’ (Copyright 1988) by Mosby, Inc.;;Schneider. Pfizer Ad for Softip [date of publication unknown].;;Shah, N.J. et al., ‘Endoscopic Pituitary Surgery—A Beginner's Guide’ Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. ‘Functional Endoscopic Sinus Surgery’ (1999); found at bhj.org/journal/1999_4104_oct99/sp_659.htm.;;Single-Pole and Multi-Pole Lightgyides for UV Spot Light Curing Systems.;;Sinusitis, Maxillary, Acute Surgical Treatment. Http://www.emedicine.com/ent/topic340.htm. Aug. 29, 2006. pp. 1-11.;;Sobol, et al. ‘Sinusitis, Maxillary, Acute Surgical Treatment.’ eMedicine. Retrieved from the Internet: <<http://emedicine.medscape.com/article/862030-print>> (Nov. 16, 2010) pp. 1-11.;;Stammberger, H. ‘Komplikationen entzundlicher Nasennebenhohlenerkrankungen eischließ iatrogen bedingter Komplikationen’ Eur Arch Oti-Rhino-Laryngol Supple. (Jan. 1993) pp. 61-102.;;Stammberger, et al. Chapter 3 ‘Special Endoscopic Anatomy of the Lateral Nasal Wall and Ethmoidal Sinuses’ Functional Endoscopic Sinus Surgery. (1991) Ch. 3, pp. 49-87.;;Strohm, et al. Die Behandlung von Stenosen der oberen Luftwege mittels rontgenologisch gesteuerter Ballondilation (Sep. 25, 1999) pp. 1-4.;;Strohm, et al ‘Le Traitenment Des Stenoses Voies Aeriennes Superieures Par Dilation Ay Balloon’ Sep. 25, 1999.;;Strohm, et al. ‘Treatment of Stenoses of the Upper Airways by Balloon Dilation’ Sudwestdeutscher Abstract 45 (Sep. 25, 1999) pp. 1-3.;;SurgTrainer Product Information 2003, Surg Trainer, Ltd. Ibaraki, Japan.;;SurgTrainer Product Information ‘Incisive Human Nasal Model for ESS Training’ Surg Trainer, Ltd. Ibaraki, Japan (2004) wwwl.accsnet.ne.jp/˜juliy/st/en/partslist.html.;;Tabor, M.H. et al., ‘Symptomatic Bilateral Duct Cysts in a Newborn—Rhinoscopic Clinic’ Ear, Nose & Throat Journal (2003) www.findarticles.com/p/articles/mi_m0BUM/is_2_82/ai_98248244 pp. 1-3.;;Tarasov, D.I. et al. ‘Application of Drugs Based on Polymers in the Treatment of Acute and Chronic Maxillary Sinusitis’ Vestn Otorinoloaringol. vol. 6 1978 pp. 45-47.;;Terumo. Medi-Tech. Boston Scientific. (1993) Ad of Glidewire.;;The Operating Theatre Journal (www.otjonline.com) ‘Disposable Medical Device for Wound Disclosure/The Tristel Purple Promotion—A Collaboration between Tristel PLC and Karl Storz Ednoscopy (UK) Ltd.’ p. 4.;;Weber, R. et al. ‘Endonasale Stirnhohlenchirugie mit Langzeiteinlage eines Platzhahers’ Laryngol. Rhinol. Otol. vol. 76 (1997) pp. 728-734. (English Abstract).;;Weber, R. et al., ‘Videoendoscopic Analysis of Nasal Steriod Distribution’ Rhinology. vol. 37 (1999) pp. 69-73.;;Weiner, R.I., D.O., et al., ‘Development and Application of Transseptal Left Heart Catheterization’ Cathet. Cardiovasc. Diagn. (1988) vol. 15, No. 2, pp. 112-120.;;Wiatrak, B.J., et al., ‘Unilateral Choanal Atresia: Initial Presentation and Endoscopic Repair’ International Journal of Pediatric Otorhinolaryngology (1998) vol. 46, pp. 27-35.;;Woog, et al. ‘Paranasal Sinus Endoscopy and Orbital Fracture Repair’ Arch Ophthalmol. vol. 116 (May 1998) pp. 688-691.;;Wormald, P.J., et al., ‘The ‘Swing-Door’ Technique for Uncinectomy in Endoscopic Sinus Surgery’ The Journal of Laryngology and Otology (1998) vol. 112, pp. 547-551.;;Xomed-Treace. Bristol-Myers Squibb. Ad for Laser Shield II. Setting the Standards for Tomorrow. [date of publication unknown].;;Yamauchi, Y. et al., ‘Development of a Silicone Model for Endoscopic Sinus Surgery’ Proc International Journal of Computer Assisted Radiology and Surgery vol. 99 (1999) p. 1039.;;Yamauchi, Y., et al., ‘A Training System for Endoscopic Sinus Surgery with Skill Evaluation’ Computer Assisted Radiology and Surgery (2001) with accompanying poster presentation.;;Yanagisawa et al. ‘Anterior and Posterior Fontanelles.’ Ear, Nose & Throat Journal (2001) vol. 80. pp. 10-12.;;Zimarino, M., M.D., et al., ‘Initial Experience with the EuropassTM: A new Ultra-Low Profile monorail Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1994) vol. 33, No. 1, pp. 76-79.;;Australian Office Action, Examiners First Report dated Apr. 8, 2010 for Application No. AU 2005274794.;;Australian Office Action, Examiners First Report dated Dec. 9, 2011 for Application No. AU 2006292818.;;Australian Office Action, Examiner's First Report dated Feb. 12, 201 for Application No. AU 2012202103.;;Australian Office Action dated Feb. 12, 2014 for Application No. AU 2012202103.;;Australian Office Action dated Aug. 1, 2014 for Application No. AU 2012244072.;;Australian Office Action dated Sep. 17, 2014 for Application No. AU 2012202103.;;Australian Office Action dated Sep. 30, 2014 for Application No. AU 2009293312.;;Australian Office Action dated Oct. 1, 2014 for Application No. AU 2009333010.;;Australian Office Action dated Jul. 8, 2015 for Application No. AU 2012244072.;;Canadian Office Action dated Jul. 10, 2015 for Application No. CA 2,617,054.;;Canadian Office Action dated Dec. 16, 2015 for Application No. CA 2,751,665.;;Chinese Office Action, First Office Action dated Nov. 5, 2012 for CN 200980137396.1.;;Chinese Search Report dated Oct. 29, 2012 for Application No. CN 200980137396.1.;;Chinese Search Report dated Jan. 11, 2013 for Application No. CN 200980152995.0.;;Chinese Office Action, First Office Action dated Jan. 29, 2013 for CN 200980152995.1.;;Chinese Office Action, Decision of Rejection, dated 2014 for Application No. CN 200980152995.1.;;Chinese Office Action, Third Office Action, dated Feb. 27, 2014 for Application No. CN 200980152995.1.;;Chinese Office Action and Search Report dated Jan. 21, 2015 for Application No. CN 201310672731.6.;;European Communication dated Sep. 4, 2008 for Application No. EP 05773189.;;European Communication dated Jun. 19, 2009 for Application No. EP 05773189.;;European Communication dated Aug. 1, 2012 for Application No. EP 06784759.0.;;European Communication dated Aug. 24, 2012 for Application No. EP 05798331.4.;;European Communication dated Nov. 9, 2012 for Application No. EP 07750248.2.;;European Communication dated Apr. 19, 2012 for Application No. EP 08746715.5.;;European Communication dated Jan. 7, 2013 for Application No. EP 08746715.5.;;European Communication dated Apr. 11, 2013 for Application No. EP 05778834.1.;;European Communication dated May 10, 2013 for Application No. EP 06751637.7.;;European Communication dated Sep. 3, 2013 for Application No. EP 12182998.0.;;European Communication dated Feb. 26, 2014 for Application No. EP 06800540.4.;;European Exam Report dated Feb. 22, 2006 for Application No. EP 02716734.5.;;European Exam Report dated Feb. 8, 2007 for Application No. EP 02716734.5.;;European Search Report and Written Opinion dated Sep. 11, 2009 for Application No. EP 06815174.;;European Search Report dated Mar. 16, 2010 re Application No. EP 06718986.;;European Search Report dated Sep. 27, 2011 for Application No. EP 10182961.;;European Search Report dated Sep. 29, 2011 for Application No. EP 10182893.;;European Search Report dated Jul. 23, 2012 for Application No. EP 12162709.;;European Search Report dated Jul. 24, 2012 for Application No. EP 12162712.;;European Search Report dated Aug. 31, 2012 for Application No. EP 12173295.;;European Search Report dated Oct. 10, 2012 for Application No. EP 12175607.;;European Search Report dated Nov. 22, 2012 for Application No. EP 12182993.;;European Search Report dated Dec. 5, 2012 for Application No. EP 12182998.;;European Search Report dated Jan. 9, 2013 for Application No. EP 12183000.;;European Search Report dated Jan. 11, 2013 for Application No. EP 12183002.;;European Search Report dated Aug. 13, 2013 for Application No. EP 13172140.;;European Search Report dated Sep. 9, 2013 for Application No. EP 13179223.;;Extended ESR dated Sep. 9, 2013 for Application No. EP 108426321.1.;;Partial European Search Report dated Sep. 20, 2007 for Application No. EP 07252018.;;Partial European Search Report dated Mar. 25, 2008 for Application No. EP 07252018.;;Supplemental Partial European Search Report dated Jun. 2, 2008 for Application No. EP 05773189.;;Supplemental Partial European Search Report dated Jul. 1, 2009 for Application No. EP 06815285.;;Supplemental Partial European Search Report dated Nov. 19, 2010 for Application No. EP 06751637.;;Supplemental European Search Report dated Jan. 29, 2010 for Application No. EP 07836108.;;Supplemental European Search Report dated Feb. 2, 2010 for Application No. EP 07836109.;;Supplemental European Search Report dated Feb. 17, 2010 for Application No. EP 07836110.;;Supplemental European Search Report dated Mar. 1, 2010 for Application No. EP 05778834.;;Supplemental European Search Report dated Mar. 16, 2010 for Application No. EP 06718986.;;Supplemental European Search Report dated Jun. 22, 2010 for Application No. EP 06784759.;;Supplemental European Search Report dated Sep. 23, 2010 for Application No. EP 08746715.;;Supplemental European Search Report dated Jan. 28, 2011 for Application No. EP 07777004.;;Supplemental European Search Report dated Mar. 31, 2011 for Application No. EP 05798331.;;Supplemental European Search Report dated Aug. 30, 2011 for Application No. EP 06800540.;;Supplemental European Search Report dated Sep. 29, 2011 for Application No. EP 07750248.;;1 Supplemental European Search Report dated Jan. 14, 2014 for Application No. EP 13184009.;;Supplemental European Search Report dated Jan. 17, 2014 for Application No. EP 10842632.;;Supplemental European Search Report dated Feb. 13, 2014 for Application No. EP 08746464.;;European Communication dated Sep. 27, 2011 for Application No. EP06800540.4.;;European Communication dated Aug. 11, 2014 for Application No. EP 12182998.0.;;European Communication dated Aug. 26, 2014 for Application No. EP 12183000.4.;;European Communication dated Nov. 26, 2014 for Application No. EP 07836108.6.;;European Communication dated Feb. 17, 2016 for Application No. EP 12162712.9.;;European Search Report dated May 19, 2015 for Application No. EP 08746464.0.;;European Search Report dated Jun. 23, 2015 for Application No. EP 12162712.9.;;European Search Report dated Jun. 23, 2015 for Application No. EP 12162709.5.;;Extended European Search Report dated Jan. 17, 2014 for Application No. EP 108426321.1.;;Extended European Search Report dated Sep. 15, 2015 for Application No. EP 15163549.7.;;Supplemental European Search Report dated Jan. 14, 2014 for Application No. EP 13184009.;;Supplemental European Search Report dated Jan. 17, 2014 for Application No. EP 1084263.;;Supplemental European Search Report dated Dec. 9, 2014 for Application No. EP 07839152.;;PCT Search Report dated Nov. 30, 2009 for Application No. UPCT/US2009/057203.;;International Preliminary Report on Patentability dated Aug. 7, 2006 for Application No. PCT/US05/25371.;;International Preliminary Report on Patentability and Written Opinion dated Sep. 25, 2007 for Application No. PCT/US06/002004.;;International Preliminary Report on Patentability dated Feb. 15, 2008 for Application No. PCT/US05/13617.;;International Preliminary Report on Patentability and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US07/11449.;;International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2009 for Application No. PCT/US07/021170.;;International Preliminary Report on Patentability and Written Opinion dated May 5, 2009 for Application No. PCT/US06/036960.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 13, 2009 for Application No. PCT/US08/059786.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 27, 2009 for Application No. PCT/US08/061343.;;International Preliminary Report on Patentability dated Jun. 29, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Jun. 3, 2002 for Application No. PCT/EP02/01228.;;International Search Report and Written Opinion dated Apr. 10, 2006 for Application No. PCT/US05/25371.;;International Search Report dated May 8, 2007 for Application No. PCT/US06/016026.;;International Search Report dated Aug. 17, 2007 for Application No. PCT/US05/013617.;;International Search Report dated Aug. 29, 2007 for Application No. PCT/US06/002004.;;International Search Report dated Sep. 25, 2007 for Application No. PCT/US06/037167.;;International Search Report dated Oct. 19, 2007 for Application No. PCT/US07/003394.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021170.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021922.;;International Search Report dated Jul. 1, 2008 for Application No. PCT/US06/022745.;;International Search Report dated Jul. 3, 2008 for Application No. PCT/US06/029695.;;International Search Report dated Jul. 7, 2008 for Application No. PCT/US07/016213.;;International Search Report dated Jul. 8, 2008 for Application No. PCT/US07/011474.;;International Search Report dated Jul. 17, 2008 for Application No. PCT/US06/036960.;;International Search Report and Written Opinion dated Jul. 21, 2008 for Application No. PCT/US05/033090.;;International Search Report dated Aug. 25, 2008 for Application No. PCT/US2008/000911.;;International Search Report dated Sep. 10, 2008 for Application No. PCT/US07/016212.;;International Search Report and Written Opinion dated Sep. 12, 2008 for Application No. PCT/US07/16214.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/059786.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/061343.;;International Search Report and Written Opinion dated Oct. 1, 2008 for Application No. PCT/US07/011449.;;International Search Report dated Oct. 15, 2008 for Application No. PCT/US2008/061048.;;International Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203.;;International Search Report dated Dec. 10, 2009 for Application No. PCT/US2009/052236.;;International Search Report dated Dec. 16, 2009 for Application No. PCT/US2009/050800.;;International Search Report dated Mar. 31, 2010 for Application No. PCT/US2009/069143.;;International Search Report dated Jul. 8, 2010 for Application No. PCT/US2010/027837.;;International Search Report and Written Opinion dated Oct. 6, 2010 for Application No. PCT/US2010/040548.;;International Search Report dated Mar. 25, 2011 for Application No. PCT/US2010/062161.;;International Search Report dated Mar. 28, 2011 for Application No. PCT/US2010/061850.;;International Written Opinion dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2010/060898.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;International Search Report dated May 18, 2012 for Application No. PCT/US2011/052321.;;Partial International Search Report dated Feb. 7, 2012 for Application No. PCT/US2011/052321.;;Japanese Office Action, Examiner's Decision of Refusal dated Oct. 18, 2011 for Application No. JP 2007-509632.;;Japanese Office Action, Notification of Reasons for Refusal dated Apr. 26, 2011 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 24, 2012 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Aug. 16, 2011 for Application No. JP 2008-516013.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 8, 2011 for Application No. JP 2008-524250.;;Japanese Office Action, Notification of Reasons for Refusal dated Jun. 25, 2013 for Application No. JP 2012-131840.;;Japanese Office Action, Notification of Reasons for Refusal dated Sep. 18, 2013 for Application No. JP 2011-527942.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 12, 2013 for Application No. JP 2011-542562.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 17, 2014 for Application No. JP 2012-266049.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 7, 2014 for Application No. JP 2012-266049.;;Japanese Office Action, Notification of Reasons for Refusal, dated Sep. 2, 2014 for Application No. JP 2012-544859.;;Japanese Office Action Notification of Reasons for Refusal, dated Jun. 9, 2015 for Application No. JP 2014-147174.;;Japanese Office Action, Notification of Reasons for Refusal dated Mar. 22, 2016 for JP 2012-266049.;;Russian Office Action dated Sep. 28, 2012 for Application No. RU 2011130530.;;Russian Office Action dated Mar. 19, 2013 for Application No. RU 2011130530.;;English Machine Translation for JP 5-503650.;;USPTO Office Action dated Sep. 16, 2005 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jul. 7, 2006 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Feb. 13, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 9, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jan. 24, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 6, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated May 29, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Nov. 14, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Dec. 6, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Apr. 9, 2008 for U.S. Appl. No. 11/037,548. et al.",ACTIVE
68,WO,A1,WO 1999/030707 A1,104-997-901-661-534,1999-06-24,1999,US 9826607 W,1998-12-15,US 6980497 P,1997-12-16,MULTICATALYTIC PROTEASE INHIBITORS FOR USE AS ANTI-TUMOR AGENTS,"The present invention relates to methods for the use of specified inhibitors of multicatalytic protease (MCP) for use as inducers of programmed cell death (i.e., apoptosis) in tumor cells, and more particularly as anti-tumor agents. The present invention provides methods for inducing apoptosis in transformed cells, inhibiting proliferation of transformed cells, and inhibiting the growth of tumors using the MCP inhibitors.",CEPHALON INC,SIMAN ROBERT;;JANI JITESH P;;GOLDFARB RONALD H;;DOU QING PING,,https://lens.org/104-997-901-661-534,Patent Application,yes,1,32,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,A61K31/16;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;C07D311/70;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,,0,0,,,,PATENTED
69,CA,A1,CA 2314259 A1,185-052-444-986-995,1999-06-24,1999,CA 2314259 A,1998-12-15,US 6980497 P;;US 9826607 W,1997-12-16,MULTICATALYTIC PROTEASE INHIBITORS FOR USE AS ANTI-TUMOR AGENTS,"The present invention relates to methods for the use of specified inhibitors of multicatalytic protease (MCP) for use as inducers of programmed cell death (i.e., apoptosis) in tumor cells, and more particularly as anti-tumor agents. The present invention provides methods for inducing apoptosis in transformed cells, inhibiting proliferation of transformed cells, and inhibiting the growth of tumors using the MCP inhibitors.",CEPHALON INC;;UNIV PITTSBURGH,SIMAN ROBERT;;DOU QING PING;;GOLDFARB RONALD H;;JANI JITESH P,,https://lens.org/185-052-444-986-995,Patent Application,no,0,0,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,C07D311/70;;A61K31/16;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,,0,0,,,,DISCONTINUED
70,AT,T1,AT E356065 T1,059-222-445-652-007,2007-03-15,2007,AT 04102854 T,2004-06-21,US 48023203 P,2003-06-23,UNTERDRUCKBEHÄLTER MIT AKTIVER SCHNELLENTLEERUNGSVENTILSTEUERUNG,"A low-pressure feed container (10) for bulk plastic grains is coupled to a pneumatic feed system. The container discharges via an inlet (14) to an enclosed hopper (12) with an outlet (20) and a valve (46) operated pneumatic gas outlet (36). The granule outlet (20) is opened and closed by a valve (52). Both valves (46, 52) are linked by a common valve shaft (44) and are operated by a single control actuator (42) located in the hopper closure (26).",MANN & HUMMEL PROTEC GMBH,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;GOLDFARB WILLIAM B;;PAQUETTE LEONARD,,https://lens.org/059-222-445-652-007,Granted Patent,no,0,0,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G53/24;;B65G53/60,,0,0,,,,INACTIVE
71,US,A1,US 2001/0012854 A1,157-726-429-726-370,2001-08-09,2001,US 21195198 A,1998-12-15,US 21195198 A;;US 6980497 P,1997-12-16,MULTICATALYTIC PROTEASE INHIBITORS FOR USE AS ANTI-TUMOR AGENTS,"
   The present invention relates to methods for the use of specified inhibitors of multicatalytic protease (MCP) for use as inducers of programmed cell death (i.e., apoptosis) in tumor cells, and more particularly as anti-tumor agents. The present invention provides methods for inducing apoptosis in transformed cells, inhibiting proliferation of transformed cells, and inhibiting the growth of tumors using the MCP inhibitors. 
",SIMAN ROBERT;;JANI JITESH P.;;GOLDFARB RONALD H.;;DOU QING PING,SIMAN ROBERT;;JANI JITESH P;;GOLDFARB RONALD H;;DOU QING PING,CEPHALON INC (1999-01-27),https://lens.org/157-726-429-726-370,Patent Application,yes,0,14,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,A61K31/16;;C07D311/70;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,514/463;;514/19;;514/183;;514/452;;514/519;;X51459;;514/616;;564/123;;554/57,0,0,,,,DISCONTINUED
72,EP,A1,EP 1491470 A1,165-291-910-720-565,2004-12-29,2004,EP 04102854 A,2004-06-21,US 48023203 P,2003-06-23,Vaccuum receiver with positive dump valve control,"Unterdruckbehälter (10) für ein pneumatisches Fördersystem zum Fördern von beispielsweise Kunststoffgranulat, umfassend einen Aufnahmebehälter (12) mit einem Materialeinlass (14), einem Materialauslass (20) und einem Fördergasauslass (36). Ein erstes Ventilelement (46) ist zum Öffnen und Schließen des Fördergasauslasses (36) sowie ein zweites Ventilelement (52) zum Öffnen und Schließen des Materialauslasses (20) vorgesehen. Beide Ventilelemente (46,52) sind über einen gemeinsamen Ventilschaft (44) verbunden und werden durch einen einzigen am Behälterdeckel (26) montierten Aktuator (42) betätigt.",MANN & HUMMEL PROTEC GMBH,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;GOLDFARB WILLIAM B;;PAQUETTE LEONARD,"MANN + HUMMEL PROTEC GMBH (2006-05-24);;PROTEC POLYMER PROCESSING GMBH, DE (2012-09-21)",https://lens.org/165-291-910-720-565,Patent Application,yes,3,4,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G53/24;;B65G53/60,,0,0,,,,ACTIVE
73,AU,B2,AU 735685 B2,092-886-950-049-864,2001-07-12,2001,AU 1999/019154 A,1998-12-15,US 6980497 P;;US 9826607 W,1997-12-16,Multicatalytic protease inhibitors for use as anti-tumor agents,,CEPHALON INC;;UNIV PITTSBURGH,SIMAN ROBERT;;JANI JITESH P;;GOLDFARB RONALD H;;DOU QING PING,,https://lens.org/092-886-950-049-864,Granted Patent,no,1,0,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,C07D311/70;;A61K31/16;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,,0,0,,,,EXPIRED
74,EP,B1,EP 1491470 B1,004-961-718-129-283,2007-03-07,2007,EP 04102854 A,2004-06-21,US 48023203 P,2003-06-23,Vaccuum receiver with positive dump valve control,"A low-pressure feed container (10) for bulk plastic grains is coupled to a pneumatic feed system. The container discharges via an inlet (14) to an enclosed hopper (12) with an outlet (20) and a valve (46) operated pneumatic gas outlet (36). The granule outlet (20) is opened and closed by a valve (52). Both valves (46, 52) are linked by a common valve shaft (44) and are operated by a single control actuator (42) located in the hopper closure (26).",MANN & HUMMEL PROTEC GMBH,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;GOLDFARB WILLIAM B;;PAQUETTE LEONARD,"MANN + HUMMEL PROTEC GMBH (2006-05-24);;PROTEC POLYMER PROCESSING GMBH, DE (2012-09-21)",https://lens.org/004-961-718-129-283,Granted Patent,yes,3,1,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G53/60;;B65G53/24,,0,0,,,,ACTIVE
75,CN,A,CN 1576204 A,134-640-271-170-680,2005-02-09,2005,CN 200410055096 A,2004-06-23,US 48023203 P,2003-06-23,Vaccuum receiver with positive dump valve control,"A low-pressure feed container (10) for bulk plastic grains is coupled to a pneumatic feed system. The container discharges via an inlet (14) to an enclosed hopper (12) with an outlet (20) and a valve (46) operated pneumatic gas outlet (36). The granule outlet (20) is opened and closed by a valve (52). Both valves (46, 52) are linked by a common valve shaft (44) and are operated by a single control actuator (42) located in the hopper closure (26).",MANN & HUMMEL PROTEC GMBH,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;GOLDFARB WILLIAM B;;LEONARD PAQUETTE,,https://lens.org/134-640-271-170-680,Patent Application,no,0,5,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G53/24;;B65G53/60,,0,0,,,,DISCONTINUED
76,US,B2,US 10631756 B2,184-654-467-120-264,2020-04-28,2020,US 201715417655 A,2017-01-27,US 201715417655 A;;US 201414221714 A;;US 64815806 A;;US 11611805 A;;US 3754805 A;;US 94427004 A;;US 91257804 A;;US 82991704 A,2004-04-21,Guidewires for performing image guided procedures,Guidewires and methods useable in conjunction with image guidance systems to facilitate performance of diagnostic or therapeutic tasks at locations within the bodies of human or animal subjects.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K,ACCLARENT INC (2017-02-10),https://lens.org/184-654-467-120-264,Granted Patent,yes,1151,5,6,298,0,A61B5/062;;A61B5/062;;A61B5/055;;A61B5/06;;A61B5/06;;A61B5/6851;;A61B5/6851;;A61B6/032;;A61B17/24;;A61B17/24;;A61B17/320725;;A61B17/320725;;A61B17/320758;;A61B17/320758;;A61B17/320783;;A61B17/320783;;A61B17/3478;;A61B17/3478;;A61B34/20;;A61B34/20;;A61B90/16;;A61B90/16;;A61B90/361;;A61B90/361;;A61B90/39;;A61B90/39;;A61B2017/22042;;A61B2017/22042;;A61B2017/22061;;A61B2017/22061;;A61B2034/2048;;A61B2034/2048;;A61B2034/2051;;A61B2034/2051;;A61B2090/363;;A61B2090/363;;A61B2090/365;;A61B2090/365;;A61B2090/3958;;A61B2090/3958;;A61B2090/3983;;A61B2090/3983;;A61M25/09;;A61M25/09041;;A61M25/09041;;A61M29/02;;A61M2025/0166;;A61M2025/0166;;A61M2025/09083;;A61M2025/09175;;A61M2025/09175;;A61M2029/025,A61B5/06;;A61B5/00;;A61B5/055;;A61B6/03;;A61B17/22;;A61B17/24;;A61B17/3207;;A61B17/34;;A61B34/20;;A61B90/00;;A61B90/16;;A61M25/01;;A61M25/09;;A61M29/02,,319,72,025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;043-068-503-393-610;;066-559-118-020-405;;062-351-127-043-686;;004-569-239-507-13X;;015-741-985-781-596;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;012-223-832-603-044;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;118-873-204-442-663;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640;;075-344-428-432-470;;035-586-137-258-637;;089-247-655-233-31X;;068-237-019-427-50X;;061-764-129-861-905;;024-069-245-302-733;;082-361-279-623-107;;137-659-727-058-857;;012-462-482-441-732,4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;19623527;;10.1177/014556130908800708;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1288/00005537-190508000-00009;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;10947988;;10.1126/science.289.5482.1197;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783;;8374351;;10.1007/978-3-642-84913-8_3;;10.1055/s-2007-997515;;9487485;;10416252;;10.1002/ccd.1810150211;;3052851;;10190702;;10.1016/s0165-5876(98)00119-0;;10.1001/archopht.116.5.688;;9596514;;10.1017/s0022215100141052;;9764294;;11209511;;10.1177/014556130108000103;;8001106;;10.1002/ccd.1810330117,"Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni—Ti Alloy Guidewire (2001).;;Aust, R., et al. ‘The Functional Size of the Human Maxillary Ostium in Vivo’ Acta. Otolaryn(9178) vol. 78 pp. 432-435.;;Baim, D.S., MD ‘Grossman's Cardiac Catheterization, Angiography, and Intervention’ (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. ‘Be Wary of Neurocranial Restructuring (NCR)’ Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html.;;Bartal, N. ‘An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia’ J. Laryngol. Otol (1988) vol. 102 pp. 146-147.;;Becker, A.E. ‘Restenosis After Angioplasty’ The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter—Balloon Catheter—Thomas Fogarty. Www.inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al.; Adult Chronic Rhinosinusitis: Defintions, Diagnosis, Epidemiology, and Pathophysilogy Arch Otolarygol Head and Neck Surg. vol. 129 (Sep. 2003) pp. 1A-S32.;;Bent et al. ‘The Frontal Cell as a Cause of Frontal Sinus Obstruction’ American Joumal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191.;;Binner et al. ‘Fibre-Optic Transillunination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease’ Clinical Otolaryngology. vol. 3 (1978) pp. 1-11.;;Brown, C.L. et al., ‘Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation’ Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al. ‘Endoscopic Lothrop Procedure: the University of Miami Experience’ Amencan Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339.;;Casserly, I.P. et al., Chapter 7. ‘Guides and Wires in Percutaneous Coronary Intervention’ Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. ‘Nasal Systemic Drug Delivery’ Drugs and Pharmaceutical Selences, vol. 39, pp. 60-63.;;Cohen et al. ‘Endoscopic Sinus Surgery: Where we are and Where we're going’ Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38.;;Colla, A. et al., ‘Trihaloacetylated Enol Ethers-General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine’ Synthesis. (Jun. 1991) pp. 483-486.;;Costa, M.N. et al. ‘Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil’ Clinics (2007) vol. 62, Issue 1, pp. 41-46.;;Cussler, E.L. ‘Diffusion: Mass transfer in Fluid Systems’ Cambridge University Press (1996).;;Davis, G.E. et al. ‘A Complication from Neurocranial Restructuring’ Arch Otolaryngol Head Neck Surg, vol. 129 (Apr. 2003) pp. 472-474.;;Deutschmann, R. et al. ‘A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication’ Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al. ‘Handbook of Biodegradable Polymers’ Harwood Academic Publishers (1997).;;Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints.htm.;;Draf, W. ‘Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept’ Op Tech Otolaryngol Head Neck Surg. vol. 2 (1991) pp. 234-240.;;Edmond, C. et al. ‘ENT Surgical Stimulator’ Nov. 1989.;;ENT Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. ‘Needles for Puncture and Drainage of the Maxillary Sinus’ Meditsinskaya Tekhnika, No. 5 (1974) pp. 54.55.;;Feldman, R.L. et al., ‘New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. ‘A Multipurpose Laryngeal Injector Device’ Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M., M.D., et al. ‘Frontal Sinus Surgery: Endoscopic Technique’ Operative Techniques in Otolarynology—Head and Neck Surgery. vol. 12, No. 2 (Jun. 2001) pp. 60-65.;;Friedman, et al. ‘Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination’ Laryngoscope. vol. 110 (Apr. 2000) pp. 683-684.;;Friedman, et al ‘Middle Turbinate Medialization and Preservation in Endoscopic Surgery’ Otolaryngology—Head and Neck Surgery. (2000) vol. 123, No. 1, part 1, pp. 76-80.;;Fung, M.K.T. ‘Template for Frontal Osteoplastic Flap’ Laryngoscope. vol. 96 (1986) pp. 578-579.;;Gatot, A. et al. ‘Early treatment of Orbital Floor Fractures with Catheter Balloon in Children’ Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al. ‘β-Ethoxyvinyl Polyfluroroalkyl Ketones—Versatile Synthones in Fluoroorganic Chemistry’ Journal of Flluorine Chemistry. vol. 69 (1994) pp. 195-198. Elesvier Science S.A.;;Good, R.H. ‘An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage’ Laryngoscope. vol. 18 (1908) pp. 266-274.;;Gopferich ‘Polymer Degradation and Erosion: Mechanisms and Application’ Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11.;;Gorlov, D.V. et al ‘Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence ot Teriary Amines’ Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottmann, et al. ‘Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses’ CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottmann, et al. ‘Balloon Dilatation of Recurrent Ostial Occlusion of the Frontal Sinus’ CIRSE Abstract (Mar. 2001) B-04353.;;Gottman, et al., Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus OASIS—Online Abstract Submission and Invitation Systems, 1996-2006, Coe Truman Technologies, Inc.;;Gottmann, et al. ‘Sucessful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation’ CIRSE. (Oct. 5, 2002).;;Gottmann, D. ‘Treatment of Stenoses of Upper Air Routes by Balloon Dilation’ Proceeding of the 83rd Annual Convention of Association of West German ENT Physicians (1999).;;Gupta, D. et al., ‘Dacrystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus’ Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi_m0BUM/is_7_88/ai_n32428620/.;;Hashim, et al. ‘Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery’ Scandinavian Journal of Plastic and reconstruction Sergery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al, ‘Electrophilic Substiutionsof Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides chemistry Letters’ (1976) pp. 499-502. Chemical Society of Japan.;;Hopf, J.U.G. et al. ‘Minature Endoscopes in Otorhinolaryngologic Applications’ Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al. A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al. ‘Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation’ American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9.;;Hosemann, M.E. et al. ‘Experimentelle Untersuchungen sur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss und medikamentose Effekte im standardisierten Wundmodell.’ HNO 39 (1991) pp. 48-54. ‘Expermental investigations on wound healing of the paranasal sinuses. II. Spontaneous would closure and pharmacological effects in a standardized animal model.’ HNO 39 (1991) pp. 48-54.;;Hosemann, W.G. et al. ‘Minimally Invasive Endonasal Sinus Surgery’ Thieme, Stuttgart, New York (2000).;;Hosemann, M.E. et al. ‘Normal Wound Healing of the Paranasal Sinuses—Clinical and Experimental Investigations’ Eur Arch Otorhinolarygol. vol. 248, (1991) pp. 390-394.;;Hosemann, W. et al. ‘Behandlung nach Nasennebenhohleneingriffen, part 2: Theapeutische Maßnahem’ HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. ‘Transillumination Durning Osteoplastic Frontal Sinusotomy’ The Laryngoscope. vol. 91 (Sep. 1981) pp. 1560.;;Ijaduola, T.G.A. ‘Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery’ Ther Journal of Laryngology and Otology. (1989) vol. 103. pp. 375.378.;;Ingals, E.F. ‘New Operation and Instruments for Draining the Frontal Sinus’ Ann. Otol. Rhinol. Layyngol. vol. 14 (1905) pp. 644-649.;;Iro, H. et al., ‘A New Device for Frontal Sinus Endoscopy: First Clinical Report’ Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. ‘100 Years of Frontal Sinus Surgery’ Laryngoscope. vol. 107 (1997) pp. 1-36.;;K-Splint Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html.;;Kaiser, H. et al ‘Cortizontherapie, Corticoide in Klinik und Praxis’ Thieme, Stuggart (1992) pp. 390-401.;;Kennedy, D.W., M.D. et al. ‘Diseases of the Sinuses: Diagnosis and Management’ (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al. ‘Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description’ Pharmaceutical Chemistry Journal. vol. 35, No. 11 (Nov. 2001) pp. 627-629.;;Kingdom, T.T. et al. ‘Image-Guided Surgery of the Sinuses: Current Technology and Applications’ Otolaryngol. Clin. North Am. vol. 37, No. 2 (Apr. 2004) pp. 381-400.;;Klossek, J.M. et al. ‘Local Safety of Intranasal Timcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis’ Rhinology. vol. 39, No. 1 (2001) pp. 17-22.;;Kozlov et al. ‘Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters’ Rhinology (1996) vol. 34, pp. 123-124.;;Kuhn, et al. ‘The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation’ Operative Techniques in Otolaryngology—Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231.;;Laliberte, F. et al. ‘Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids’ Allergy. vol. 55, No. 8 (2000) pp. 718-722.;;Lang, E.V., et al., ‘Access Systems for Puncture at an Acute Angle’ J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. ‘Postoperative Care and Avoiding Frontal Recess Stenosis’ Internatinal Advanced Sinus Symposium Jul. 21-24, 1993.;;Large, G.C. ‘Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis’ Canad. M.A.J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. ‘Maximal Medical Therapy for Chronic Rhinosinusitis’ Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310.;;Maran, A.G.D. et al. ‘The Use of the Foley Balloon Catheter in the Tripod Fracture’ J. Laryngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902.;;May, M. et al. ‘Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach’ Op Tech Otolaryngo Head Neck Surgery. 6 (1995) pp. 184-192.;;Medtronic, xomed.com—MicroFrance Catalog Browser. Www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al., ‘Coronary Angioplasty through 4 French Diagnostic Catheters’ Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al ‘Synthesis of Trifluromethylnaphthalenes’ Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd.;;Metson, R., et al., ‘Endoscopic Treatment of Sphenoid Sinusitis’ Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. ‘Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study’ Laryngoscope. vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18.;;Miller, et al. ‘Management of Fractures of the Supraorbital Rim’ Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512.;;Min, Y-G et al. ‘Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer’ Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842.;;Mols, B. ‘Movable Tool Tip for Keyhole Surgery’ Delft Outlook, vol. 3 (2005) pp. 13-17.;;Mooney, M.R. et al., ‘Monorail™ Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System’ Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al. ‘Additional-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins’ J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523.3528. American Chemical Society.;;Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html.;;Park, K. et al. ‘Biodegradable Hydrogels for Durg Delivery’ (1993) Technomic Publishing Inc. Lancaster.;;Piccirillo, J.F. et al. ‘Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)’ Copyright 1996 Washington University, St. Louis, MO.;;Piers, et al. ‘A Flexible Distal Tip with Two Degrees of Freedon for Enhanced Dexterity in Endoscopic Robot Surgery’ Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L et al. ‘Balloon Technique for Treatment of Frontal Sinus Fractures’ The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al., ‘Diagnostic Nasal Endoscopy’ plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458.;;Prince, et al. ‘Analysis of the Intranasal Distribution of Ointment’ J Otolaryngol. vol. 26 (1997) pp. 357-360.;;Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Maxillary Sinusitis’ J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. ‘Pressure of Purulent Maxillary Sinusitis’ Texas State Journal of Medicine (May 1952) pp. 281-288.;;St. Croix et al. ‘Genes Expressed in Human Tumor Endothelium’ Science, vol. 289 (May 15, 2000) pp. 1197-1202.;;Sama, A., et al., ‘Current Opinions on the Surgical Management of Frontal Sinus Disease’ ENT News. Www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63.;;Sanborn, T.A. et al., ‘Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance’ Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon Washington 98070 USA.;;Saxon, R.R. et al., ‘Technical Aspects of Accessing the Portal Vein During the TIPS Procedure’ J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. ‘Rhinology and Sinus Disease: A Problem-Oriented Approach’ (Copyright 1988) by Mosby, Inc.;;Schneider. Pfizer Ad for Softip [date of publication unknown].;;Shah, N.J. et al., ‘Endoscopic Pituitary Surgery—A Beginner's Guide’ Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. ‘Functional Endoscopic Sinus Surgery’ (1999); found at bhj.org/journal/1999_4104_oct99/sp_659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems.;;Sinusitis, Maxillary, Acute Surgical Treatment. Http://www.emedicine.com/ent/topic340.htm. Aug. 29, 2006. pp. 1-11.;;Sobol, et al. ‘Sinusitis, Maxillary, Acute Surgical Treatment.’ eMedicine. Retrieved from the Internet: <<http://emedicine.medscape.com/article/862030-print>> (Nov. 16, 2010) pp. 1-11.;;Stammberger, H. ‘Komplikationen entzundlicher Nasennebenhohlenerkrankungen eischließ iatrogen bedingter Komplikationen’ Eur Arch Oti-Rhino-Laryngol Supple. (Jan. 1993) pp. 61-102.;;Stammberger, et al. Chapter 3 ‘Special Endoscopic Anatomy of the Lateral Nasal Wall and Ethmoidal Sinuses’ Functional Endoscopic Sinus Surgery. (1991) Ch. 3, pp. 49-87.;;Strohm, et al. Die Behandlung von Stenosen der oberen Luftwege mittels rontgenologisch gesteuerter Ballondilation (Sep. 25, 1999) pp. 1-4.;;Strohm, et al ‘Le Traitenment Des Stenoses Voies Aeriennes Superieures Par Dilation Ay Balloon’ Sep. 25, 1999.;;Strohm, et al. ‘Treatment of Stenoses of the Upper Airways by Balloon Dilation’ Sudwestdeutscher Abstract 45 (Sep. 25, 1999) pp. 1-3.;;SurgTrainer Product Information 2003, Surg Trainer, Ltd. Ibaraki, Japan.;;SurgTrainer Product Information ‘Incisive Human Nasal Model for ESS Training’ Surg Trainer, Ltd. Ibaraki, Japan (2004) www1.accsnet.ne.jp/˜juliy/st/en/partslist.html.;;Tabor, M.H. et al., ‘Symptomatic Bilateral Duct Cysts in a Newborn—Rhinoscopic Clinic’ Ear, Nose & Throat Journal (2003) www.findarticles.com/p/articles/mi_m0BUM/is_2_82/ai_98248244 pp. 1-3.;;Tarasov, D.I. et al. ‘Application of Drugs Based on Polymers in the Treatment of Acute and Chronic Maxillary Sinusitis’ Vestn Otorinoloaringol. vol. 6 (1978) pp. 45-47.;;Terumo. Medi-Tech. Boston Scientific. (1993) Ad of Glidewire.;;The Operating Theatre Journal (www.otjonline.com) ‘Disposable Medical Device for Wound Disclosure/The Tristel Purple Promotion—A Collaboration between Tristel PLC and Karl Storz Ednoscopy (UK) Ltd.’ p. 4.;;Weber, R. et al. ‘Endonasale Stirnhohlenchirugie mit Langzeiteinlage eines Platzhalters’ Laryngol. Rhinol. Otol. vol. 76 (1997) pp. 728-734. (English Abstract).;;Weber, R. et al., ‘Videoendoscopic Analysis of Nasal Steriod Distribution’ Rhinology. vol. 37 (1999) pp. 69-73.;;Weiner, R.I., D.O., et al., ‘Development and Application of Transseptal Left Heart Catheterization’ Cathet. Cardiovasc. Diagn. (1988) vol. 15, No. 2, pp. 112-120.;;Wiatrak, B.J. et al., ‘Unilateral Choanal Atresia: Initial Presentation and Endoscopic Repair’ International Journal of Pediatric Otorhinolaryngology (1998) vol. 46, pp. 27-35.;;Woog, et al. ‘Paranasal Sinus Endoscopy and Orbital Fracture Repair’ Arch Ophthalmol. vol. 116 (May 1998) pp. 688-691.;;Wormald, P.J. et al., ‘The ‘Swing-Door’ Technique for Uncinectomy in Endoscopic Sinus Surgery’ The Journal of Laryngology and Otology (1998) vol. 112, pp. 547-551.;;Xomed-Treace. Bristol-Myers Squibb. ad for Laser Shield II. Setting the Standards for Tomorrow. [date of publication unknown].;;Yamauchi, Y. et al., ‘Development of a Silicone Model for Endoscopic Sinus Surgery’ Proc International Journal of Computer Assisted Radiology and Surgery vol. 99 (1999) p. 1039.;;Yamauchi, Y., et al., ‘A Training System for Endoscopic Sinus Surgery with Skill Evaluation’ Computer Assisted Radiology and Surgery (2001) with accompanying poster presentation.;;Yanagisawa et al. ‘Anterior and Posterior Fontanelles.’ Ear, Nose & Throat Journal (2001) vol. 80. pp. 10-12.;;Zimarino, M., M.D., et al., ‘Initial Experience with the EuropassTM: A new Ultra-Low Profile monorail Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1994) vol. 33, No. 1, pp. 76-79.;;Australian Office Action, Examiners First Report dated Apr. 8, 2010 for Application No. AU 2005274794.;;Australian Office Action, Examiners First Report dated Dec. 9, 2011 for Application No. AU 2006292818.;;Australian Office Action, Examiner's First Report dated Feb. 12, 201 for Application No. AU 2012202103.;;Chinese Office Action, First Office Action dated Nov. 5, 2012 for CN 200980137396.1.;;Chinese Search Report dated Oct. 29, 2012 for Application No. CN 200980137396.1.;;Chinese Search Report dated Jan. 11, 2013 for Application No. CN 200980152995.0.;;Chinese Office Action, First Office Action dated Jan. 29, 2013 for CN 200980152995.1.;;European Communication dated Sep. 4, 2008 for Application No. EP 05773189.;;European Communication dated Jun. 19, 2009 for Application No. EP 05773189.;;European Communication dated Aug. 1, 2012 for Application No. EP 06784759.0.;;European Communication dated Aug. 24, 2012 for Application No. EP 05798331.4.;;European Communication dated Nov. 9, 2012 for Application No. EP 07750248.2.;;European Communication dated Apr. 19, 2012 for Application No. EP 08746715.5.;;European Communication dated Jan. 7, 2013 for Application No. EP 08746715.5.;;European Communication dated Apr. 11, 2013 for Application No. EP 05778834.1.;;European Communication dated May 10, 2013 for Application No. EP 06751637.7.;;European Communication dated Sep. 3, 2013 for Application No. EP 12182998.0.;;European Communication dated Feb. 26, 2014 for Application No. EP 06800540.4.;;European Exam Report dated Feb. 22, 2006 for Application No. EP 02716734.5.;;European Exam Report dated Feb. 8, 2007 for Application No. EP 02716734.5.;;European Search Report and Written Opinion dated Sep. 11, 2009 for Application No. EP 06815174.;;European Search Report dated Mar. 16, 2010 re Application No. EP 06718986.;;European Search Report dated Sep. 27, 2011 for Application No. EP 10182961.;;European Search Report dated Sep. 29, 2011 for Application No. EP 10182893.;;European Search Report dated Jul. 23, 2012 for Application No. EP 12162709.;;European Search Report dated Jul. 24, 2012 for Application No. EP 12162712.;;European Search Report dated Aug. 31, 2012 for Application No. EP 12173295.;;European Search Report dated Oct. 10, 2012 for Application No. EP 12175607.;;European Search Report dated Nov. 22, 2012 for Application No. EP 12182993.;;European Search Report dated Dec. 5, 2012 for Application No. EP 12182998.;;European Search Report dated Jan. 9, 2013 for Application No. EP 12183000.;;European Search Report dated Jan. 11, 2013 for Application No. EP 12183002.;;European Search Report dated Aug. 13, 2013 for Application No. EP 13172140.;;European Search Report dated Sep. 9, 2013 for Application No. EP 13179223.;;Extended ESR dated Sep. 9, 2013 for Application No. EP 108426321.1.;;Partial European Search Report dated Sep. 20, 2007 for Application No. EP 07252018.;;Partial European Search Report dated Mar. 25, 2008 for Application No. EP 07252018.;;Supplemental Partial European Search Report dated Jun. 2, 2008 for Application No. EP 05773189.;;Supplemental Partial European Search Report dated Jul. 1, 2009 for Application No. EP 06815285.;;Supplemental Partial European Search Report dated Nov. 19, 2010 for Application No. EP 06751637.;;Supplemental European Search Report dated Jan. 29, 2010 for Application No. EP 07836108.;;Supplemental European Search Report dated Feb. 2, 2010 for Application No. EP 07836109.;;Supplemental European Search Report dated Feb. 17, 2010 for Application No. EP 07836110.;;Supplemental European Search Report dated Mar. 1, 2010 for Application No. EP 05778834.;;Supplemental European Search Report dated Mar. 16, 2010 for Application No. EP 06718986.;;Supplemental European Search Report dated Jun. 22, 2010 for Application No. EP 06784759.;;Supplemental European Search Report dated Sep. 23, 2010 for Application No. EP 08746715.;;Supplemental European Search Report dated Jan. 28, 2011 for Applicatlon No. EP 07777004.;;Supplemental European Search Report dated Mar. 31, 2011 for Application No. EP 05798331.;;Supplemental European Search Report dated Aug. 30, 2011 for Application No. EP 06800540.;;Supplemental European Search Report dated Sep. 29, 2011 for Application No. EP 07750248.;;Supplemental European Search Report dated Jan. 14, 2014 for Application No. EP 13184009.;;Supplemental European Search Report dated Jan. 17, 2014 for Application No. EP 10842632.;;Supplemental European Search Report dated Feb. 13, 2014 for Application No EP 08746464.;;PCT Search Report dated Nov. 30, 2009 for Application No. UPCT/US2009/057203.;;International Preliminary Report on Patentability dated Aug. 7, 2006 for Application No. PCT/US05/25371.;;International Preliminary Report on Patentability and Written Opinion dated Sep. 25, 2007 for Application No. PCT/US06/002004.;;International Preliminary Report on Patentability dated Feb. 15, 2008 for Application No. PCT/US05/13617.;;International Preliminary Report on Patentability and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US07/11449.;;International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2009 for Application No. PCT/US07/021170.;;International Preliminary Report on Patentability and Written Opinion dated May 5, 2009 for Application No. PCT/US06/036960.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 13, 2009 for Application No. PCT/US08/059786.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 27, 2009 for Application No. PCT/US08/061343.;;International Preliminary Report on Patentability dated Jun. 29, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Jun. 3, 2002 for Application No. PCT/EP02/01228.;;International Search Report and Written Opinion dated Apr. 10, 2006 for Application No. PCT/US05/25371.;;International Search Report dated May 8, 2007 for Application No. PCT/US06/016026.;;International Search Report dated Aug. 17, 2007 for Application No. PCT/US05/013617.;;International Search Report dated Aug. 29, 2007 for Application No. PCT/US06/002004.;;International Search Report dated Sep. 25, 2007 for Application No. PCT/US06/037167.;;International Search Report dated Oct. 19, 2007 for Application No. PCT/US07/003394.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021170.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021922.;;International Search Report dated Jul. 1, 2008 for Application No. PCT/US06/022745.;;International Search Report dated Jul. 3, 2008 for Application No. PCT/US06/029695.;;International Search Report dated Jul. 7, 2008 for Application No. PCT/US07/016213.;;International Search Report dated Jul. 8, 2008 for Application No. PCT/US07/011474.;;International Search Report dated Jul. 17, 2008 for Application No. PCT/US06/036960.;;International Search Report and Written Opinion dated Jul. 21, 2008 for Application No. PCT/US05/033090.;;International Search Report dated Aug. 25, 2008 for Application No. PCT/US2008/000911.;;International Search Report dated Sep. 10, 2008 for Application No. PCT/US07/016212.;;International Search Report and Written Opinion dated Sep. 12, 2008 for Application No. PCT/US07/16214.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/059786.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/061343.;;International Search Report and Written Opinion dated Oct. 1, 2008 for Application No. PCT/US07/011449.;;International Search Report dated Oct. 15, 2008 for Application No. PCT/US2008/061048.;;International Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203.;;International Search Report dated Dec. 10, 2009 for Application No. PCT/US2009/052236.;;International Search Report dated Dec. 16, 2009 for Application No. PCT/US2009/050800.;;International Search Report dated Mar. 31, 2010 for Application No. PCT/US2009/069143.;;International Search Report dated Jul. 8, 2010 for Application No. PCT/US2010/027837.;;International Search Report and Written Opinion dated Oct. 6, 2010 for Application No. PCT/US2010/040548.;;International Search Report dated Mar. 25, 2011 for Application No. PCT/US2010/062161.;;International Search Report dated Mar. 28, 2011 for Application No. PCT/US2010/061850.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2010/060898.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;International Search Report dated May 18, 2012 for Application No. PCT/US2011/052321.;;Partial International Search Report dated Feb. 7, 2012 for Application No. PCT/US2011/052321.;;Japanese Office Action, Examiner's Decision of Refusal dated Oct. 18, 2011 for Application No. JP 2007-509632.;;Japanese Office Action, Notification of Reasons for Refusal dated Apr. 26, 2011 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 24, 2012 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Aug. 16, 2011 for Application No. JP 2008-516013.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 8, 2011 for Application No. JP 2008-524250.;;Japanese Office Action, Notification of Reasons for Refusal dated Jun. 25, 2013 for Application No. JP 2012-131840.;;Japanese Office Action, Notification of Reasons for Refusal dated Sep. 18, 2013 for Application No. JP 2011-527942.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 12, 2013 for Application No. JP 2011-542562.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 17, 2014 for Application No. JP 2012-266049.;;Russian Office Action dated Sep. 28, 2012 for Application No. RU 2011130530.;;Russian Office Action dated Mar. 19, 2013 for Application No. RU 2011130530.;;English Machine Translation for JP 5-503650.;;USPTO Office Action dated Sep. 16, 2005 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jul. 7, 2006 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Feb. 13, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 9, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jan. 24, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 6, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated May 29, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Nov. 14, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Dec. 6, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Apr. 9, 2008 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Nov. 28, 2007 for U.S. Appl. No. 11/234,395.;;USPTO Office Action dated Sep. 12, 2008 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Mar. 18, 2009 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Nov. 9, 2009 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Oct. 29, 2008 for U.S. Appl. No. 11/347,147.;;USPTO Office Action dated Feb. 4, 2009 for U.S. Appl. No. 11/347,147.;;USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 11/347,147.;;USPTO Office Action dated Nov. 7, 2008 for U.S. Appl. No. 10/944,270.;;USPTO Office Action dated Jan. 28, 2009 for U.S. Appl. No. 10/944,270.;;USPTO Office Action dated Apr. 21, 2009 for U.S. Appl. No. 10/944,270.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/117,582.;;USPTO Office Action dated Mar. 3, 2009 for U.S. Appl. No. 12/117,582.;;USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,582.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/118,931.;;USPTO Office Action dated Mar. 4, 2009 for U.S. Appl. No. 12/118,931.;;USPTO Office Action dated Jul. 30, 2009 for U.S. Appl. No. 12/118,931.;;USPTO Office Action dated Nov. 25, 2008 for U.S. Appl. No. 12/117,961.;;USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,961.;;USPTO Office Action dated Dec. 5, 2008 for U.S. Appl. No. 12/120,902.;;USPTO Office Action dated Oct. 21, 2009 for U.S. Appl. No. 12/120,902.;;USPTO Office Action dated Mar. 17, 2009 for U.S. Appl. No. 11/690,127.;;USPTO Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/804,309.;;USPTO Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/926,326.;;USPTO Office Action dated Aug. 28, 2009 for U.S. Appl. No. 11/150,847.;;USPTO Office Action dated Dec. 29, 2008 for U.S. Appl. No. 11/193,020.;;USPTO Office Action dated May 13, 2009 for U.S. Appl. No. 11/193,020.;;U.S. Appl. No. 11/789,705, filed Apr. 24, 2007.;;U.S. Appl. No. 11/804,308, filed May 16, 2007.;;U.S. Appl. No. 11/804,309, filed May 16, 2007.;;U.S. Appl. No. 14/221,550, filed Mar. 21, 2014.;;U.S. Appl. No. 14/221,621, filed Mar. 21, 2014.;;U.S. Appl. No. 60/844,874, filed Sep. 15, 2006.;;U.S. Appl. No. 60/922,730, filed Apr. 9, 2007.;;U.S. Appl. No. 61/052,413, filed May 12, 2008.;;U.S. Appl. No. 61/084,949, filed Jul. 30, 2008.;;Australian Office Action dated Feb. 12, 2014 for Application No. AU 2012202103.;;Australian Office Action dated Aug. 1, 2014 for Application No. AU 2012244072. et al.",ACTIVE
77,DE,D1,DE 502004003104 D1,155-477-578-440-301,2007-04-19,2007,DE 502004003104 T,2004-06-21,US 48023203 P,2003-06-23,Unterdruckbehälter mit aktiver Schnellentleerungsventilsteuerung,"A low-pressure feed container (10) for bulk plastic grains is coupled to a pneumatic feed system. The container discharges via an inlet (14) to an enclosed hopper (12) with an outlet (20) and a valve (46) operated pneumatic gas outlet (36). The granule outlet (20) is opened and closed by a valve (52). Both valves (46, 52) are linked by a common valve shaft (44) and are operated by a single control actuator (42) located in the hopper closure (26).",MANN & HUMMEL PROTEC GMBH,RAINVILLE DONALD D;;CRAWFORD ROBERT R;;GOLDFARB WILLIAM B;;PAQUETTE LEONARD,"PROTEC POLYMER PROCESSING GMBH, DE (2012-09-21)",https://lens.org/155-477-578-440-301,Granted Patent,no,0,0,7,7,0,B65G53/24;;B65G53/60;;B65G2201/042;;B65G53/24;;B65G53/60;;B65G2201/042,B65G53/60;;B65G53/24,,0,0,,,,ACTIVE
78,US,A1,US 2014/0200444 A1,012-338-114-887-644,2014-07-17,2014,US 201414221714 A,2014-03-21,US 201414221714 A;;US 64815806 A;;US 11611805 A;;US 3754805 A;;US 94427004 A;;US 91257804 A;;US 82991704 A,2004-04-21,GUIDEWIRES FOR PERFORMING IMAGE GUIDED PROCEDURES,Guidewires and methods useable in conjunction with image guidance systems to facilitate performance of diagnostic or therapeutic tasks at locations within the bodies of human or animal subjects.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K,,https://lens.org/012-338-114-887-644,Patent Application,yes,6,94,6,298,0,A61B5/062;;A61B5/062;;A61B5/055;;A61B5/06;;A61B5/06;;A61B5/6851;;A61B5/6851;;A61B6/032;;A61B17/24;;A61B17/24;;A61B17/320725;;A61B17/320725;;A61B17/320758;;A61B17/320758;;A61B17/320783;;A61B17/320783;;A61B17/3478;;A61B17/3478;;A61B34/20;;A61B34/20;;A61B90/16;;A61B90/16;;A61B90/361;;A61B90/361;;A61B90/39;;A61B90/39;;A61B2017/22042;;A61B2017/22042;;A61B2017/22061;;A61B2017/22061;;A61B2034/2048;;A61B2034/2048;;A61B2034/2051;;A61B2034/2051;;A61B2090/363;;A61B2090/363;;A61B2090/365;;A61B2090/365;;A61B2090/3958;;A61B2090/3958;;A61B2090/3983;;A61B2090/3983;;A61M25/09;;A61M25/09041;;A61M25/09041;;A61M29/02;;A61M2025/0166;;A61M2025/0166;;A61M2025/09083;;A61M2025/09175;;A61M2025/09175;;A61M2029/025,A61B19/00,600/424,0,0,,,,DISCONTINUED
79,EP,A1,EP 1037626 A1,012-257-944-745-78X,2000-09-27,2000,EP 98963927 A,1998-12-15,US 9826607 W;;US 6980497 P,1997-12-16,MULTICATALYTIC PROTEASE INHIBITORS FOR USE AS ANTI-TUMOR AGENTS,,CEPHALON INC;;UNIV PITTSBURGH,SIMAN ROBERT;;JANI JITESH P;;GOLDFARB RONALD H;;DOU QING PING,,https://lens.org/012-257-944-745-78X,Patent Application,yes,0,0,9,9,0,A61K31/277;;A61K31/353;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;A61K31/33;;A61K31/69;;A61K31/4035;;A61K31/353;;A61K31/277,A61K31/16;;A61K31/175;;A61K31/275;;A61K31/277;;A61K31/335;;C07D311/70;;A61K31/352;;A61K31/353;;A61K31/403;;A61K31/4035;;A61K31/69;;A61P35/00;;A61P43/00;;C07D209/48,,0,0,,,,DISCONTINUED
80,US,A1,US 2020/0196907 A1,115-620-434-128-675,2020-06-25,2020,US 202016808452 A,2020-03-04,US 202016808452 A;;US 201715417655 A;;US 201414221714 A;;US 64815806 A;;US 11611805 A;;US 3754805 A;;US 94427004 A;;US 91257804 A;;US 82991704 A,2004-04-21,GUIDEWIRES FOR PERFORMING IMAGE GUIDED PROCEDURES,Guidewires and methods useable in conjunction with image guidance systems to facilitate performance of diagnostic or therapeutic tasks at locations within the bodies of human or animal subjects.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K,,https://lens.org/115-620-434-128-675,Patent Application,yes,3,0,6,298,0,A61B5/062;;A61B5/062;;A61B5/055;;A61B5/06;;A61B5/06;;A61B5/6851;;A61B5/6851;;A61B6/032;;A61B17/24;;A61B17/24;;A61B17/320725;;A61B17/320725;;A61B17/320758;;A61B17/320758;;A61B17/320783;;A61B17/320783;;A61B17/3478;;A61B17/3478;;A61B34/20;;A61B34/20;;A61B90/16;;A61B90/16;;A61B90/361;;A61B90/361;;A61B90/39;;A61B90/39;;A61B2017/22042;;A61B2017/22042;;A61B2017/22061;;A61B2017/22061;;A61B2034/2048;;A61B2034/2048;;A61B2034/2051;;A61B2034/2051;;A61B2090/363;;A61B2090/363;;A61B2090/365;;A61B2090/365;;A61B2090/3958;;A61B2090/3958;;A61B2090/3983;;A61B2090/3983;;A61M25/09;;A61M25/09041;;A61M25/09041;;A61M29/02;;A61M2025/0166;;A61M2025/0166;;A61M2025/09083;;A61M2025/09175;;A61M2025/09175;;A61M2029/025,A61B5/06;;A61B5/00;;A61B5/055;;A61B6/03;;A61B17/24;;A61B34/20;;A61B90/00;;A61B90/16;;A61M25/09;;A61M29/02,,0,0,,,,ACTIVE
81,US,A1,US 2017/0202480 A1,088-267-500-780-29X,2017-07-20,2017,US 201715417655 A,2017-01-27,US 201715417655 A;;US 201414221714 A;;US 64815806 A;;US 11611805 A;;US 3754805 A;;US 94427004 A;;US 91257804 A;;US 82991704 A,2004-04-21,GUIDEWIRES FOR PERFORMING IMAGE GUIDED PROCEDURES,Guidewires and methods useable in conjunction with image guidance systems to facilitate performance of diagnostic or therapeutic tasks at locations within the bodies of human or animal subjects.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K,ACCLARENT INC (2017-02-10),https://lens.org/088-267-500-780-29X,Patent Application,yes,0,9,6,298,0,A61B5/062;;A61B5/062;;A61B5/055;;A61B5/06;;A61B5/06;;A61B5/6851;;A61B5/6851;;A61B6/032;;A61B17/24;;A61B17/24;;A61B17/320725;;A61B17/320725;;A61B17/320758;;A61B17/320758;;A61B17/320783;;A61B17/320783;;A61B17/3478;;A61B17/3478;;A61B34/20;;A61B34/20;;A61B90/16;;A61B90/16;;A61B90/361;;A61B90/361;;A61B90/39;;A61B90/39;;A61B2017/22042;;A61B2017/22042;;A61B2017/22061;;A61B2017/22061;;A61B2034/2048;;A61B2034/2048;;A61B2034/2051;;A61B2034/2051;;A61B2090/363;;A61B2090/363;;A61B2090/365;;A61B2090/365;;A61B2090/3958;;A61B2090/3958;;A61B2090/3983;;A61B2090/3983;;A61M25/09;;A61M25/09041;;A61M25/09041;;A61M29/02;;A61M2025/0166;;A61M2025/0166;;A61M2025/09083;;A61M2025/09175;;A61M2025/09175;;A61M2029/025,A61B5/06;;A61B5/00;;A61B5/055;;A61B6/03;;A61B17/24;;A61B34/20;;A61M25/09;;A61M29/02,,0,0,,,,ACTIVE
82,US,B1,US 8702626 B1,149-626-432-967-601,2014-04-22,2014,US 64815806 A,2006-12-29,US 64815806 A;;US 11611805 A;;US 82991704 A;;US 91257804 A;;US 94427004 A;;US 3754805 A,2004-04-21,Guidewires for performing image guided procedures,Guidewires and methods useable in conjunction with image guidance systems to facilitate performance of diagnostic or therapeutic tasks at locations within the bodies of human or animal subjects.,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K;;ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;VO TOM T;;DECKMAN ROBERT K,ACCLARENT INC (2007-05-02),https://lens.org/149-626-432-967-601,Granted Patent,yes,108,128,6,298,0,A61B5/062;;A61B5/062;;A61B5/055;;A61B5/06;;A61B5/06;;A61B5/6851;;A61B5/6851;;A61B6/032;;A61B17/24;;A61B17/24;;A61B17/320725;;A61B17/320725;;A61B17/320758;;A61B17/320758;;A61B17/320783;;A61B17/320783;;A61B17/3478;;A61B17/3478;;A61B34/20;;A61B34/20;;A61B90/16;;A61B90/16;;A61B90/361;;A61B90/361;;A61B90/39;;A61B90/39;;A61B2017/22042;;A61B2017/22042;;A61B2017/22061;;A61B2017/22061;;A61B2034/2048;;A61B2034/2048;;A61B2034/2051;;A61B2034/2051;;A61B2090/363;;A61B2090/363;;A61B2090/365;;A61B2090/365;;A61B2090/3958;;A61B2090/3958;;A61B2090/3983;;A61B2090/3983;;A61M25/09;;A61M25/09041;;A61M25/09041;;A61M29/02;;A61M2025/0166;;A61M2025/0166;;A61M2025/09083;;A61M2025/09175;;A61M2025/09175;;A61M2029/025,A61B5/05;;A61B5/00;;A61M25/00,600/585;;600/424,99,62,090-798-792-511-247;;130-499-350-444-007;;025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;009-319-672-632-222;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;026-029-145-609-339;;043-068-503-393-610;;066-559-118-020-405;;004-569-239-507-13X;;015-741-985-781-596;;006-017-396-056-413;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;130-657-825-626-105;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;008-078-192-419-026,14835484;;14927373;;10.1001/jama.1952.02930220026009;;4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.1016/s0194-5998(03)01397-4;;12958561;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1016/0022-1139(94)03130-4;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.3109/13645709809152853;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1177/000348940501400308;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t,"Göttman, et al.; Balloon Dilation of Recurrent Ostial Occlusion of the frontal sinus; Abstract No. B-04353, European Congress of Radiology, Mar. 2001.;;Göttman, et al., Balloon dilatation of recurrent ostial occlusion of the front sinus; ECR, Mar. 2, 2001.;;Göttman, et al., Successful Treatment of Recurrent Post-operative Frontal Sinus Stenoses by Balloon Dilatation; CIRSE, Oct. 5, 2002.;;Göttman, et al., Balloon dilatation in the nasal cavity and paranasal sinuses; CIRSE, Sep. 25, 2004.;;Robison, J. Mathews, M.D., Pressure Treatment of Purulent Maxillary Sinusitis, Texas State Journal of Medicine, May 1951, pp. 281-288.;;Robison, J. Mathews, M.D., Pressure Treatment of Maxillary Sinusitis, J.A.M.A., May 31, 1952, pp. 436-440.;;Strohm et al. Die Behandlung von Stenosen der oberen Luftwege mittels röntgenologisch gesteuerter Ballondilation Sep. 25, 1999.;;Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni-Ti Alloy Guidewire (2001).;;Aust, R., et al 'The Functional Size of the Human Maxillary Ostium in Vivo' Acta. Otolaryn. (1978) vol. 78 pp. 432-435.;;Baim, D.S., MD Grossman's Cardiac Catheterization, Angiography, and Intervention (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. 'Be Wary of Neurocranial Restructuring (NCR)' Chirobase (available at: http://www.chirobase.org/06DD/ncr.html) (Jul. 2003.).;;Bartal, N. 'An Improved Stent for Use in the Surgical Management of Congenital Posterior Choanal Atresia' J. Laryngol. Otol. (1988) vol. 102 pp. 146-147.;;Becker, A.E. 'Restenosis After Angioplasty' The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter-Balloon Catheter- Thomas Fogarty. http://inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al. Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysiology' Arch Otolarygol Head and Neck Surg. (Sep. 2003) vol. 129 pp. S1-S32.;;Bent et al. 'The Frontal Cell as a Cause of Frontal Sinus Obstruction' American Journal of Rhinology. (1994) vol. 8, No. 4 pp. 185.;;Binner et al. 'Fibre-Optic Transillumination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease' Clinical Otolaryngology. (1978) vol. 3 pp. 1-11.;;Brown, C.L. et al 'Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation' Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Bumm, P., H. Kaiser et al 'Cortizontherapie, Corticoide in Klinik and Praxis' Thieme, Stuggart (1992) pp. 390-401 [Summary of textbook].;;Casiano et al. 'Endoscopic Lothrop Procedure: The University of Miami Experience' American Journal of Rhinology (1998) vol. 12, No. 5 pp. 335-339.;;Casserly, I.P. et al Chapter 7. 'Guides and Wires in Percutaneous Coronary Intervention' Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. Nasal Systemic Drug Delivery, Drugs and the Pharmaceutical Sciences (1989) Marcel Dekker, Inc. Chapter 3, pp. 39-88.;;Cohen et al 'Endoscopic Sinus Surgery: Where we are and where we're going' Current Opinion in Otolaryngology & Head and Neck Surgery (2005) vol. 13 pp. 32-38.;;Colla, A. et al 'Trihaloacetylated Enol Ethers-General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine' Synthesis. (Jun. 1991) pp. 483-486.;;Costa, M.N. et al 'Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5- Flurorouracil' Clinics. (2007) vol. 62, Issue 1 pp. 41-46. http://www.scielo.br/scielo.php?pid=S1807-59322007000100007&script=sci-arttext.;;Cussler, E.L. Diffusion: Mass Transfer in Fluid Systems Cambridge University Press (1996) [Summary of textbook].;;Davis, G.E. et al., 'A Complication From Neurocranial Restructuring' Arch Otolaryngology Head Neck Surg. (Apr. 2003) vol. 129 pp. 472-474.;;Deutschmann, R. et al. 'A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication' Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al Handbook of Biodegradable Polymers Harwood Academic Publishers (1997) [Summary of textbook].;;Draf, W. 'Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept' Op Tech Otolaryngol Head Neck Surg. (1991) vol. 2 pp. 234-240.;;Edmond et al 'ENT Surgical Stimulator' Nov. 1998 Final Report Cooperative Agreement No. DAMD17-95-2-5023.;;ENT Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. 'Needles for Puncture and Drainage of the Maxillary Sinus' Meditsinskaya Tekhnika, No. 5 (1974) pp. 54-55.;;Feldman, R.L. et al 'New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis Orion(TM) Steerable PTCA Balloon Catheter' Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. 'A Multipurpose Laryngeal Injector Device' Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M. M.D., et al 'Frontal Sinus Surgery: Endoscopic Technique' Operative Techniques in Otolarynology-Head and Neck Surgery. (Jun. 2001) vol. 12, No. 2 pp. 60-65.;;Friedman, et al 'Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination' Laryngoscope. (Apr. 2000) vol. 110 pp. 683-684.;;Friedman et al 'Middle Turbinate Medialization and Preservation in Endoscopic Surgery' Otolaryngol. Head Neck Surg. (2000) vol. 123, No. 1, Part 1. pp. 76-80.;;Fung, M.K.T. 'How I Do It-Head and Neck and Plasic Surgery. A Targeted Problem and its Solution. Template for Frontal Osteoplastic Flap' Laryngoscope. (1986) vol. 96 pp. 578-579.;;Gatot, A. et al., 'Early Treatment of Orbital Floor Fractures with Catheter Balloon in Children' Int. J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al 'beta-Ethoxyvinyl Polyfluroroalkyl Ketones-Versatile Synthones in Fluoroorganic Chemistry' Journal of Fluorine Chemistry. (1994) vol. 69 pp. 195-198. Elsevier Science S.A.;;Good, R.H. 'An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage' Laryngoscope. (1908) vol. 18 pp. 266-274.;;Gopferich 'Polymer Degradation and Erosion: Mechanisms and Applications' Eur. J. Pharm. Biophar. (1996) vol. 42 pp. 1-11.;;Gorlov, D.V. et al 'Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Tertiary Amines' Russian Chemical Bulletin. (Sep. 1999) vol. 48 No. 9 pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottman, et al. 'Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses' CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottman, et al. 'Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus' Abstract No. B-04353. European Congress of Radiology. (Mar. 2, 2001).;;Gottman, et al. 'Successful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation' CIRSE. (Oct. 5, 2002).;;Gupta, D. et al 'Dacryocystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus' Ear, Nose & Throat Journal (2009) http://findarticles.com/p/articles/mi-m0BUM/is-7-88/ai-n32428620/.;;Hashim, et al 'Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery' Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al 'Electrophilic Substitutions of Olefinic Hydrogens II. Acylation of Vinyl Ethers and N Vinyl Amides' Chemistry Letters (1976) pp. 499-502.;;Hopf, J.U.G. et al 'Miniature Endoscopes in Otorhinolaryngologic Applications' Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al 'Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation' American Journal of Rhinology (1997) vol. 11, No. 1 pp. 1-9.;;Hosemann, M.E. et al 'Experimentelle Untersuchungen zur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss and medikamentose Effekte im standardisierten Wundmodell.' HNO 39 (1991) pp. 48-54.;;Hosemann W.G. et al Minimally Invasive Endonasal Sinus Surgery Thieme, Stuttgart, New York (2000) [Summary of textbook].;;Hosemann, M.E. et al 'Normal Wound Healing of the Paranasal Sinuses-Clinical and Experimental Investigations' Eur Arch Otorhinolarygol. (1991) vol. 248 pp. 390-394.;;Hosemann, W. et al 'Weiterbehandlung nach Nasennebenhohleneingriffen, Part 2: Theapeutische Mabetanahmen' HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) http://www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. 'Transillumination During Osteoplastic Frontal Sinusotomy' The Laryngoscope (Sep. 1981) vol. 91 pp. 1560.;;Ijaduola, T.G.A. 'Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery' The Journal of Laryngology and Otology. (1989) vol. 103 pp. 375-378.;;Ingals, F. 'New Operation and Instruments for Draining the Frontal Sinus' Ann. Otol Rhinol Laryngol. (1905) vol. 14 pp. 515-519.;;Iro, H. et al 'A New Device for Frontal Sinus Endoscopy: First Clinical Report' Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. '100 Years of Frontal Sinus Surgery' Laryngoscope. (1997) vol. 107 pp. 1-36.;;Kennedy, D.W., M.D. et al Diseases of the Sinuses Diagnosis and Management (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al 'Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: A Model Description' Pharmaceutical Chemistry Journal. (Nov. 2001) vol. 35, No. 11 pp. 627-629.;;Kingdom, T.T. et al 'Image-Guided Surgery of the Sinuses: Current Technology and Applications' Otolaryngol. Clin. North Am. (Apr. 2004) vol. 37, No. 2 pp. 381-400.;;Klossek, J.M. et al 'Local Safety of Intranasal Triamcinolone Acetonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis' Rhinology (2001) vol. 39, No. 1 pp. 17-22.;;Kozlov et al 'Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters' Rhinology (1996) vol. 34. pp. 123-124.;;Kuhn, et al. 'The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation' Operative Techniques in Otolaryngology-Head and Neck Surgery (1991) vol. 2, No. 4 pp. 226-231.;;Laliberte F. et al 'Clinical and Pathologic Methods to Assess the Long-Term Safety or Nasal Corticosteroids' Allergy (2000) vol. 55, No. 8 pp. 718-722.;;Lang, E.V. et al 'Access Systems for Puncture at an Acute Angle' J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. 'Postoperative Care and Avoiding Frontal Recess Stenosis' International Advanced Sinus Symposium. General Session Abstracts. (1993) Jul. 21-24.;;Large, G.C. 'Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis' Canad. M. A. J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. 'Maximal Medical Therapy for Chronic Rhinosinusitis' Otolaryngol Clin N Am. (2005) vol. 38 pp. 1301-1310.;;Maran, A.G.D. et al 'The Use of the Foley Catheter in the Tripod Fracture' J. Laryngol. Otol (1971) vol. 85, Issue 9 pp. 897-902.;;May, M. et al 'Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach' Op Tech Otolaryngo Head Neck Surgery (1995) vol. 6, No. 3 pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser. http://www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al 'Coronary Angioplasty through 4 French Diagnostic Catheters' Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al 'Synthesis of Trifluromethylnaphthalenes' Tetrahedron (2000) vol. 56 pp. 10067-10074. Elseview Science Ltd.;;Metson, R. et al 'Endoscopic Treatment of Sphenoid Sinusitis' Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. 'Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study' Laryngoscope (Jan. 1996) vol. 106, Issue 1, Supplement 77 pp. 1-18.;;Miller et al. 'Management of Fractures of the Supraorbital Rim' Journal of Trauma (Jul. 1978) vol. 18, No. 7 pp. 507-512.;;Min, Y-G et al. 'Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer' Laryngoscope (Aug. 1995) vol. 105 pp. 835-842.;;Mols, B. 'Moveable Tool Tip for Keyhole Surgery' Delft Outlook (2005) vol. 3 pp. 13-17.;;Mooney, M.R. et al 'Monorail(TM) Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System' Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al 'Addition-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins' J. Org. Chem. (1995) vol. 60, No. 11 pp. 3523-3528. American Chemical Society.;;Park, K. et al Biodegreadable Hydrogels for Medicinal Substance Delivery (1993) Technomic Publishing Inc. Lancaster.;;Piccirillo, J.F. et al 'Psychometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20)' Otolaryngol. Head Neck Surg (2002) vol. 126, No. 1 pp. 41-47.;;Piers, et al 'A Flexible Distal Tip with Two Degrees of Freedom for Enhanced Dexterity in Endoscopic Robot Surgery' Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L. et al 'Balloon Technique for Treatment of Frontal Sinus Fractures' The Journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al 'Diagnostic Nasal Endoscopy' Plastic & Reconstructive Surgery (1997) vol. 99, Iss. 5 pp. 1451-1458.;;Prince et al 'Analysis of the Intranasal Distribution of Ointment' J Otolaryngol. (1997) vol. 26 pp. 357-360.;;Ramsdale, D.R. Illustrated Coronary Intervention A case- oriented approach (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Maxillary Sinusitis' J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Purulent Maxillary Sinusitis' Texas State Journal of Medicine. (May 1951) pp. 281-288.;;Sama, A. et al 'Current Opinions on the Surgical Management of Frontal Sinus Disease' ENT News. www.pinpointmendical.com/ent-news (2009) vol. 17 No. 6 pp. 60-63.;;Sanborn, T.A., et al 'Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance' Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon, Washington 98070 USA.",ACTIVE
83,SU,A1,SU 1293187 A1,078-455-454-037-934,1987-02-28,1987,SU 3900734 A,1985-05-20,SU 3900734 A,1985-05-20,METHOD OF PRODUCING BETA-NITROALKYLPHOSPHORYLIC COMPOUNDS,,NI VETERINARNYJ INST,GAREEV ROBERT D;;LOGINOVA GALINA M;;GOLDFARB EDUARD I;;GORTYSHOVA LIDIYA I,,https://lens.org/078-455-454-037-934,Limited Patent,no,0,0,1,1,0,,C07F9/32;;C07F9/40;;C07F9/53,,0,0,,,,EXPIRED
84,TW,B,TW 253029 B,129-272-746-968-710,1995-08-01,1995,TW 83110459 A,1994-11-11,US 19904294 A,1994-02-18,Non-destructive flex testing method and means,Describes a process for applying non-destructive cyclical mechanical stress to planar items in order to simulate the effects of cyclical thermal stresses. Latent defects are accelerated and screened early in a manufacturing process.,IBM,SAMUEL MARK GOLDFARB;;PAUL ROBERT HERB;;JOSEPH MICHAEL LUKAITIS;;LEATHEN NMN SHI,,https://lens.org/129-272-746-968-710,Granted Patent,no,0,0,4,4,0,G01N3/20;;G01N3/36;;G01N3/36;;G01N2203/0005;;G01N2203/0005;;G01N2203/0023;;G01N2203/0023;;G01N2203/0044;;G01N2203/0044;;G01N2203/0224;;G01N2203/0224;;G01N2203/0282;;G01N2203/0282;;G01R31/2817;;G01R31/2817,G01N3/00;;G01N3/02;;G01N3/36;;G01R31/28,,0,0,,,,EXPIRED
85,US,B2,US 9198736 B2,042-998-981-605-23X,2015-12-01,2015,US 201213451020 A,2012-04-19,US 201213451020 A;;US 43689706 A,2006-05-17,Adapter for attaching electromagnetic image guidance components to a medical device,Devices and methods wherein an adapter is used to attach an electromagnetic image guidance component to a medical device such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K;;ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,ACCLARENT INC (2006-07-17),https://lens.org/042-998-981-605-23X,Granted Patent,yes,104,46,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B19/00,,99,62,017-705-556-162-740;;099-120-884-682-48X;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;026-029-145-609-339;;043-068-503-393-610;;066-559-118-020-405;;062-351-127-043-686;;004-569-239-507-13X;;015-741-985-781-596;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;012-223-832-603-044;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640,3346594;;10.1017/s0022215100104360;;2893945;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1016/0022-1139(94)03130-4;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;19623527;;10.1177/014556130908800708;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1288/00005537-190508000-00009;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783,"Argon Medical, Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni-Ti Alloy Guidewire (2001).;;Baim, D.S., MD 'Grossman's Cardiac Catheterization, Angiography, and Intervention' (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. 'Be Wary of Neurocranial Restructuring (NCR)' Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html.;;Bartal, N. 'An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia' J. Laryngol. Otol (1988) vol. 102 pp. 146-7.;;Becker, A.E. 'Restenosis After Angioplasty' The Lancet (1988) vol. 331, No. 8584 p. 532.;;Benninger et al.; Adult Chronic Rhinosinusitis: Defintions, Diagnosis, Epidemiology, and Pathophysilogy Arch Otolarygol Head and Neck Surg. vol. 129 (Sep. 2003) pp. A1-S32.;;Bent et al. 'The Frontal Cell as a Cause of Frontal Sinus Obstruction' American Journal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191.;;Binner et al, 'Fibre-Optic Transillunination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease' Clinical Otolaryngology, vol. 3 (1978) pp. 1-11.;;Brown, C.L. et al., 'Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation' Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al. 'Endoscopic Lothrop Procedure: the University of Miami Experience' American Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339.;;Casserly, I.P. et al., Chapter 7. 'Guides and Wires in Percutaneous Coronary Intervention' Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Cohen et al. 'Endoscopic Sinus Surgery: Where we are and where we're going' Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38.;;Colla, A. et al., 'Trihaloacetylated Enol Ethers-General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine' Synthesis, (Jun. 1991) pp. 483-486.;;Costa, M.N. et al. 'Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil' Clinics (2007) vol. 62, Issue1, pp. 41-46.;;Cussler, E.L. 'Diffusion: Mass transfer in Fluid Systems' Cambridge University Press (1996).;;Davis, G.E. et al. 'A Complication from Neurocranial Restructuring' Arch Otolaryngol Head Neck Surg. vol. 129 (Apr. 2003) pp. 472-474.;;Deutschmann, R. et al. 'A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication' Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al. 'Handbook of Biodegradable Polymers' Harwood Academic Publishers (1997).;;Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints.htm.;;Draf, W. 'Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept' Op Tech Otolaryngol Head Neck Surg. vol. 2 (1991) pp. 234-240.;;Edmond, C. et al. 'ENT Surgical Stimulator' Nov. 1989.;;Eremychev, V.A. 'Needles for Puncture and Drainage of the Maxillary Sinus' Meditsinskaya Tekhnika, No. 5 (1974) pp. 54.55.;;Feldman, R.L. et al., 'New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter' Cathet. Cardiovasc. Diagn. vol. 19, No. 2 pp. 142-145.;;Ford, C.N. 'A Multipurpose Laryngeal Injector Device' Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M., M.D., et al. 'Frontal Sinus Surgery: Endoscopic Technique' Operative Techniques in Otolarynology-Head and Neck Surgery. vol. 12, No. 2 (Jun. 2001) pp. 60-65.;;Friedman, et al. 'Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination' Laryngoscope. vol. 110 (Apr. 2000) pp. 683-684.;;Friedman, et al 'Middle Turbinate Medialization and Preservation in Endoscopic Surgery' Otolaryngology-Head and Neck Surgery. (2000) vol. 123, No. 1, part 1, pp. 76-80.;;Fung, M.K.T. 'Template for Frontal Osteoplastic Flap' Laryngoscope. vol. 96 (1986) pp. 578-579.;;Gatot, A. et al. 'Early treatment of Orbital Floor Fractures with Catheter Balloon in Children' Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al. 'beta-Ethoxyvinyl Polyfluroroalkyl Ketones-Versatile Synthones in Fluoroorganic Chemistry' Journal of Fluorine Chemistry. vol. 69 (1994) pp. 195-198. Elesvier Science S.A.;;Good, R.H. 'An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage' Laryngoscope. vol. 18 (1908) pp. 266-274.;;Gopferich 'Polymer Degradation and Erosion: Mechanisms and Application' Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11.;;Gorlov, D.V. et al 'Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Teriary Amines' Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottmann, et al. 'Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses' CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottman, et al.; Balloon Dilatation of Recurrent Ostial Occlusion of the frontal sinus; Abstract No. B-04353, European Congress of Radiology, Mar. 2001.;;Gottman, et al. 'Balloon Dilatation of recurrent ostial occlusion of the front sinus' ECR, Mar. 2, 2001.;;Gottman, D. 'Treatment of Stenoses of Upper Air Routes by Balloon Dilatation' Proceeding of the 83rd Annual Convention of the Association of West German ENT Physicians (1999).;;Gottman, et al. 'Successful treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation' CIRSE. Oct. 5, 2002.;;Gottman, et al. 'Balloon Dilatation in the nasal cavity and paranasal sinuses' CIRSE, Sep. 25, 2004.;;Gupta, D. et al., 'Dacrystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus' Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi-m0BUM/is-7-88/ai-n32428620/.;;Hashim, et al. 'Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery' Scandinavian Journal of Plastic and reconstruction Sergery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al, 'Electrophilic Substiutions of Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides Chemistry Letters' (1976) pp. 499-502. Chemical Society of Japan.;;Hopf, J.U.G. et al. 'Minature Endoscopes in Otorhinolaryngologic Applications' Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al. A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen. pp. 4-37.;;Hosemann, W. et al. 'Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation' American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9.;;Hosemann, M.E. et al. 'Experimental investigations on wound healing of the paranasal sinuses. II. Spontaneous wound closure and pharmacological effects in a standardized animal model.' HNO 39 (1991) pp. 48-54.;;Hosemann, W.G. et al. 'Minimally Invasive Endonasal Sinus Surgery' Thieme, Stuttgart, New York (2000).;;Hosemann, M.E. et al. 'Normal Wound Healing of the Paranasal Sinuses-Clinical and Experimental Investigations' Eur Arch Otorhinolarygol. vol. 248, (1991) pp. 390-394.;;Hosemann, W. et al. 'Behandlung nach Nasennebenhohleneingriffen, part 2: Theapeutische Mabetanahem' HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. 'Transillumination Durning Osteoplastic Frontal Sinusotomy' The Laryngoscope. vol. 91 (Sep. 1981) pp. 1560.;;Ijaduola, T.G.A. 'Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery' Ther Journal of Laryngology and Otology. (1989) vol. 103. pp. 375-378.;;Ingals, E.F. 'New Operation and Instruments for Draining the Frontal Sinus' Ann. Otol. Rhinol. Layyngol, vol. 14 (1905) pp. 644-649.;;Iro, H. et al., 'A New Device for Frontal Sinus Endoscopy: First Clinical Report' Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. '100 Years of Frontal Sinus Surgery' Laryngoscope. vol. 107 (1997) pp. 1-36.;;K-Splints Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html.;;Kaiser, H. et al 'Cortizontherapie, Corticoide in Klinik und Praxis' Thieme, Stuggart (1992) pp. 390-401.;;Kennedy, D.W., M.D. et al. 'Diseases of the Sinuses: Diagnosis and Management' (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al. 'Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description' Pharmaceutical Chemistry Journal. vol. 35, No. 11 (Nov. 2001) pp. 627-629.;;Kingdom, T. et al, Image-Guided Surgery of the Sinuses: Current Technology and Applications, Otolaryngol. Clin. North Am. 37(2):381-400 (Apr. 2004).;;Klossek, J.M. et al. 'Local Safety of Intranasal Trimcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa Allergic Rhinitis' Rhinology. vol. 39, No.1 (2001) pp. 17-22.;;Kozlov et al. 'Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters' Rhinology (1996) vol. 34, pp. 123-124.;;Kuhn, et al. 'The Agger Nasi Cell in Radiology and Clinical Correlation' Operative Techniques in Otolaryngology-Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231.;;Laliberte, F. et al, 'Clinical and Pathological Methods to Assess the Long-Term Safety of Nasal Corticosteroids' Allergy. vol. 55, No. 8 (2000) pp. 718-722.;;Lang, E.V., et al., 'Access Systems for Puncture at an Acute Angle' J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. 'Postoperative Care and Advoiding Frontal Recess Stenosis' International Advanced Sinus Symposium (1993) Jul. 21-24.;;Large, G.C. 'Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis' Canad. M.A.J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. 'Maximal Medical Therapy for Chronic Rhinosinusitis' Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310.;;Maran, A.G.D. et al. 'The Use of the Foley Balloon Catheter in the Tripod Fracture' J. Latyngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902.;;May, M. et al. 'Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach' Op Tech Otolaryngo Head Neck Surgery. 6 (1995) pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser. Www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodlin=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al., 'Coronary Angioplasty through 4 French Diagnostic Catheters' Cathet. Cardiovasc. Diagn, (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al 'Synthesis of Trifluromethylnaphthalenes' Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd.;;Metson, R., et al., 'Endoscopic Treatment of Sphenoid Sinusitis' Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R, 'Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study' Laryngoscope, vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18.;;Miller, et al, 'Management of Fractures of the Supraorbital Rim' Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512.;;Min, Y-G et al. 'Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer' Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842.;;Mols, B. 'Movable Tool Tip for Keyhole Surgery' Delft Outlook, vol. 3 (2005) pp. 13-17.;;Mooney, M.R., et al., 'Monorail(TM) Piccolino Catheter: A New Exchange/Ultralow Profile Coronary Angioplasty System' Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al. 'Additional-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins' J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523.3528. American Chemical Society.;;Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html.;;Park, K. et al. 'Biodegradable Hydrogels for Durg Delivery' (1993) Technomic Publishing Inc, Lancaster.;;Peirs, et al. 'A Flexible Distal Tip with Two Degrees of Freedon for Enhanced Dexterity in Endoscopic Robot Surgery' Proceedings 13th Micromechanics Workshop (2002) pp. 271-274.;;Piccirillo, J.F. et al. 'Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)' Copyright 1996 Washington University, St. Louis, MO.;;Podoshin, L et al. 'Balloon Technique for Treatment of Frontal Sinus Fractures' The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al., 'Diagnostic Nasal Endoscopy' plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458.;;Prince, et al. 'Analysis of the Intranasal Distribution of Ointment' J Otolaryngol. vol. 26 (1997) pp. 357-360.;;Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Maxillary Sinusitis' J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Purulent Maxillary Sinusitis' TEXAS State Journal of Medicine (May 1952) pp. 281-288.;;Sama, A., et al., 'Current Opinions on the Surgical Management of Frontal Sinus Disease' ENT News. Www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63.;;Sanborn, T.A. et al., 'Percutaneous Endocardial Transfer and the Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance' Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon Washington 98070 USA.;;Saxon, R.R. et al., 'Technical Aspects of Accessing the Portal Vein During the TIPS Procedure' J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. 'Rhinology and Sinus Disease: A Problem-Oriented Approach' (Copyright 1988) by Mosby, Inc.;;Shah, N.J. et al., 'Endoscopic Pituitary Surgery-A Beginner's Guide' Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. 'Functional Endoscopic Sinus Surgery' (1999); found at bhj.org/journal/1999-4104-oct99/sp-659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems. Www.dymax.com/products/curing-equipment/lightguids/light. (2004) pp. 1-2.",ACTIVE
86,ES,T3,ES 2392460 T3,102-771-454-696-692,2012-12-10,2012,ES 07252018 T,2007-05-16,US 43689706 A,2006-05-17,Adaptador para fijar componentes electrónicos de orientación de imagen a un dispositivo médico,"Un sistema para guiar el avance de un dispositivo dentro del cuerpo de un paciente que comprende:un catéter guía (14) dimensionado para permitir el avance del dispositivo en el cuerpo, comprendiendo el catéterguía (14) una parte de salida distal que tiene un eje orientado a un ángulo de entre 20 y 80 grados en relacióncon un eje del catéter guía (14) y una parte proximal que tiene una características radialmente no uniforme (40)orientada en una relación fija con respecto al ángulo de la parte de salida distal;un dispositivo adaptador (10, 10a) capaz de sujetarse libremente a la característica radialmente no uniforme(40) sobre el catéter guía (14);un elemento de navegación (12) capaz de ser detectado por un sistema de navegación basado en unordenador, estando alojado el elemento de navegación (12) dentro del dispositivo adaptador (10) durante suuso;un dispositivo médico colocado en el catéter guía (14) y que puede avanzar a lo largo del catéter guía (14); yuna herramienta de calibración (50) para su uso en la calibración de dicho sistema, comprendiendo dichaherramienta de calibración: un cuerpo rígido que tiene una ranura que recibe el eje del catéter (51) que seextiende en una primera punta de calibración (52) sobre un lado y una segunda punta de calibración (54) sobreel otro lado; en el que dichas puntas de calibración son capaces de ser detectadas por dicho sistema denavegación y en el que un eje del catéter guía se abrocha por presión dentro de la ranura que recibe el eje (51)con un extremo distal (ED) de dicho catéter colocado en la segunda punta de calibración (54), de tal maneraque un eje que corre a través de las dos puntas de calibración (52, 54) es coincidente con el eje del de la partede salida distal del catéter guía.",ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,,https://lens.org/102-771-454-696-692,Granted Patent,no,0,0,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B19/00,,0,0,,,,ACTIVE
87,US,A1,US 2016/0058469 A1,048-135-567-373-394,2016-03-03,2016,US 201514845604 A,2015-09-04,US 201514845604 A;;US 201213451020 A;;US 43689706 A,2006-05-17,ADAPTER FOR ATTACHING ELECTROMAGNETIC IMAGE GUIDANCE COMPONENTS TO A MEDICAL DEVICE,Devices and methods wherein an adapter is used to attach an electromagnetic image guidance component to a medical device such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,ACCLARENT INC (2015-09-28),https://lens.org/048-135-567-373-394,Patent Application,yes,5,0,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B17/34;;A61B1/313;;A61B6/00;;A61B6/12,,0,0,,,,ACTIVE
88,US,B2,US 8190389 B2,059-692-932-411-514,2012-05-29,2012,US 43689706 A,2006-05-17,US 43689706 A,2006-05-17,Adapter for attaching electromagnetic image guidance components to a medical device,Devices and methods wherein an adapter is used to attach an electromagnetic image guidance component to a medical device such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K;;ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,ACCLARENT INC (2006-07-17),https://lens.org/059-692-932-411-514,Granted Patent,yes,115,113,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,G01C25/00;;G06F19/00,702/85;;33/501;;73/1.01;;73/1.79;;702/97,99,66,090-798-792-511-247;;130-499-350-444-007;;025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;009-319-672-632-222;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;026-029-145-609-339;;043-068-503-393-610;;066-559-118-020-405;;062-351-127-043-686;;004-569-239-507-13X;;015-741-985-781-596;;006-017-396-056-413;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640;;118-873-204-442-663;;075-344-428-432-470,14835484;;14927373;;10.1001/jama.1952.02930220026009;;4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.1016/s0194-5998(03)01397-4;;12958561;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1016/0022-1139(94)03130-4;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;19623527;;10.1177/014556130908800708;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.3109/13645709809152853;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783;;10947988;;10.1126/science.289.5482.1197;;8374351;;10.1007/978-3-642-84913-8_3,"Göttman, et al.; Balloon Dilation of Recurrent Ostial Occlusion of the frontal sinus; Abstract No. B-04353, European Congress of Radiology, Mar. 2001.;;Göttman, et al., Balloon dilatation of recurrent ostial occlusion of the front sinus; ECR, Mar. 2, 2001.;;Göttman, et al., Successful Treatment of Recurrent Post-operative Frontal Sinus Stenoses by Balloon Dilatation; CIRSE, Oct. 5, 2002.;;Göttman, et al., Balloon dilatation in the nasal cavity and paranasal sinuses; CIRSE, Sep. 25, 2004.;;Robison, J. Mathews, M.D., Pressure Treatment of Purulent Maxillary Sinusitis, Texas State Journal of Medicine, May 1951, pp. 281-288.;;Robison, J. Mathews, M.D., Pressure Treatment of Maxillary Sinusitis, J.A.M.A., May 31, 1952, pp. 436-440.;;Strohm et al. Die Behandlung von Stenosen der oberen Luftwege mittels röntgenologisch gesteuerter Ballondilation Sep. 25, 1999.;;Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni-Ti Alloy Guidewire (2001).;;Aust, R., et al 'The Functional Size of the Human Maxillary Ostium in Vivo' Acta. Otolaryn. (1978) vol. 78 pp. 432-435.;;Baim, D.S., MD Grossman's Cardiac Catheterization, Angiography, and Intervention (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. 'Be Wary of Neurocranial Restructuring (NCR)' Chirobase (available at: .chirobase.org/06DD/ncr.html) (Jul. 2003.).;;Bartal, N. 'An Improved Stent for Use in the Surgical Management of Congenital Posterior Choanal Atresia' J. Laryngol. Otol. (1988) vol. 102 pp. 146-147.;;Becker, A.E. 'Restenosis After Angioplasty' The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter-Balloon Catheter-Thomas Fogarty. inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al. Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysiology Arch Otolarygol Head and Neck Surg. (Sep. 2003) vol. 129 pp. S1-S32.;;Bent et al. 'The Frontal Cell as a Cause of Frontal Sinus Obstruction' American Journal of Rhinology. (1994) vol. 8, No. 4 pp. 185-191.;;Binner et al. 'Fibre-Optic Transillumination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease' Clinical Otolaryngology. (1978) vol. 3 pp. 1-11.;;Brown, C.L. et al 'Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation' Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al. 'Endoscopic Lothrop Procedure: The University of Miami Experience' American Journal of Rhinology (1998) vol. 12, No. 5 pp. 335-339.;;Casserly, I.P. et al Chapter 7. 'Guides and Wires in Percutaneous Coronary Intervention' Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. Nasal Systemic Drug Delivery, Drugs and the Pharmaceutical Sciences (1989) Marcel Dekker, Inc. Chapter 3, pp. 39-88.;;Cohen et al 'Endoscopic Sinus Surgery: Where we are and where we're going' Current Opinion in Otolaryngology & Head and Neck Surgery (2005) vol. 13 pp. 32-38.;;Colla, A. et al 'Trihaloacetylated Enol Ethers-General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine' Synthesis. (Jun. 1991) pp. 483-486.;;Costa, M.N. et al 'Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5Flurorouracil' Clinics. (2007) vol. 62, Issue 1 pp. 41-46. scielo.br/scielo.php?pid=S1807-59322007000100007&script=sci-arttext.;;Davis, G.E. et al., 'A Complication From Neurocranial Restructuring' Arch Otolaryngology Head Neck Surg. (Apr. 2003) vol. 129 pp. 472-474.;;Deutschmann, R. et al. 'A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication' Stomat DDR 26, (1976) pp. 585-592.;;Draf, W. 'Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept' Op Tech Otolaryngol Head Neck Surg. (1991) vol. 2 pp. 234-240.;;Edmond et al 'ENT Surgical Stimulator' Nov. 1998 Final Report Cooperative Agreement No. DAMD17-95-2-5023.;;ENT Checklist; Physical Examination Performance Checklist.;;Eremychev, V.A. 'Needles for Puncture and Drainage of the Maxillary Sinus' Meditsinskaya Tekhnika, No. 5 (1974) pp. 54-55.;;Feldman, R.L. et al 'New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter' Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. 'A Multipurpose Layngeal Injector Device' Otolaryngol. Head Neck Surg (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M. M.D., et al 'Frontal Sinus Surgery: Endoscopic Technique' Operative Techniques in Otolarynology-Head and Neck Surgery. (Jun. 2001) vol. 12, No. 2 pp. 60-65.;;Friedman, et al 'Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination' Laryngoscope. (Apr. 2000) vol. 110 pp. 683-684.;;Friedman et al 'Middle Turbinate Medialization and Preservation in Endoscopic Surgery' Otolaryngol. Head Neck Surg. (2000) vol. 123, No. 1, Part 1. pp. 76-80.;;Fung, M.K.T. 'How I Do It-Head and Neck and Plasic Surgery. A Targeted Problem and its Solution. Template for Frontal Osteoplastic Flap' Laryngoscope. (1986) vol. 96 pp. 578-579.;;Gatot, A. et al., 'Early Treatment of Orbital Floor Fractures with Catheter Balloon in Children' Int. J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al 'beta-Ethoxyvinyl Polyfluroroalkyl Ketones-Versatile Synthones in Fluoroorganic Chemistry' Journal of Fluorine Chemistry. (1994) vol. 69 pp. 195-198. Elsevier Science S.A.;;Good, R.H. 'An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage' Laryngoscope. (1908) vol. 18 pp. 266-274.;;Gopferich 'Polymer Degradation and Erosion: Mechanisms and Applications' Eur. J. Pharm. Biophar. (1996) vol. 42 pp. 1-11.;;Gorlov, D.V. et al 'Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Tertiary Amines' Russian Chemical Bulletin. (Sep. 1999) vol. 48 No. 9 pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottman, et al. 'Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus' Abstract No. B-04353. European Congress of Radiology. (Mar. 2, 2001).;;Gupta, D. et al 'Dacryocystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus' Ear, Nose & Throat Journal (2009) findarticles.com/p/articles/mi-m0BUM/is-7-88/ai-n32428620/.;;Hashim, et al 'Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery' Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al 'Electrophilic Substitutions of Olefinic Hydrogens II. Acylation of Vinyl Ethers and N Vinyl Amides' Chemistry Letters (1976) pp. 499-502.;;Hopf, J.U.G. et al 'Miniature Endoscopes in Otorhinolaryngologic Applications' Min Invas Ther & Allied Technol (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al 'Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation' American Journal of Rhinology (1997) vol. 11, No. 1 pp. 1-9.;;Hosemann, M.E. et al 'Experimentelle Untersuchungen zur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss and medikamentose Effekte im standardisierten Wundmodell.' HNO 39 (1991) pp. 48-54.;;Hosemann, M.E. et al 'Normal Wound Healing of the Paranasal Sinuses-Clinical and Experimental Investigations' Eur Arch Otorhinolarygol. (1991) vol. 248 pp. 390-394.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. 'Transillumination During Osteoplastic Frontal Sinusotomy' The Laryngoscope (Sep. 1981) vol. 91 pp. 1560.;;Ijaduola, T.G.A. 'Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery' The Journal of Laryngology and Otology. (1989) vol. 103 pp. 375-378.;;Iro, H. et al 'A New Device for Frontal Sinus Endoscopy: First Clinical Report' Otolaryngol. Head Neck Surg (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. '100 Years of Frontal Sinus Surgery' Laryngoscope. (1997) vol. 107 pp. 1-36.;;Kennedy, D.W., M.D. et al Diseases of the Sinuses Diagnosis and Management (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al 'Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description' Pharmaceutical Chemistry Journal. (Nov. 2001) vol. 35, No. 11 pp. 627-629.;;Kingdom, T.T. et al 'Image-Guided Surgery of the Sinuses: Current Technology and Applications' Otolaryngol. Clin. North Am. (Apr. 2004) vol. 37, No. 2 pp. 381-400.;;Klossek, J.M. et al 'Local Safety of Intranasal Triamcinolone Acetonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis' Rhinology (2001) vol. 39, No. 1 pp. 17-22.;;Kozlov et al 'Diagnosis and Treatment of Sinusitis by Yamik Sinus Catheters' Rhinology (1996) vol. 34. pp. 123-124.;;Kuhn, et al. 'The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation' Operative Techniques in Otolaryngology-Head and Neck Surgery (1991) vol. 2, No. 4 pp. 226-231.;;Laliberte F. et al 'Clinical and Pathologic Methods to Assess the Long-Term Safety or Nasal Corticosteroids' Allergy (2000) vol. 55, No. 8 pp. 718-722.;;Lang, E.V. et al 'Access Systems for Puncture at an Acute Angle' J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. 'Postoperative Care and Avoiding Frontal Recess Stenosis' International Advanced Sinus Symposium. General Session Abstracts. Jul. 21-24, 1993.;;Large, G.C. 'Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis' Canad. M. A. J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. 'Maximal Medical Therapy for Chronic Rhinosinusitis' Otolaryngol Clin N Am. (2005) vol. 38 pp. 1301-1310.;;Maran, A.G.D. et al 'The Use of the Foley Catheter in the Tripod Fracture' J. Laryngol. Otol (1971) vol. 85, Issue 9 pp. 897-902.;;May, M. et al 'Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach' Op Tech Otolaryngo Head Neck Surgery (1995) vol. 6, No. 3 pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser. xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al 'Coronary Angioplasty through 4 French Diagnostic Catheters' Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al 'Synthesis of Trifluromethylnaphthalenes' Tetrahedron (2000) vol. 56 pp. 10067-10074. Elseview Science Ltd.;;Metson, R. et al 'Endoscopic Treatment of Sphenoid Sinusitis' Otolaryngol. Head Neck Surg (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. 'Holmium: Yag Laser Endoscopic Sinus Surgery: A Randomized Controlled Study' Laryngoscope (Jan. 1996) vol. 106, Issue 1, Supplement 77 pp. 1-18.;;Miller et al. 'Management of Fractures of the Supraorbital Rim' Journal of Trauma (Jul. 1978) vol. 18, No. 7 pp. 507-512.;;Min, Y-G et al. 'Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer' Laryngoscope (Aug. 1995) vol. 105 pp. 835-842.;;Mols, B. 'Moveable Tool Tip for Keyhole Surgery' Delft Outlook (2005) vol. 3 pp. 13-17.;;Mooney, M.R. et al 'Monorail(TM) Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System' Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al 'Addition-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins' J. Org. Chem. (1995) vol. 60, No. 11 pp. 3523-3528. American Chemical Society.;;Piccirillo, J.F. et al 'Psychometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20)' Otolaryngol. Head Neck Surg (2002) vol. 126, No. 1 pp. 41-47.;;Piers, et al 'A Flexible Distal Tip with Two Degrees of Freedom for Enhanced Dexterity in Endoscopic Robot Surgery' Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L. et al 'Balloon Technique for Treatment of Frontal Sinus Fractures' The Journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al 'Diagnostic Nasal Endoscopy' Plastic & Reconstructive Surgery (1997) vol. 99, Iss. 5 pp. 1451-1458.;;Prince et al 'Analysis of the Intranasal Distribution of Ointment' J Otolaryngol. (1997) vol. 26 pp. 357-360.;;Ramsdale, D.R. Illustrated Coronary Intervention A case-oriented approach (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Maxillary Sinusitis' J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Purulent Maxillary Sinusitis' Texas State Journal of Medicine. (May 1951) pp. 281-288.;;Sama, A. et al 'Current Opinions on the Surgical Management of Frontal Sinus Disease' Ent News. pinpointmendical.com/ent-news (2009) vol. 17 No. 6 pp. 60-63.;;Sanborn, T.A., et al 'Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance' Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon, Washington 98070 USA.;;Saxon, R.R., et al 'Technical Aspects of Accessing the Portal Vein During the Tips Procedure' J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. Rhinology and Sinus Disease A Problem-Oriented Approach (Copyright 1988) by Mosby, Inc.;;Schneider. Pfizer Ad for Softip.;;Shah, N. J. et al 'Endoscopic Pituitary Surgery-A Beginner's Guide' Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N. J. 'Functional Endoscopic Sinus Surgery' (1999); found at bhj.org/journal/1999-4104-oct99/sp-659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems. dymax.com/products/curing-equipment/lightguids/light. (2004) pp. 1-2.;;Sobol, et al 'Sinusitis, Maxillary, Acute Surgical Treatment.' eMedicine. Retrieved from the Internet: > (Nov. 16, 2010) pp. 1-11.;;St. Croix, et al 'Genes Expressed in Human Tumor Endothelium' Science (May 15, 2000) vol. 289 pp. 1197-1202.;;Stammberger H. 'Komplikationen entzundlicher Nasennebenhohlenerkrankungen eischliebetalich iatrogen bedingter Komplikationen.' Eur Arch Oti-Rhino-Laryngol Suppl. (Jan. 1993) pp. 61-102.",ACTIVE
89,EP,B1,EP 1857071 B1,123-179-314-107-437,2012-08-01,2012,EP 07252018 A,2007-05-16,US 43689706 A,2006-05-17,Adapter for attaching electronic image guidance components to a medical device,,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,,https://lens.org/123-179-314-107-437,Granted Patent,yes,8,0,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B19/00,,0,0,,,,ACTIVE
90,EP,A3,EP 1857071 A3,184-199-259-032-209,2008-05-07,2008,EP 07252018 A,2007-05-16,US 43689706 A,2006-05-17,Adapter for attaching electronic image guidance components to a medical device,"Devices and methods wherein an adapter (10) is used to attach an electromagnetic image guidance component (12) to a medical device (14) such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.
 
 
",ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,,https://lens.org/184-199-259-032-209,Search Report,yes,8,0,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B19/00,,0,0,,,,ACTIVE
91,US,B2,US 9629656 B2,147-707-349-337-977,2017-04-25,2017,US 201514845604 A,2015-09-04,US 201514845604 A;;US 201213451020 A;;US 43689706 A,2006-05-17,Adapter for attaching electromagnetic image guidance components to a medical device,Devices and methods wherein an adapter is used to attach an electromagnetic image guidance component to a medical device such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.,ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,ACCLARENT INC (2015-09-28),https://lens.org/147-707-349-337-977,Granted Patent,yes,861,0,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B1/313;;A61B6/00;;A61B6/12;;A61B17/00;;A61B17/34;;A61B34/20;;A61B90/00;;A61B90/50;;A61B90/94,,234,71,025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;009-319-672-632-222;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;043-068-503-393-610;;066-559-118-020-405;;062-351-127-043-686;;004-569-239-507-13X;;015-741-985-781-596;;021-250-660-000-916;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;012-223-832-603-044;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640;;118-873-204-442-663;;035-586-137-258-637;;089-247-655-233-31X;;068-237-019-427-50X;;061-764-129-861-905;;024-069-245-302-733;;082-361-279-623-107;;137-659-727-058-857;;012-462-482-441-732,4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.1016/s0194-5998(03)01397-4;;12958561;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;19623527;;10.1177/014556130908800708;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.2500/105065897781446793;;9065341;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1288/00005537-190508000-00009;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783;;10947988;;10.1126/science.289.5482.1197;;10.1055/s-2007-997515;;9487485;;10416252;;10.1002/ccd.1810150211;;3052851;;10190702;;10.1016/s0165-5876(98)00119-0;;10.1001/archopht.116.5.688;;9596514;;10.1017/s0022215100141052;;9764294;;11209511;;10.1177/014556130108000103;;8001106;;10.1002/ccd.1810330117,"Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni-Ti Alloy Guidewire (2001).;;Aust, R., et at., ‘The Functional Size of the Human Maxillary Ostium in Vivo’ Acta. Otolaryn. (9178) vol. 78 pp. 432-435.;;Baim, D.S., MD ‘Grossman's Cardiac Catheterization, Angiography, and Intervention’ (200) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. ‘Be Wary of Neurocranial Restructuring (NCR)’ Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html.;;Bartal, N. ‘An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia’ J. Laryngol. Otol (1988) vol. 102 pp. 146-7.;;Becker, A.E. ‘Restenosis After Angioplasty’ The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter-Balloon Catheter—Thomas Fogarty. Www.inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al.; Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysilogy Arch Otolarygol Head and Neck Surg. vol 129 (Sep. 2003) pp. A1-S32.;;Bent et al., ‘The Frontal Cell as a Cause of Frontal Sinus Obstruction’ American Journal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191.;;Binner et al., ‘Fibre-Optic Transillunination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Diseas’ Clinical Otolaryngology, vol.3 (1978) pp. 1-11.;;Brown, C.L. et al., ‘Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation’ Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al., ‘Endoscopic Lothrop Procedure: the University of Miami Experience’ American Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339.;;Casserly, I.P. et al., Chapter 7. ‘Guides and Wires in Percutaneous Coronary Intervention’ Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al., ‘Nasal Systemic Drug Delivery’, Drugs and Pharmaceutical Sciences, vol. 39, pp. 60-63.;;Cohen et al. ‘Endoscopic Sinus Surgery: Where we are and where we're going’ Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38.;;Colla, A. et al., ‘Trihaloacetylated Enol Ethers-General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine’ Synthesis, (Jun. 1991) pp. 483-486.;;Costa, M.N. et al. ‘Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil’ Clinics (2007) vol. 62, Issue 1, pp. 41-46.;;Cussler, E.L. ‘Diffusion: Mass transfer in Fluid Systems’ Cambridge University Press (1996).;;Davis, G.E. et al. ‘A Complication from Neurocranial Restructuring’ Arch Otolaryngol Head Neck Surg. vol. 129 (Apr. 2003) pp. 472-474.;;Deutschmann, R. et al., ‘A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication’ Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al., ‘Handbook of Biodegradable Polymers’ Harwood Academic Publishers (1997).;;Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints htm.;;Draf, W. ‘Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept’ Op Tech Otolaryngol Head Neck Surg. vol. 2 (1991) pp. 234-240.;;Edmond, C. et al., ‘ENT Surgical Stimulator’ Nov. 1989.;;Ent Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. ‘Needles for Puncture and Drainage of the Maxillary Sinus’ Meditsinskaya Tekhnika, No. 5 (1974) pp. 54.55.;;Feldman, R.L. et al., ‘New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. ‘A Multipurpose Laryngeal Injector Device’ Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M., M.D., et al. ‘Frontal Sinus Surgery: Endoscopic Technique’ Operative Techniques in Otolarynology—Head and Neck Surgery. vol. 12, No. 2 (Jun. 2001) pp. 60-65.;;Friedman, et al., ‘Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination’ Laryngoscope. vol. 110 (Apr. 2000) pp. 683-684.;;Friedman, et al., ‘Middle Turbinate Medialization and Preservation in Endoscopic Surgery’ Otolaryngology—Head and Neck Surgery. (2000) vol. 123, No. 1, part 1, pp. 76-80.;;Fung, M.K.T. ‘Template for Frontal Osteoplastic Flap’ Laryngoscope. vol. 96 (1986) pp. 578-579.;;Gatot, A. et al., ‘Early treatment of Orbital Floor Fractures with Catheter Balloon in Children’ Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al. ‘β-Ethoxyvinyl Polyfluroroalkyl Ketones—Versatile Synthones in Fluoroorganic Chemistry’ Journal of Fluorine Chemistry. vol. 69 (1994) pp. 195-198.;;Good, R.H. ‘An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage’ Laryngoscope. vol. 18 (1908) pp. 266-274.;;Gopferich ‘Polymer Degradation and Erosion: Mechanisms and Application’ Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11.;;Gorlov, D.V. et al., ‘Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence ot Teriary Amines’ Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottmann, et al., ‘Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses’CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottman, et al., Balloon Dilation of Recurrent Ostial Occlusion of the frontal sinus; Abstract No. B-04353, European Congress of Radiology, Mar. 2001.;;Gottman, et al., ‘Balloon Dilatation of recurrent ostial occlusion of the front sinus’ ECR, Mar. 2, 2001.;;Gottman, D. ‘Treatment of Stenoses of Upper Air Routes by Balloon Dilatation’ Proceeding of the 83rd Annual Convention of the Association of West German ENT Physicians (1999).;;Gottman, et al., ‘Successful treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilation’ CIRSE. Oct. 5, 2002.;;Gottman, et al., ‘Balloon Dilatation in the nasal cavity and paranasal sinuses’ CIRSE, Sep. 25, 2004.;;Gupta, D. et al., ‘Dacrystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus’ Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi—m0BUM/is—7—88/ai—n32428620/.;;Hashim, et al., ‘Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery’ Scandinavian Journal of Plastic and reconstruction Sergery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al., ‘Electrophilic Substiutions of Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides Chemistry Letters’ (1976) pp. 499-502. Chemical Society of Japan.;;Hopf, J.U.G. et al., ‘Minature Endoscopes in Otorhinolaryngologic Applications’Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al., A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al., ‘Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation’ American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9.;;Hosemann, M.E. et al., ‘Experimental investigations on wound healing of the paranasal sinuses. II. Spontaneous would closure and pharmacological effects in a standardized animal model.’ HNO 39 (1991) pp. 48-54.;;Hosemann, W.G. et al. ‘Minimally Invasive Endonasal Sinus Surgery’ Thieme, Stuttgart, New York (2000).;;Hosemann, M.E. et al. ‘Normal Wound Healing of the Paranasal Sinuses- Clinical and Experimental Investigations’ Eur Arch Otorhinolarygol. vol. 248, (1991) pp. 390-394.;;Hosemann, W. et al. ‘Behandlung nach Nasennebenhohleneingriffen, part 2: Theapeutische Malβnahem’ HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr., 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. ‘Transillumination Durning Osteoplastic Frontal Sinusotomy’ the Laryngoscope. vol. 91 (Sep. 1981) pp. 1560.;;Ijaduola, T.G.A. ‘Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery’ Ther Journal of Laryngology and Otology. (1989) vol. 103. pp. 375-378.;;Ingals, E.F. ‘New Operation and Instruments for Draining the Frontal Sinus’ Ann. Otol. Rhinol. Layyngol. vol. 14 (1905) pp. 644-649.;;Iro, H. et al., ‘A New Device for Frontal Sinus Endoscopy: First Clinical Report’ Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. ‘100 Years of Frontal Sinus Surgery’ Laryngoscope. vol. 107 (1997) pp. 1-36.;;K-Splints Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html.;;Kaiser, H. et al., ‘Cortizontherapie, Corticoide in Klinik and Praxis’ Thieme, Stuggart (1992) pp. 390-401.;;Kennedy, D.W., M.D. et al. ‘Diseases of the Sinuses: Diagnosis and Management’ (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al. ‘Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description’ Pharmaceutical Chemistry Journal. vol. 35, No. 11 (Nov. 2001) pp. 627-629.;;Kingdom, T. et al., Image-Guided Surgery of the Sinuses: Current Technology and Applications, Otolaryngol. Clin. North Am. 37(2):381-400 (Apr. 2004);;Klossek, J.M. et al. ‘Local Safety of Intranasal Trimcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis’ Rhinology. vol. 39, No. 1 (2001) pp. 17-22.;;Kozlov et al. ‘Diagnosis and Treatment of Sinusitis by Yamik Sinus Catheters’ Rhinology (1996) vol. 34, pp. 123-124.;;Kuhn, et al. ‘The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation’ Operative Techniques in Otolaryngology-Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231.;;Laliberte, F. et al. ‘Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids’ Allergy. vol. 55, No. 8 (2000) pp. 718-722.;;Lang, E.V. et al., ‘Access Systems for Puncture at an Acute Angle’ J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. ‘Postoperative Care and Avoiding Frontal Recess Stenosis’ International Advanced Sinus Symposium (1993) Jul. 21-24.;;Large, G.C. ‘Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis’ Canad. M.A.J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. ‘Maximal Medical Therapy for Chronic Rhinosinusitis’ Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310.;;Maran, A.G.D. et al., ‘The Use of the Foley Balloon Catheter in the Tripod Fracture’ J. Laryngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902.;;May, M. et al., ‘Frontal Sinus Surgery: Endonasal Drainage instead of an External Osteopolstic Approach’ Op Tech Otolaryngo Head Neck Surgery. 6 (1995) pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser, www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al., ‘Coronary Angioplasty through 4 French Diagnostic Catheters’ Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al ‘Synthesis of Trifluromethylnaphthalenes’ Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd.;;Metson, R., et al., ‘Endoscopic Treatment of Sphenoid Sinusitis’ Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. ‘Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study’ Laryngoscope. vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18.;;Miller, et al. ‘Management of Fractures of the Supraorbital Rim’ Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512.;;Min, Y-G et al. ‘Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer’ Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842.;;Mols, B. ‘Movable Tool Tip for Keyhole Surgery’ Delft Outlook, vol. 3 (2005) pp. 13-17.;;Mooney, M.R., et al., ‘Monorail™ Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System’ Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al. ‘Additional-Elimination Reaction in the Trifluoroacetylation of Electron- Rich Olefins’ J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523-3528. American Chemical Society.;;Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html.;;Park, K. et al. ‘Biodegradable Hydrogels for Durg Delivery’ (1993) Technomic Publishing Inc. Lancaster.;;Peirs, et al. ‘A Flexible Distal Tip with Two Degrees of Freedon for Enhanced Dexterity in Endoscopic Robot Surgery’ Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Piccirillo, J.F. et al. ‘Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)’ Copyright 1996 Washington University, St. Louis, MO.;;Podoshin, L et al. ‘Balloon Technique for Treatment of Frontal Sinus Fractures’ The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al., ‘Diagnostic Nasal Endoscopy’ plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458.;;Prince, et al. ‘Analysis of the Intranasal Distribution of Ointment’ J Otolaryngol. vol. 26 (1997) pp. 357-360.;;Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Maxillary Sinusitis’ J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Purulent Maxillary Sinusitis’ Texas State Journal of Medicine (May 1952) pp. 281-288.;;Schneider. Pfizer Ad for Softip [date of publication unknown].;;Sama, A., et al., ‘Current Opinions on the Surgical Management of Frontal Sinus Disease’ ENT News. Www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63.;;Sanborn, T.A. et al., ‘Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance’ Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vachon Washington 1 98070 USA.;;Saxon, R.R. et al., ‘Technical Aspects of Accessing the Portal Vein During the TIPS Procedure’ J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. ‘Rhinology and Sinus Disease: A Problem-Oriented Approach’ (Copyright 1988) by Mosby, Inc.;;Shah, N.J. et al., ‘Endoscopic Pituitary Surgery- A Beginner’s Guide' Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. et al., ‘Functional Endoscopic Sinus Surgery’ (1999); found at bhj.org/journal/1999—4104—oct99/sp—659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems. Www.dymax.com/products/curing—equipment/lightguids/light. (2004) pp. 1-2.;;Sobol, et al. ‘Sinusitis, Maxillary, Acute Surgical Treatment.’ eMedicine. Retrieved from the Internet: <<http://emedicine.medscape.com/article/862030-print>> (Nov. 16, 2010) pp. 1-11.;;St. Croix, et al., ‘Genes Expressed in Human Tumor Endothelium’ Science (May 15, 2000) vol. 289 pp. 1197-1202.;;Stammberger, H. ‘Komplikationen entzundlicher Nasennebenhohlenerkrankungen eischlieβ iatrogen bedingter Komplikationen’ Eur Arch Oti-Rhino-Laryngol Supple. (1993/1) pp. 61-102.;;Stammberger, et al. Chapter 3 ‘Special Endoscopic Anatomy of the Lateral Nasal Wall and Ethmoidal Sinuses’ Functional Endoscopic Sinus Surgery. (1991) Ch. 3, pp. 49-87.;;Strohm, et al., Die Behandlung von Stenosen der oberen Luftwege mittels rontgenologisch gesteuerter Ballondilation (Sep. 25, 1999) pp. 1-4.;;Strohm, et al., ‘Treatment of the Stenoses of the Upper Air Routes by Balloon Dilation’ Sudwestdeutscher (Sep. 25, 1999) Abstract 45 pp. 1-3.;;SurgTrainer Product Information ‘Incisive Human Nasal Model for ESS Training’ Surg Trainer, Ltd. Ibaraki, Japan (2004) www1.accsnet.ne.jp/˜juliy/st/en/partslist.html.;;Tabor, M.H. et al., ‘Symptomatic Bilateral Duct Cysts in a Newborn- Rhinoscopic Clinic’ Ear, Nose & Throat Journal (2003) www.findarticles.com/p/articles/mi—m0BUM/is—2—82/ai—98248244 pp. 1-3.;;Tarasov, D.I. et al. ‘Application of Drugs Based on Polymers in the Treatment of Acute and Chronic Maxillary Sinusitis’ Vestn Otorinoloaringol. vol. 6 (1978) pp. 45-47.;;Terumo. Medi-Tech. Boston Scientific. (1993) Ad of Glidewire.;;The Operating Theatre Journal (www.otjonline.com) ‘Disposable Medical Device for Wound Disclosure/The Tristel Purple Promotion- A Collaboration between Tristel PLC and Karl Storz Ednoscopy (UK) Ltd.’ p. 4.;;Weber, R. et al. ‘Endonsale Stirnhohlenchirugie mit Langzeiteinlage eines Platzhalters’ Laryngol. Rhinol. Otol. vol. 76 (1997) pp. 728-734. (English Abstract).;;Weber, R. et al., ‘Videoendoscopic Analysis of Nasal Steroid Distribution’ Rhinology. vol. 37 (1999) pp. 69-73.;;Weiner, R.I., D.O., et al., ‘Development and Application of Transseptal Left Heart Catheterization’ Cathet. Cardiovasc. Diagn. (1988) vol. 15, No. 2, pp. 112-120.;;Wiatrak, B.J., et al., ‘Unilateral Choanal Atresia: Initial Presentation and Endoscopic Repair’ International Journal of Pediatric Otorhinolaryngology (1998) vol. 46, pp. 27-35.;;Woog, et al. ‘Paranasal Sinus Endoscopy and Orbital Fracture Repair’Arch Ophthalmol. vol. 116 (May 1998) pp. 688-691).;;Wormald, P.J., et al., ‘The 'Swing-Door' Technique for Uncinectomy in Endoscopic Sinus Surgery’ The Journal of Laryngology and Otology (1998) vol. 112, pp. 547-551.;;Xomed-Treace. Bristol-Myers Squibb. Ad for Laser Shield II. Setting the Standards for Tomorrow. [date of publication unknown].;;Yamauchi, Y. et al., ‘Development of a Silicone Model for Endoscopic Sinus Surgery’ Proc International Journal of Computer Assisted Radiology and Surgery vol. 99 (1999) p. 1039.;;Yamauchi, T., et al., ‘A Training System for Endoscopic Sinus Surgery with Skill Evaluation’ Computer Assisted Radiology and Surgery (2001) with accompanying copy of poster presentation.;;Yanagisawa et al. ‘Anterior and Posterior Fontanelles.’ Ear, Nose & Throat Journal (2001) vol. 80. pp. 10-12.;;Zimarino, M., M.D., et al., ‘Initial Experience with the EuropassTM: A new Ultra-Low Profile monorail Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1994) vol. 33, No. 1, pp. 76-79.;;Australian Office Action, Examiner's First Report, dated Apr. 8, 2010 for AU 2005274794.;;European Communication dated Sep. 4, 2008 for Application No. EP 05773189.;;European Communication dated Jun. 19, 2009 for Application No. EP 05773189.;;European Exam Report dated Feb. 22, 2006 for Application No. 02716734.5.;;European Exam Report dated Feb. 8, 2007 for Application No. 02716734.5.;;Partial European Search Report dated Sep. 20, 2007 for Application No. EP 07252018.;;Partial European Search Report dated Mar. 25, 2008 for Application No. EP 07252018.;;Supplemental Partial European Search Report dated Jun. 2, 2008 for Application No. EP 05773189.;;Supplemental Partial European Search Report dated Jul. 1, 2009 for Application No. EP 06815285.;;Supplemental European Search Report and Written Opinion dated Sep. 11, 2009 for Application No. EP 06815174.;;Supplemental European Search Report dated Jan. 29, 2010 for Application No. EP 07836108.;;Supplemental European Search Report dated Feb. 2, 2010 for Application No. EP 07836109.;;Supplemental European Search Report dated Feb. 17, 2010 for Application No. EP 1 07836110.;;Supplemental European Search Report dated Mar. 1, 2010 for Application No. EP 05778834.;;Supplemental European Search Report dated Mar. 16, 2010 for Application No. EP 06718986.;;Supplemental European Search Report dated Jun. 22, 2010 for Application No. EP 06784759.;;Supplemental European Search Report dated Sep. 23, 2010 for Application No. EP 08746715.;;Supplemental Partial European Search Report dated Nov. 19, 2010 for Application No. EP 06751637.;;Supplemental European Search Report dated Jan. 28, 2011 for Application No. EP 07777004.;;Supplemental European Search Report dated Mar. 31, 2011 for Application No. EP 05798331.;;Supplemental European Search Report dated Aug. 30, 2011 for Application No. EP 06800540.;;Supplemental European Search Report dated Sep. 29, 2011 for Application No. EP 07750248.;;European Search Report and Written Opinion dated Oct. 6, 2011 for Application No. EP 1 10182961.2.;;International Search Report dated Jun. 3, 2002 for Application No. PCT/EP02/01228.;;International Search Report and Written Opinion dated Apr. 10, 2006 for Application No. PCT/US05/25371.;;International Search Report dated May 8, 2007 for Application No. PCT/US2006/16026.;;International Search Report dated Aug. 17, 2007 for Application No. PCT/US05/013617.;;International Search Report dated Aug. 29, 2007 for Application No. PCT/US06/002004.;;International Search Report dated Sep. 25, 2007 for Application No. PCT/US06/037167.;;International Search Report dated Oct. 19, 2007 for Application No. PCT/US07/003394.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021170.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021922.;;International Search Report dated Jul. 1, 2008 for Application No. PCT/US06/022745.;;International Search Report dated Jul. 3, 2008 for Application No. PCT/US2006/029695.;;International Search Report dated Jul. 7, 2008 for Application No. PCT/US07/016213.;;International Search Report dated Jul. 8, 2008 for Application No. PCT/US07/011474.;;International Search Report dated Jul. 17, 2008 for Application No. PCT/US06/036960.;;International Search Report and Written Opinion dated Jul. 21, 2008 for Application No. PCT/US05/033090.;;International Search Report dated Aug. 25, 2008 for Application No. PCT/US2008/000911.;;International Search Report dated Sep. 10, 2008 for Application No. PCT/US07/016212.;;International Search Report and Written Opinion dated Sep. 12, 2008 for Application No. PCT/US07/16214.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/059786.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/061343.;;International Search Report and Written Opinion dated Oct. 1, 2008 for Application No. PCT/US07/011449.;;International Search Report dated Oct. 15, 2008 for Application No. PCT/US2008/061048.;;International Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203.;;International Search Report from PCT Application No. PCT/US2009/057203 dated Nov. 30, 2009 as issued by the European Patent Office as searching authority.;;International Search Report dated Dec. 10, 2009 for Application No. PCT/US2009/052236.;;International Search Report dated Dec. 16, 2009 for Application No. PCT/US2009/050800.;;International Search Report dated Mar. 31, 2010 for Application No. PCT/US2009/069143.;;International Search Report dated Jul. 8, 2010 for Application No. PCT/US2010/027837.;;International Search Report and Written Opinion dated Oct. 6, 2010 for Application No. PCT/US2010/040548.;;International Search Report dated Mar. 25, 2011 for Application No. PCT/US2010/062161.;;International Search Report dated Mar. 28, 2011 for Application No. PCT/US2010/061850.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2010/060898.;;International Search Report dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;International Preliminary Report on Patentability dated Aug. 7, 2006 for Application No. PCT/US05/25371.;;International Preliminary Report on Patentability and Written Opinion dated Sep. 25, 2007 for Application No. PCT/US06/002004.;;International Preliminary Report on Patentability dated Feb. 15, 2008 for Application No. PCT/US05/13617.;;International Preliminary Report onPatentability and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US07/11449.;;International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2009 for Application No. PCT/US07/021170.;;International Preliminary Report on Patentability and Written Opinion dated May 5, 2009 for Application No. PCT/US06/036960.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 13, 2009 for Application No. PCT/US08/059786.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 27, 2009 for Application No. PCT/US08/061343.;;USPTO Office Action dated Dec. 29, 2008 for U.S. Appl. No. 11/193,020.;;USPTO Office Action dated May 13, 2009 for U.S. Appl. No. 11/193,020.;;USPTO Office Action dated Sep. 16, 2005 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jul. 7, 2006 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Feb. 13, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 9, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jan. 24, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 06, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated May 29, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Nov. 14, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Dec. 6, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Apr. 9, 2008 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Nov. 28, 2007 for U.S. Appl. No. 11/234,395.;;USPTO Office Action dated Sep. 12, 2008 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Mar. 18, 2009 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Nov. 9, 2009 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Oct. 29, 2008 for U.S. Appl. No. 11/347,147.;;USPTO Office Action dated Feb. 4, 2009 for U.S. Appl. No. 11/347,147.;;USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 11/347,147.;;USPTO Office Action dated Nov. 7, 2008 for U.S. Appl. No. 10/944,270.;;USPTO Office Action dated Jan. 28, 2009 for U.S. Appl. No. 10/944,270.;;USPTO Office Action dated Apr. 21, 2009 for U.S. Appl. No. 10/944,270.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/117,582.;;USPTO Office Action dated Mar. 3, 2009 for U.S. Appl. No. 12/117,582.;;USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,582.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/118,931.;;USPTO Office Action dated Mar. 4, 2009 for U.S. Appl. No. 12/118,931.;;USPTO Office Action dated Jul. 30, 2009 for U.S. Appl. No. 12/118,931.;;USPTO Office Action dated Nov. 25, 2008 for U.S. Appl. No. 12/117,961.;;USPTO Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,961.;;USPTO Office Action dated Dec. 5, 2008 for U.S. Appl. No. 12/120,902.;;USPTO Office Action dated Oct. 21, 2009 for U.S. Appl. No. 12/120,902.;;USPTO Office Action dated Mar. 17, 2009 for U.S. Appl. No. 11/690,127.;;USPTO Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/804,309.;;USPTO Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/926,326.;;USPTO Office Action dated Aug. 28, 2009 for U.S. Appl. No. 11/150,847.;;U.S. Appl. No. 11/789,705, filed Apr. 24, 2007.;;U.S. Appl. No. 60/844,874, filed Sep. 15, 2006.;;U.S. Appl. No. 60/922,730, filed Apr. 9, 2007.;;U.S. Appl. No. 61/052,413, filed May 12, 2008.;;U.S. Appl. No. 61,084,949, filed Jul. 30, 2008.",ACTIVE
92,EP,A2,EP 1857071 A2,011-565-468-002-464,2007-11-21,2007,EP 07252018 A,2007-05-16,US 43689706 A,2006-05-17,Adapter for attaching electronic image guidance components to a medical device,"Devices and methods wherein an adapter (10) is used to attach an electromagnetic image guidance component (12) to a medical device (14) such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.
 
 
",ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,,https://lens.org/011-565-468-002-464,Patent Application,yes,0,0,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B19/00,,0,0,,,,ACTIVE
93,US,A1,US 2012/0245456 A1,047-217-336-190-200,2012-09-27,2012,US 201213451020 A,2012-04-19,US 201213451020 A;;US 43689706 A,2006-05-17,Adapter for Attaching Electromagnetic Image Guidance Components to a Medical Device,Devices and methods wherein an adapter is used to attach an electromagnetic image guidance component to a medical device such that an electromagnetic image guidance system may be used to track the location of the medical device within the body of a human or animal subject.,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K;;ACCLARENT INC,KIM ISAAC J;;GOLDFARB ERIC;;MUNI KETAN P;;MAKOWER JOSHUA;;DECKMAN ROBERT K,ACCLARENT INC (2006-07-17),https://lens.org/047-217-336-190-200,Patent Application,yes,5,20,10,10,0,A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B90/94;;A61B2034/2051;;A61B2090/3958;;A61B2090/3983;;A61B2090/3975;;A61B90/50;;A61B90/39;;A61B2090/397;;A61B1/313;;A61B6/12;;A61B6/485;;A61B17/3415;;A61B2017/00292;;A61B2017/3407;;A61B2017/3486,A61B5/05;;A61B1/00;;A61M25/01,600/424,0,0,,,,ACTIVE
94,US,A1,US 2006/0136274 A1,085-555-278-967-287,2006-06-22,2006,US 22526605 A,2005-09-12,US 22526605 A;;US 60920104 P,2004-09-10,"System, method, and apparatus for providing a single-entry and multiple company interface (SEMCI) for insurance applications and underwriting and management thereof","A system, method, and apparatus provides a real-time single-entry, multiple company interface (SEMCI) that allows users to complete applications via in an automated and efficient manner. data is collected in standard forms and stored in a database managed by a Managing General Agency (MGA). Underwriting personnel at the MGA can also enter client data on behalf of a User or unregistered Broker in a variety of scenarios. The Underwriter processes the application by performing real-time rating, binding, and policy issuance functions. Documents are communicated automatically using built-in communications functions. Automated system generated notes, non-automated user generated notes, and tracking and information control panels are provided. Automated reassignment of pending matters is enabled. Automated Endorsement, Renewal Application and Cancellation Request management systems exist. Online enrollment and re-authentication systems provide access to the data entry forms and document repository to retrieve and manage client information.",OLIVIER LYLE E;;ESKANAZY AL;;CARERI DENISE;;INTOCI FRANK;;GOLDFARB ROBERT;;PERISH DAVID L,OLIVIER LYLE E;;ESKANAZY AL;;CARERI DENISE;;INTOCI FRANK;;GOLDFARB ROBERT;;PERISH DAVID L,,https://lens.org/085-555-278-967-287,Patent Application,yes,10,24,1,3,0,G06Q40/00;;G06Q40/08;;G06Q40/00;;G06Q40/08,G06Q40/00,705/4,0,0,,,,DISCONTINUED
95,US,B2,US 8137874 B2,026-434-415-195-340,2012-03-20,2012,US 1854108 A,2008-01-23,US 1854108 A,2008-01-23,Organic graded spin on BARC compositions for high NA lithography,An antireflective coating that contains at least two polymer components and comprises chromophore moieties and transparent moieties is provided. The antireflective coating is useful for providing a single-layer composite graded antireflective coating formed beneath a photoresist layer.,GOLDFARB DARIO L;;VYKLICKY LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D;;IBM,GOLDFARB DARIO L;;VYKLICKY LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D,INTERNATIONAL BUSINESS MACHINES CORPORATION (2008-03-24);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/026-434-415-195-340,Granted Patent,yes,8,7,4,4,0,G03F7/091;;G03F7/091,G03F7/09;;G03F7/40,430/14;;430/271.1;;430/273.1;;430/325;;430/326;;430/311;;430/323;;430/313,0,0,,,,INACTIVE
96,EP,A1,EP 3998930 A1,033-725-830-000-76X,2022-05-25,2022,EP 20753579 A,2020-07-17,US 201962875298 P;;US 2020/0042484 W,2019-07-17,"SYSTEMS, DEVICES, AND METHODS FOR VISUALIZATION DURING MEDICAL PROCEDURES",,TUSKER MEDICAL INC,DOMECUS BRIAN;;KERMANI MAHYAR Z;;GIROTRA ROHIT;;GOLDFARB ERIC;;LANTZ ANDREW;;SCHNEIDER ROBERT EDWIN;;BIGHAM TYLER BENNETT,,https://lens.org/033-725-830-000-76X,Patent Application,yes,0,0,6,6,0,A61B1/227;;A61B1/04;;A61B1/018;;A61B1/00052;;A61B1/00105;;A61B1/227;;A61B1/018;;A61B1/00045;;A61B1/00114;;A61B1/00165;;A61B1/05;;A61B1/06;;A61B1/227;;A61B1/32,A61B1/00;;A61B1/227,,0,0,,,,PENDING
97,US,B2,US 8652762 B2,066-126-551-546-99X,2014-02-18,2014,US 201213423838 A,2012-03-19,US 201213423838 A;;US 1854108 A,2008-01-23,Organic graded spin on BARC compositions for high NA lithography,An antireflective coating that contains at least two polymer components and comprises chromophore moieties and transparent moieties is provided. The antireflective coating is useful for providing a single-layer composite graded antireflective coating formed beneath a photoresist layer.,GOLDFARB DARIO L;;VYKLICKY LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D;;IBM,GOLDFARB DARIO L;;VYKLICKY LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-15);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/066-126-551-546-99X,Granted Patent,yes,10,2,4,4,0,G03F7/091;;G03F7/091,H01L21/312;;G03F7/38;;H01L29/02,430/311;;430/271.1;;430/275.1;;430/272.1;;430/330;;430/325;;438/952,0,0,,,,ACTIVE
98,CN,A,CN 113993440 A,038-662-428-676-522,2022-01-28,2022,CN 202080043813 A,2020-07-17,US 201962875298 P;;US 2020/0042484 W,2019-07-17,"SYSTEMS, DEVICES, AND METHODS FOR VISUALIZATION DURING MEDICAL PROCEDURES","Visualization during medical procedures is provided using a visualization system comprising: a control device defining an upper surface and a lower surface; a display visible through the upper surface of the control device; a handle coupled to the lower surface and extending away from the lower surface; a knob coupled to the control device, the knob configured to rotate about a rotational axis; an imaging assembly mechanically coupled to the knob and communicatively coupled to the control device, the imaging assembly configured to rotate around the rotational axis based on rotation of the knob; and the control device configured to display an image on the display, the image captured by the imaging assembly.",TUSKER MEDICAL INC,DOMECUS BRIAN;;KERMANI MAHYAR Z;;GIROTRA ROHIT;;GOLDFARB ERIC;;LANTZ ANDREW;;SCHNEIDER ROBERT EDWIN;;BIGHAM TYLER BENNETT,,https://lens.org/038-662-428-676-522,Patent Application,no,0,0,6,6,0,A61B1/227;;A61B1/04;;A61B1/018;;A61B1/00052;;A61B1/00105;;A61B1/227;;A61B1/018;;A61B1/00045;;A61B1/00114;;A61B1/00165;;A61B1/05;;A61B1/06;;A61B1/227;;A61B1/32,A61B1/227;;A61B1/018;;A61B1/04;;A61F11/20,,0,0,,,,PENDING
99,WO,A1,WO 2021/011855 A1,069-033-310-395-461,2021-01-21,2021,US 2020/0042484 W,2020-07-17,US 201962875298 P,2019-07-17,"SYSTEMS, DEVICES, AND METHODS FOR VISUALIZATION DURING MEDICAL PROCEDURES","Visualization during medical procedures is provided using a visualization system comprising: a control device defining an upper surface and a lower surface; a display visible through the upper surface of the control device; a handle coupled to the lower surface and extending away from the lower surface; a knob coupled to the control device, the knob configured to rotate about a rotational axis; an imaging assembly mechanically coupled to the knob and communicatively coupled to the control device, the imaging assembly configured to rotate around the rotational axis based on rotation of the knob; and the control device configured to display an image on the display, the image captured by the imaging assembly.",TUSKER MEDICAL INC,DOMECUS BRIAN;;KERMANI MAHYAR Z;;GIROTRA ROHIT;;GOLDFARB ERIC;;LANTZ ANDREW;;SCHNEIDER ROBERT EDWIN;;BIGHAM TYLER BENNETT,,https://lens.org/069-033-310-395-461,Patent Application,yes,12,3,6,6,0,A61B1/227;;A61B1/04;;A61B1/018;;A61B1/00052;;A61B1/00105;;A61B1/227;;A61B1/018;;A61B1/00045;;A61B1/00114;;A61B1/00165;;A61B1/05;;A61B1/06;;A61B1/227;;A61B1/32,A61B1/00;;A61B1/227,,0,0,,,,PENDING
100,US,A1,US 2009/0186294 A1,066-094-338-175-639,2009-07-23,2009,US 1854108 A,2008-01-23,US 1854108 A,2008-01-23,ORGANIC GRADED SPIN ON BARC COMPOSITIONS FOR HIGH NA LITHOGRAPHY,An antireflective coating that contains at least two polymer components and comprises chromophore moieties and transparent moieties is provided. The antireflective coating is useful for providing a single-layer composite graded antireflective coating formed beneath a photoresist layer.,IBM,GOLDFARB DARIO L;;VYKLICKY LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D,INTERNATIONAL BUSINESS MACHINES CORPORATION (2008-03-24);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/066-094-338-175-639,Patent Application,yes,8,10,4,4,0,G03F7/091;;G03F7/091,G03F7/26;;G03F7/004,430/270.1;;430/322;;430/323,0,0,,,,INACTIVE
101,US,A1,US 2022/0240771 A1,163-302-015-376-751,2022-08-04,2022,US 202017623726 A,2020-07-17,US 202017623726 A;;US 201962875298 P;;US 2020/0042484 W,2019-07-17,"SYSTEMS, DEVICES, AND METHODS FOR VISUALIZATION DURING MEDICAL PROCEDURES","Visualization during medical procedures is provided using a visualization system comprising: a control device defining an upper surface and a lower surface; a display visible through the upper surface of the control device; a handle coupled to the lower surface and extending away from the lower surface; a knob coupled to the control device, the knob configured to rotate about a rotational axis; an imaging assembly mechanically coupled to the knob and communicatively coupled to the control device, the imaging assembly configured to rotate around the rotational axis based on rotation of the knob; and the control device configured to display an image on the display, the image captured by the imaging assembly.",TUSKER MEDICAL INC,DOMECUS BRIAN;;KERMANI MAHYAR Z;;GIROTRA ROHIT;;GOLDFARB ERIC;;LANTZ ANDREW;;SCHNEIDER ROBERT EDWIN;;BIGHAM TYLER BENNETT,TUSKER MEDICAL INC (2019-08-08);;TENSENTRIC INC (2019-08-07),https://lens.org/163-302-015-376-751,Patent Application,yes,0,3,6,6,0,A61B1/227;;A61B1/04;;A61B1/018;;A61B1/00052;;A61B1/00105;;A61B1/227;;A61B1/018;;A61B1/00045;;A61B1/00114;;A61B1/00165;;A61B1/05;;A61B1/06;;A61B1/227;;A61B1/32,A61B1/00;;A61B1/227;;A61B1/05;;A61B1/06;;A61B1/32,,0,0,,,,PENDING
102,AU,A1,AU 2020/313973 A1,085-639-097-866-012,2022-01-27,2022,AU 2020/313973 A,2020-07-17,US 201962875298 P;;US 2020/0042484 W,2019-07-17,"Systems, devices, and methods for visualization during medical procedures","Visualization during medical procedures is provided using a visualization system comprising: a control device defining an upper surface and a lower surface; a display visible through the upper surface of the control device; a handle coupled to the lower surface and extending away from the lower surface; a knob coupled to the control device, the knob configured to rotate about a rotational axis; an imaging assembly mechanically coupled to the knob and communicatively coupled to the control device, the imaging assembly configured to rotate around the rotational axis based on rotation of the knob; and the control device configured to display an image on the display, the image captured by the imaging assembly.",TUSKER MEDICAL INC,DOMECUS BRIAN;;KERMANI MAHYAR Z;;GIROTRA ROHIT;;GOLDFARB ERIC;;LANTZ ANDREW;;SCHNEIDER ROBERT EDWIN;;BIGHAM TYLER BENNETT,,https://lens.org/085-639-097-866-012,Patent Application,no,0,0,6,6,0,A61B1/227;;A61B1/04;;A61B1/018;;A61B1/00052;;A61B1/00105;;A61B1/227;;A61B1/018;;A61B1/00045;;A61B1/00114;;A61B1/00165;;A61B1/05;;A61B1/06;;A61B1/227;;A61B1/32,A61B1/00;;A61B1/227,,0,0,,,,PENDING
103,US,A1,US 2012/0205787 A1,129-962-388-031-319,2012-08-16,2012,US 201213423838 A,2012-03-19,US 201213423838 A;;US 1854108 A,2008-01-23,ORGANIC GRADED SPIN ON BARC COMPOSITIONS FOR HIGH NA LITHOGRAPHY,An antireflective coating that contains at least two polymer components and comprises chromophore moieties and transparent moieties is provided. The antireflective coating is useful for providing a single-layer composite graded antireflective coating formed beneath a photoresist layer.,GOLDFARB DARIO L;;VYKLICK LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D;;IBM,GOLDFARB DARIO L;;VYKLICK LIBOR;;BURNS SEAN D;;MEDEIROS DAVID R;;SANDERS DANIEL P;;ALLEN ROBERT D,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-15);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/129-962-388-031-319,Patent Application,yes,2,3,4,4,0,G03F7/091;;G03F7/091,H01L21/312;;H01L29/02,257/642;;438/763;;X257E21259;;X257E29001,0,0,,,,ACTIVE
104,US,A1,US 2019/0075168 A1,101-918-081-720-019,2019-03-07,2019,US 201615171347 A,2016-06-02,US 201615171347 A;;US 201562169823 P,2015-06-02,COMPUTER SECURITY AND USAGE-ANALYSIS SYSTEM,"Provided is a private and secure network that uses an authentication mechanism with a uniquely assigned private IP address and network credentials issued as part of a VPN certificate exchange. A first layer of authentication establishes a secure tunnel between user and VPN server, and a second layer of authentication connects that secure tunnel to the web site or resource, without passing the VPN certificate. Once authenticated, interaction between website or resource and user are automatically monitored for abnormal or malicious behavior and, if required, automatic verification and authentication response is generated.",HUMANITY CARES LLC,GOLDFARB SCOTT NATHANIEL;;BEECHAM JAMES DOUGLAS;;STRUTTMANN CHRISTOPHER EDWARD;;MARTIN GORDON EARL;;MARTIN PETER REUBEN;;SAVAGE IAN ROBERT,ALTR SOLUTIONS LLC (2017-06-23);;ALTR SOLUTIONS INC (2018-04-06);;HC HOLDING GROUP LLC (2017-06-23),https://lens.org/101-918-081-720-019,Patent Application,yes,0,29,2,83,0,H04L63/0272;;H04L63/0281;;H04L63/0823;;H04L63/168;;H04L67/02;;H04L67/02;;H04L63/0823;;H04L63/168;;H04L63/0281;;H04L63/0272;;H04L67/141,H04L29/08,,0,0,,,,ACTIVE
105,SU,A1,SU 905210 A1,187-355-443-377-689,1982-02-15,1982,SU 2751116 A,1979-04-05,SU 2751116 A,1979-04-05,METHOD FOR TREATING PRECIPITATE OF WASTE LIQUORS,,AKAD KOMMUNAL KHOZ,AGRANONIK ROBERT YA;;GOLDFARB LEONID L;;AROMATOV YURIJ L;;BORISOV BORIS R;;ZAEN ISAAK KH;;GORBACHEVA LYUDMILA B,,https://lens.org/187-355-443-377-689,Limited Patent,no,0,0,1,1,0,,C02F11/12;;C02F103/00,,0,0,,,,EXPIRED
106,SU,A2,SU 835498 A2,099-677-909-854-283,1981-06-07,1981,SU 2801677 A,1979-07-19,SU 2801677 A,1979-07-19,APPARATUS FOR DISCHARGING DEPOSIT FROM SEPARATOR SLIME RECIEVER,,BORISOV BORIS R;;AROMATOV YURIJ L;;GORBACHEVA LYUDMILA B;;AGRANONIK ROBERT YA;;GOLDFARB LEONID L;;GOLENISHCHEVA ELVIRA V,BORISOV BORIS R;;AROMATOV YURIJ L;;GORBACHEVA LYUDMILA B;;AGRANONIK ROBERT YA;;GOLDFARB LEONID L;;GOLENISHCHEVA ELVIRA V,,https://lens.org/099-677-909-854-283,Limited Patent,no,0,0,1,1,0,,B04B11/02,,0,0,,,,EXPIRED
107,SU,A1,SU 833583 A1,010-552-217-793-039,1981-05-30,1981,SU 2851788 A,1979-10-26,SU 2851788 A,1979-10-26,METHOD OF TREATMENT OF WASTE WATER PRECIPITATE,,NII KOMMUNALNOGO VODOSNABZHENI,GOLDFARB LEONID L;;DOROFEEV EVGENIJ E;;AGRANONIK ROBERT YA;;TUROVSKIJ IZRAIL S;;TATARINTSEV VYACHESLAV A;;BAJTALSKIJ VYACHESLAV I,,https://lens.org/010-552-217-793-039,Limited Patent,no,0,0,1,1,0,,C02F11/12;;C02F11/00;;C02F103/00,,0,0,,,,EXPIRED
108,BR,A2,BR PI0919195 A2,144-498-296-630-805,2019-09-24,2019,BR PI0919195 A,2009-09-16,US 2009/0057203 W;;US 9815708 P;;US 56114709 A,2008-09-18,"metodos e aparelhos para o tratamento de transtornos do ouvido, nariz e garganta",,ACCLARENT INC,CHRISTOPHER LARSEN;;DANIEL T HARFE;;ERIC GOLDFARB;;JOSHUA MAKOWER;;ROBERT N WOOD;;RONDA M HEISER;;THOMAS JENKINS;;TOM THANH VO,,https://lens.org/144-498-296-630-805,Patent Application,no,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B1/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10;;A61M29/00,,0,0,,,,DISCONTINUED
109,CN,B,CN 102159276 B,076-057-231-719-966,2014-01-15,2014,CN 200980137396 A,2009-09-16,US 2009/0057203 W;;US 9815708 P;;US 56114709 A,2008-09-18,Methods and apparatus for treating disorders of ear nose and throat,,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/076-057-231-719-966,Granted Patent,no,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/02;;A61B1/00;;A61B1/233;;A61B17/24;;A61F2/958;;A61M25/10,,0,0,,,,INACTIVE
110,AU,B2,AU 2009/293312 B2,139-086-350-921-768,2015-07-09,2015,AU 2009/293312 A,2009-09-16,US 9815708 P;;US 56114709 A;;US 2009/0057203 W,2008-09-18,Methods and apparatus for treating disorders of the ear nose and throat,A device (400) for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/139-086-350-921-768,Granted Patent,no,4,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B1/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10;;A61M29/00,,0,0,,,,INACTIVE
111,WO,A8,WO 2010/033629 A8,095-356-212-514-059,2010-05-27,2010,US 2009/0057203 W,2009-09-16,US 56114709 A;;US 9815708 P,2008-09-18,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,A device (400) for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC;;JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/095-356-212-514-059,Amended Application,yes,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,PENDING
112,JP,A,JP 2015037540 A,152-302-235-756-917,2015-02-26,2015,JP 2014147174 A,2014-07-17,US 56114709 A;;US 9815708 P,2008-09-18,"METHOD AND APPARATUS FOR TREATING DISORDER OF EAR, NOSE AND THROAT",PROBLEM TO BE SOLVED: To provide methods and apparatuses for accessing to an opening of the paranasal sinus for dilating.SOLUTION: A device 400 for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle 402; an elongate shaft 414 having a proximal end coupled with the handle and extending to a distal end; a guidewire 410 disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening 408 of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCARLENT INC,THOMAS JENKINS;;ERIC GOLDFARB;;VO TOM THAN;;JOSHUA MAKOWER;;ROBERT N WOOD;;RONDA M HEISER;;CHRISTOPHER LARSEN;;DANIEL T HARFE,,https://lens.org/152-302-235-756-917,Patent Application,no,1,2,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B17/24;;A61B1/00;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,INACTIVE
113,AU,A1,AU 2009/293312 A1,123-892-194-487-765,2010-03-25,2010,AU 2009/293312 A,2009-09-16,US 9815708 P;;US 56114709 A;;US 2009/0057203 W,2008-09-18,Methods and apparatus for treating disorders of the ear nose and throat,,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/123-892-194-487-765,Patent Application,no,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,INACTIVE
114,MX,A,MX 2011003025 A,156-574-204-508-632,2011-04-21,2011,MX 2011003025 A,2009-09-16,US 9815708 P;;US 56114709 A;;US 2009/0057203 W,2008-09-18,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT.,A device (400) for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,MAKOWER JOSHUA;;GOLDFARB ERIC;;JENKINS THOMAS;;VO TOM THANH;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/156-574-204-508-632,Patent Application,no,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B1/00;;A61M29/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,ACTIVE
115,EP,A1,EP 2323724 A1,078-888-952-121-155,2011-05-25,2011,EP 09792627 A,2009-09-16,US 2009/0057203 W;;US 56114709 A;;US 9815708 P,2008-09-18,APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,"ACCLARENT, INC. (2019-09-18)",https://lens.org/078-888-952-121-155,Patent Application,yes,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B1/12;;A61B1/233;;A61B17/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10;;A61M29/02,,0,0,,,,DISCONTINUED
116,RU,C2,RU 2506056 C2,195-470-667-413-099,2014-02-10,2014,RU 2011115098 A,2009-09-16,US 9815708 P;;US 56114709 A;;US 2009/0057203 W,2008-09-18,"METHODS AND APPARATUS FOR TREATING EAR, NOSE AND THROAT DISEASES","FIELD: medicine.SUBSTANCE: apparatus may comprise: a dilator, a wire guide, a handle and an extended trunk with its proximal end coupled with the handle and reaching a distal end. The wire guide extends through at least a portion of a trunk lumen. The dilator has an unexpanded configuration and an expanded configuration. A sliding element is coupled with the wire guide and (or) the dilator through a long slot for projecting the wire guide and (or) dilator in relation to the trunk.EFFECT: invention refers to medicine and may be used for the dilation of a human or animal paranasal sinus.13 cl, 20 dwg",AKKLARENT INK,DZHENKINS TOMAS;;GOLDFARB EHRIK;;VO TOM TKHANKH;;MAKOVER DZHOSHUA;;VUD ROBERT N;;KHEJZER RONDA M;;LARSEN KRISTOFER;;KHARFE DEHNIEL T,,https://lens.org/195-470-667-413-099,Granted Patent,no,8,1,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61F2/958;;A61B17/24;;A61M25/10;;A61M29/00,,0,0,,,,INACTIVE
117,WO,A1,WO 2010/033629 A1,064-728-433-980-977,2010-03-25,2010,US 2009/0057203 W,2009-09-16,US 56114709 A;;US 9815708 P,2008-09-18,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,A device (400) for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC;;JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/064-728-433-980-977,Patent Application,yes,3,26,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B17/24;;A61F2/958;;A61M25/10,,0,0,,,,PENDING
118,CN,A,CN 102159276 A,149-554-241-013-08X,2011-08-17,2011,CN 200980137396 A,2009-09-16,US 2009/0057203 W;;US 9815708 P;;US 56114709 A,2008-09-18,Methods and apparatus for treating disorders of ear nose and throat,The present invention discloses a device (400) for dilating an ostium of a paranasal sinus of a human or animal subject including: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,THOMAS JENKINS;;ERIC GOLDFARB;;THANH VO TOM;;JOSHUA MAKOWER;;WOOD ROBERT N;;HEISER RONDA M;;CHRISTOPHER LARSEN;;HARFE DANIEL T,,https://lens.org/149-554-241-013-08X,Patent Application,no,2,24,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,INACTIVE
119,KR,A,KR 20110056409 A,163-807-970-685-388,2011-05-27,2011,KR 20117008349 A,2009-09-16,US 56114709 A;;US 9815708 P,2008-09-18,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/163-807-970-685-388,Patent Application,no,4,3,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/02;;A61B1/32;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,ACTIVE
120,US,B2,US 10702295 B2,166-810-628-477-926,2020-07-07,2020,US 201715814984 A,2017-11-16,US 201715814984 A;;US 201313858580 A;;US 56114709 A;;US 19302005 A;;US 15084705 A;;US 11611805 A;;US 94427004 A;;US 82991704 A;;US 9815708 P,2004-04-21,Methods and apparatus for treating disorders of the ear nose and throat,A device for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle; an elongate shaft having a proximal end coupled with the handle and extending to a distal end; a guidewire disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS R;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/166-810-628-477-926,Granted Patent,yes,1179,1,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B17/24;;A61B1/00;;A61B1/12;;A61B1/233;;A61B17/00;;A61F2/958;;A61M25/00;;A61M25/09;;A61M25/10;;A61M29/02,,328,73,025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;009-319-672-632-222;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;043-068-503-393-610;;066-559-118-020-405;;062-351-127-043-686;;004-569-239-507-13X;;015-741-985-781-596;;006-017-396-056-413;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;012-223-832-603-044;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;118-873-204-442-663;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640;;035-586-137-258-637;;089-247-655-233-31X;;068-237-019-427-50X;;061-764-129-861-905;;024-069-245-302-733;;082-361-279-623-107;;137-659-727-058-857;;012-462-482-441-732,4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.1016/s0194-5998(03)01397-4;;12958561;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;19623527;;10.1177/014556130908800708;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.3109/13645709809152853;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1288/00005537-190508000-00009;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;10947988;;10.1126/science.289.5482.1197;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783;;10.1055/s-2007-997515;;9487485;;10416252;;10.1002/ccd.1810150211;;3052851;;10190702;;10.1016/s0165-5876(98)00119-0;;10.1001/archopht.116.5.688;;9596514;;10.1017/s0022215100141052;;9764294;;11209511;;10.1177/014556130108000103;;8001106;;10.1002/ccd.1810330117,"Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni—Ti Alloy Guidewire (2001).;;Aust, R., et al. ‘The Functional Size of the Human Maxillary Ostium in Vivo’ Acta. Otolaryn. (9178) vol. 78 pp. 432-435.;;Baim, D.S., MD ‘Grossman's Cardiac Catheterization, Angiography, and Intervention’ (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. ‘Be Wary of Neurocranial Restructuring (NCR)’ Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html.;;Bartal, N. ‘An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia’ J. Laryngol. Otol (1988) vol. 102 pp. 146-147.;;Becker, A.E. ‘Restenosis After Angioplasty’ The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter—Balloon Catheter—Thomas Fogarty. www.inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al.; Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysilogy Arch Otolarygol Head and Neck Surg. vol. 129 (Sep. 2003) pp. A1-S32.;;Bent et al. ‘The Frontal Cell as a Cause of Frontal Sinus Obstruction’ American Journal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191.;;Binner et al. ‘Fibre-Optic Transillumination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease’ Clinical Otolaryngology. vol. 3 (1978) pp. 1-11.;;Brown, C.L. et al., ‘Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation’ Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al. ‘Endoscopic Lothrop Procedure: The University of Miami Experience’ American Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339.;;Casserly, I.P. et al., Chapter 7. ‘Guides and Wires in Percutaneous Coronary Intervention’ Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. ‘Nasal Systemic Drug Delivery’ Drugs and Pharmaceutical Sciences, vol. 39, pp. 60-63.;;Cohen et al. ‘Endoscopic Sinus Surgery: Where we are and where we're going’ Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38.;;Colla, A. et al., ‘Trihaloacetylated Enol Ethers—General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine’ Synthesis, (Jun. 1991) pp. 483-486.;;Costa, M.N. et al. ‘Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil’ Clinics (2007) vol. 62, Issue 1, pp. 41-46.;;Cussler, E.L. ‘Diffusion: Mass transfer in Fluid Systems’ Cambridge University Press (1996).;;Davis, G.E. et al. ‘A Complication from Neurocranial Restructuring’ Arch Otolaryngol Head Neck Surg. vol. 129 (Apr. 2003) pp. 472-474.;;Deutschmann, R. et al. ‘A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication’ Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al. ‘Handbook of Biodegradable Polymers’ Harwood Academic Publishers (1997).;;Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints.htm.;;Draf, W. ‘Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept’ Op Tech Otolaryngol Head Neck Surg. vol. 2 (1991) pp. 234-240.;;“Durometer Made Easy Durometer Hardness Scales—General Reference Guide.” Paramount Industries, Inc. 2008. Accessed online: http://www.paramountind.com/pdfs/paramount_durometer_scale_guide.pdf.;;“Durometer Shore Hardness Scale.” Smooth-On, Inc. 2016. Accessed online: https://www.smooth-on.com/page/durometer-shore-hardness-scale/.;;Edmond, C. et al. ‘ENT Surgical Stimulator’ Nov. 1989.;;ENT Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. ‘Needles for Puncture and Drainage of the Maxillary Sinus’ Meditsinskaya Tekhnika, No. 5 (1974) pp. 54.55.;;Feldman, R.L. et al., ‘New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience with the Cordis OrionTM Steerable PTCA Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. ‘A Multipurpose Laryngeal Injector Device’ Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M., M.D., et al. ‘Frontal Sinus Surgery: Endoscopic Technique’ Operative Techniques in Otolarynology—Head and Neck Surgery. vol. 12, No. 2 (Jun. 2001) pp. 60-65.;;Friedman, et al. ‘Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination’ Laryngoscope. vol. 110 (Apr. 2000) pp. 683-684.;;Friedman, et al ‘Middle Turbinate Medialization and Preservation in Endoscopic Surgery’ Otolaryngology—Head and and Neck Surgery. (2000) vol. 123, No. 1, part 1, pp. 76-80.;;Fung, M.K.T. ‘Template for Frontal Osteoplastic Flap’ Laryngoscope. vol. 96 (1986) pp. 578-579.;;Gatot, A. et al. ‘Early treatment of Orbital Floor Fractures with Catheter Balloon in Children’ Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al. ‘β-Ethoxyvinyl Polyfluroroalkyl Ketones—Versatile Synthones in Fluoroorganic Chemistry’ Journal of Fluorine Chemistry. vol. 69 (1994) pp. 195-198. Elsevier Science S.A.;;Good, R.H. ‘An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage’ Laryngoscope. vol. 18 (1908) pp. 266-274.;;Gopferich ‘Polymer Degradation and Erosion: Mechanisms and Application’ Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11.;;Gorlov, D.V. et al ‘Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Teriary Amines’ Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottmann, et al. ‘Balloon Dilatation in the Nasal Cavity and Paranasal Sinus’ CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottmann, et al., ‘Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus’ CIRSE Abstract (Mar. 2001) B-04353.;;Gottmann, et al., Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus' OASIS—Online Abstract Submission and Invitation System, 1996-2006, Coe Truman Technologies, Inc.;;Gottmann, et al. ‘Successful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation’ CIRSE. (Oct. 5, 2002).;;Gottmann, D. ‘Treatment of Stenoses of Upper Air Routes by Balloon Dilation’ Proceeding of the 83rd Annual Convention of Association of West German ENT Physicians (1999).;;Gupta, D. et al., ‘Dacrystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus’ Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi_m0BUM/is_7_88/ai_n32428620/.;;Hashim, et al. ‘Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery’ Scandinavian Journal of Plastic and reconstruction Surgery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al, ‘Electrophilic Substitutions of Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides Chemistry Letters’ (1976) pp. 499-502. Chemical Society of Japan.;;Hopf, J.U.G. et al. ‘Miniature Endoscopes in Otorhinolaryngologic Applications’ Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al. A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al. ‘Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation’ American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9.;;Hosemann, M.E. et al. ‘Experimentelle Untersuchungen sur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss und medikamentose Effekte im standardisierten Wundmodell.’ HNO 39 (1991) pp. 48-54. ‘Experimental investigations on wound healing of the paranasal sinuses. II. Spontaneous wound closure and pharmacological effects in a standardized animal model.’ HNO 39 (1991) pp. 48-54.;;Hosemann, W.G. et al. ‘Minimally Invasive Endonasal Sinus Surgery’ Thieme, Stuttgart, New York (2000).;;Hosemann, M.E. et al. ‘Normal Wound Healing of the Paranasal Sinuses—Clinical and Experimental Investigations’ Eur Arch Otorhinolarygol. vol. 248, (1991) pp. 390-394.;;Hosemann, W. et al. ‘Behandlung nach Nasennebenhohleneingriffen, part 2: Theapeutische Maßnehem’ HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. ‘Transillumination During Osteoplastic Frontal Sinusotomy’ The Laryngoscope. vol. 91 (Sep. 1981) pp. 1560.;;Ijaduola, T.G.A. ‘Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery’ The Journal of Laryngology and Otology. (1989) vol. 103. pp. 375.378.;;Ingals, E.F. ‘New Operation and Instruments for Draining the Frontal Sinus’ Ann. Otol. Rhinol. Layyngol. vol. 14 (1905) pp. 644-649.;;Iro, H. et al., ‘A New Device for Frontal Sinus Endoscopy: First Clinical Report’ Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. ‘100 Years of Frontal Sinus Surgery’ Laryngoscope. vol. 107 (1997) pp. 1-36.;;K-Splint Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html.;;Kaiser, H. et al ‘Cortizontherapie, Corticoide in Klinik und Praxis’ Thieme, Stuggart (1992) pp. 390-401.;;Kennedy, D.W., M.D. et al. ‘Diseases of the Sinuses: Diagnosis and Management’ (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al. ‘Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description’ Pharmaceutical Chemistry Journal. vol. 35, No 11 (Nov. 2001) pp. 627-629.;;Kingdom, T.T. et al. ‘Image-Guide Surgery of the Sinuses: Current Technology and Applications’ Otolaryngol. Clin. North Am. vol. 37, No. 2 (Apr. 2004) pp. 381-400.;;Klossek, J.M. et al. ‘Local Safety of Intranasal Trimcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis’ Rhinology. vol. 39, No. 1 (2001) pp. 17-22.;;Kozlov et al. ‘Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters’ Rhinology (1996) vol. 34, pp. 123-124.;;Kuhn, et al. ‘The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation’ Operative Techniques in Otolaryngology—Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231.;;Laliberte, F. et al. ‘Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids’ Allergy. vol. 55, No. 8 (2000) pp. 718-722.;;Lang, E.V., et al., ‘Access Systems for Puncture at an Acute Angle’ J. Vasc. Inverv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. ‘Postoperative Care and Avoiding Frontal Recess Stenosis’ Internatinal Advanced Sinus Symposium (Jul. 21-24, 1993).;;Large, G.C. ‘Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis’ Canada. M.A.J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. ‘Maximal Medical Therapy for Chronic Rhinosinusitis’ Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310.;;Maran, A.G.D. et al. ‘The Use of the Foley Balloon Catheter in the Tripod Fracture’ J. Laryngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902.;;May, M. et al. ‘Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach’ Op Tech Otolaryngo Head Neck Surgery. 6 (1996) pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser. Www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1271 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al., ‘Coronary Angioplasty through 4 French Diagnostic Catheters’ Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al ‘Synthesis of Trifluromethylnaphthalenes’ Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd.;;Metson, R., et al., ‘Endoscopic Treatment of Sphenoid Sinusitis’ Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. ‘Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study’ Laryngoscope. vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18.;;Miller, et al. ‘Management of Fractures of the Supraorbital Rim’ Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512.;;Min, Y-G et al. ‘Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer’ Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842.;;Mols, B. ‘Movable Tool Tip for Keyhole Surgery’ Delft Outlook, vol. 3 (2005) pp. 13-17.;;Mooney, M.R., et al., ‘Monorail™ Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System’ Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al. ‘Additional-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins’ J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523.3528. American Chemical Society.;;Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html.;;Park, K. et al. ‘Biodegradable Hydrogels for Durg Delivery’ (1993) Technomic Publishing Inc. Lancaster.;;Piccirillo, J.F. et al. ‘Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)’ Copyright 1996 Washingtion University, St. Louis, MO.;;Piers, et al. ‘A Flexible Distal Tip with Two Degrees of Freedom for Enhanced Dexterity in Endoscopic Robot Surgery’ Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L et al. ‘Balloon Technique for Treatment of Frontal Sinus Fractures’ The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al., ‘Diagnostic Nasal Endoscopy’ plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458.;;Prince, et al. ‘Analysis of the Intranasal Distribution of Ointment’ J Otolaryngol. vol. 26 (1997) pp. 357-360.;;Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Maxillary Sinusitis’ J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Purulent Maxillary Sinusitis’ TEXAS State Journal of Medicine (May 1952) pp. 281-288.;;St. Croix et al. ‘Genes Expressed in Human Tumor Endothelium’ Science, vol. 289 (May 15, 2000) pp. 1197-1202.;;Sama, A., et al., ‘Current Opinions on the Surgical Management of Frontal Sinus Disease’ ENT News. Www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63.;;Sanborn, T.A. et al., ‘Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance’ Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon Washington 98070 USA.;;Saxon, R.R. et al., ‘Technical Aspects of Accessing the Portal Vein During the TIPS Procedure’ J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. ‘Rhinology and Sinus Disease: A Problem-Oriented Approach’ (Copyright 1988) by Mosby, Inc.;;Schneider. Pfizer Ad for Softip [date of publication unknown].;;Shah, N.J. ‘Endoscopic Pituitary Surgery—A Beginner's Guide’ Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. ‘Functional Endoscopic Sinus Surgery’ (1999); found at bhj.org/journal/1999_4104_oct99/sp_659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems.;;Sinusitis, Maxillary, Acute Surgical Treatment. Http://www.emedicine.com/ent/topic340.htm. Aug. 29, 2006. pp. 1-11.;;Sobol, et al. ‘Sinusitis, Maxillary, Acute Surgical Treatment.’ eMedicine. Retrieved from the Internet: <<http://emedicine.medscape.com/article/862030-print>> (Nov. 16, 2010) pp. 1-11.;;Stammberger, H. ‘Komplikationen entzundlicher Nasennebenhohlenerkrankungen eischlieβ iatrogen bedingter Komplikationen’ Eur Arch Oti-Rhino-Laryngol Supple. (Jan. 1993) pp. 61-102.;;Stammberger, et al. Chapter 3 ‘Special Endoscopic Anatomy of the Lateral Nasal Wall and Ethmoidal Sinuses’ Functional Endoscopic Sinus Surgery. (1991) Ch. 3, pp. 49-87.;;Strohm, et al. Die Behandlung von Stenosen der oberen Luftwege mittels rontgenologisch gesteuerter Ballondilation (Sep. 25, 1999) pp. 1-4.;;Strohm, et al ‘Le Traitenment des Stenoses Voies Aeriennes Superieures Par Dilation Ay Balloon’ Sep. 25, 1999.;;Strohm, et al ‘Treatment of Stenoses of the Upper Airways by Balloon Dilation’ Sudwestdeutscher Abstract 45 (Sep. 25, 1999) pp. 1-3.;;SurgTrainer Product Information 2003, Surg Trainer, Ltd. Ibaraki, Japan.;;SurgTrainer Product Information ‘Incisive Human Nasal Model for ESS Training’ Surg Trainer, Ltd. Ibaraki, Japan (2004) www1.accsnet.ne.jp/˜juliy/st/en/partslist.html.;;Tabor, M.H. et al., ‘Symptomatic Bilateral Duct Cysts in a Newborn—Rhinoscopic Clinic’ Ear, Nose & Throat Journal (2003) www.findarticles.com/p/articles/mi_m0BUM/is_2_82/ai_98248244 pp. 1-3.;;Tarasov, D.I. et al. ‘Application of Drugs Based on Polymers in the Treatment of Acute and Chronic Maxillary Sinusitis’ Vestn Otorinoloaringol. vol. 6 (1978) pp. 45-47.;;Terumo. Medi-Tech. Boston Scientific. (1993) Ad of Glidewire.;;The Operating Theatre Journal (www.otjonline.com) ‘Disposable Medical Device for Wound Disclosure/The Tristel Purple Promotion—A Collaboration between Tristel PLC and Karl Storz Endoscopy (UK) Ltd.’ p. 4.;;Weber, R. et al. ‘Endonasale Stirnhohlenchirugie mit Langzeiteinlage eines Platzhalters’ Laryngol. Rhinol. Otol. vol. 76 (1997) pp. 728-734. (English Abstract).;;Weber, R. et al., ‘Videoendoscopic Analysis of Nasal Steroid Distribution’ Rhinology. vol. 37 (1999) pp. 69-73.;;Weiner, R.I., D.O., et al., ‘Development and Application of Transseptal Left Heart Catheterization’ Cathet. Cardiovasc. Diagn. (1988) vol. 15, No. 2, pp. 112-120.;;Wiatrak, B.J., et al., ‘Unilateral Choanal Atresia: Initial Presentation and Endoscopic Repair’ International Journal of Pediatric Otorhinolaryngology (1998) vol. 46, pp. 27-35.;;Woog, et al. ‘Paranasal Sinus Endoscopy and Orbital Fracture Repair’ Arch Ophthalmol. vol. 116 (May 1998) pp. 688-691.;;Wormald, P.J., et al., ‘The ‘Swing-Door’ Technique for Uncinectomy in Endoscopic Sinus Surgery’ The Journal of Laryngology and Otology (1998) vol. 112, pp. 547-551.;;Xomed-Treace. Bristol-Myers Squibb. Ad for Laser Shield II. Setting the Standards for Tomorrow. [date of publication unknown].;;Yamauchi, Y. et al., ‘Development of a Silicone Model for Endoscopic Sinus Surgery’ Proc International Journal of Computer Assisted Radiology and Surgery vol. 99 (1999) p. 1039.;;Yamauchi, Y., et al., ‘A Training System for Endoscopic Sinus Surgery with Skill Evaluation’ Computer Assisted Radiology and Surgery (2001) with accompanying copy of poster presentation.;;Yanagisawa et al. ‘Anterior and Posterior Fontanelles.’ Ear, Nose & Throat Journal (2001) vol. 80. pp. 10-12.;;Zimarino, M., M.D., et al., ‘Initial Experience with the EuropassTM: A new Ultra-Low-Profile Monorail Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1994) vol. 33, No. 1, pp. 76-79.;;Australian Office Action, Examiners First Report dated Apr. 8, 2010 for Application No. AU 2005274794.;;Australian Office Action, Examiners First Report dated Dec. 9, 2011 for Application No. AU 2006292818.;;Australian Office Action dated Feb. 12, 2014 for Application No. AU 2012202103.;;Australian Office Action dated Aug. 1, 2014 for Application No. AU 2012244072.;;Australian Office Action dated Sep. 17, 2014 for Application No. AU 2012202103.;;Australian Office Action dated Sep. 30, 2014 for Application No. AU 2009293312.;;Australian Office Action dated Oct. 1, 2014 for Application No. AU 2009333010.;;Australian Office Action dated Jul. 8, 2015 for Application No. AU 2012244072.;;Canadian Office Action dated Jul. 10, 2015 for Application No. CA 2,617,054.;;Canadian Office Action dated Dec. 16, 2015 for Application No. CA 2,751,665.;;Chinese Office Action, First Office Action dated Nov. 5, 2012 for CN 200980137396.1.;;Chinese Search Report dated Oct. 29, 2012 for Application No. CN 200980137396.1.;;Chinese Search Report dated Jan. 11, 2013 for Application No. CN 200980152995.0.;;Chinese Office Action, First Office Action dated Jan. 29, 2013 for CN 200980152995.1.;;Chinese Office Action, Decision of Rejection, dated 2014 for Application No. CN 200980152995.1.;;Chinese Office Action, Third Office Action, dated Feb. 27, 2014 for Application No. CN 200980152995.1.;;Chinese Office Action and Search Report dated Jan. 21, 2015 for Application No. CN 201310672731.6.;;European Communication dated Sep. 4, 2008 for Application No. EP 05773189.;;European Communication dated Jun. 19, 2009 for Application No. EP 05773189.;;European Communication dated Sep. 27, 2011 for Application No. EP 06800540.4.;;European Communication dated Aug. 1, 2012 for Application No. EP 06784759.0.;;European Communication dated Aug. 24, 2012 for Application No. EP 05798331.4.;;European Communication dated Nov. 9, 2012 for Application No. EP 07750248.2.;;European Communication dated Apr. 19, 2012 for Application No. EP 08746715.5.;;European Communication dated Jan. 7, 2013 for Application No. EP 08746715.5;;European Communication dated Apr. 11, 2013 for Application No. EP 05778834.1.;;European Communication dated May 10, 2013 for Application No. EP 06751637.7.;;European Communication dated Sep. 3, 2013 for Application No. EP 12182998.0.;;European Communication dated Feb. 26, 2014 for Application No. EP 06800540.4.;;European Communication dated Aug. 11, 2014 for Application No. EP 12182998.0.;;European Communication dated Aug. 26, 2014 for Application No. EP 12183000.4.;;European Communication dated Nov. 26, 2014 for Application No. EP 07836108.6.;;European Communication dated Feb. 17, 2016 for Application No. EP 12162712.9.;;European Exam Report dated Feb. 22, 2006 for Application No. EP 02716734.5.;;European Exam Report dated Feb. 8, 2007 for Application No. EP 02716734.5.;;European Search Report and Written Opinion dated Sep. 11, 2009 for Application No. EP 06815174.;;European Search Report dated Mar. 16, 2010 re Application No. EP 06718986.;;European Search Report dated Sep. 27, 2011 for Application No. EP 10182961.;;European Search Report dated Sep. 29, 2011 for Application No. EP 10182893.;;European Search Report dated Jul. 23, 2012 for Application No. EP 12162709.;;European Search Report dated Jul. 24, 2012 for Application No. EP 12162712.;;European Search Report dated Aug. 31, 2012 for Application No. EP 12173295.;;European Search Report dated Oct. 10, 2012 for Application No. EP 12175607.;;European Search Report dated Nov. 22, 2012 for Application No. EP 12182993.;;European Search Report dated Dec. 5, 2012 for Application No. EP 12182998.;;European Search Report dated Jan. 9, 2013 for Application No. EP 12183000.;;European Search Report dated Jan. 11, 2013 for Application No. EP 12183002.;;European Search Report dated Aug. 13, 2013 for Application No. EP 13172140.;;European Search Report dated Sep. 9, 2013 for Application No. EP 13179223.;;European Search Report dated May 19, 2015 for Application No. EP 08746464.0.;;European Search Report dated Jun. 23, 2015 for Application No. EP 12162712.9.;;European Search Report dated Jun. 23, 2015 for Application No. EP 12162709.5.;;Extended European Search Report dated Jan. 17, 2014 for Application No. EP 108426321.1.;;Extended European Search Report dated Sep. 15, 2015 for Application No. EP 15163549.7.;;Partial European Search Report dated Sep. 20, 2007 for Application No. EP 07252018.;;Partial European Search Report dated Mar. 25, 2008 for Application No. EP 07252018.;;Supplemental Partial European Search Report dated Jun. 2, 2008 for Application No. EP 05773189.;;Supplemental Partial European Search Report dated Jul. 1, 2009 for Application No. EP 06815285.;;Supplemental Partial European Search Report dated Nov. 19, 2010 for Application No. EP 06751637.;;Supplemental European Search Report dated Jan. 29, 2010 for Application No. EP 07836108.;;Supplemental European Search Report dated Feb. 2, 2010 for Application No. EP 07836109.;;Supplemental European Search Report dated Feb. 17, 2010 for Application No. EP 07836110.;;Supplemental European Search Report dated Mar. 1, 2010 for Application No. EP 05778834.;;Supplemental European Search Report dated Mar. 16, 2010 for Application No. EP 06718986.;;Supplemental European Search Report dated Jun. 22, 2010 for Application No. EP 06784759.;;Supplemental European Search Report dated Sep. 23, 2010 for Application No. EP 08746715.;;Supplemental European Search Report dated Jan. 28, 2011 for Application No. EP 07777004.;;Supplemental European Search Report dated Mar. 31, 2011 for Application No. EP 05798331.;;Supplemental European Search Report dated Aug. 30, 2011 for Application No. EP 06800540.;;Supplemental European Search Report dated Sep. 29, 2011 for Application No. EP 07750248.;;Supplemental European Search Report dated Jan. 14, 2014 for Application No. EP 13184009.;;Supplemental European Search Report dated Jan. 17, 2014 for Application No. EP 1084263.;;Supplemental European Search Report dated Dec. 9, 2014 for Application No. EP 07839152.;;Supplemental European Search Report dated Feb. 13, 2014 for Application No. EP 08746464.;;PCT Search Report dated Nov. 30, 2009 for Application No. UPCT/US2009/057203.;;International Preliminary Report on Patentability dated Aug. 7, 2006 for Application No. PCT/US05/25371.;;International Preliminary Report on Patentability and Written Opinion dated Sep. 25, 2007 for Application No. PCT/US06/002004.;;International Preliminary Report on Patentability dated Feb. 15, 2008 for Application No. PCT/US05/13617.;;International Preliminary Report on Patentability and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US07/11449.;;International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2009 for Application No. PCT/US07/021170.;;International Preliminary Report on Patentability and Written Opinion dated May 5, 2009 for Application No. PCT/US06/036960.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 13, 2009 for Application No. PCT/US08/059786.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 27, 2009 for Application No. PCT/US08/061343.;;International Preliminary Report on Patentability dated Jun. 29, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Jun. 3, 2002 for Application No. PCT/EP02/01228.;;International Search Report and Written Opinion dated Apr. 10, 2006 for Application No. PCT/US05/25371.;;International Search Report dated May 8, 2007 for Application No. PCT/US2006/16026.;;International Search Report dated Aug. 17, 2007 for Application No. PCT/US05/013617.;;International Search Report dated Aug. 29, 2007 for Application No. PCT/US06/002004.;;International Search Report dated Sep. 25, 2007 for Application No. PCT/US06/037167.;;International Search Report dated Oct. 19, 2007 for Application No. PCT/US07/003394.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021170.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021922.;;International Search Report dated Jul. 1, 2008 for Application No. PCT/US06/022745.;;International Search Report dated Jul. 3, 2008 for Application No. PCT/US2006/029695.;;International Search Report dated Jul. 7, 2008 for Application No. PCT/US07/016213.;;International Search Report dated Jul. 8, 2008 for Application No. PCT/US07/011474.;;International Search Report dated Jul. 17, 2008 for Application No. PCT/US06/036960.;;International Search Report and Written Opinion dated Jul. 21, 2008 for Application No. PCT/US05/033090.;;International Search Report dated Aug. 25, 2008 for Application No. PCT/US2008/000911.;;International Search Report dated Sep. 10, 2008 for Application No. PCT/US07/016212.;;International Search Report and Written Opinion dated Sep. 12, 2008 for Application No. PCT/US07/16214.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/059786.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/061343.;;International Search Report and Written Opinion dated Oct. 1, 2008 for Application No. PCT/US07/011449.;;International Search Report dated Oct. 15, 2008 for Application No. PCT/US2008/061048.;;International Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203.;;International Search Report dated Dec. 10, 2009 for Application No. PCT/US2009/052236.;;International Search Report dated Dec. 16, 2009 for Application No. PCT/US2009/050800.;;International Search Report dated Mar. 31, 2010 for Application No. PCT/US2009/069143.;;International Search Report dated Jul. 8, 2010 for Application No. PCT/US2010/027837.;;International Search Report and Written Opinion dated Oct. 6, 2010 for Application No. PCT/US2010/040548.;;International Search Report dated Mar. 25, 2011 for Application No. PCT/US2010/062161.;;International Search Report dated Mar. 28, 2011 for Application No. PCT/US2010/061850.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2010/060898.;;International Search Report dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;International Search Report dated May 18, 2012 for Application No. PCT/US2011/052321.;;International Written Opinion dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;Partial International Search Report dated Feb. 7, 2012 for Application No. PCT/US2011/052321.;;Japanese Office Action, Examiner's Decision of Refusal dated Oct. 18, 2011 for Application No. JP 2007-509632.;;Japanese Office Action, Notification of Reasons for Refusal dated Apr. 26, 2011 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 24, 2012 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Aug. 16, 2011 for Application No. JP 2008-516013.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 8, 2011 for Application No. JP 2008-524250.;;Japanese Office Action, Notification of Reasons for Refusal dated Jun. 25, 2013 for Application No. JP 2012-131840.;;Japanese Office Action, Notification of Reasons for Refusal dated Sep. 18, 2013 for Application No. JP 2011-527942.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 12, 2013 for Application No. JP 2011-542562.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 7, 2014 for Application No. JP 2012-266049.;;Japanese Office Action, Reasons for Refusal, dated Sep. 2, 2014 for Application No. JP 2012-544859.;;Japanese Office Action, Reasons for Refusal, dated Jun. 9, 2015 for Application No. JP 2014-147174.;;Russian Office Action dated Sep. 28, 2012 for Application No. RU 2011130530.;;Russian Office Action dated Mar. 19, 2013 for Application No. RU 2011130530.;;USPTO Office Action dated Sep. 16, 2005 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jul. 7, 2006 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Feb. 13, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 9, 2007 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Jan. 24, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated Oct. 6, 2008 for U.S. Appl. No. 10/259,300.;;USPTO Office Action dated May 29, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Nov. 14, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/912,578.;;USPTO Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Dec. 6, 2007 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Apr. 9, 2008 for U.S. Appl. No. 11/037,548.;;USPTO Office Action dated Nov. 28, 2007 for U.S. Appl. No. 11/234,395.;;USPTO Office Action dated Sep. 12, 2008 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Nov. 17, 2008 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Mar. 18, 2009 for U.S. Appl. No. 10/829,917.;;USPTO Office Action dated Nov. 9, 2009 for U.S. Appl. No. 10/829,917. et al.",ACTIVE
121,CN,A,CN 103623498 A,063-464-508-848-602,2014-03-12,2014,CN 201310672731 A,2009-09-16,US 9815708 P;;US 56114709 A;;CN 200980137396 A,2008-09-18,Methods and apparatus for treating disorders of the ear nose and throat,A device (400) for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS R;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/063-464-508-848-602,Patent Application,no,6,5,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/02;;A61B1/00;;A61B1/233;;A61B17/24;;A61F2/958;;A61M25/10,,0,0,,,,INACTIVE
122,US,B2,US 9826999 B2,027-390-443-731-280,2017-11-28,2017,US 201313858580 A,2013-04-08,US 201313858580 A;;US 56114709 A;;US 19302005 A;;US 15084705 A;;US 11611805 A;;US 94427004 A;;US 82991704 A;;US 9815708 P,2004-04-21,Methods and apparatus for treating disorders of the ear nose and throat,A device for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle; an elongate shaft having a proximal end coupled with the handle and extending to a distal end; a guidewire disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS R;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/027-390-443-731-280,Granted Patent,yes,1129,2,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B1/12;;A61B1/233;;A61B17/00;;A61B17/24;;A61F2/958;;A61M25/00;;A61M25/09;;A61M25/10;;A61M29/02,,371,71,025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;009-319-672-632-222;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;043-068-503-393-610;;066-559-118-020-405;;004-569-239-507-13X;;015-741-985-781-596;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;012-223-832-603-044;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;118-873-204-442-663;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640;;035-586-137-258-637;;089-247-655-233-31X;;068-237-019-427-50X;;061-764-129-861-905;;024-069-245-302-733;;082-361-279-623-107;;137-659-727-058-857;;012-462-482-441-732,4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.1016/s0194-5998(03)01397-4;;12958561;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1288/00005537-190508000-00009;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;10947988;;10.1126/science.289.5482.1197;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783;;10.1055/s-2007-997515;;9487485;;10416252;;10.1002/ccd.1810150211;;3052851;;10190702;;10.1016/s0165-5876(98)00119-0;;10.1001/archopht.116.5.688;;9596514;;10.1017/s0022215100141052;;9764294;;11209511;;10.1177/014556130108000103;;8001106;;10.1002/ccd.1810330117,"http://dictionary.reference.com/browse/bent; Definition of “bent” as accessed on Sep. 10, 2015.;;Merriam-Webster definition of “lumen” as accessed Jun. 10, 2016; http://www.merriam-webster.com/dictionary/lumen.;;Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni—Ti Alloy Guidewire (2001).;;Aust, R., et al. ‘The Functional Size of the Human Maxillary Ostium in Vivo’ Acta. Otolaryn. (9178) vol. 78 pp. 432-435.;;Baim, D.S., MD ‘Grossman's Cardiac Catheterization, Angiography, and Intervention’ (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. ‘Be Wary of Neurocranial Restructuring (NCR)’ Chirobase; Jul. 2003; www.chirobase.org/06DD/ncr.html.;;Bartal, N. ‘An Improved stent for Use in the Surgical Management of Congential Posterior Choanal Atresia’ J. Laryngol. Otol (1988) vol. 102 pp. 146-147.;;Becker, A.E. ‘Restenosis After Angioplasty’ The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter—Balloon Catherter—Thomas Fogarty. www.inventors.about.com/library/inventors/blcatheter.htm?p=1;;Benninger et al.; Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysilogy' Arch Otolarygol Head and Neck Surg. vol. 129 (Sep. 2003) pp. A1-S32.;;Bent et al. ‘The Frontal Cell as a Cause of Frontal Sinus Obstruction’ Amercian Journal of Rhinology, vol. 8, No. 4 (1994) pp. 185-191.;;Binner et al. ‘Fibre-Optic Transillunination of the Sinueses: A Comparison of the Value of Radiography and Transillumination in Antral Disease’Clinical Otolaryngology. vol. 3 (1978) pp. 1-11.;;Brown, C.L. et al., ‘Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation’ Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Casiano et al. ‘Endoscopic Lothrop Procedure: the University of Miami Experience’ American Journal of Rhinology, vol. 12, No. 5 (1998) pp. 335-339.;;Casserly, I.P. et al., Chapter 7. ‘Guides and Wires in Percutaneous Coronary Intervention’ Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. ‘Nasal Systemic Drug Delivery’ Drugs and Pharmaceutical Sciences, vol. 39, pp. 60-63.;;Cohen et al. ‘Endoscopic Sinus Surgery: Where we are and where we're going ’ Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 13 (2005) pp. 32-38.;;Colla, A. et al., ‘Trihaloacetylated Enol Ethers—General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine’ Synthesis, (Jun. 1991) pp. 483-486.;;Costa, M.N. et al. ‘Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influences of Saline Solution and 5-Flurorouracil’ Clinics (2007) vol. 62, Issue1, pp. 41-46.;;Cussler, E.L. ‘Diffusion: Mass transfer in Fluid Systems’ Cambridge University Press (1996).;;Davis, G.E. et al. ‘A Complication from Neurocranial Restructuring’ Arch Otolaryngol Head Neck Surg. vol. 129 (Apr. 2003) pp. 472-474.;;Deutschmann, R. et al. ‘A Contribution of the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication’ Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al. ‘Handbook of Biodegradable Polymers’ Harwood Academic Publishers (1997);;Doyle Nasal Splints, Jan. 25, 2007; www.doylemedical.com/nasalsplints.htm.;;Draf, W. ‘Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept’ Op Tech Otolaryngol Head Neck Surg. vol. 2 (1991) pp. 234-240.;;Edmond, C. et al. ‘ENT Surgical Stimulator’ Nov. 1989.;;ENT Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. ‘Needles for Puncture and Drainage of the Maxillary Sinus’ Meditsinskaya Tekhnika, No. 5 (1974) pp. 54.55.;;Feldman, R.L. et al., ‘New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis OrionTM Steerable PTCA Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. ‘A Multipurpose Laryngeal Injector Device’ Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M., M.D., et al. ‘Frontal Sinus Surgery: Endoscopic Technique’ Operative Techniques in Otolarynology—Head and Neck Surgery. vol. 12, No. 2 (Jun. 2001) pp. 60-65.;;Friedman, et al. ‘Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination’ Laryngoscope. vol. 110 (Apr. 2000) pp. 683-684.;;Friedman, et al. ‘Middle Turbinate Medialization and Preservation in Endoscopic Surgery’ Otolaryngology—Head and Neck Surgery. (2000) vol. 123, No. 1, part 1, pp. 76-80.;;Fung, M.K.T. ‘Template for Frontal Osteoplastic Flap’ Laryngoscope. vol. 96 (1986) pp. 578-579.;;Gatot, A. et al. ‘Early treatment of Orbital Floor Fractures with Catheter Balloon in Children’ Int J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al. ‘β-Ethoxyvinyl Polyfluroroalkyl Ketones—Versatile Synthones in Fluoroorganic Chemistry’ Journal of Fluorine Chemistry. vol. 69 (1994) pp. 195-198. Elesvier Science S.A.;;Good, R.H. ‘An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage’ Laryngoscope. vol. 18 (1908) pp. 266-274.;;Gopferich ‘Polymer Degradation and Erosion: Mechanisms and Application’ Eur. J. Parm. Biophar. vol. 42 (1996) pp. 1-11.;;Gorlov, D.V. et al. ‘Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Teriary Amines’ Russian Chemical Bulletin. vol. 48 No. 9 (Sep. 1999) pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottmann, et al. ‘Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses’ CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottmann, et al. ‘Balloon Dilatation of Recurrent Ostial Occlusion of the Frontal Sinus’ CIRSE Abstract (Mar. 2001) B-04353.;;Gottman, et al., Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus' OASIS-Online Abstract Submission and Invitation System, 1996-2006, Coe Truman Technologies, Inc.;;Gottmann, et al. ‘Successful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation’ CIRSE. (Oct. 5, 2002);;Gottmann, D. ‘Treatment of Stenoses of Upper Air Routes by Balloon Dilation’ Proceeding of the 83rd Annual Convention of Association of West German ENT Physicians (1999).;;Gupta, D. et al., ‘Dacrystitis Secondary to an Iatrogenic Foreign Body in Lacrimal Apparatus’ Ear, Nose & Throat Journal (2009) www.findarticles.com/p/articles/mi—mOBUM/is—7—88/ai—n32428620/.;;Hashim, et al. ‘Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery’ Scandinavian Journal of Plastic reconstruction Sergery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al, ‘Electrophilic Substiutions of Olefinic Hydrogens II. Acylation of Vinyle Ethers and N Vinyl Amides Chemistry Letters’ (1976) pp. 499-502. Chemical Society of Japan.;;Hopf, J.U.G. et al. ‘Minature Endoscopes in Otorhinolaryngologic Applications’ Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al. A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al. ‘Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation’ American Journal of Rhinology. vol. 11, No. 1 (1997) pp. 1-9.;;Hosemann, M.E. et al. ‘Experimentelle Untersuchungen sur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss und medikamentose Effekte im standardisierten Wundmodell.’ HNO 39 (1991) pp. 48-54. ‘Experimental investigations on wound healing of the paranasal sinuses. II. Spontaneous wound closure and pharmacological effects in a standardized animals.’ HNO 39 (1991) pp. 48-54.;;Hosemann, W.G. et al. ‘Minimally Invasive Endonasal Sinus Surgery’ Thieme, Stuttgart, New York (2000).;;Hosemann, M.E. et al. ‘Normal Wound Healing of the Paranasal Sinuses—Clinical and Experimental Investigations’ Eur Arch Otorhinolarygol. vol. 248, (1991) pp. 390-394.;;Hosemann, W. et al. ‘Behandlung nach Nasennebenhohleneingriffen, part 2: Theapeutische Maβnahem’ HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. ‘Transillumination Durning Osteoplastic Frontal Sinusotomy’ The Laryngoscope. vol. 91 (Sep. 1981) pp. 1560.;;Ijaduola, T.G.A. ‘Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery’ Ther Journal of Laryngology and Otology. (1989) vol. 103. pp. 375.378.;;Ingals, E.F. ‘New Operation and Instruments for Drainage the Frontal Sinus’ Ann. Otol. Rhinol. Layyngol. vol. 14 (1905) pp. 644-649.;;Iro, H. et al., ‘A New Device for Frontal Sinus Endoscopy: First Clinical Report’ Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. ‘100 Years of Frontal Sinus Surgery’ Laryngoscope. vol. 107 (1997) pp. 1-36.;;K-Splint Internal Nasal Splints; Jan. 25, 2007; www.invotec.net/rhinology/ksplint.html.;;Kaiser, H. et al ‘Cortizontherapie, Corticoide in Klinik and Praxis’ Thieme, Stuggart (1992) pp. 390-401.;;Kennedy, D.W., M.D. et al. ‘Diseases of the Sinuses: Diagnosis and Management’ (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al. ‘Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description’ Pharmaceutical Chemistry Journal. vol. 35, No. 11 ( Nov. 2001) pp. 627-629.;;Kingdom, T.T. et al. ‘Image-Guided Surgery of the Sinuses: Current Technology and Applications’ Otolaryngol. Clin. North Am. vol. 37, No. 2 (Apr. 2004) pp. 381-400.;;Klossek, J.M. et al. ‘Local Safety of Intranasal Trimcinolone Acentonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis’ Rhinology. vol. 39, No. 1 (2001) pp. 17-22.;;Kozlov et al. ‘Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters’ Rhinology (1996) vol. 34, pp. 123-124.;;Kuhn, et al. ‘The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation’ Operative Techniques in Otolaryngology-Head and Neck Surgery. vol. 2, No. 4 (1991) pp. 226-231.;;Laliberte, F. et al. ‘Clinical and Pathologic Methods to Assess the Long-Term Safety of Nasal Corticosteroids’ Allergy. vol. 55, No. 8 (2000) pp. 718-722.;;Lang, E.V., et al., ‘Access Systems for Puncture at an Acute Angle’ J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. ‘Postoperative Care and Avoiding Frontal Recess Stenosis’ Internatinal Advanced Sinus Symposium (1993) Jul. 21-24.;;Large, G.C. ‘Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis’ Canad. M.A.J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. ‘Maximal Medical Therapy for Chronic Rhinosinusitis’ Otolaryngol Clin N. Am. vol. 38 (2005) pp. 1301-1310.;;Maran, A.G.D. et al. ‘The Use of the Foley Balloon Catheter in the Tripod Fracture’ J. Laryngol. Otol. (1971) vol. 85, Issue 9, pp. 897-902.;;May, M. et al. ‘Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach’ Op Tech Otolaryngo Head Neck Surgery. 6 (1995) pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser. www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 I (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al., ‘Coronary Angioplasty through 4 French Diagnostic Catheters’ Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al ‘Synthesis of Trifluromethylnaphthalenes’ Tetrahedron. vol. 56 (2000) pp. 10067-10074. Elsevier Science Ltd.;;Metson, R., et al., ‘Endoscopic Treatment of Sphenoid Sinusitis’ Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. ‘Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study’ Laryngoscope. vol. 106, Issue 1, Supplement 77 (Jan. 1996) pp. 1-18.;;Miller, et al. ‘Management of Fractures of the Supraorbital Rim’ Journal of Trauma. vol. 18, No. 7 (Jul. 1978) pp. 507-512.;;Min, Y-G et al. ‘Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer’ Laryngoscope. vol. 105 (Aug. 1995) pp. 835-842.;;Mols, B. ‘Movable Tool Tip for Keyhole Surgery’ Delft Outlook, vol. 3 (2005) pp. 13-17.;;Mooney, M.R., et al., ‘Monorail™ Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System’ Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al. ‘Additional-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins’ J. Org. Chem. vol. 60, No. 11 (1995) pp. 3523.3528. American Chemical Society.;;Nasal Surgery and Accessories, Jan. 25, 2007; www.technologyforlife.com.au/ent/nasal.html.;;Park, K. et al. ‘Biodegradable Hydrogels for Durg Delivery’ (1993) Technomic Publishing Inc. Lancaster.;;Piccirillo, J.F. et al. ‘Physchometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome test (SNOT-20)’ Copyright 1996 Washington University, St. Louis, MO.;;Piers, et al. ‘A Flexible Distal Tip with Two Degrees of Freedon for Enhanced Dexterity in Endoscopic Robot Surgery’ Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L et al. ‘Balloon Technique for Treatment of Frontal Sinus Fractures’ The journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al., ‘Diagnostic Nasal Endoscopy’ plastic & Reconstructive Surgery (1997) vol. 99, Iss5 pp. 1451-1458.;;Prince, et al. ‘Analysis of the Intranasal Distribution of Ointment’ J Otolaryngol. vol. 26 (1997) pp. 357-360.;;Ramsdale, D.R., Illustrated Coronary Intervention: A case-oriented approach, (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al., Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Maxillary Sinusitis’ J.A.M.A. May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. ‘Pressure Treatment of Purulent Maxillary Sinusitis’ Texas State Journal of Medicine (May 1952) pp. 281-288.;;St. Croix et al. ‘Genes Expressed in Human Tumor Endothelium’ Science, vol. 289 (May 15, 2000) pp. 1197-1202.;;Sama, A., et al., ‘Current Opinions on the Surgical Management of Frontal Sinus Disease’ ENT News. www.pinpointmedical.com/ent-news (2009) vol. 17, No. 6 pp. 60-63.;;Sanborn, T.A. et al., ‘Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance’ Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon Washington 98070 USA.;;Saxon, R.R. et al., ‘Technical Aspects of Accessing the Portal Vein During the TIPS Procedure’ J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. ‘Rhinology and Sinus Disease: A Problem-Oriented Approach’ (Copyright 1988) by Mosby, Inc.;;Schneider. Pfizer Ad for Softip [date of publication unknown].;;Shah, N.J. et al., ‘Endoscopic Pituitary Surgery—A Beginner's Guide’ Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. ‘Functional Endoscopic Sinus Surgery’ (1999); found at bhj.org/journa1/1999—4104—oct99/sp—659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems.;;Sinusitis, Maxillary, Acute Surgical Treatment. Http://www.emedicine.com/ent/topic340.htm. Aug. 29, 2006. pp. 1-11.;;Sobol, et al. ‘Sinusitis, Maxillary, Acute Surgical Treatment.’ eMedicine. Retrieved from the Internet: <<http://emedicine.medscape.com/article/862030-print>> (Nov. 16, 2010) pp. 1-11.;;Stammberger, H. ‘Komplikationen entzundlicher Nasennebenhohlenerkrankungen eischlieβ iatrogen bedingter Komplikationen’ Eur Arch Oti-Rhino-Laryngol Supple. (Jan. 1993) pp. 61-102.;;Stammberger, et al. Chapter 3 ‘Special Endoscopic Anatomy of the Lateral Nasal Wall and Ethmoidal Sinuses’ Functional Endoscopic Sinus Surgery. (1991) Ch. 3, pp. 49-87.;;Strohm, et al. Die Behandlung von Stenosen der oberen Luftwege mittels rontgenologisch gesteuerter Ballondilation (Sep. 25, 1999) pp. 1-4.;;Strohm, et al ‘Le Traitenment Des Stenoses Voies Aeriennes Superieures Par Dilation Ay Balloon’ Sep. 25, 1999.;;Strohm, et al. ‘Treatment of Stenoses of the Upper Airways by Balloon Dilation’ Sudwestdeutscher Abstract 45 (Sep. 25, 1999) pp. 1-3.;;SurgTrainer Product Information 2003, Surg Trainer, Ltd. Ibaraki, Japan.;;SurgTrainer Product Information ‘Incisive Human Nasal Model for ESS Training’ Surg Trainer, Ltd. Ibaraki, Japan (2004) www1.accsnet.ne.jp/˜juliy/st/en/partslist.html.;;Tabor, M.H. et al., ‘Symptomatic Bilateral Duct Cysts in a Newborn—Rhinoscopic Clinic’ Ear, Nose & Throat Journal (2003) www.findarticles.com/p/articles/mi—m0BUM/is—2—82/ai—98248244 pp. 1-3.;;Tarasov, D.I. et al. ‘Application of Drugs Based on Polymers in the Treatment of Acute and Chronic Maxillary Sinusitis’ Vestn Otorinoloaringol. vol. 6 (1978) pp. 45-47.;;Terumo. Medi-Tech. Boston Scientific. (1993) Ad of Glidewire.;;The Operating Theatre Journal (www.otjonline.com) ‘Disposable Medical Device for Wound Disclosure/The Tristel Purple Promotion—A Collaboration between Tristel PLC and Karl Storz Ednoscopy (UK) Ltd.’ p. 4.;;Weber, R. et al. ‘Endonasale Stirnhohlenchirugie mit Langzeiteinlage eines I Platzhalters’ Laryngol. Rhinol. Otol. vol. 76 (1997) pp. 728-734. (English Abstract).;;Weber, R. et al., ‘Videoendoscopic Analysis of Nasal Steriod Distribution’ Rhinology. vol. 37 (1999) pp. 69-73.;;Weiner, R.I., D.O., et al., ‘Development and Application of Transseptal Left Heart Catheterization’ Cathet. Cardiovasc. Diagn. (1988) vol. 15, No. 2, pp. 112-120.;;Wiatrak, B.J., et al., ‘Unilateral Choanal Atresia: Initial Presentation and Endoscopic Repair’ International Journal of Pediatric Otorhinolaryngology (1998) vol. 46, pp. 27-35.;;Woog, et al. ‘Paranasal Sinus Endoscopy and Orbital Fracture Repair’ Arch Ophthalmol. vol. 116 (May 1998) pp. 688-691.;;Wormald, P.J., et al., ‘The ‘Swing-Door’ Technique for Uncinectomy in Endoscopic Sinus Surgery’ The Journal of Laryngology and Otology (1998) vol. 112, pp. 547-551.;;Xomed-Treace. Bristol-Myers Squibb. Ad for Laser Shield II. Setting the Standards for Tomorrow. [date of publication unknown].;;Yamauchi, Y. et al., ‘Development of a Silicone Model for Endoscopic Sinus Surgery’ Proc International Journal of Computer Assisted Radiology and Surgery vol. 99 (1999) p. 1039.;;Yamauchi, Y., et al., ‘A Training System for Endoscopic Sinus Surgery with Skill Evaluation’ Computer Assisted Radiology and Surgery (2001) with accompanying copy of poster presentation.;;Yanagisawa et al. ‘Anterior and Posterior Fontanelles.’ Ear, Nose & Throat Journal (2001) vol. 80. pp. 10-12.;;Zimarino, M., M.D., et al., ‘Initial Experience with the EuropassTM: A new Ultra-Low Profile monorail Balloon Catheter’ Cathet. Cardiovasc. Diagn. (1994) vol. 33, No. 1, pp. 76-79.;;Australian Office Action, Examiners First Report dated Apr. 8, 2010 for Application No. AU 2005274794.;;Chinese Office Action, First Office Action dated Nov. 5, 2012 for CN 200980137396.1.;;Chinese Search Report dated Oct. 29, 2012 for Application No. CN 200980137396.1.;;Chinese Search Report dated Jan. 11, 2013 for Application No. CN 200980152995.0.;;Chinese Office Action, First Office Action dated Jan. 29, 2013 for CN 200980152995.1.;;European Communication dated Sep. 4, 2008 for Application No. EP 05773189.;;European Communication dated Jun. 19, 2009 for Application No. EP 05773189.;;European Communication dated Aug. 1, 2012 for Application No. EP 06784759.0.;;European Communication dated Aug. 24, 2012 for Application No. EP 05798331.4.;;European Communication dated Nov. 9, 2012 for Application No. EP 07750248.2.;;European Communication dated Apr. 19, 2012 for Application No. EP 08746715.5.;;European Communication dated Jan. 7, 2013 for Application No. EP 08746715.5.;;European Communication dated Apr. 11, 2013 for Application No. EP 05778834.1.;;European Communication dated May 10, 2013 for Application No. EP 06751637.7.;;European Exam Report dated Feb. 22, 2006 for Application No. EP 02716734.5.;;European Exam Report dated Feb. 8, 2007 for Application No. EP 02716734.5.;;European Search Report and Written Opinion dated Sep. 11, 2009 for Application No. EP 06815174.;;European Search Report dated Mar. 16, 2010 re Application No. EP 06718986.;;European Search Report dated Sep. 27, 2011 for Application No. EP 10182961.;;European Search Report dated Sep. 29, 2011 for Application No. EP 10182893.;;European Search Report dated Jul. 23, 2012 for. Application No. EP 12162709.;;European Search Report dated Jul. 24, 2012 for Application No. EP 12162712.;;European Search Report dated Aug. 31, 2012 for Application No. EP 12173295.;;European Search Report dated Oct. 10, 2012 for Application No. EP 12175607.;;European Search Report dated Nov. 22, 2012 for Application No. EP 12182993.;;European Search Report dated Dec. 5, 2012 for Application No. EP 12182998.;;European Search Report dated Jan. 9, 2013 for Application No. EP 12183000.;;European Search Report dated Jan. 11, 2013 for Application No. EP 12183002.;;European Search Report dated Aug. 13, 2013 for Application No. EP 13172140.;;European Search Report dated Sep. 9, 2013 for Application No. EP 13179223.;;Partial European Search Report dated Sep. 20, 2007 for Application No. EP 07252018.;;Partial European Search Report dated Mar. 25, 2008 for Application No. EP 07252018.;;Supplemental Partial European Search Report dated Jun. 2, 2008 for Application No. EP 05773189.;;Supplemental Partial European Search Report dated Jul. 1, 2009 for Application No. EP 06815285.;;Supplemental Partial European Search Report dated Nov. 19, 2010 for Application No. EP 06751637.;;Supplemental European Search Report dated Jan. 29, 2010 for Application No. EP 07836108.;;Supplemental European Search Report dated Feb. 2, 2010 for Application No. EP 07836109.;;Supplemental European Search Report dated Feb. 17, 2010 for Application No. EP 07836110.;;Supplemental European Search Report dated Mar. 1, 2010 for Application No. EP 05778834.;;Supplemental European Search Report dated Mar. 16, 2010 for Application No. EP 06718986.;;Supplemental European Search Report dated Jun. 22, 2010 for Application No. EP 06784759.;;Supplemental European Search Report dated Sep. 23, 2010 for Application No. EP 08746715.;;Supplemental European Search Report dated Jan. 28, 2011 for Application No. EP 07777004.;;Supplemental European Search Report dated Mar. 31, 2011 for Application No. EP 05798331.;;Supplemental European Search Report dated Aug. 30, 2011 for Application No. EP 06800540.;;Supplemental European Search Report dated Sep. 29, 2011 for Application No. EP 07750248.;;PCT Search Report dated Nov. 30, 2009 for Application No. UPCT/US2009/057203.;;International Preliminary Report on Patentability dated Aug. 7, 2006 for Application No. PCT/US05/25371.;;International Preliminary Report on Patentability and Written Opinion dated Sep. 25, 2007 for Application No. PCT/US06/002004.;;International Preliminary Report on Patentability dated Feb. 15, 2008 for Application No. PCT/US05/13617.;;International Preliminary Report on Patentability and Written Opinion dated Nov. 18, 2008 for Application No. PCT/US07/11449.;;International Preliminary Report on Patentability and Written Opinion dated Apr. 7, 2009 for Application No. PCT/US07/021170.;;International Preliminary Report on Patentability and Written Opinion dated May 5, 2009 for Application No. PCT/US06/036960.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 13, 2009 for Application No. PCT/US08/059786.;;International Preliminary Report on Patentability and Written Opinion dated Oct. 27, 2009 for Application No. PCT/US08/061343.;;International Preliminary Report on Patentability dated Jun. 29, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Jun. 3, 2002 for Application No. PCT/EP02/01228.;;International Search Report and Written Opinion dated Apr. 10, 2006 for Application No. PCT/US05/25371.;;International Search Report dated May 8, 2007 for Application No. PCT/US2006/16026.;;International Search Report dated Aug. 17, 2007 for Application No. PCT/US05/013617.;;International Search Report dated Aug. 29, 2007 for Application No. PCT/US06/002004.;;International Search Report dated Sep. 25, 2007 for Application No. PCT/US06/037167.;;International Search Report dated Oct. 19, 2007 for Application No. PCT/US07/003394.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021170.;;International Search Report dated May 29, 2008 for Application No. PCT/US07/021922.;;International Search Report dated Jul. 1, 2008 for Application No. PCT/US06/022745.;;International Search Report dated Jul. 3, 2008 for Application No. PCT/US2006/029695.;;International Search Report dated Jul. 7, 2008 for Application No. PCT/US07/016213.;;International Search Report dated Jul. 8, 2008 for Application No. PCT/US07/011474.;;International Search Report dated Jul. 17, 2008 for Application No. PCT/US06/036960.;;International Search Report and Written Opinion dated Jul. 21, 2008 for Application No. PCT/US05/033090.;;International Search Report dated Aug. 25, 2008 for Application No. PCT/US2008/000911.;;International Search Report dated Sep. 10, 2008 for Application No. PCT/US07/016212.;;International Search Report and Written Opinion dated Sep. 12, 2008 for Application No. PCT/US07/16214.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/059786.;;International Search Report and Written Opinion dated Sep. 17, 2008 for Application No. PCT/US08/061343.;;International Search Report and Written Opinion dated Oct. 1, 2008 for Application No. PCT/US07/011449.;;International Search Report dated Oct. 15, 2008 for Application No. PCT/US2008/061048.;;International Search Report dated Nov. 30, 2009 for Application No. PCT/US2009/057203.;;International Search Report dated Dec. 10, 2009 for Application No. PCT/US2009/052236.;;International Search Report dated Dec. 16, 2009 for Application No. PCT/US2009/050800.;;International Search Report dated Mar. 31, 2010 for Application No. PCT/US2009/069143.;;International Search Report dated Jul. 8, 2010 for Application No. PCT/US2010/027837.;;International Search Report and Written Opinion dated Oct. 6, 2010 for Application No. PCT/US2010/040548.;;International Search Report dated Mar. 25, 2011 for Application No. PCT/US2010/062161.;;International Search Report dated Mar. 28, 2011 for Application No. PCT/US2010/061850.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2010/060898.;;International Search Report dated Mar. 31, 2011 for Application No. PCT/US2009/069143.;;International Search Report dated Aug. 9, 2011 for Application No. PCT/US2011/038751.;;International Search Report dated May 18, 2012 for Application No. PCT/US2011/052321.;;Partial International Search Report dated Feb. 7, 2012 for Application No. PCT/US2011/052321.;;Japanese Office Action, Examiner's Decision of Refusal dated Oct. 18, 2011 for Application No. JP 2007-509632.;;Japanese Office Action, Notification of Reasons for Refusal dated Apr. 26, 2011 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Jan. 24, 2012 for Application No. JP 2007-532485.;;Japanese Office Action, Notification of Reasons for Refusal dated Aug. 16, 2011 for Application No. JP 2008-516013.;;Japanese Office Action, Notification of Reasons for Refusal dated Nov. 8, 2011 for Application No. JP 2008-524250.;;Japanese Office Action, Notification of Reasons for Refusal dated Jun. 25, 2013 for Application No. JP 2012-131840.;;Russian Office Action dated Sep. 28, 2012 for Application No. RU 2011130530.;;Russian Office Action dated Mar. 19, 2013 for Application No. RU 2011130530.;;U.S. Office Action dated Sep. 16, 2005 for U.S. Appl. No. 10/259,300.;;U.S. Office Action dated Jul. 7, 2006 for U.S. Appl. No. 10/259,300.;;U.S. Office Action dated Feb. 13, 2007 for U.S. Appl. No. 10/259,300.;;U.S. Office Action dated Oct. 9, 2007 for U.S. Appl. No. 10/259,300.;;U.S. Office Action dated Jan. 24, 2008 for U.S. Appl. No. 10/259,300.;;U.S. Office Action dated Oct. 6, 2008 for U.S. Appl. No. 10/259,300.;;U.S. Office Action dated May 29, 2007 for U.S. Appl. No. 10/912,578.;;U.S. Office Action dated Nov. 14, 2007 for U.S. Appl. No. 10/912,578.;;U.S. Office Action dated Dec. 10, 2007 for U.S. Appl. No. 10/912,578.;;U.S. Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/037,548.;;U.S. Office Action dated Dec. 6, 2007 for U.S. Appl. No. 11/037,548.;;U.S. Office Action dated Apr. 9, 2008 for U.S. Appl. No. 11/037,548.;;U.S. Office Action dated Nov. 28, 2007 for U.S. Appl. No. 11/234,395.;;U.S. Office Action dated Sep. 12, 2008 for U.S. Appl. No. 10/829,917.;;U.S. Office Action dated Nov. 17, 2008 for U.S. Appl. No. 10/829,917.;;U.S. Office Action dated Mar. 18, 2009 for U.S. Appl. No. 10/829,917.;;U.S. Office Action dated Nov. 9, 2009 for U.S. Appl. No. 10/829,917.;;U.S. Office Action dated Oct. 29, 2008 for U.S. Appl. No. 11/347,147.;;U.S. Office Action dated Feb. 4, 2009 for U.S. Appl. No. 11/347,147.;;U.S. Office Action dated Aug. 6, 2009 for U.S. Appl. No. 11/347,147.;;U.S. Office Action dated Nov. 7, 2008 for U.S. Appl. No. 10/944,270.;;U.S. Office Action dated Jan. 28, 2009 for U.S. Appl. No. 10/944,270.;;U.S. Office Action dated Apr. 21, 2009 for U.S. Appl. No. 10/944,270.;;U.S. Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/117,582.;;U.S. Office Action dated Mar. 3, 2009 for U.S. Appl. No. 12/117,582.;;U.S. Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,582.;;U.S. Office Action dated Nov. 17, 2008 for U.S. Appl. No. 12/118,931.;;U.S. Office Action dated Mar. 4, 2009 for U.S. Appl. No. 12/118,931.;;U.S. Office Action dated Jul. 30, 2009 for U.S. Appl. No. 12/118,931.;;U.S. Office Action dated Nov. 25, 2008 for U.S. Appl. No. 12/117,961.;;U.S. Office Action dated Aug. 6, 2009 for U.S. Appl. No. 12/117,961.;;U.S. Office Action dated Dec. 5, 2008 for U.S. Appl. No. 12/120,902.;;U.S. Office Action dated Oct. 21, 2009 for U.S. Appl. No. 12/120,902.;;U.S. Office Action dated Mar. 17, 2009 for U.S. Appl. No. 11/690,127.;;U.S. Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/804,309.;;U.S. Office Action dated Mar. 23, 2009 for U.S. Appl. No. 11/926,326.;;U.S. Office Action dated Aug. 28, 2009 for U.S. Appl. No. 11/150,847.;;U.S. Office Action dated Dec. 29, 2008 for U.S. Appl. No. 11/193,020.;;U.S. Office Action dated May 13, 2009 for U.S. Appl. No. 11/193,020.;;U.S. Appl. No. 60/844,874, filed Sep. 15, 2006.;;U.S. Appl. No. 60/922,730, filed Apr. 9, 2007.;;U.S. Appl. No. 61/052,413, filed May 12, 2008.;;U.S. Appl. No. 61/084,949, filed Jul. 30, 2008.;;U.S. Appl. No. 11/789,705, filed Apr. 24, 2007.;;U.S. Appl. No. 13/840,430, filed Mar. 15, 2013.;;U.S. Appl. No. 11/355,512.;;U.S. Appl. No. 11/438,090.;;U.S. Appl. No. 11/655,794.;;U.S. Appl. No. 11/725,151.;;U.S. Appl. No. 11/789,704.;;U.S. Appl. No. 11/888,284.;;U.S. Appl. No. 11/926,565.;;U.S. Appl. No. 11/928,097.;;U.S. Appl. No. 11/930,716.;;U.S. Appl. No. 11/930,786.;;U.S. Appl. No. 12/100,361.;;U.S. Appl. No. 12/341,602.;;U.S. Appl. No. 12/543,445.;;U.S. Appl. No. 12/727,190.;;U.S. Appl. No. 12/729,109.;;U.S. Appl. No. 12/756,099.;;U.S. Appl. No. 12/768,963.;;U.S. Appl. No. 12/769,915.;;U.S. Appl. No. 12/828,170.;;U.S. Appl. No. 13/315,191.;;U.S. Appl. No. 13/355,758.;;U.S. Appl. No. 13/429,857.;;U.S. Appl. No. 13/784,293.;;Japanese Office Action, Notification of Reasons for Refusal dated Sep. 18, 2013 for Application No. JP 2011-527942.;;English Machine Translation for Application No. JP 5-503650.;;U.S. Appl. No. 11/648,158, filed Dec. 29, 2006;;U.S. Appl. No. 10/912,557.;;U.S. Appl. No. 10/944,270.;;U.S. Appl. No. 11/193,020.;;U.S. Appl. No. 11/436,892.;;U.S. Appl. No. 11/647,530.;;U.S. Appl. No. 11/789,705.;;U.S. Appl. No. 11/803,695.;;U.S. Appl. No. 11/804,308.;;U.S. Appl. No. 11/929,667.;;U.S. Appl. No. 11/929,808.;;U.S. Appl. No. 12/143,698.;;U.S. Appl. No. 12/184,166.;;U.S. Appl. No. 12/496,226. et al.",ACTIVE
123,US,B2,US 8414473 B2,106-098-377-513-204,2013-04-09,2013,US 56114709 A,2009-09-16,US 56114709 A;;US 19302005 A;;US 82991704 A;;US 94427004 A;;US 11611805 A;;US 15084705 A;;US 9815708 P,2004-04-21,Methods and apparatus for treating disorders of the ear nose and throat,A device for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle; an elongate shaft having a proximal end coupled with the handle and extending to a distal end; a guidewire disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD JR ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T;;ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD JR ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,ACCLARENT INC (2009-10-28),https://lens.org/106-098-377-513-204,Granted Patent,yes,113,116,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B1/00;;A61F2/958;;A61M25/10,600/104;;600/137,99,64,025-156-740-825-269;;017-705-556-162-740;;099-120-884-682-48X;;009-319-672-632-222;;058-795-106-119-138;;001-587-153-855-029;;176-641-495-314-442;;016-283-648-637-017;;062-137-615-055-259;;037-607-517-222-380;;005-062-484-246-491;;100-025-025-350-522;;186-528-475-637-357;;052-445-010-706-604;;119-217-157-114-616;;054-089-920-123-728;;000-190-809-189-320;;081-342-189-359-998;;021-097-107-538-923;;032-512-397-029-063;;056-483-407-311-486;;035-150-343-174-058;;026-029-145-609-339;;043-068-503-393-610;;066-559-118-020-405;;004-569-239-507-13X;;015-741-985-781-596;;006-017-396-056-413;;021-250-660-000-916;;031-531-139-211-441;;116-591-251-529-464;;160-431-910-170-858;;098-072-365-612-295;;130-657-825-626-105;;018-585-778-259-479;;088-627-474-618-18X;;108-720-882-644-723;;042-366-103-157-183;;140-038-299-567-888;;118-082-313-703-956;;138-834-150-176-702;;010-637-420-805-755;;016-158-671-669-348;;083-952-277-919-706;;003-649-039-232-147;;078-385-068-066-429;;041-854-577-938-21X;;032-707-415-641-636;;054-363-816-914-764;;040-233-574-483-653;;007-699-329-714-68X;;016-747-321-581-210;;024-179-695-153-875;;023-013-236-174-62X;;093-101-023-880-167;;142-747-701-744-665;;095-149-571-866-441;;044-665-456-793-33X;;048-975-994-978-779;;130-499-350-444-007;;090-798-792-511-247;;008-078-192-419-026;;011-379-832-152-348;;122-655-553-157-640,4451093;;10.3109/00016487409126376;;3346594;;10.1017/s0022215100104360;;2893945;;10.1016/s0194-5998(03)01397-4;;12958561;;10.2500/105065894781874278;;10.1111/j.1365-2273.1978.tb00659.x;;0648003;;648003;;10.1177/000348940611500407;;16676826;;10.2500/105065898780182444;;9805533;;15654213;;10.1097/00020840-200502000-00009;;10.1055/s-1991-26501;;10.1590/s1807-59322007000100007;;17334548;;12707197;;10.1001/archotol.129.4.472;;1068575;;10.1016/s1043-1810(10)80087-9;;10.1007/bf00556991;;2306777;;10.1002/ccd.1810190215;;10.1177/019459989010300124;;2117725;;10.1053/otot.2001.25030;;10.1097/00005537-200004000-00027;;10764019;;10.1067/mhn.2000.105921;;10889485;;10.1288/00005537-198605000-00020;;3702574;;10.1016/0165-5876(91)90139-3;;1889957;;10.1016/0022-1139(94)03130-4;;10.1288/00005537-190804000-00004;;10.1007/bf02494832;;10505447;;10.1080/02844319950159316;;10.1246/cl.1976.499;;10.3109/13645709809152853;;10.2500/105065897781446793;;9065341;;2032874;;1747245;;10.1007/bf01463560;;10.1288/00005537-198109000-00019;;7346699;;2715691;;10.1017/s0022215100109004;;10.1177/000348940501400308;;10.1067/mhn.2001.119439;;11743462;;9365106;;10.1023/a:1015102028756;;10.1016/s0030-6665(03)00158-0;;15064069;;11340690;;8876077;;10.1016/s1043-1810(10)80085-5;;10.1034/j.1398-9995.2000.00649.x;;10955697;;10.1016/s1051-0443(95)71171-x;;8541673;;pmc1830102;;13547019;;10.1016/j.otc.2005.07.003;;16326186;;5571875;;10.1017/s0022215100074223;;10.1016/s1043-1810(06)80011-4;;8402858;;10.1002/ccd.1810300106;;10.1016/s0040-4020(00)00977-7;;8643296;;10.1016/s0194-5998(96)70095-5;;10.1016/s0194-59989670095-5;;10.1097/00005537-199601001-00001;;8538352;;10.1097/00005373-197807000-00005;;671569;;10.1288/00005537-199508000-00013;;7630296;;2354510;;10.1002/ccd.1810200210;;10.1021/jo00116a045;;10.1067/mhn.2002.121022;;11821764;;10.1017/s0022215100068171;;6058519;;9105379;;10.1097/00006534-199704001-00042;;9438931;;14927373;;10.1001/jama.1952.02930220026009;;14835484;;11170342;;10.1002/1522-726x(200102)52:2<260::aid-ccd1061>3.0.co;2-t;;9314363;;10.1016/s1051-0443(97)70655-9;;pmc3451970;;23120037;;10.1007/bf02968783,"PCT search report from PCT application No. PCT/US2009/057203 dated Nov. 30, 2009 as issued by the European Patent Office as searching authority.;;Argon Medical. Maxxim Medical. Ad for Sniper EliteTM Hydrophilic Ni-Ti Alloy Guidewire (2001).;;Aust, R., et al 'The Functional Size of the Human Maxillary Ostium in Vivo' Acta. Otolaryn. (1978) vol. 78 pp. 432-435.;;Baim, D.S., MD Grossman's Cardiac Catheterization, Angiography, and Intervention (2000) Lippincott Williams & Wilkins pp. 76, 84 & 214.;;Barrett, S. 'Be Wary of Neurocranial Restructuring (NCR)' Chirobase (available at: http://www.chirobase.org/06DD/ncr.html) (Jul. 2003.).;;Bartal, N. 'An Improved Stent for Use in the Surgical Management of Congenital Posterior Choanal Atresia' J. Laryngol. Otol. (1988) vol. 102 pp. 146-147.;;Becker, A.E. 'Restenosis After Angioplasty' The Lancet (1988) vol. 331, No. 8584 p. 532.;;Bellis, M. History of the Catheter-Balloon Catheter-Thomas Fogarty. http://inventors.about.com/library/inventors/blcatheter.htm?p=1.;;Benninger et al. Adult Chronic Rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysiology Arch Otolarygol Head and Neck Surg. (Sep. 2003) vol. 129 pp. S1-S32.;;Bent et al. 'The Frontal Cell as a Cause of Frontal Sinus Obstruction' American Journal of Rhinology. (1994) vol. 8, No. 4 pp. 185.;;Binner et al. 'Fibre-Optic Transillumination of the Sinuses: A Comparison of the Value of Radiography and Transillumination in Antral Disease' Clinical Otolaryngology. (1978) vol. 3 pp. 1-11.;;Brown, C.L. et al 'Safety and Feasibility of Balloon Catheter Dilation of Paranasal Sinus Ostia: A Preliminary Investigation' Annals of Otology, Rhinology & Laryngology (2006) vol. 115, No. 4 pp. 293-299.;;Bumm, P., H. Kaiser et al 'Cortizontherapie, Corticoide in Klinik und Praxis' Thieme, Stuggart (1992) pp. 390-401 [Summary of textbook].;;Casiano et al. 'Endoscopic Lothrop Procedure: The University of Miami Experience' American Journal of Rhinology (1998) vol. 12, No. 5 pp. 335-339.;;Casserly, I.P. et al Chapter 7. 'Guides and Wires in Percutaneous Coronary Intervention' Strategic Approaches in Coronary Intervention (2006) Lippincott Williams & Wilkins pp. 91-99.;;Chien, Y.W. et al. Nasal Systemic Drug Delivery, Drugs and the Pharmaceutical Sciences (1989) Marcel Dekker, Inc. Chapter 3, pp. 39-88.;;Cohen et al 'Endoscopic Sinus Surgery: Where we are and where we're going' Current Opinion in Otolaryngology & Head and Neck Surgery (2005) vol. 13 pp. 32-38.;;Colla, A. et al 'Trihaloacetylated Enol Ethers-General Synthetic Procedure and Heterocyclic Ring Closure Reactions with Hydroxylamine' Synthesis. (Jun. 1991) pp. 483-486.;;Costa, M.N. et al 'Endoscopic Study of the Intranasal Ostium in External Dacryocystorhinostomy Postoperative. Influence of Saline Solution and 5-Flurorouracil' Clinics. (2007) vol. 62, Issue 1 pp. 41-46. http://www.scielo.br/scielo.php?pid=S1807-59322007000100007&script=sci-arttext.;;Cussler, E.L. Diffusion: Mass Transfer in Fluid Systems Cambridge University Press (1996) [Summary of textbook].;;Davis, G.E. et al., 'A Complication From Neurocranial Restructuring' Arch Otolaryngology Head Neck Surg. (Apr. 2003) vol. 129 pp. 472-474.;;Deutschmann, R. et al. 'A Contribution to the Topical Treatment of [Maxillary] Sinusitis Preliminary Communication' Stomat DDR 26, (1976) pp. 585-592.;;Domb, A. et al Handbook of Biodegradable Polymers Harwood Academic Publishers (1997) [Summary of textbook].;;Draf, W. 'Endonasal Micro-Endoscopic Frontal Sinus Surgery: the Fulda Concept' Op Tech Otolaryngol Head Neck Surg. (1991) vol. 2 pp. 234-240.;;Edmond et al 'ENT Surgical Stimulator' Nov. 1998 Final Report Cooperative Agreement No. DAMD17-95-2-5023.;;ENT Checklist; Physical Examination Performance Checklist [date of publication unknown].;;Eremychev, V.A. 'Needles for Puncture and Drainage of the Maxillary Sinus' Meditsinskaya Tekhnika, No. 5 (1974) pp. 54-55.;;Feldman, R.L. et al 'New Steerable, Ultra-Low-Profile, Fixed Wire Angioplasty Catheter: Initial Experience With the Cordis Orion(TM) Steerable PTCA Balloon Catheter' Cathet. Cardiovasc. Diagn. (1990) vol. 19, No. 2 pp. 142-145.;;Ford, C.N. 'A Multipurpose Laryngeal Injector Device' Otolaryngol. Head Neck Surg. (1990) vol. 103, No. 1 pp. 135-137.;;Friedman, M. M.D., et al 'Frontal Sinus Surgery: Endoscopic Technique' Operative Techniques in Otolarynology-Head and Neck Surgery. (Jun. 2001) vol. 12, No. 2 pp. 60-65.;;Friedman, et al 'Intraoperative and Postoperative Assessment of Frontal Sinus Patency by Transillumination' Laryngoscope. (Apr. 2000) vol. 110 pp. 683-684.;;Friedman et al 'Middle Turbinate Medialization and Preservation in Endoscopic Surgery' Otolaryngol. Head Neck Surg. (2000) vol. 123, No. 1, Part 1. pp. 76-80.;;Fung, M.K.T. 'How I Do It-Head and Neck and Plasic Surgery. A Targeted Problem and its Solution. Template for Frontal Osteoplastic Flap' Laryngoscope. (1986) vol. 96 pp. 578-579.;;Gatot, A. et al., 'Early Treatment of Orbital Floor Fractures with Catheter Balloon in Children' Int. J. Pediatric Otorhinolaryngol (1991) vol. 21 pp. 97-101.;;Gerus, I.I. et al 'beta-Ethoxyvinyl Polyfluroroalkyl Ketones-Versatile Synthones in Fluoroorganic Chemistry' Journal of Fluorine Chemistry. (1994) vol. 69 pp. 195-198. Elsevier Science S.A.;;Good, R.H. 'An Intranasal Method for Opening the Frontal Sinus Establishing the Largest Possible Drainage' Laryngoscope. (1908) vol. 18 pp. 266-274.;;Gopferich 'Polymer Degradation and Erosion: Mechanisms and Applications' Eur. J. Pharm. Biophar. (1996) vol. 42 pp. 1-11.;;Gorlov, D.V. et al 'Acylation of 2-Methoxypropene with Anhydrides and Halides of Perflurocarboxylic Acids in the Presence of Tertiary Amines' Russian Chemical Bulletin. (Sep. 1999) vol. 48 No. 9 pp. 1791-1792. Kluwer Academic/Plenum Publishers.;;Gottman, et al. 'Balloon Dilatation in the Nasal Cavity and Paranasal Sinuses' CIRSE. (Sep. 25, 2004) pp. 1-27.;;Gottman, et al. 'Balloon Dilatation of Recurrent Ostial Occlusion of the Front Sinus' Abstract No. B-04353. European Congress of Radiology. (Mar. 2, 2001).;;Gottman, et al. 'Successful Treatment of Recurrent Post-Operative Frontal Sinus Stenoses by Balloon Dilatation' CIRSE. (Oct. 5, 2002).;;Gupta, D. et al 'Dacryocystitis Secondary to an Iatrogenic Foreign Body in the Lacrimal Apparatus' Ear, Nose & Throat Journal (2009) http://findarticles.com/p/articles/mi-m0BUM/is-7-88/ai-n32428620/.;;Hashim, et al 'Balloon Compression of the Intermaxillary Sinus for Intractable Post Traumatic Bleeding from the Maxillary Artery' Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery (1999) vol. 33 pp. 321-324.;;Hojo, M. et al 'Electrophilic Substitutions of Olefinic Hydrogens II. Acylation of Vinyl Ethers and N Vinyl Amides' Chemistry Letters (1976) pp. 499-502.;;Hopf, J.U.G. et al 'Miniature Endoscopes in Otorhinolaryngologic Applications' Min Invas Ther & Allied Technol. (1998) vol. 7, No. 3 pp. 209-218.;;Hosemann, W. et al A Dissection Course on Endoscopic Endonasal Sinus Surgery (2005) Endo-Press, Tuttlingen pp. 4-37.;;Hosemann, W. et al 'Endonasal Frontal Sinusotomy in Surgical Management of Chronic Sinusitis: A Critical Evaluation' American Journal of Rhinology (1997) vol. 11, No. 1 pp. 1-9.;;Hosemann, M.E. et al 'Experimentelle Untersuchungen zur Wundheilung in den Nasennebenholhlen. II. Spontaner Wundschluss und medikamentose Effekte im standardisierten Wundmodell.' HNO 39 (1991) pp. 48-54.;;Hosemann W.G. et al Minimally Invasive Endonasal Sinus Surgery Thieme, Stuttgart, New York (2000) [Summary of textbook].;;Hosemann, M.E. et al 'Normal Wound Healing of the Paranasal Sinuses-Clinical and Experimental Investigations' Eur Arch Otorhinolarygol. (1991) vol. 248 pp. 390-394.;;Hosemann, W. et al 'Weiterbehandlung nach Nasennebenhohleneingriffen, Part 2: Theapeutische Mabetanahmen' HNO akutell 7 (1999) pp. 291-302.;;Hospital Corpsman Sickcall Screener's Handbook. Naval Hospital Great Lakes (Apr. 1999) http://www.brooksidepress.org/Products/Operationa.Medicine/DATA. 2001 pp. 1-6.;;Hybels, R.L. 'Transillumination During Osteoplastic Frontal Sinusotomy' The Laryngoscope (Sep. 1981) vol. 91 pp. 1560.;;Ijaduola, T.G.A. 'Use of a Foley Catheter for Short-Term Drainage in Frontal Sinus Surgery' The Journal of Laryngology and Otology. (1989) vol. 103 pp. 375-378.;;Ingals, F. 'New Operation and Instruments for Draining the Frontal Sinus' Ann. Otol Rhinol Laryngol. (1905) vol. 14 pp. 515-519.;;Iro, H. et al 'A New Device for Frontal Sinus Endoscopy: First Clinical Report' Otolaryngol. Head Neck Surg. (2001) vol. 125 No. 6 pp. 613-616.;;Jacobs, J.B. '100 Years of Frontal Sinus Surgery' Laryngoscope. (1997) vol. 107 pp. 1-36.;;Kennedy, D.W., M.D. et al Diseases of the Sinuses Diagnosis and Management (Copyright 2001) by B.C. Decker Inc.;;Khomutov, S.M. et al 'Dissolution of a Mixture of Steroids in Cyclodextrin Solutions: a Model Description' Pharmaceutical Chemistry Journal. (Nov. 2001) vol. 35, No. 11 pp. 627-629.;;Kingdom, T.T. et al 'Image-Guided Surgery of the Sinuses: Current Technology and Applications' Otolaryngol. Clin. North Am. (Apr. 2004) vol. 37, No. 2 pp. 381-400.;;Klossek, J.M. et al 'Local Safety of Intranasal Triamcinolone Acetonide: Clinical and Histological Aspects of Nasal Mucosa in the Long-Term Treatment of Perennial Allergic Rhinitis' Rhinology (2001) vol. 39, No. 1 pp. 17-22.;;Kozlov et al 'Diagnosis and Treatment of Sinusitis by YAMIK Sinus Catheters' Rhinology (1996) vol. 34. pp. 123-124.;;Kuhn, et al. 'The Agger Nasi Cell in Frontal Recess Obstruction: An Anatomic, Radiology and Clinical Correlation' Operative Techniques in Otolaryngology-Head and Neck Surgery (1991) vol. 2, No. 4 pp. 226-231.;;Laliberte F. et al 'Clinical and Pathologic Methods to Assess the Long-Term Safety or Nasal Corticosteroids' Allergy (2000) vol. 55, No. 8 pp. 718-722.;;Lang, E.V. et al 'Access Systems for Puncture at an Acute Angle' J. Vasc. Interv. Radiol. (1995) vol. 6, No. 5 pp. 711-713.;;Lanza, D.C. 'Postoperative Care and Avoiding Frontal Recess Stenosis' International Advanced Sinus Symposium. General Session Abstracts. Jul. 21-24, 1993.;;Large, G.C. 'Crystalline Tetracycline Hydrochloride in the Treatment of Acute and Chronic Maxillary Sinusitis' Canad. M. A. J. (1958) vol. 79 pp. 15-16.;;Lund, V.J. 'Maximal Medical Therapy for Chronic Rhinosinusitis' Otolaryngol Clin N Am. (2005) vol. 38 pp. 1301-1310.;;Maran, A.G.D. et al 'The Use of the Foley Catheter in the Tripod Fracture' J. Laryngol. Otol (1971) vol. 85, Issue 9 pp. 897-902.;;May, M. et al 'Frontal Sinus Surgery: Endonasal Drainage Instead of an External Osteopolstic Approach' Op Tech Otolaryngo Head Neck Surgery (1995) vol. 6, No. 3 pp. 184-192.;;Medtronic, xomed.com-MicroFrance Catalog Browser. http://www.xomcat.com/xomfrance/index.php?zone=both&cat=18&sub=58&prodline=1272 (Dec. 31, 2003) pp. 1-2.;;Mehan, V.K. et al 'Coronary Angioplasty through 4 French Diagnostic Catheters' Cathet. Cardiovasc. Diagn. (1993) vol. 30, No. 1 pp. 22-26.;;Mellor, J.M. et al 'Synthesis of Trifluromethylnaphthalenes' Tetrahedron (2000) vol. 56 pp. 10067-10074. Elseview Science Ltd.;;Metson, R. et al 'Endoscopic Treatment of Sphenoid Sinusitis' Otolaryngol. Head Neck Surg. (1996) vol. 114, No. 6 pp. 736-744.;;Metson, R. 'Holmium: YAG Laser Endoscopic Sinus Surgery: A Randomized Controlled Study' Laryngoscope (Jan. 1996) vol. 106, Issue 1, Supplement 77 pp. 1-18.;;Miller et al. 'Management of Fractures of the Supraorbital Rim' Journal of Trauma (Jul. 1978) vol. 18, No. 7 pp. 507-512.;;Min, Y-G et al. 'Mucociliary Activity and Histopathology of Sinus Mucosa in Experimental Maxilary Sinusitis: A Comparison of Systemic Administration of Antibiotic and Antibiotic Delivery by Polylactic Acid Polymer' Laryngoscope (Aug. 1995) vol. 105 pp. 835-842.;;Mols, B. 'Moveable Tool Tip for Keyhole Surgery' Delft Outlook (2005) vol. 3 pp. 13-17.;;Mooney, M.R. et al 'Monorail(TM) Piccolino Catheter: A New Rapid Exchange/Ultralow Profile Coronary Angioplasty System' Cathet. Cardiovasc. Diagn. (1990) vol. 20, No. 2 pp. 114-119.;;Moriguchi, T. et al 'Addition-Elimination Reaction in the Trifluoroacetylation of Electron-Rich Olefins' J. Org. Chem. (1995) vol. 60, No. 11 pp. 3523-3528. American Chemical Society.;;Park, K. et al Biodegreadable Hydrogels for Medicinal Substance Delivery (1993) Technomic Publishing Inc. Lancaster.;;Piccirillo, J.F. et al 'Psychometric and Clinimetric Validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20)' Otolaryngol. Head Neck Surg (2002) vol. 126, No. 1 pp. 41-47.;;Piers, et al 'A Flexible Distal Tip with Two Degrees of Freedom for Enhanced Dexterity in Endoscopic Robot Surgery' Proceedings 13th Micromechanics Europe Workshop (2002) pp. 271-274.;;Podoshin, L. et al 'Balloon Technique for Treatment of Frontal Sinus Fractures' The Journal of Laryngology & Otology (1967), vol. 81. pp. 1157-1161.;;Pownell, P.H. et al 'Diagnostic Nasal Endoscopy' Plastic & Reconstructive Surgery (1997) vol. 99, Iss. 5 pp. 1451-1458.;;Prince et al 'Analysis of the Intranasal Distribution of Ointment' J Otolaryngol. (1997) vol. 26 pp. 357-360.;;Ramsdale, D.R. Illustrated Coronary Intervention A case-oriented approach (2001) Martin Dunitz Ltd. pp. 1-5.;;Ritter, F.N. et al Atlas of Paranasal Sinus Surgery (1991) Igaku-Shoin Medical Pub. pp. 1-81.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Maxillary Sinusitis' J.A.M.A. (May 31, 1952) pp. 436-440.;;Robison, J. Mathews, M.D. 'Pressure Treatment of Purulent Maxillary Sinusitis' Texas State Journal of Medicine. (May 1951) pp. 281-288.;;Sama, A. et al 'Current Opinions on the Surgical Management of Frontal Sinus Disease' ENT News. www.pinpointmendical.com/ent-news (2009) vol. 17 No. 6 pp. 60-63.;;Sanborn, T.A., et al 'Percutaneous Endocardial Transfer and Expression of Genes to the Myocardium Utilizing Fluropscopic Guidance' Catheter Cardiovasc. Interv. (2001) vol. 52, No. 2 pp. 260-266.;;Sawbones Catalog 2001, Pacific Research Laboratories, Inc., Vashon, Washington 98070 USA.;;Saxon, R.R., et al 'Technical Aspects of Accessing the Portal Vein During the TIPS Procedure' J. Vasc. Interv. Radiol. (1997) vol. 8, No. 5 pp. 733-744.;;Schaefer, S.D., M.D. Rhinology and Sinus Disease A Problem-Oriented Approach (Copyright 1988) by Mosby, Inc.;;Schneider. Pfizer Ad for Softip [date of publication unknown].;;Shah, N.J. et al 'Endoscopic Pituitary Surgery-A Beginner's Guide' Indian Journal of Otolaryngology and Head and Neck Surgery (2004) vol. 56, No. 1 pp. 71-78.;;Shah, N.J. 'Functional Endoscopic Sinus Surgery' (1999); found at www.bhj.org/journal/1999-4104-oct99/sp-659.htm.;;Single-Pole and Multi-Pole Lightguides for UV Spot Light Curing Systems. http://www.dymax.com/products/curing-equipment/lightguids/light. (2004) pp. 1-2.",ACTIVE
124,US,A1,US 2013/0261388 A1,009-824-785-904-922,2013-10-03,2013,US 201313858580 A,2013-04-08,US 201313858580 A;;US 56114709 A;;US 19302005 A;;US 15084705 A;;US 11611805 A;;US 94427004 A;;US 82991704 A;;US 9815708 P,2004-04-21,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,A device for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle; an elongate shaft having a proximal end coupled with the handle and extending to a distal end; a guidewire disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS R;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/009-824-785-904-922,Patent Application,yes,0,59,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B17/24;;A61F2/958;;A61M25/10,600/104;;606/196;;606/185,0,0,,,,ACTIVE
125,US,A1,US 2010/0099946 A1,080-306-270-588-064,2010-04-22,2010,US 56114709 A,2009-09-16,US 56114709 A;;US 19302005 A;;US 82991704 A;;US 94427004 A;;US 11611805 A;;US 15084705 A;;US 9815708 P,2004-04-21,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,A device for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle; an elongate shaft having a proximal end coupled with the handle and extending to a distal end; a guidewire disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD JR ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,ACCLARENT INC (2009-10-28),https://lens.org/080-306-270-588-064,Patent Application,yes,112,102,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B1/018;;A61M29/02;;A61F2/958;;A61M25/10,600/104;;606/199;;606/196,0,0,,,,ACTIVE
126,CA,A1,CA 2737804 A1,115-040-565-388-521,2010-03-25,2010,CA 2737804 A,2009-09-16,US 9815708 P;;US 56114709 A;;US 2009/0057203 W,2008-09-18,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,A device (400) for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle (402); an elongate shaft (414) having a proximal end coupled with the handle and extending to a distal end; a guidewire (410) disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member (406) coupled with at least one of the guidewire or the dilator through the longitudinal opening (408) of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N JR;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/115-040-565-388-521,Patent Application,no,0,0,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61M29/00;;A61B1/00;;A61B17/24;;A61F2/958;;A61M25/09;;A61M25/10,,0,0,,,,DISCONTINUED
127,US,A1,US 2018/0125515 A1,016-730-489-841-425,2018-05-10,2018,US 201715814984 A,2017-11-16,US 201715814984 A;;US 201313858580 A;;US 56114709 A;;US 19302005 A;;US 15084705 A;;US 11611805 A;;US 94427004 A;;US 82991704 A;;US 9815708 P,2004-04-21,METHODS AND APPARATUS FOR TREATING DISORDERS OF THE EAR NOSE AND THROAT,A device for dilating an ostium of a paranasal sinus of a human or animal subject may include: a handle; an elongate shaft having a proximal end coupled with the handle and extending to a distal end; a guidewire disposed through at least a portion of the shaft lumen; a dilator having a non-expanded configuration and an expanded configuration; and a slide member coupled with at least one of the guidewire or the dilator through the longitudinal opening of the shaft for advancing the guidewire and/or the dilator relative to the shaft.,ACCLARENT INC,JENKINS THOMAS R;;GOLDFARB ERIC;;VO TOM THANH;;MAKOWER JOSHUA;;WOOD ROBERT N;;HEISER RONDA M;;LARSEN CHRISTOPHER;;HARFE DANIEL T,,https://lens.org/016-730-489-841-425,Patent Application,yes,0,3,26,26,0,A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10185;;A61M25/10186;;A61B17/24;;A61B1/32;;A61B17/24;;A61M25/09;;A61M29/02;;A61M2025/09116;;A61M25/10181;;A61M25/0068;;A61B1/0014;;A61B1/126;;A61B1/233;;A61B2017/00535;;A61M25/09;;A61M25/1018;;A61M29/02;;A61M2210/0618;;A61M25/10186;;A61M25/10185;;A61B17/24,A61B17/24;;A61B1/00;;A61B1/12;;A61B1/233;;A61B17/00;;A61F2/958;;A61M25/00;;A61M25/09;;A61M25/10;;A61M29/02,,0,0,,,,ACTIVE
128,US,B2,US 10276384 B2,026-175-946-466-062,2019-04-30,2019,US 201715419065 A,2017-01-30,US 201715419065 A,2017-01-30,Plasma shallow doping and wet removal of depth control cap,"A gas is ionized into a plasma. A compound of a dopant is mixed into the plasma, forming a mixed plasma. Using a semiconductor device fabrication system, a layer of III-V material is exposed to the mixed plasma to dope the layer with the dopant up to a depth in the layer, forming a shallow doped portion of the layer. The depth of the dopant is controlled by a second layer of the dopant formed at the shallow doped portion of the layer. The second layer is exposed to a solution, where the solution is prepared to erode the dopant in the second layer at a first rate. After an elapsed period, the solution is removed from the second layer, wherein the elapsed period is insufficient to erode a total depth of the layer and the shallow doped portion by more than a tolerance erosion amount.",IBM;;TOKYO ELECTRON LTD,BRUCE ROBERT L;;CHAN KEVIN K;;ENGELMANN SEBASTIAN U;;GOLDFARB DARIO L;;HOPSTAKEN MARINUS;;KHOJASTEH MAHMOUD;;TOTIR GEORGE G;;YAN HONGWEN;;YAMAZAKI MASAHIRO,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-09-26);;TOKYO ELECTRON LIMITED (2016-09-26),https://lens.org/026-175-946-466-062,Granted Patent,yes,7,2,4,4,0,H01L21/02046;;H01L21/2236;;H01L21/2233;;H01L29/1029;;H01L29/207;;H01L21/30612;;H01L21/2236;;H01L21/2233;;H01L21/02046,H01L21/223;;H01L21/306;;H01L29/10;;H01L29/207,,1,0,,,"Appendix P, 2018.",ACTIVE
129,US,B2,US 7521172 B2,054-726-960-794-701,2009-04-21,2009,US 38078206 A,2006-04-28,US 38078206 A,2006-04-28,Topcoat material and use thereof in immersion lithography processes,"Disclosed is a topcoat composition comprising a polymer having a dissolution rate of at least 1500 Å/second in an aqueous alkaline developer, and at least one solvent. The topcoat composition can be used to coat a photoresist layer on a material layer on a substrate, for example, a semiconductor chip. Also disclosed is a method of forming a pattern in the material layer of the coated substrate.",IBM,DAVID ROBERT ALLEN;;BROCK PHILLIP JOE;;BURNS SEAN DAVID;;GOLDFARB DARIO LEONARDO;;MEDEIROS DAVID;;PFEIFFER DIRK;;PINNOW MATT;;SOORIYAKUMARAN RATNAM;;SUNDBERG LINDA KARIN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-04-26),https://lens.org/054-726-960-794-701,Granted Patent,yes,8,7,2,8,0,G03F7/091;;G03F7/091;;G03F7/11;;G03F7/11;;G03F7/2041;;G03F7/2041,G03F7/20;;C08F220/22;;G03F7/26,430/270.1;;430/273.1;;526/242;;526/245;;526/308;;526/309;;526/318,0,0,,,,ACTIVE
130,US,A1,US 2018/0218908 A1,069-120-336-910-703,2018-08-02,2018,US 201815895610 A,2018-02-13,US 201815895610 A;;US 201715419065 A,2017-01-30,PLASMA SHALLOW DOPING AND WET REMOVAL OF DEPTH CONTROL CAP,"A gas is ionized into a plasma. A compound of a dopant is mixed into the plasma, forming a mixed plasma. Using a semiconductor device fabrication system, a layer of III-V material is exposed to the mixed plasma to dope the layer with the dopant up to a depth in the layer, forming a shallow doped portion of the layer. The depth of the dopant is controlled by a second layer of the dopant formed at the shallow doped portion of the layer. The second layer is exposed to a solution, where the solution is prepared to erode the dopant in the second layer at a first rate. After an elapsed period, the solution is removed from the second layer, wherein the elapsed period is insufficient to erode a total depth of the layer and the shallow doped portion by more than a tolerance erosion amount.",IBM;;TOKYO ELECTRON LTD,BRUCE ROBERT L;;CHAN KEVIN K;;ENGELMANN SEBASTIAN U;;GOLDFARB DARIO L;;HOPSTAKEN MARINUS;;KHOJASTEH MAHMOUD;;TOTIR GEORGE G;;YAN HONGWEN;;YAMAZAKI MASAHIRO,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-09-26);;TOKYO ELECTRON LIMITED (2016-09-26),https://lens.org/069-120-336-910-703,Patent Application,yes,8,0,4,4,0,H01L21/02046;;H01L21/2236;;H01L21/2233;;H01L29/1029;;H01L29/207;;H01L21/30612;;H01L21/2236;;H01L21/2233;;H01L21/02046,H01L21/223;;H01L21/306;;H01L29/10;;H01L29/207,,0,0,,,,DISCONTINUED
131,US,A1,US 2007/0254237 A1,192-021-258-162-126,2007-11-01,2007,US 38078206 A,2006-04-28,US 38078206 A,2006-04-28,TOPCOAT MATERIAL AND USE THEREOF IN IMMERSION LITHOGRAPHY PROCESSES,"Disclosed is a topcoat composition comprising a polymer having a dissolution rate of at least 1500 Å/second in an aqueous alkaline developer, and at least one solvent. The topcoat composition can be used to coat a photoresist layer on a material layer on a substrate, for example, a semiconductor chip. Also disclosed is a method of forming a pattern in the material layer of the coated substrate.",IBM,ALLEN ROBERT D;;BROCK PHILLIP J;;BURNS SEAN D;;GOLDFARB DARIO L;;MEDEIROS DAVID;;PFEIFFER DIRK;;PINNOW MATT;;SOORIYAKUMARAN RATNAM;;SUNDBERG LINDA K,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-04-26),https://lens.org/192-021-258-162-126,Patent Application,yes,8,34,2,8,0,G03F7/091;;G03F7/091;;G03F7/11;;G03F7/11;;G03F7/2041;;G03F7/2041,G03C1/00,430/270.1,0,0,,,,ACTIVE
132,US,A1,US 2018/0218907 A1,163-463-410-094-305,2018-08-02,2018,US 201715419065 A,2017-01-30,US 201715419065 A,2017-01-30,PLASMA SHALLOW DOPING AND WET REMOVAL OF DEPTH CONTROL CAP,"A gas is ionized into a plasma. A compound of a dopant is mixed into the plasma, forming a mixed plasma. Using a semiconductor device fabrication system, a layer of III-V material is exposed to the mixed plasma to dope the layer with the dopant up to a depth in the layer, forming a shallow doped portion of the layer. The depth of the dopant is controlled by a second layer of the dopant formed at the shallow doped portion of the layer. The second layer is exposed to a solution, where the solution is prepared to erode the dopant in the second layer at a first rate. After an elapsed period, the solution is removed from the second layer, wherein the elapsed period is insufficient to erode a total depth of the layer and the shallow doped portion by more than a tolerance erosion amount.",IBM;;TOKYO ELECTRON LTD,BRUCE ROBERT L;;CHAN KEVIN K;;ENGELMANN SEBASTIAN U;;GOLDFARB DARIO L;;HOPSTAKEN MARINUS;;KHOJASTEH MAHMOUD;;TOTIR GEORGE G;;YAN HONGWEN;;YAMAZAKI MASAHIRO,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-09-26);;TOKYO ELECTRON LIMITED (2016-09-26),https://lens.org/163-463-410-094-305,Patent Application,yes,14,0,4,4,0,H01L21/02046;;H01L21/2236;;H01L21/2233;;H01L29/1029;;H01L29/207;;H01L21/30612;;H01L21/2236;;H01L21/2233;;H01L21/02046,H01L21/306;;H01L21/223;;H01L29/10;;H01L29/207,,0,0,,,,ACTIVE
133,US,A1,US 2018/0218909 A1,145-641-912-265-166,2018-08-02,2018,US 201815895664 A,2018-02-13,US 201815895664 A;;US 201715419065 A,2017-01-30,PLASMA SHALLOW DOPING AND WET REMOVAL OF DEPTH CONTROL CAP,"A gas is ionized into a plasma. A compound of a dopant is mixed into the plasma, forming a mixed plasma. Using a semiconductor device fabrication system, a layer of III-V material is exposed to the mixed plasma to dope the layer with the dopant up to a depth in the layer, forming a shallow doped portion of the layer. The depth of the dopant is controlled by a second layer of the dopant formed at the shallow doped portion of the layer. The second layer is exposed to a solution, where the solution is prepared to erode the dopant in the second layer at a first rate. After an elapsed period, the solution is removed from the second layer, wherein the elapsed period is insufficient to erode a total depth of the layer and the shallow doped portion by more than a tolerance erosion amount.",IBM;;TOKYO ELECTRON LTD,BRUCE ROBERT L;;CHAN KEVIN K;;ENGELMANN SEBASTIAN U;;GOLDFARB DARIO L;;HOPSTAKEN MARINUS;;KHOJASTEH MAHMOUD;;TOTIR GEORGE G;;YAN HONGWEN;;YAMAZAKI MASAHIRO,INTERNATIONAL BUSINESS MACHINES CORPORATION (2016-09-26);;TOKYO ELECTRON LIMITED (2016-09-26),https://lens.org/145-641-912-265-166,Patent Application,yes,8,0,4,4,0,H01L21/02046;;H01L21/2236;;H01L21/2233;;H01L29/1029;;H01L29/207;;H01L21/30612;;H01L21/2236;;H01L21/2233;;H01L21/02046,H01L21/223;;H01L21/306;;H01L29/10;;H01L29/207,,0,0,,,,DISCONTINUED
134,WO,A1,WO 2023/159305 A1,159-712-621-083-083,2023-08-31,2023,CA 2023050221 W,2023-02-22,US 202263314200 P,2022-02-25,METHOD AND SYSTEM TO PROVIDE INDIVIDUALIZED INTERVENTIONS BASED ON A WELLNESS MODEL,"Embodiments described herein relate to systems and methods for an individualized intervention to generate and provide wellness pattern aware interventions. The system generates digital instructions and output for an online web application, device hosted application, smart device, or similar system. In one embodiment, the system provides the individualized intervention that matches device capacity, user context, and the best intervention type for a multi feel state longitudinal journey over a multi-day duration.",LULULEMON ATHLETICA CANADA INC,BERGMANN-GOOD SAMUEL HASKEL;;SANTRY JOSEPH JOHN;;SANDE PEDER RICHARD DOUGLAS;;SMITH TODD JAMES;;LAI GILLIAN;;GATHERCOLE ROBERT JOHN;;GOLDFARB JORDAN STUART;;SANGHERA DALJINDER SINGH,,https://lens.org/159-712-621-083-083,Patent Application,yes,5,0,1,1,0,G16H50/30;;G16H20/30;;G16H50/20;;G16H50/50;;G16H20/70;;G16H20/60;;A61B5/165;;A61B5/7425;;A61B5/7445,G16H20/00;;A61B5/00;;A61B5/16;;G16H20/30;;G16H50/30,,0,0,,,,PENDING
135,DE,D1,DE 68928433 D1,036-506-599-502-431,1997-12-11,1997,DE 68928433 T,1989-09-13,US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24411488 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A;;US 24449588 A;;US 40239189 A;;US 8903993 W,1988-09-14,VERWALTUNGSSYSTEM FÜR VERBUNDENE EINHEITEN IN EINEM VERTEILTEN RECHNERSYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ROGERS DENNIS;;SMITH DANNY;;O'BRIEN LINSEY;;ROSS ROBERT;;SCHUCHARD ROBERT;;CHAN-LIZARDO CHRISTINE;;CALLANDER JILL;;GOLDFARB STANLEY;;FEHSKENS LEONARD;;ROSENBAUM RICHARD;;NAMOGLU SHERYL;;SYLOR MARK;;SEGER MARK;;LEMMON JAMES;;SHURTLEFF DAVID;;STRUTT COLIN;;TRASATTI PHILIP;;ADAMS WILLIAM;;DIXON TIMOTHY,,https://lens.org/036-506-599-502-431,Granted Patent,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
136,US,A,US 5832224 A,052-445-994-945-578,1998-11-03,1998,US 66362096 A,1996-06-14,US 66362096 A;;US 41692895 A;;US 15985893 A;;US 40239189 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24450688 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A,1988-09-14,Entity management system,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands.",DIGITAL EQUIPMENT CORP,FEHSKENS LEONARD G;;SYLOR MARK W;;CHAPMAN KENNETH W;;SCHUCHARD ROBERT C;;GOLDFARB STANLEY I;;O'BRIEN LINSEY B;;ROSENBAUM RICHARD L;;KOHLS RUTH E J;;NAMOGLU SHERYL F;;SEGER MARK J,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/052-445-994-945-578,Granted Patent,yes,63,60,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,395/200.53,22,4,016-703-504-310-785;;053-631-785-808-409;;091-966-662-077-127;;038-404-709-374-393,10.1109/6.24153;;10.1145/320434.320440;;10.1109/65.3256;;10.1145/7474.7475,"Mark Sylor, The NMCC/DECnet Monitor Design , Digital Technical Journal, No. 3, pp. 129 141, Sep. 1986.;;Brusil et al., Toward a Unified Theory of Managing Large Networks IEEE Spectrum, Apr. 1989, pp. 39 42.;;Chen, The Entity Relationship Model Toward a Unified View of Data ACM Transactions on Database System, 1:9 36, 1976.;;LaPelle et al., The Evolution of of Network Management Products Digital Technical Journal, No. 3, Sep. 1986, pp. 117 128.;;Supnik, Debugging Technique in Large Systems Pro. Courant Computer Science Symposium 1, Jun.29 Jul.1, 1970.;;Sylor, Managing Phase V DECnet Networks: The Entity Model IEEE Network, Mar.3,1988, vol. 2, No. 2, pp. 30 36.;;Sylor, The NMCC/DECnet Monitor Design Digital Technical Journal, No. 3, Sep.9,1986, pp. 129 141.;;Teorey et al., A Logical Design Methodology for Relational Databases Using the Extended Entity Relationship Model , Computer Surveys, 18:198 222; 1986.;;ANSI, ISO/TC9/SC21/N2066, Information Processing Open Systems Interconnection Management Information Services Structure of Management Information , U.S. Secretariat for OSI, Jul. 1987.;;ANSI, X3T5.4, Recommendation for User Network Management and Maintenance Protocol General Aspects Output Document X3T5.4/87 100, Draft, 1987.;;ANSI, X3T5.4, A Model of Managed Objects Operations and Informations Output Document X3T5.4/87 167, Sep.18,1987, X3 Secretariat.;;ANSI, X3T5.4, A Model Of Managed Objects Concepts Output Document X3T5.4/1987 166, Sep.18,1987, X3 Secretariat.;;ANSI, X3T5.4, Structure of OSI Management Information Output Document X3T5.4/84 124, Oct.5,1984.;;ANSI, X3T5.4/84 101, Conceptual Schema for OSI Management Information Aug. 3, 1984.;;Digital Equipment Corp., Output Document X3T5.4/87 168 of the X3T5.4 ANSI Standards Group Sep. 18, 1987.;;IEEE Task Group, Layer Specific Systems Management Guidelines 802.1 Network Management Task Group, Rev.A, Sep.2,1987, X3T5.4/87 193.;;ISO, Towards a Model for the Structure of Management Information X3T5.4/87 70, Mar.9,1987 SMI.;;ISO, TC97/SC21/N2058 9595 1 Annex A ; TC97/SC21/N2058 9595 1; TC97/SC21/N2058 9595 2 Nov. 1987; Dec. 16, 1987; Dec. 16, 1987; respectively.;;JISC, ISO/TC97/SC21/N2061, Information Processing Systems Open Systems Interconnection Basic Reference Model Part 4 OSI Management Framework ; Japan Secretariat, Aug.10,1987.;;JISC, ISO/TC97/SC21/WG4/N397, Statement Concerning the Identification of Management Information Japan Secretariat, Jun. 9, 1987.;;Draft IEEE Standard 802.1, Overview, Interworking and Systems Management Output Document X3T5.4/87 63, Jan. 1987.;;U.S.A., OSI Secretariat, Structure of OSI Management Information Output Document X3T5.4/87 149, Dec. 6, 1984.",EXPIRED
137,DE,T2,DE 68928433 T2,076-761-062-988-776,1998-04-16,1998,DE 68928433 T,1989-09-13,US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24411488 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A;;US 24449588 A;;US 40239189 A;;US 8903993 W,1988-09-14,VERWALTUNGSSYSTEM FÜR VERBUNDENE EINHEITEN IN EINEM VERTEILTEN RECHNERSYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ROGERS DENNIS;;SMITH DANNY;;O'BRIEN LINSEY;;ROSS ROBERT;;SCHUCHARD ROBERT;;CHAN-LIZARDO CHRISTINE;;CALLANDER JILL;;GOLDFARB STANLEY;;FEHSKENS LEONARD;;ROSENBAUM RICHARD;;NAMOGLU SHERYL;;SYLOR MARK;;SEGER MARK;;LEMMON JAMES;;SHURTLEFF DAVID;;STRUTT COLIN;;TRASATTI PHILIP;;ADAMS WILLIAM;;DIXON TIMOTHY,,https://lens.org/076-761-062-988-776,Granted Patent,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
138,WO,A3,WO 2008/134288 A3,057-165-154-111-533,2008-12-24,2008,US 2008/0061048 W,2008-04-21,US 78970507 A,2007-04-24,"MECHANICAL DILATION OF THE OSTIA OF PARANASAL SINUSES AND OTHER PASSAGEWAYS OF THE EAR, NOSE AND THROAT","Devices and methods for dilating the ostia of paranasal sinuses and other passageways within the ear, nose and throat. A mechanical dilator is inserted through a nostril and used to dilate an ostium or a paranasal sinus or other passageway within the ear, nose or throat (e.g., a Eustachian tube or nasolacrimal duct). The mechanical dilator may be an expandable dilators that comprises one or more non-balloon structures with or without an accompanying balloon or a members of varying diameter or cross dimension (e.g., a tapered member) that may be advanced into the ostium or other passageway to cause dilation of that passageway.",ACCLARENT INC;;MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;SWEI SERENA;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;SWEI SERENA;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,,https://lens.org/057-165-154-111-533,Search Report,yes,4,0,4,298,0,A61B17/24;;A61B17/0218;;A61M29/02,A61M29/00;;A61B17/24;;A61M1/00,,1,0,,,See also references of EP 2148717A4,PENDING
139,EP,A2,EP 2148717 A2,007-575-290-801-270,2010-02-03,2010,EP 08746464 A,2008-04-21,US 2008/0061048 W;;US 78970507 A,2007-04-24,"MECHANICAL DILATION OF THE OSTIA OF PARANASAL SINUSES AND OTHER PASSAGEWAYS OF THE EAR, NOSE AND THROAT",,ACCLARENT INC,MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;SWEI SERENA;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,,https://lens.org/007-575-290-801-270,Patent Application,yes,0,0,4,298,0,A61B17/24;;A61B17/0218;;A61M29/02,A61M29/00;;A61B17/24;;A61M1/00,,0,0,,,,DISCONTINUED
140,EP,A4,EP 2148717 A4,139-795-580-660-497,2014-04-02,2014,EP 08746464 A,2008-04-21,US 2008/0061048 W;;US 78970507 A,2007-04-24,"MECHANICAL DILATION OF THE OSTIA OF PARANASAL SINUSES AND OTHER PASSAGEWAYS OF THE EAR, NOSE AND THROAT",,ACCLARENT INC,MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;SWEI SERENA;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,,https://lens.org/139-795-580-660-497,Search Report,no,6,0,4,298,0,A61B17/0218;;A61B17/24;;A61M29/02,A61M29/00;;A61B17/24;;A61M1/00,,1,0,,,See also references of WO 2008134288A2,DISCONTINUED
141,WO,A2,WO 2008/134288 A2,031-380-732-579-217,2008-11-06,2008,US 2008/0061048 W,2008-04-21,US 78970507 A,2007-04-24,"MECHANICAL DILATION OF THE OSTIA OF PARANASAL SINUSES AND OTHER PASSAGEWAYS OF THE EAR, NOSE AND THROAT","Devices and methods for dilating the ostia of paranasal sinuses and other passageways within the ear, nose and throat. A mechanical dilator is inserted through a nostril and used to dilate an ostium or a paranasal sinus or other passageway within the ear, nose or throat (e.g., a Eustachian tube or nasolacrimal duct). The mechanical dilator may be an expandable dilators that comprises one or more non-balloon structures with or without an accompanying balloon or a members of varying diameter or cross dimension (e.g., a tapered member) that may be advanced into the ostium or other passageway to cause dilation of that passageway.",ACCLARENT INC;;MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;SWEI SERENA;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;SWEI SERENA;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,,https://lens.org/031-380-732-579-217,Patent Application,yes,3,11,4,298,0,A61B17/24;;A61B17/0218;;A61M29/02,A61M29/00;;A61B17/24;;A61M1/00,,1,0,,,See also references of EP 2148717A4,PENDING
142,US,A1,US 2015/0250992 A1,160-277-666-889-648,2015-09-10,2015,US 201514658432 A,2015-03-16,US 201514658432 A;;US 78970507 A;;US 65579407 A;;US 15084705 A;;US 94427004 A;;US 82991704 A,2004-04-21,"MECHANICAL DILATION OF THE OSTIA OF PARANASAL SINUSES AND OTHER PASSAGEWAYS OF THE EAR, NOSE AND THROAT","Devices and methods for dilating the ostia of paranasal sinuses and other passageways within the ear, nose and throat. A mechanical dilator is inserted through a nostril and used to dilate an ostium or a paranasal sinus or other passageway within the ear, nose or throat (e.g., a Eustachian tube or nasolacrimal duct). The mechanical dilator may be an expandable dilators that comprises one or more non-balloon structures with or without an accompanying balloon or a members of varying diameter or cross dimension (e.g., a tapered member) that may be advanced into the ostium or other passageway to cause dilation of that passageway.",ACCLARENT INC,MORRISS JOHN H;;JENKINS THOMAS R;;GOLDFARB ERIC;;BARON SCOTT J;;MUNI KETAN P;;CHANG JOHN Y;;VRANY JULIA D;;HARFE DANIEL T;;LOH SERENA SWEI;;WOOD ROBERT N;;CHAN RANDY S;;HA HUNG V,,https://lens.org/160-277-666-889-648,Patent Application,yes,4,55,1,298,0,A61M29/02;;A61M29/02;;A61B17/24;;A61B17/24;;A61M25/0074;;A61M25/0074,A61M29/02;;A61B17/24,,0,0,,,,DISCONTINUED
143,WO,A1,WO 1990/003005 A1,124-950-810-801-025,1990-03-22,1990,US 8903993 W,1989-09-13,US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities which interface within the assemblage for control of information handling functions and interface with the system for management functions includes management modules performing management functions by independently interpreting and executing commands, a kernel (13) including a table of dispatch pointers (28) for directing commands to the respective modules, and an enroller for enrolling modules into the system by adding pointers to the table. Additionally, the system includes: stored records relating to management information, each record indicating an associated time; an information manager (15, 20), responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing access at multiple times; domain information defining groups of entities; a common command syntax; module including a generator of rules and alarm detector for detecting an alarm condition in response to rules module for self-management functions.",DIGITAL EQUIPMENT CORP,ROGERS DENNIS O;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL F;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR,,https://lens.org/124-950-810-801-025,Patent Application,yes,7,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,PATENTED
144,US,B1,US 6438591 B1,108-144-975-684-801,2002-08-20,2002,US 60978600 A,2000-07-05,US 60978600 A;;US 18462298 A;;US 66362096 A;;US 41692895 A;;US 15985893 A;;US 18518694 A;;US 40239189 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24450688 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A,1988-09-14,Entity management system,"
    A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands and a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed. In addition, the system includes storage containing domain information defining groups of entities, where the kernel may issue a command to a group by issuing individual commands to appropriate modules. 
",COMPAQ INFORMATION TECHNOLOGIE,FEHSKENS LEONARD G;;STRUTT COLIN;;WONG STEVEN K;;CALLANDER JILL F;;NELSON KATHY JO;;GOLDFARB STANLEY I;;O'BRIEN LINSEY B;;ENGLAND BENJAMIN M;;KOHLS RUTH E J;;ROSS ROBERT R N;;SMITH DANNY L;;ADAMS JR WILLIAM C;;SEGER MARK J;;HARROW JEFFREY R,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (2001-06-20);;COMPAQ COMPUTER CORPORATION (1999-12-09),https://lens.org/108-144-975-684-801,Granted Patent,yes,69,57,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,709/223;;709/102;;709/224;;709/225;;709/226,22,4,016-703-504-310-785;;053-631-785-808-409;;091-966-662-077-127;;038-404-709-374-393,10.1109/6.24153;;10.1145/320434.320440;;10.1109/65.3256;;10.1145/7474.7475,"Brusil et al., ""Toward A Unified Theory of Managing Large Networks,"" IEEE Spectrum, Apr. 1989, pp. 39-42.;;Chen, ""The Entity-Relationship Model-Toward a Unified View of Data,"" ACM Transactions on Database System, 1:9-36, 1976.;;LaPelle et al., ""The Evolution of Network Management Products,"" Digital Technical Journal, No. 3, Sep. 1986, pp. 117-128.;;Supnik, ""Debugging Techniques in Large Systems,"" Pro. Courant Computer Science Symposium 1, Jun. 29-Jul. 1, 1970.;;Sylor, ""Managing Phase V DECnet Networks: The Entity Model,"" IEEE Network, Mar. 3, 1988, vol. 2, No. 2, pp. 30-36.;;Sylor, ""The NMCC/DECnet Monitor Design,"" Digital Technical Journal, No. 3, Sep. 9, 1986, pp. 129-141.;;Teorey et al., ""A Logical Design Methodology for Relational Databases Using the Extended Entity-Relationship Model,"" Computer Surveys, 18:198-222; 1986.;;ANSI, ISO/TC9/SC21/N2066, ""Information Processing-Open Systems Interconnection-Management Information Services-Structure of Management Information,"" U.S. Secretariat for OSI, Jul. 1987.;;ANSI, X3T5.4, ""Recommendation for User-Network Management and Maintenance Protocol General Aspects,"" Output Document X3T5.4/87-100, Draft, 1987.;;ANSI, X3T5.4, ""A Model of Managed Objects-Operations and Informations, "" Output Document X3T5.4/87-167, Sep. 18, 1987, X3 Secretariat.;;ANSI, X3T5.4, ""A Model of Managed Objects-Concepts,"" Output Document X3T5.4/87-166, Sep. 18, 1987, X3 Secretariat.;;ANSI, X3T5.4, ""Structure of OSI Management Information,"" Output Document X3T5.4/84-124, Oct. 5, 1984.;;ANSI, X3T5.4/84-101, ""Conceptual Schema for OSI Management Information,"" Aug. 3, 1984.;;Digital Equipment Corp., ""Output Document X3T5.4/87-168 of the X3T5.4 ANSI Standards Group"" Sep. 18, 1987.;;IEEE Task Group, ""Layer-Specific Systems Management Guidelines"" 802.1 Network Management Task Group, Rev. A, Sep. 2, 1987, X3T5.4/87-193.;;ISO, ""Towards a Model for the Structure of Management Information,"" X3T5.4/87-70, Mar. 9, 1987-SMI.;;ISO, ""TC97/SC21/N2058-9595-1 Annex A""; ""TC97/SC21/N2058-9595-1""; TC97/SC21/N2058-9595-2 Nov. 1987, Dec. 16, 1987; Dec. 16, 1987; respectively.;;JSIC, ISO/TC97/SC21/N2061, ""Information Processing Systems-Open Systems Interconnection Basic Reference Model Part 4-OSI Management Framework""; Japan Secretariat, Aug. 10, 1987.;;JISC, ISO/TC97/SC21/WG4/N397, ""Statement Concerning the Identification of Management Information"" Japan Secretariat, Jun. 9, 1987.;;Draft IEEE Standard 802.1, ""Overview, Interworking and Systems Management,"" Output Document X3T5.4/87-63, Jan. 1987.;;U.S.A., OSI Secretariat,""Structure of OSI Management Information"" Output Document X3T5.4/87-149, Dec. 6, 1984.;;Anonymous, ""Expert System Rulebase for a Network Adapter,"" IBM Technical Disclosure Bulletin, vol. 28, No. 7, Dec. 1985, New York, pp. 3241-3243.",EXPIRED
145,EP,A1,EP 0441798 A1,110-904-200-215-496,1991-08-21,1991,EP 89910805.0,1989-09-13,US 1988/0244691;;US 1988/0244503;;US 1988/0244834;;US 1988/0244742;;US 1988/0244114;;US 1988/0244845;;US 1988/0244919;;US 1988/0244851;;US 1988/0244730;;US 1988/0244850;;US 1988/0244495,1988-09-13,ENTITY MANAGEMENT SYSTEM,,DIGITAL EQUIPMENT CORPORATION,"ROGERS, Dennis, O.;;SMITH, Danny, L.;;O'BRIEN, Linsey, B.;;ROSS, Robert, R., N.;;SCHUCHARD, Robert, C.;;CHAN-LIZARDO, Christine, C.;;CALLANDER, Jill, F.;;GOLDFARB, Stanley, I.;;FEHSKENS, Leonard, G.;;ROSENBAUM, Richard, L.;;NAMOGLU, Sheryl, F.;;SYLOR, Mark, W.;;SEGER, Mark, J.;;LEMMON, James, L., Jr.;;SHURTLEFF, David, L.;;STRUTT, Colin;;TRASATTI, Philip, J.;;ADAMS, William, C., Jr.;;DIXON, Timothy, M.",,https://lens.org/110-904-200-215-496,Patent Application,yes,0,1,1,1,0,,G06F12/00;;G06F13/00;;H04L12/24;;H04L29/00,,0,0,,,,UNKNOWN
146,EP,A4,EP 0441798 A4,160-627-275-532-868,1991-10-16,1991,EP 89910805 A,1989-09-13,US 8903993 W;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORPORATION,"ROGERS, DENNIS, O.;;SMITH, DANNY, L.;;O'BRIEN, LINSEY, B.;;ROSS, ROBERT, R., N.;;SCHUCHARD, ROBERT, C.;;CHAN-LIZARDO, CHRISTINE, C.;;CALLANDER, JILL, F.;;GOLDFARB, STANLEY, I.;;FEHSKENS, LEONARD, G.;;ROSENBAUM, RICHARD, L.;;NAMOGLU, SHERYL, F.;;SYLOR, MARK, W.;;SEGER, MARK, J.;;LEMMON, JAMES, L., JR.;;SHURTLEFF, DAVID, L.;;STRUTT, COLIN;;TRASATTI, PHILIP, J.;;ADAMS, WILLIAM, C., JR.;;DIXON, TIMOTHY, M.",,https://lens.org/160-627-275-532-868,Search Report,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
147,EP,B1,EP 0441798 B1,046-802-466-299-387,1997-11-05,1997,EP 89910805 A,1989-09-13,US 8903993 W;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,ENTITY MANAGEMENT SYSTEM FOR A DISTRIBUTED COMPUTER SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ROGERS DENNIS O;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL F;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M,,https://lens.org/046-802-466-299-387,Granted Patent,yes,1,2,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
148,EP,A1,EP 0441798 A1,174-593-433-887-126,1990-03-22,1990,EP 89910805 A,1989-09-13,US 8903993 W;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,ENTITY MANAGEMENT SYSTEM.,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORPORATION,"ROGERS, DENNIS, O.;;SMITH, DANNY, L.;;O'BRIEN, LINSEY, B.;;ROSS, ROBERT, R., N.;;SCHUCHARD, ROBERT, C.;;CHAN-LIZARDO, CHRISTINE, C.;;CALLANDER, JILL, F.;;GOLDFARB, STANLEY, I.;;FEHSKENS, LEONARD, G.;;ROSENBAUM, RICHARD, L.;;NAMOGLU, SHERYL, F.;;SYLOR, MARK, W.;;SEGER, MARK, J.;;LEMMON, JAMES, L., JR.;;SHURTLEFF, DAVID, L.;;STRUTT, COLIN;;TRASATTI, PHILIP, J.;;ADAMS, WILLIAM, C., JR.;;DIXON, TIMOTHY, M.",,https://lens.org/174-593-433-887-126,Patent Application,no,0,1,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
149,AT,T1,AT E160034 T1,106-390-448-638-003,1997-11-15,1997,AT 89910805 T,1989-09-13,US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24411488 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A;;US 24449588 A;;US 40239189 A,1988-09-14,VERWALTUNGSSYSTEM FÜR VERBUNDENE EINHEITEN IN EINEM VERTEILTEN RECHNERSYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ROGERS DENNIS O;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL F;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M,,https://lens.org/106-390-448-638-003,Granted Patent,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,DISCONTINUED
150,EP,B1,EP 0767427 B1,069-215-339-641-985,2006-12-13,2006,EP 96203153 A,1989-09-13,EP 89910805 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,Entity management system,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",HEWLETT PACKARD DEVELOPMENT CO,ROGERS DENNIS;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL E;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M;;KONING G PAUL,"COMPAQ COMPUTER CORPORATION (2000-05-31);;HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2004-09-01)",https://lens.org/069-215-339-641-985,Granted Patent,yes,1,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F9/46;;G06F12/00;;G06F9/44;;G06F13/00;;G06F13/14;;G06F15/16;;H04L12/24;;H04L29/00,,1,0,,,"ANONYMOUS: ""Expert System Rulebase for a Network Adapter"" IBM TECHNICAL DISCLOSURE BULLETIN, vol. 28, no. 7, December 1985, NEW YORK, US, pages 3241-3243, XP002048249",EXPIRED
151,US,A,US 5557796 A,083-220-255-468-162,1996-09-17,1996,US 18518694 A,1994-01-21,US 18518694 A;;US 40239189 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24450688 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A,1988-09-14,Extensible entity management system including a dispatching kernel and modules which independently interpret and execute commands,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands.",DIGITAL EQUIPMENT CORP,FEHSKENS LEONARD G;;STRUTT COLIN;;CALLANDER JILL F;;NELSON KATHY J;;GUERTIN MATTHEW J;;SYLOR MARK W;;CHAPMAN KENNETH W;;SCHUCHARD ROBERT C;;GOLDFARB STANLEY I;;ROGERS DENNIS O;;O'BRIEN LINSEY B;;CHAN-LIZARDO CHRISTINE C;;ENGLAND BENJAMIN M;;ROSENBAUM RICHARD L;;KOHLS RUTH E J;;ARONSON DAVID L;;MOORE ALLAN B;;ROSS ROBERT R N;;SMITH DANNY L;;SANKAR ARUNDAHATI G;;KONING G PAUL;;NAMOGLU SHERYL F;;SEGER MARK J;;DIXON TIMOTHY M;;HARROW JEFFREY R,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/083-220-255-468-162,Granted Patent,yes,61,44,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,395/650;;395/800;;395/828;;364/280.9;;364/284;;X364DIG  1,21,4,016-703-504-310-785;;053-631-785-808-409;;091-966-662-077-127;;038-404-709-374-393,10.1109/6.24153;;10.1145/320434.320440;;10.1109/65.3256;;10.1145/7474.7475,"Brusil et al., Toward A Unified Theory of Managing Large Networks , IEEE Spectrum, Apr., 1989, pp. 39 42.;;Chen; The Entity Relationship Model Toward a Unified View of Data, ACM Transactions on Database System, 1:9 36, 1976.;;LaPelle et al., The Evolution of Network Management Products Digital Technical Journal, No. 3, Sep., 1986, pp. 117 128.;;Supnik, Debugging Techniques in Large Systems , Proc. Courant Computer Science Symposium 1, Jun. 29 Jul. 1, 1970.;;Sylor, Managing Phase V DECnet Networks: The Entity Model , IEEE Network, Mar., 1988, vol. 2, No. 2, pp. 30 36.;;Sylor, The NMCC/DECnet Monitor Design , Digital Technical Journal, No. 3, Sep., 1986, pp. 129 141.;;Teorey et al.; A Logical Design Metholdology for Relational Databases Using the Extended Entity Relationship Model, Computer Surveys, 18: 198 222, 1986.;;ANSI, ISO/TC97/SC21/N2066, US Secretariat for OSI, Jul. 1987, Information Processing Open Systems Interconnection Management Information Services Structure of Management Information .;;ANSI X3T5.4, Output Document X3T5.4/87 100, Draft, Recommendation for User Network Management and Maintenance Protocol General Aspects , 1987.;;ANSI X3T5.4, Output Document X3T5.4/87 167, Sep. 18, 1987, A Model of Managed Objects Operations and Informations , X3 Secretariat.;;ANSI X3T5.4, Output Document X3T5.4/87 166, Sep. 18, 1987, A MOdel of Managed Objects Concepts , X3 Secretariat.;;ANSI X3T5.4, Output Document X3T5.4/84 124, Structure of OSI Management Information , Oct. 5, 1984.;;ANSI X3T5.4/84 101, Aug. 3, 1984, Conceptual Schema for OSI Management Information .;;Digital Equipment Corporation, Output Document X3T5.4/87 168 of the X3T5.4 ANSI standards group, Sep. 18, 1987.;;IEEE Task Group, Layer Specific Systems Management Guidelines , 802.1 Network Management Task Group, Revision A, Sep. 2, 1987, X3T5.4/87 193.;;ISO, X3T5.4/87 70, Mar. 19, 1987, Towards a Model for the Structure of Management Information (SMI) .;;ISO, Documents TC97/SC21/N2058 9595 1 Annex A, Nov., 1987; TC97/SC21/N20958 9595 1, Dec. 16, 1987, and TC97/SC21/N2058 9595 2, Dec. 16, 1987.;;JISC, ISO/TC97/SC21/N2061, Japan Secretariat, Aug. 10, 1987, Information Processing Systems Open Systems Interconnection Basic Reference Model Part 4 OSI Management Framework .;;JISC, ISO/TC9/SC21/WG4/N397, Japan Secretariat, Jun. 9, 1987, Statement Concerning the Idetification of Management Information .;;Output Document X3T5.4/87 63, Draft IEEE Standard 802.1, Overview, Interworking and Systems Management , Jan. 1987.;;USA OSI Secretariat, Output Document X3T5.4/87 149, Structure of OSI Management Information , Dec. 6, 1984.",EXPIRED
152,US,A,US 5345587 A,087-785-039-479-653,1994-09-06,1994,US 40239189 A,1989-09-07,US 40239189 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24450688 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A,1988-09-14,Extensible entity management system including a dispatching kernel and modules which independently interpret and execute commands,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands.",DIGITAL EQUIPMENT CORP,FEHSKENS LEONARD G;;STRUTT COLIN;;WONG STEVEN K;;CALLANDER JILL F;;BURGESS PETER H;;NELSON KATHY J;;GUERTIN MATTHEW J;;SYLOR MARK W;;CHAPMAN KENNETH W;;SCHUCHARD ROBERT C;;GOLDFARB STANLEY I;;ROGERS DENNIS O;;O'BRIEN LINSEY B;;TRASATTI PHILIP J;;ENGLAND BENJAMIN M;;LEMMON JR JAMES L;;ROSENBAUM RICHARD L;;KOHLS RUTH E J;;ARONSON DAVID L;;ROSS ROBERT R N;;SMITH DANNY L;;ADAMS JR WILLIAM C;;KONING G PAUL;;NAMOGLU SHERYL F;;SEGER MARK J;;DIXON TIMOTHY M;;HARROW JEFFREY R,DIGITAL EQUIPMENT CORPORATION A CORP OF MA (1990-02-15);;COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;DIGITAL EQUIPMENT CORPORATION (1990-02-27);;EQUIPMENT CORPORATION A CORP. OF MA (1990-02-26);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/087-785-039-479-653,Granted Patent,yes,56,110,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,395/650;;395/600;;364/280;;364/280.9;;364/281.3;;364/282.1;;364/286;;X364DIG 1,21,4,016-703-504-310-785;;091-966-662-077-127;;038-404-709-374-393;;053-631-785-808-409,10.1109/6.24153;;10.1109/65.3256;;10.1145/7474.7475;;10.1145/320434.320440,"Brusil et al., Toward A Unified Theory of Managing Large Networks , IEEE Spectrum, Apr. 1989, pp. 39 42.;;Sylor, Managing Phase V DECnet Networks: the Entity Model , IEEE Network, Mar. 1988, vol. 2, No. 2, pp. 30 36.;;Sylor, The NMCC/DECnet Monitor Design , Digital Technical Journal, No. 3, Sep. 1986, pp. 129 141.;;LaPelle et al., The Evolution of Network Management Products , Digital Technical Journal, No. 3, Sep. 1986, pp. 117 128.;;Supnik, Debugging Techniques in Large Systems , Proc. Courant Computer Science Symposium 1, Jun. 29 Jul. 1, 1970.;;Digital Equipment Corporation, Output Document X3T5.4/87 168 of the X3T5.4 ANSI standards group, Sep. 18, 1987.;;JISC, ISO/TC97/SC21/N2061, Japan Secretariat, Aug. 10, 1987, Information Processing Systems Open Systems Interconnection Basic Reference Model Part 4 OSI Management Framework .;;JISC, ISO/TC97/SC21/WG4/N397, Japan Secretariat, Jun. 9, 1987, Statement Concerning the Identification of Management Information .;;ANSI, ISO/TC9/SC21/N2066, US Secretariat for OSI, Jul. 1987, Information Processing Open Systems Interconnection Management Information Services Structure of Management Information .;;Output Document X3T5.4/87 63, Draft IEEE Standard 802.1, Overview, Interworking and Systems Management , Jan. 1987.;;ANSI X3T5.4, Output Document X3T5.4/87 100, Draft, Recommendation for User Network Management and Maintenance Protocol General Aspects , 1987.;;USA OSI Secretariat, Output Document X3T5.4/87 149, Structure of OSI Management Information , Dec. 6, 1984.;;ANSI X3T5.4, Output Document X3T5.4/84 124, Structure of OSI Management Information , Oct. 5, 1984.;;IEEE Task Group, Layer Specific Systems Management Guidelines , 802.1 Network Management Task Group, Revision A, Sep. 2, 1987, X3T5.4/87 193.;;ANSI X3T5.4, Output Document X3T5.4/87 167, Sep. 18, 1987, A Model of Managed Objects Operations and Informations , X3 Secretariat.;;ANSI X3T5.4, Output Document X3T5.4/87 166, Sep. 18, 1987, A Model of Managed Objects Concepts , X3 Secretariat.;;ISO, X3T5.4/87 70, Mar. 9, 1987, Towards a Model for the Structure of Management Information (SMI) .;;ANSI X3T5.4/84 101, Aug. 3, 1984, Conceptual Schema for OSI Management Information .;;ISO, Documents TC97/SC21/N2058 9595 1 Annex A, Nov. 1987; TC97/SC21/N2058 9595 1, Dec. 16, 1987, and TC97/SC21/N2058 9595 2, Dec. 16, 1987.;;Teorey et al.; A Logical Design Methodology for Relational Databases Using the Extended Entity Relationship Model, Computer Surveys, 18: 198 222, 1986.;;Chen; The Entity Relationship Model Toward a Unified View of Data, ACM Transactions on Database System, 1: 9 36, 1976.",EXPIRED
153,AU,B2,AU 639416 B2,177-733-713-230-736,1993-07-29,1993,AU 1989/043052 A,1989-09-13,US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ROGERS DENNIS O;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;ZOLFONOON RIAZ;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL F;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J,,https://lens.org/177-733-713-230-736,Granted Patent,no,3,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
154,AU,A,AU 1989/043052 A,155-880-793-389-385,1990-04-02,1990,AU 1989/043052 A,1989-09-13,US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ROGERS DENNIS O;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL F;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;ZOLFONOON RIAZ,,https://lens.org/155-880-793-389-385,Patent Application,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
155,US,A,US 5475838 A,140-817-992-366-091,1995-12-12,1995,US 15973793 A,1993-11-30,US 15973793 A;;US 40239189 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24450688 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A,1988-09-14,Extensible entity management system including rule-based alarms,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands.",DIGITAL EQUIPMENT CORP,FEHSKENS LEONARD G;;STRUTT COLIN;;WONG STEVEN K;;CALLANDER JILL F;;BURGESS PETER H;;NELSON KATHY J;;GUERTIN MATTHEW J;;PLOUFFE GERARD R;;SYLOR MARK W;;CHAPMAN KENNETH W;;SCHUCHARD ROBERT C;;GOLDFARB STANLEY I;;NAVKAL ANIL V;;ROGERS DENNIS O;;O'BRIEN LINSEY B;;TRASATTI PHILIP J;;CHAN-LIZARDO CHRISTINE C;;ENGLAND BENJAMIN M;;LEMMON JR JAMES L;;ROSENBAUM RICHARD L;;KOHLS RUTH E J;;ARONSON DAVID L;;MOORE ALLAN B;;ROSS ROBERT R N;;SMITH DANNY L;;ADAMS JR WILLIAM C;;SANKAR ARUNDAHATI G;;KONING G PAUL;;NAMOGLU SHERYL F;;SEGER MARK J;;DIXON TIMOTHY M;;HARROW JEFFREY R,COMPAQ INFORMATION TECHNOLOGIES GROUP L.P (1999-12-09);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/140-817-992-366-091,Granted Patent,yes,56,45,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,395/185.1;;395/54;;395/650;;395/200.11;;364/229;;364/232.7;;364/242.95;;364/284.4;;364/285;;X364DIG 1;;370/13,21,4,016-703-504-310-785;;053-631-785-808-409;;091-966-662-077-127;;038-404-709-374-393,10.1109/6.24153;;10.1145/320434.320440;;10.1109/65.3256;;10.1145/7474.7475,"Brusil et al., Toward A Unified Theory of Managing Large Networks , IEEE Spectrum, Apr., 1989, pp. 39 42.;;Chen; The Entity Relationship Model Toward a Unified View of Data, ACM Transactions on Database System, 1:9 36, 1976.;;LaPelle et al., The Evolution of Network Management Products , Digital Technical Journal, No. 3, Sep., 1986, pp. 129 141.;;Supnik, Debugging Techniques in Large Systems Proc. Courant Computer Science Symposium 1, Jun. 29 Jul. 1, 1970.;;Sylor, Managing Phase V DECnet Networks: The Entity Model , IEEE Network, Mar. 1988, vol. 2, No. 2, pp. 30 36.;;Sylor, The NMCC/DECnet Monitor Design , Digital Technical Journal, No. 3, Sep. 1986, pp. 129 141.;;Teorey et al.; A Logical Design Methodology for Relational Databases Using the Extended Entity Relationship Model, Computer Surveys, 18: 198 222, 1986.;;ANSI, ISO/T97/SC21/N2066, US Secretariat for OSI, Jul. 1987, Information Processing Open Systems Interconnection Management Information Services Structure of Management Information .;;ANSI, X3T5.4, Output Document X3T5.4/87 100, Draft, Recommendation for User Network Management and Maintenance Protocol General Aspects , 1987.;;ANSI X3T5.4, Output Document X3T5.4/87 167, Sep. 18, 1987, A Model of Managed Objects Operations and Informations , X3 Secretariat.;;ANSI X3T5.4, Output Document X3T5.4/87 166, Sep. 18, 1987, A MOdel of Managed Objects Concepts , X3 Secretariat.;;ANSI X3T5.4, Output Document X3T5.4/84 124, Structure of OSI Management Information , Oct. 5, 1984.;;ANSI X3T5.4/84 101, Aug. 3, 1984, Conceptual Schema for OSI Management Information .;;Digital Equipment Corporation, Output Document X3T5.4/87 168 of the X3T5.4 ANSI standards group, Sep. 18, 1987.;;IEEE Task Group, Layer Specific Systems Management Guidelines , 802.1 Network Management Task Group, Revision A, Sep. 2, 1987, X3T5.4/87 19.;;ISO, X3T5.4/87 70, Mar. 9, 1987, Towards a Model for the Structure of Management Information (SMI).;;ISO, Documents TC97/SC21/N2058 9595 1 Annex A, Nov. 1987; TC97/SC21/N2058 9595 1, Dec. 16, 1987, and TC97/SC21/N2058 9595 2, Dec. 16, 1987.;;JISC, ISO/TC97/SC21/N2061, Japan Secretariat, Aug. 10, 1987, Information Processing Systems Open Systems Interconnection Basic Reference Model Part 4 OSI Management Framework .;;JISC, ISO/TC97/SC21/WG4/N397, Japan Secretariat, Jun. 9, 1987, Statement Concerning the Identification of Management Information .;;Output Document X3T5.4/87 63, Draft IEEE Standard 802.1, Overview, Interworking and Systems Management , Jan. 1987.;;USA OSI Secretariat, Output Document X3T5.4/87 149, Structure of OSI Management Information , Dec. 6, 1984.",EXPIRED
156,EP,A3,EP 0767427 A3,113-146-249-520-618,1998-01-28,1998,EP 96203153 A,1989-09-13,EP 89910805 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,Entity management system,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands.",DIGITAL EQUIPMENT CORP,ROGERS DENNIS;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL E;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;SANKAR ARUNDAHATI G;;PLOUFFE GERARD R;;ROBERTS D KEITH;;GUERTIN MATTHEW W;;KOCH PAMELA J;;BURGESS PETER H;;ROSENBERG JEFF;;DENSMORE MICHAEL;;HUPPER THEODORE F;;ARONSON DAVID;;ZOLFONOON RIAZ,"COMPAQ COMPUTER CORPORATION (2000-05-31);;HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2004-09-01)",https://lens.org/113-146-249-520-618,Search Report,yes,1,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,1,0,,,"ANONYMOUS: ""Expert System Rulebase for a Network Adapter"", IBM TECHNICAL DISCLOSURE BULLETIN, vol. 28, no. 7, December 1985 (1985-12-01), NEW YORK, US, pages 3241 - 3243, XP002048249",EXPIRED
157,DE,T2,DE 68929549 T2,149-555-266-990-471,2007-06-21,2007,DE 68929549 T,1989-09-13,US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24411488 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 40239189 A,1988-09-14,Verwaltungssystem für verbundene Einheiten,,HEWLETT PACKARD DEVELOPMENT CO,ROGERS DENNIS;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL E;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;SANKAR ARUNDAHATI G;;PLOUFFE GERARD R;;ROBERTS D KEITH;;GUERTIN MATTHEW W;;KOCH PAMELA J;;BURGESS PETER H;;ROSENBERG JEFF;;DENSMORE MICHAEL;;HUPPER THEODORE F;;ARONSON DAVID;;ZOLFONOON RIAZ,,https://lens.org/149-555-266-990-471,Granted Patent,no,0,0,2,37,0,,G06F9/46;;G06F9/44;;G06F15/16,,0,0,,,,EXPIRED
158,EP,A2,EP 0767427 A2,138-174-470-936-386,1997-04-09,1997,EP 96203153 A,1989-09-13,EP 89910805 A;;US 24411488 A;;US 24449588 A;;US 24450388 A;;US 24469188 A;;US 24473088 A;;US 24474288 A;;US 24483488 A;;US 24484588 A;;US 24485088 A;;US 24485188 A;;US 24491988 A;;US 40239189 A,1988-09-14,Entity management system,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands.",DIGITAL EQUIPMENT CORP,ROGERS DENNIS;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL E;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;SANKAR ARUNDAHATI G;;PLOUFFE GERARD R;;ROBERTS D KEITH;;GUERTIN MATTHEW W;;KOCH PAMELA J;;BURGESS PETER H;;ROSENBERG JEFF;;DENSMORE MICHAEL;;HUPPER THEODORE F;;ARONSON DAVID;;ZOLFONOON RIAZ,"COMPAQ COMPUTER CORPORATION (2000-05-31);;HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2004-09-01)",https://lens.org/138-174-470-936-386,Patent Application,yes,1,1,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
159,AT,T1,AT E348360 T1,048-395-933-188-051,2007-01-15,2007,AT 96203153 T,1989-09-13,US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24411488 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A;;US 24449588 A;;US 40239189 A,1988-09-14,VERWALTUNGSSYSTEM FÜR VERBUNDENE EINHEITEN,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",HEWLETT PACKARD DEVELOPMENT CO,ROGERS DENNIS;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL E;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L JR;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C JR;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;SANKAR ARUNDAHATI G;;PLOUFFE GERARD R;;ROBERTS D KEITH;;GUERTIN MATTHEW W;;KOCH PAMELA J;;BURGESS PETER H;;ROSENBERG JEFF;;DENSMORE MICHAEL;;HUPPER THEODORE F;;ARONSON DAVID;;ZOLFONOON RIAZ,,https://lens.org/048-395-933-188-051,Granted Patent,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,EXPIRED
160,DE,D1,DE 68929549 D1,002-133-922-388-665,2007-01-25,2007,DE 68929549 T,1989-09-13,US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24411488 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 40239189 A,1988-09-14,Verwaltungssystem für verbundene Einheiten,,HEWLETT PACKARD DEVELOPMENT CO,ROGERS DENNIS;;SMITH DANNY L;;O'BRIEN LINSEY B;;ROSS ROBERT R N;;SCHUCHARD ROBERT C;;CHAN-LIZARDO CHRISTINE C;;CALLANDER JILL F;;GOLDFARB STANLEY I;;FEHSKENS LEONARD G;;ROSENBAUM RICHARD L;;NAMOGLU SHERYL E;;SYLOR MARK W;;SEGER MARK J;;LEMMON JAMES L;;SHURTLEFF DAVID L;;STRUTT COLIN;;TRASATTI PHILIP J;;ADAMS WILLIAM C;;DIXON TIMOTHY M;;KONING G PAUL;;CHAPMAN KENNETH W;;NELSON KATHY JO;;FLETCHER DOUGLAS R;;KOHLS RUTH E J;;WONG STEVEN K;;DANG REENA;;MOORE ALLAN B;;NAVKAL ANIL V;;ENGLAND BENJAMIN M;;SANKAR ARUNDAHATI G;;PLOUFFE GERARD R;;ROBERTS D KEITH;;GUERTIN MATTHEW W;;KOCH PAMELA J;;BURGESS PETER H;;ROSENBERG JEFF;;DENSMORE MICHAEL;;HUPPER THEODORE F;;ARONSON DAVID;;ZOLFONOON RIAZ,,https://lens.org/002-133-922-388-665,Granted Patent,no,0,0,2,37,0,,G06F9/46;;G06F9/44;;G06F15/16,,0,0,,,,EXPIRED
161,AU,A,AU 1993/039801 A,002-448-927-605-709,1993-08-19,1993,AU 1993/039801 A,1993-05-25,US 24449588 A;;US 40239189 A;;US 24411488 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24469188 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ADAMS WILLIAM C JR;;ARONSON DAVID L;;BURGESS PETER H;;CALLANDER JILL F;;CHAN-LIZARDO CHRISTINE C;;CHAPMAN KENNETH W;;DANG REENA;;DENSMORE MICHAEL;;DIXON TIMOTHY M;;ENGLAND BENJAMIN M;;FEHSKENS LEONARD G;;FLETCHER DOUGLAS R;;GOLDFARB STANLEY I;;GUERTIN MATTHEW J;;HUPPER THEODORE F;;KOCH PAMELA J;;KOHLS RUTH E J;;KONING G PAUL;;LEMMON JAMES L JR;;MOORE ALLAN B;;NAMOGLU SHERYL F;;NAVKAL ANIL V;;NELSON KATHY JO;;O'BRIEN LINSEY B;;PLOUFFE GERARD R;;ROBERTS D KEITH;;ROGERS DENNIS O;;ROSENBAUM RICHARD L;;ROSENBERG JEFFREY L;;ROSS ROBERT R N;;SANKAR ARUNDAHATI G;;SCHUCHARD ROBERT C;;SEGER MARK J;;SHURTLEFF DAVID L;;SMITH DANNY L;;STRUTT COLIN;;SYLOR MARK W;;TRASATTI PHILIP J;;WONG STEVEN K;;WOOD RICHARD,,https://lens.org/002-448-927-605-709,Patent Application,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,PENDING
162,AU,A,AU 1993/039800 A,166-167-815-739-960,1993-08-19,1993,AU 1993/039800 A,1993-05-25,US 24449588 A;;US 40239189 A;;US 24411488 A;;US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ADAMS WILLIAM C JR;;ARONSON DAVID L;;BURGESS PETER H;;CALLANDER JILL F;;CHAN-LIZARDO CHRISTINE C;;CHAPMAN KENNETH W;;DANG REENA;;DENSMORE MICHAEL;;DIXON TIMOTHY M;;ENGLAND BENJAMIN M;;FEHSKENS LEONARD G;;FLETCHER DOUGLAS R;;GOLDFARB STANLEY I;;GUERTIN MATTHEW J;;HUPPER THEODORE F;;KOCH PAMELA J;;KOHLS RUTH E J;;KONING G PAUL;;LEMMON JAMES L JR;;MOORE ALLAN B;;NAMOGLU SHERYL F;;NAVKAL ANIL V;;NELSON KATHY JO;;O'BRIEN LINSEY B;;PLOUFFE GERARD R;;ROBERTS D KEITH;;ROGERS DENNIS O;;ROSENBAUM RICHARD L;;ROSENBERG JEFFREY L;;ROSS ROBERT R N;;SANKAR ARUNDAHATI G;;SCHUCHARD ROBERT C;;SEGER MARK J;;SHURTLEFF DAVID L;;SMITH DANNY L;;STRUTT COLIN;;SYLOR MARK W;;TRASATTI PHILIP J;;WONG STEVEN K;;WOOD RICHARD,,https://lens.org/166-167-815-739-960,Patent Application,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,PENDING
163,AU,A,AU 1993/039804 A,149-818-160-061-377,1993-08-05,1993,AU 1993/039804 A,1993-05-25,US 24449588 A;;US 40239189 A;;US 24411488 A;;US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ADAMS WILLIAM C JR;;ARONSON DAVID L;;BURGESS PETER H;;CALLANDER JILL F;;CHAN-LIZARDO CHRISTINE C;;CHAPMAN KENNETH W;;DANG REENA;;DENSMORE MICHAEL;;DIXON TIMOTHY M;;ENGLAND BENJAMIN M;;FEHSKENS LEONARD G;;FLETCHER DOUGLAS R;;GOLDFARB STANLEY I;;GUERTIN MATTHEW J;;HUPPER THEODORE F;;KOCH PAMELA J;;KOHLS RUTH E J;;KONING G PAUL;;LEMMON JAMES L JR;;MOORE ALLAN B;;NAMOGLU SHERYL F;;NAVKAL ANIL V;;NELSON KATHY JO;;O'BRIEN LINSEY B;;PLOUFFE GERARD R;;ROBERTS D KEITH;;ROGERS DENNIS O;;ROSENBAUM RICHARD L;;ROSENBERG JEFFREY L;;ROSS ROBERT R N;;SANKAR ARUNDAHATI G;;SCHUCHARD ROBERT C;;SEGER MARK J;;SHURTLEFF DAVID L;;SMITH DANNY L;;STRUTT COLIN;;SYLOR MARK W;;TRASATTI PHILIP J;;WONG STEVEN K;;WOOD RICHARD,,https://lens.org/149-818-160-061-377,Patent Application,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,PENDING
164,AU,A,AU 1993/039803 A,099-803-867-152-033,1993-08-19,1993,AU 1993/039803 A,1993-05-25,US 24449588 A;;US 40239189 A;;US 24411488 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24469188 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ADAMS WILLIAM C JR;;ARONSON DAVID L;;BURGESS PETER H;;CALLANDER JILL F;;CHAN-LIZARDO CHRISTINE C;;CHAPMAN KENNETH W;;DANG REENA;;DENSMORE MICHAEL;;DIXON TIMOTHY M;;ENGLAND BENJAMIN M;;FEHSKENS LEONARD G;;FLETCHER DOUGLAS R;;GOLDFARB STANLEY I;;GUERTIN MATTHEW J;;HUPPER THEODORE F;;KOCH PAMELA J;;KOHLS RUTH E J;;KONING G PAUL;;LEMMON JAMES L JR;;MOORE ALLAN B;;NAMOGLU SHERYL F;;NAVKAL ANIL V;;NELSON KATHY JO;;O'BRIEN LINSEY B;;PLOUFFE GERARD R;;ROBERTS D KEITH;;ROGERS DENNIS O;;ROSENBAUM RICHARD L;;ROSENBERG JEFFREY L;;ROSS ROBERT R N;;SANKAR ARUNDAHATI G;;SCHUCHARD ROBERT C;;SEGER MARK J;;SHURTLEFF DAVID L;;SMITH DANNY L;;STRUTT COLIN;;SYLOR MARK W;;TRASATTI PHILIP J;;WONG STEVEN K;;WOOD RICHARD,,https://lens.org/099-803-867-152-033,Patent Application,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,PENDING
165,AU,A,AU 1993/039802 A,066-123-168-583-807,1993-08-05,1993,AU 1993/039802 A,1993-05-25,US 24449588 A;;US 40239189 A;;US 24411488 A;;US 24469188 A;;US 24450388 A;;US 24483488 A;;US 24474288 A;;US 24484588 A;;US 24491988 A;;US 24485188 A;;US 24473088 A;;US 24485088 A,1988-09-14,ENTITY MANAGEMENT SYSTEM,"A system for managing an assemblage of entities. The entities interface within the assemblage for control of primary information handling functions and further interface with the system to permit the carrying out of management functions. The system includes management modules adapted to carry out management functions by independently interpreting and executing commands, a kernel including a table of dispatch pointers for directing the commands to the respective modules in which they are to be interpreted and executed, and an enroller for enrolling new modules into the system by adding further pointers to the table. In addition, the system includes: a module adapted to independently interpret and execute selected management-related commands; stored records relating to accessed management information, each record indicating an associated time; an information manager, responsive to commands having a time schedule, for retrieving information from the records or accessing information from the entities, including a scheduler for issuing subsidiary accesses or retrievals at possibly multiple times according to the schedule; storage containing domain information defining groups of entities, where the kernel may issue a commands to a group by issuing individual commands to appropriate modules; a common command syntax including fields for identifying the entity and the operation to be performed; a module that stores rules identifying alarm conditions, including a generator for generating rules and an alarm detector for detecting an alarm condition in response to the rules; a module adapted to carry out self-management functions by interpreting and executing commands. <IMAGE>",DIGITAL EQUIPMENT CORP,ADAMS WILLIAM C JR;;ARONSON DAVID L;;BURGESS PETER H;;CALLANDER JILL F;;CHAN-LIZARDO CHRISTINE C;;CHAPMAN KENNETH W;;DANG REENA;;DENSMORE MICHAEL;;DIXON TIMOTHY M;;ENGLAND BENJAMIN M;;FEHSKENS LEONARD G;;FLETCHER DOUGLAS R;;GOLDFARB STANLEY I;;GUERTIN MATTHEW J;;HUPPER THEODORE F;;KOCH PAMELA J;;KOHLS RUTH E J;;KONING G PAUL;;LEMMON JAMES L JR;;MOORE ALLAN B;;NAMOGLU SHERYL F;;NAVKAL ANIL V;;NELSON KATHY JO;;O'BRIEN LINSEY B;;PLOUFFE GERARD R;;ROBERTS D KEITH;;ROGERS DENNIS O;;ROSENBAUM RICHARD L;;ROSENBERG JEFFREY L;;ROSS ROBERT R N;;SANKAR ARUNDAHATI G;;SCHUCHARD ROBERT C;;SEGER MARK J;;SHURTLEFF DAVID L;;SMITH DANNY L;;STRUTT COLIN;;SYLOR MARK W;;TRASATTI PHILIP J;;WONG STEVEN K;;WOOD RICHARD,,https://lens.org/066-123-168-583-807,Patent Application,no,0,0,26,37,0,H04L41/00;;H04L41/042;;H04L69/00;;H04L41/00;;Y10S707/99931;;H04L41/042;;H04L69/00,G06F12/00;;G06F13/00;;G06F13/14;;H04L12/24;;H04L29/00,,0,0,,,,PENDING
